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In the anal canal, human papillomavirus (HPV) infection is associated with the
development of Condyloma accuminata, low-and high-grade dysplasia, and squamous
carcinoma. In a population of men who have sex with men (MSM), anal HPV is
common with 61% ofHIV-negative and 93% ofHIV-positive men testing positive for
the virus using the polymerase chain reaction (PCR) technique. MSM also have high
rates of anal dysplasia, the putative precursor of anal cancer. This lesion may be
detected by anal cytology sampling and reported using Bethesda 2001 terminology.
Definitive staging of anal dysplasia requires high-resolution anoscopy (HRA) with
biopsy of lesions that are visually suspicious for dysplasia using criteria established
for cervical colposcopy and validated for the anal canal. Data from the largest anal
dysplasia natural history cohort report anal dysplasia rates of 7% in HIV-negative
MSM, and 36% in HIV-positive MSM. In a population of MSM prior to the HIV-
epidemic anal cancer rates were reported as 35 per 100,000 - similar to that of cervical
cancer prior to routine cervical cytology screening in developed countries, and 35
times the rate of anal cancer in the general population. Currently, in a population of
HIV-positive MSM, anal cancer rates are between 70-80 per 100,000 and unlike other
HIV associated opportunistic infections and malignancies, show little if any response
to highly active antiretroviral therapy (HAART).
The goal of this thesis is to describe clinical and molecular aspects of anal HPV and
its' associated anal lesions, and has four main aims:
1. Identification of risk factors for the development of anal cancer: Eight subjects
were identified from the UCSF pathology database with anal cancer and previously
diagnosed high-grade anal dysplasia diagnosed by anal cytology or anal biopsy.
Standard risk factors for anal cancer such as cigarette smoking and anal wart
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diagnosis were each present in 5 individuals. However, compared to the general
population, these subjects developed anal cancer at an earlier age (mean age 45.1
years with range 39-44 years), were predominantly male (7 out of 8), were
predominantly HIV-positive (all males were diagnosed for at least 10 years and were
all taking HAART), and had a short time from diagnosis of high-grade anal dysplasia
to the development of anal cancer (average 14.4 months with a range of 3-23 months).
These cases indicate that high-grade anal dysplasia may be a risk factor or marker for
the subsequent development of anal cancer and that in the context of long-standing
HIV infection, anal cancer may be diagnosed at an earlier age than in the general
population.
2. Investigation of the efficacy of self-taken anal cytology swabs: No international
or national standard exists for anal cytology testing and few medical centres provide
this service. This study aimed to assess the efficacy of self-administered anal cytology
sampling compared to clinician obtained specimens. 102 (82 HIV-positive and 20
HIV-negative) predominantly Caucasian MSM with previous paired anal cytology
and anal biopsies completed the study. Satisfactory anal cytology specimens were
obtained in 91% of self-collected samples and 99% of clinician-collected samples
(p=0.02). The self-collected specimen adequacy rate was similar for HIV-positive
(93%) and HIV-negative (85%) subjects (p=0.37). The sensitivity of self-collected
and clinician-collected anal cytology to predict any grade of anal dysplasia was 68%
and 70% respectively. However, HIV-positive subjects demonstrated higher
sensitivity in detecting both cytological abnormality of any grade and high-grade
cytological abnormality compared to HIV-negative subjects. Overall cytologic results
did not differ by grade between clinician-collected and self-collected samples. These
results suggest that a population of MSM with previous experience of anal cytology
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testing and anal biopsy, with only written instructions, are capable of self-collecting
samples with sensitivity comparable to experienced clinicians. In addition the
sensitivity of anal cytology collected by clinicians and subjects to detect AIN 2 or 3
on biopsy was comparable. Thus self-collected anal cytology may allow high-risk
populations to be screened outside of a medical setting.
3. Investigation of the feasibility of cytokine detection by reverse transcription
PCR: The cytokine environment of the cervical canal in both health and disease states
has previously been investigated. In particular, analyses have been performed using
cervical cytological specimens and cervical biopsies from women with and without
HPV associated cervical dysplasia. These finding tend to suggest that there is a down
regulation of T helper (Th) type 1 cytokines, such as interferon gamma (IF-y) and
interleukin 2 (IL-2), that favour a cell mediated immune response compared to Th2
cytokines, such as Interleukin 4 (IL-4) and Interleukin 10 (IL-10), that favour a
humoral immune response that is also associated with tumour progression. Such a
Thl to Th2 shift has also been described in the context of HIV/AIDS. In the context
of anal dysplasia it was hypothesised that detection of a predominantly Th2
environment may be a marker for disease progression. The study aimed to detect IF-y,
IL-2, IL-4, and IL-10 by reverse transcription polymerase chain reaction (RT-PCR) of
ribonucleic acid (RNA) derived from anal cytology specimens. Subsequently cytokine
type would be related to the degree of anal dysplasia. Initial set-up experiments were
performed to optimise parameters such as RNA isolation, PCR cycling, positive
control sequence verification, quantification of lower limit of detection, magnesium
and Thermus aquaticus concentration, and PCR machine function. However, likely
due to the nature of the samples, RNA purity was low with resulting multiplicity of
bands when PCR product was run on agarose gel. Southern transfer analysis of bands
iv
likely to conform to two of the cytokines investigated showed no detectable signal.
Likely causes for experimental failure include faecal contamination of specimens and
low quantities of investigational cytokines in cytology specimens. Future experiments
using RT-PCR or immuno-histochemical staining on fresh or fixed biopsy specimens
respectively may be more likely to result in detectable cytokines, as has been reported
from other gastrointestinal sites.
4. Investigation of the prevalence of age-related anal HPV and anal cytological
abnormality, and their association with incident HIV infection in a cohort of
HIV-negative MSM: Project EXPLORE was a two group randomized controlled
phase lib trial of a behavioural intervention to prevent HIV infection in a cohort of
4295 HIV-negative MSM. The HPV sub-study of EXPLORE was conducted in four
cities in North America and aimed to characterise anal HPV and anal cytological
changes in a wide age range of approximately 1200 HIV-negative MSM. Results
showed a high anal HPV prevalence of 57% in all age ranges studied with a high-risk
HPV prevalence of 26%, with HPV-16 the most commonly isolated type. Multiple
anal HPV type infections were detected in 45% of participants. Risk factors for anal
HPV detection were history of receptive anal intercourse and number of sex partners
in the preceding 6 months. Anal cytological abnormalities were also common in this
population with a prevalence of 20%. Risk factors identified for abnormal anal
cytology were detection of anal HPV, detection ofmultiple HPV types, number of sex
partners, number of receptive sex partners, injection drug use, and the use of amyl
nitrate (poppers). This study illustrated for the first time the epidemiology of anal
HPV infection and anal cytological diagnoses in a population of HIV-negative MSM
recruited from a wide age-range. Additionally, detection of anal HPV and atypical
anal cytology was associated with incident HIV infection.
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HIV human immunodeficiency virus
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MMLV Maloney murine leukaemia virus








PBS phosphate buffered saline
PCR polymerase chain reaction
RT reverse transcription
RT-PCR reverse transcription polymerase chain reaction
s second
see squamous cell cancer
SD standard deviation
SDS sodium dodecyl sulphate
SE standard error of the mean
SSC standard sodium citrate
SSPE saline, sodium phosphate, EDTA
TAE Tris-Acetate-EDTA
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CHAPTER 1
THE VIROLOGY OF HUMAN PAPILLOMAVIRUS
1.1 INTRODUCTION
This chapter will introduce the molecular biology of human papillomavirus (HPV)
with emphasis on the function of HPV genomic products and their link to cell
transformation.
1.2 HPV MORPHOLOGY
HPV is a non-enveloped icosohedral particle with a diameter of 55nm. The spherical
viral shell is formed by 72 pentameric capsomers that enclose episomal double
stranded DNA.(l) Both the capsid shell and enclosed HPV DNA are required to form
an infectious viral particle. (See Figure 1.1)
Figure 1.1 Electron micrographic appearance of an HPV particle
1.3 HPV TROPISM
HPV infects stratified squamous epithelium of skin and mucous membranes. Some
HPV types are epithelium-site specific, e.g. the HPV types that cause plantar warts are
not detected in the oral cavity. Recent studies have shown that while HPV receptors
are present and generally expressed on stratified squamous epithelium, viral
replication may only occur in tissues that have intracellular regulators that facilitate
type-specific HPV replication, thus explaining HPV's anatomical tropism.(2) While
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this tropism is absolute for some HPV types, others such as HPV 16 may be found in
both anogenital and oral locations.(3)
1.4 HPV ATTACHMENT AND INFECTION
While it was generally accepted that a receptor was necessary for HPV cell
attachment and infection, until recently little was known about the cellular HPV
receptor itself. In 1999 Joyce proposed that heparan sulphate proteoglycans (HSPG)
function as universal HPV attachment receptors, that have since been shown to be
essential for HPV internalisation for experimental virus like particles (VLP).(4) (5)
(6) VLP are composed of self-assembled LI proteins, without HPV DNA, that form
the outer shell of infectious HPV.
While HSPG appear to be ubiquitous, other authors suggest that other ligands such as
alpha-6 integrin and as yet uncharacterised secondary receptors may also be involved
in the infection process.(7) However, it is also worth noting that most HPV infection
studies to date have used manufactured VLP that may or may not reflect natural
infection. (7) Following attachment HPV internalisation has been shown to occur via
clathrin-dependent receptor-mediated endocytosis.(8)
1.5 HPV REPLICATION
Following viral entry into the basal epithelial cell nucleus, HPV replicates by three
methods that are dependent upon on the maturity and differentiation of the host cell.
Squamous epithelium is arranged in five layers increasing in differentiation from
basal, parabasal, small intermediate, large intermediate to superficial cells. (See
Figure 1.2) Initially, plasmid replication occurs in the basal cell where HPV viral
DNA is amplified to between 50-400 copies per diploid genome. Subsequently the
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HPV genome replicates once per cell division as the epithelial cell matures,
maintaining a constant HPV copy number per cell with equal division of genomic
material to each daughter cell thus ensuring both latent and persistent infection. With
maturation and terminal differentiation of the superficial layers of the epithelium,
control ofHPV replication is lost, and by an unknown mechanism, HPV replicates in
an uncontrolled vegetative fashion. This replication, independent of cell division in
the non-dividing cell, results in the formation of lOOO's of copies ofHPV per cell.
Figure 1.2: Cross section of normal squamous epithelium
1.6 VIRAL ASSEMBLY
Viral assembly occurs in the small intermediate and more superficial layers of the
epithelium in terminally differentiated non-mitotically active cells where both early
and late gene products are present.
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1.7 HPV GENOME AND GENE PRODUCTS
HPV exists in the cell nucleus as a non-enveloped double-stranded DNA episome
consisting of approximately 7,900 base pairs, and is associated with cellular histones
to form a chromatin-like substance.(9) (10) The HPV genome encodes DNA
sequences for six early (E) proteins associated with viral gene regulation and cell
transformation, two late (L) proteins which form the protein shell of the virus, and a
long control region (LCR) that contains regulatory sequences.(11) (12) In addition,
there are two additional open reading frame's (ORF) whose function is unknown, E3
and E8. The ORF is a long DNA sequence that is uninterrupted by a stop codon and
encodes part or all of a protein. (See Figure 1.3)
Following viral infection, HPV E gene expression can be demonstrated in the basal
cells of the epithelium.(13) (14) Subsequently, L gene expression occurs but is
restricted to terminally differentiated non-replicating cells of the epithelium.(15) It is
this dependence on differentiating epithelia for full genomic expression and viral
assembly that has hampered attempts to propagate HPV in the laboratory. Current
methods of HPV propagation include inoculation under the renal capsule of nude
mice, using a 'raft' culture system comprised of a stratified squamous epithelium at an
air-water interface, or using monolayered cell cultures that can be modified to
produce infectious viral particles. (16) (17) (18)
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Figure 1.3: HPV open reading frame
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Image adapted from Fields (19)
1.7.1 E1
Both El and E2 are required for stable HPV replication. El maintains the viral
episomal form, controls DNA unwinding prior to transcription, and subsequently
initiates transcription with E2 acting as a cofactor, by the action of a helicase
enzyme.(l) (20)
1.7.2 E2
E2 functions as a transcription regulator by binding to the origin of plasmid
replication in addition to down-regulating expression of E6 and E7. Disruption at E2,
which occurs after linearization and integration of the HPV episome into the host cell
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genome, results in abrogation of E2 function and unchecked viral E6 and E7 genomic
expression. This event is associated with development of a malignant cell phenotype.
An integrated genome is more commonly demonstrated in high-grade dysplasia and
squamous cell cancer than in low-grade dysplasia.(l 1)
1.7.3 E5
The role of E5 following HPV infection is poorly defined, but in high-risk HPV, E5
may speculatively be involved in the initiation and facilitation of the transformation
process.(l) (21) E5 facilitates hyper-activation and increased recycling of epidermal
derived growth factor (EDGF), enhancing the infected cells' response to growth
factors and facilitating mitosis.(22) These E5 effects occur while the high-risk HPV is
in the episomal form within the host cell nucleus. E5 is not expressed in HPV
associated cancers and may be deleted following integration of the HPV episome into
the host chromosome.(23) (24)
1.7.4 E6 and E7
There are numerous interconnected pathways involved in E6, E7 and cell cycle
regulation and what follows are the most established mechanisms presented in the
literature.
The two most important HPV proteins in the pathogenesis of malignant disease in
high-risk HPVs are the oncoproteins E6 and E7. The continued expression of both
these proteins is associated with the development of a malignant cell phenotype,
although E7 alone in vitro is capable of transforming cells.(25) (26) (27)
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The genotypic variations in the DNA base-sequences of E6 and E7 in different HPV
types characterize the oncogenic phenotype of the virus into high- and low-risk types,
with reference to their association with cervical cancer.(28) (29) (11)
At the molecular level, the ability of E6 and E7 proteins to transform cells relates in
part to their interaction with two intracellular proteins, p53 and retinoblastoma (Rb).
1.7.4.1 E6
E6 protein from different HPVs form complexes with p53 with more (high-risk HPV)
or less (low-risk HPV) avidity that correlates with the in vivo clinical behaviour and
the in vitro transforming activity of these different papillomaviruses.(30)
In the normal cell p53 is a negative regulator of cell growth that acts by inducing
protein p21 expression. Protein 21 controls cell cycle transit from the resting (Gl) to
the synthetic (S) phase. (See Figure 1.4) It also functions as a tumour suppressor
protein that halts cell growth following chromosomal damage, and allows either DNA
repair enzymes to function, or induces apoptosis.(l) (31) (32) (33) (34) HPV E6 binds
to E6 associated-protein (E6AP) leading to degradation of p53 by a ubiquitin
dependent pathway that results in unchecked cellular cycling and the accumulation of
chromosomal mutations without DNA repair. Other natural substrates of E6AP may
also have an effect on E6AP function following E6 binding that may enhance or
inhibit its effect on cell transformation. It is postulated that chromosomal mutations
and genomic instability are required for HPV associated cell transformation and the
development of a malignant phenotype.
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1.7.4.2 E7
The Rb protein inhibits the effect of positive growth regulation and responds to DNA
damage by halting cell growth and allowing DNA repair enzymes to work, or
inducing cell apoptosis.(34) (35) One of the functions of Rb is to bind and render
inactive the E2F transcription factor. E2F controls DNA synthesis and cyclin function
and promotes the Gl/S phase of cell cycling. (See Figure 1.4) E7 interacts with Rb
protein in the E2F/Rb protein complex. When E7 binds to Rb protein, E2F is released
and allows cyclin A to promote unregulated cell cycling.(23) (1, 36) These processes
allow unchecked cell growth in the presence of genomic instability that may again
lead to cell transformation, and the development of a malignant phenotype.
Rb changes phosphorylation status throughout the cell cycle, becoming
phosphorylated and active in inhibiting cell cycling at the Gl/S boundary and
hypophosphorylated, without cell cycling inhibitory effects at late M. E7 binds to the
hypophosphorylated form of Rb protein, thus the inactive stage is prolonged and cell
cycling continues unchecked.(37) E7 binding can additionally lead to the destruction
ofRb.(38)




(DNA Synthesis) Cells that stop
dividing
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1.7.5 TELOMERES AND TELOMERASE
A telomere is a specialized structure made up of a recurring motif of 6 nucleotide
bases (namely, the sequence TTAGGG) in addition to various other associated
proteins involved in the replication and stability of the chromosome. Telomeres are
found at the 5' end of eukaryotic chromosomes and function to protect the end of the
DNA strand from destruction.(39, 40) Most cells do not have a mechanism for
telomere repair and with successive mitoses the telomeres shorten until the cell
undergoes p53 associated apoptosis.(41) However some cells such as germ cells have
telomerase, a ribonucleoprotein enzyme complex (a cellular reverse transcriptase) in
eukaryotic cells that can add telomeres to the ends of chromosomes after they divide,
thus increasing the cells capacity for continued replication.(42)
In the context of HR-HPV infection, in addition to the effects of oncoproteins on p53
and Rb protein, HR-HPV E6 also activates telomerase. Telomerase is present in over
90% of anogenital cancers, it is present in cells immortalized in vitro by HPV E6, and
is currently being investigated as a possible marker of high-grade lesions in cervical
cytology samples.(43, 44)
1.7.6 L1 and L2
Both late proteins are expressed only in fully differentiated epithelial cells, and are
therefore not expressed in high-grade dysplastic tissue or squamous cell cancer. LI
codes for the major capsid protein that induces both cellular and humoral immune
responses and may be involved in viral cell attachment. L2 codes for the smaller
minor capsid protein and has no currently defined function. Both LI and L2 together,
and LI alone can self-assemble without viral DNA and form VLPs.(l 1) (45) This will
be discussed further in the HPV vaccine section below.
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1.7.7 LCR
The non-protein encoding LCR of HPV contains enhancer/promoter elements
responsive to cellular factors as well as to virus encoded transcription factors. These
enhancer elements are essential for the initial expression of viral genes.(11) (46) The
LCR is responsible at least in part for the cell/tissue tropism of each HPV type, as the
enhancer elements present in the LCR are tissue specific and involved in initiation of
viral gene expression.(2)
Table 1.1 Summary of HPV gene product function and the LCR
HPV gene HPV gene product function
El Maintains viral episomal form and controls and initiates transcription
E2 Transcription regulation and down-regulation ofE6 and E7 expression
E5 Poorly defined but facilitates initiation of transformation in episomal
HR-HPV by enhancing cell growth factor response
E6 Binds to E6 associated-protein leading to degradation of p53 resulting
in unchecked cellular cycling
E7 Binds to Rb protein, E2F is released and allows cyclin A to promote
unregulated cell cycling
Ll/2 Form major and minor capsid proteins that encapsulate HPV DNA
LCR Contains enhancer/promoter elements responsive to cellular factors and
virus encoded transcription factors
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1.8 GENOTYPIC CLASSIFICATION OF HPV
Recent molecular biological techniques using the polymerase chain reaction (PCR)
and DNA probes have facilitated HPV typing and characterisation. Each HPV type is
formally defined as unique by having less than 90 percent DNA nucleotide sequence
homology with any another identified HPV type LI, E6 and E7 ORFs.(9) (47) There
are currently over 110 types of HPV, with 38 of these displaying genitotropism.(48)
(49) (50)
Within type HPV variants also exist that show 0-2% sequence heterogeneity in the LI,
L2 and E6 genes.(51) These variants have ethnic and geographical correlations and
show differing oncogenic potential in their association with dysplastic and malignant
processes that may be related to virus infectivity, persistence, and ability to cause cell
immortalisation or avoid immune surveillance.(52, 53) (54)
1.9 HPVPHENOTYPE
The association of HPV with malignant disease was first described by zur Hausen in
1976 with reference to cancer of the uterine cervix.(55) Lorincz subsequently
suggested a HPV classification system based on this association using 3 categories:
low-, intermediate-, and high-risk.(56) This classification has since been modified to
high-risk types (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and low-
risk types (6, 11, 42, 43, 44) only.(9) (57) Although helpful, this classification system
is not absolute in that low-risk HPV may occasionally be found in cervical cancer
tissue.
The phenotypic association of HPV and cervical dysplasia and cancer has also been
demonstrated for HPV identified in anal dysplasia and anal cancer tissue. HPV 16 was
the most common HPV type isolated from pathological specimens in a cohort ofmen
12
and women with an anal cancer diagnosis.(58) In 1997 Palefsky et al reported that
high-risk HPV detected by Hybrid Capture (HC) was a risk factor for abnormal anal
cytology in a population of men who have sex with men (MSM) with Centres for
Disease Control (CDC) group IV HIV disease - an association subsequently
confirmed by other authors.(59) (60) (61) Williams et al had previously reported the
association of abnormal anal cytology with HPV infection detected by dot blot in a
cohort ofHIV-positive and HIV-negative women.(62)
1.10 TRANSFORMATION CO-FACTORS
In the female cervix, HPV is required but is not adequate for malignant transformation
that only occurs when oncogenic co-factors are present. Co-factors implicated in the
development of cervical squamous cancer include cigarette smoking, and possibly
also prior infection with Chlamydia trachomatis. (63) (64) (65) (66) (67) It is also
possible that cigarette smoking may be a co-factor in the development of anal
cancer.(68)
Recently a large epidemiology study addressing the development of cervical cancer in
women reported that among HPV positive women, high parity, and long-term oral
contraceptive (OC) use in addition to smoking and co-infection with other sexually
transmitted agents are consistently identified as environmental co-factors that increase
the risk of progression from cervical HPV infection to high-grade squamous
intraepithelial lesions (HSIL) and invasive cervical cancer. The authors also noted that
there is limited evidence for a role of dietary factors in HPV carcinogenesis.(69)
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1.11 SUMMARY OF SQUAMOUS CELL TRANSFORMATION
Following epithelial basal cell infection with HR-FIPV and viral replication, the
nuclear episome may linearise and become integrated into the host cell genome. This
fracture within the viral El and E2 ORFs critically disrupts the suppressor functions
of E2 with resulting uncontrolled expression of E6 and E7 oncoproteins. Uncontrolled
cell cycling in the presence of telomerase occurs with resulting disruption of DNA
repair mechanisms and accumulation of mutated DNA that may facilitate cell
transformation, clonal expansion, and tumour formation.
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CHAPTER 2
CLINICAL HUMAN PAPILLOMAVIRUS INFECTION
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2.1 INTRODUCTION
This chapter will describe HPV infection, HPV/HIV co-infection, HPV detection, and
different modalities of HPV and HPV associated lesion treatment with particular
reference to the anal canal.
2.2 HPV INFECTION
HPV infects keratinizing and non-keratinizing stratified squamous epithelia and elicits
a wide range of tissue responses ranging from histological latency to benign
proliferative disease to invasive squamous cancer in the presence of co-factors.(l)
(70)
HPV infection is commonly asymptomatic, but may cause itch and burning and is
usually diagnosed clinically by the presence of clinical manifestations such as
exophytic lesions, or subclinically in the form of abnormal cytology.(71) However it
is now possible with molecular techniques such as Hybrid Capture (HC) and the
polymerase chain reaction (PCR) (see below) to diagnose HPV infection per se for
investigation purposes and clinical management, such as currently occurs in the triage
of cervical cytology that shows atypical squamous cells of undetermined significance
(ASCUS). However, diagnosing HPV in subjects without clinical evidence of
infection has also been shown to negatively impact the individual's psychological
well being and many subjects variously react with anger and distress upon learning of
their infection indicating a sexually transmitted infection, as occurs with a diagnosis
of genital warts.(72, 73)
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2.3 HPV TRANSMISSION
Genitotropic HPVs are transmitted by close physical contact including sexual contact.
The epidemiological evidence for this was derived from studies showing an
increasing prevalence of HPV infection with increasing numbers of sexual partners,
partners of individuals with genital warts subsequently developing genital warts, and
concordance ofHPV types between partners.(74) (75) (76) (77) (78) The rate of HPV
transmission per sexual contact is unknown, but given the high prevalence of HPV
infection in the general population it is likely to be high.
2.4 HPV IN THE GENERAL POPULATION
Warts were first associated with a viral cause by Ciuffo in 1907, with a viral
cytopathic effect in 1968, and with HPV in 1981.(79) HPV is the most common viral
sexually transmitted infection in the United States (US) with an increasing incidence,
as in all developed countries, since the 1950's.(80) It is estimated that the majority of
the sexually active adult population in the US have been infected with a genitotropic
HPV based on antibody studies although only 1% (approximately 1.4 million persons)
display clinical genital warts.(81) Sub-clinical HPV infections may be detected by
colposcopy and cytology, and increasingly by molecular techniques.(82) (83)
2.5 EPIDEMIOLOGY OF HPV INFECTION
In a random sample ofwomen attending primary care clinics, a seven-fold increase in
the detection of clinically diagnosed genital warts was seen between 1966 and
1984.(80) Cytological evidence of HPV infection ranges between 8 and 24%
depending upon the population sampled, with highest infections prevalence in women
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under 25 years of age.(84) (85) (82) Cervical HPV infection prevalence rises rapidly
after sexual debut and then decreases over subsequent years.
2.6 HPV AND IMMUNOSUPPRESSION
Immunosuppression per se, whether by HIV or induced iatrogenically in the context
of solid organ transplantation, is associated with more frequent isolation of HPV,
higher detectable HPV DNA levels, and the more frequent detection of multiple HPV
types.(86) (87) (88) There is also a higher burden of clinical disease related to HPV
infection in this population.(89-91)
2.7 HPV/HIV CO-INFECTION
HPV associated clinical disease occurs more commonly in the context of HIV
infection. Women with HIV infection are at increased risk for cervicovaginal HPV
infection and cervical intraepithelial neoplasia (CIN), and in 1993 cervical carcinoma
was added to the list of AIDS defining conditions by the Centres for Disease Control
(CDC).(92) (93) The effect of HAART has been investigated in women and has not
been shown to affect HPV detection.(94) (95) However, data on the effect ofHAART
on the natural history of cervical dysplasia are conflicted with some studies showing
no effect of HAART,(95, 96) and others show a statistically significant but modest
beneficial effect.(94) (97) HIV infected MSM are at higher risk of HPV infection of
the penile coronal sulcus, and are more likely to have capsid antibodies to high-risk
HPV (but not low-risk HPV) than HIV-negative MSM. (98) (99) Anal HPV infection
in the context ofHIV will be discussed below.
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2.7.1 HPV/HIV INTERACTION
HPV associated disease such as condylamata, anogenital dysplasias and anogenital
cancer is more commonly diagnosed in HIV infected individuals.(100) (12) The
possible mechanisms of pathogenesis include impairment of cell mediated immune
(CMI) responses, epithelial cytokine dysregulation, and a direct effect ofHIV proteins
such as tat on HPV replication.(lOl) It is theoretically feasible that one or all of these
mechanisms may also contribute to the increased incidence of anal cancer seen in an
HIV-infected population.
2.8 ANAL HPV
Most studies of anal HPV have been undertaken in MSM. The spectrum ofHPV types
in the anal canal is similar to that described in the cervix and is associated with the
same 'risk' phenotypes. HPV 16 is the most commonly detected HPV type associated
with anal dysplasia and cancer, as well as cervical dysplasia and cancer.(102) (57)
(103) (58) However, a few of the more commonly isolated HPV types in the anal
samples have only rarely been reported in cervical samples (types 53, 58, 61, 70). As
a group, these types show homology with HPV 39, which is high-risk in its
association with cervical cancer.(104) HPV 32, characteristically an oral HPV type,
has also been isolated in anal samples and may indicate transmission by oral-anal
intercourse.(102)
The range of anal HPV types detected is similar in both HIV-positive and HIV-
negative MSM with HIV-positive MSM more frequently diagnosed with multiple
types, have a higher prevalence of HPV, and higher levels of high-risk HPV when
semi-quantitative methods of detection are used.(102) (105)
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2.8.1 RISK FACTORS FOR ANAL HPV
HPV may be detected in the epithelium of the penis, scrotum, anal canal, cervix,
vagina, vulva and peri-anal area. Genital HPV infections are spread by penetrative sex
and close physical contact involving an infected area, (86) however digital/anal,
oral/anal and digital/vaginal contact are also likely to spread the virus as may fomites
such as sex toys.(86) Risk factors reported for anal HPV infection are shown in Table
2.1.
Table 2.1 Risk-factors for anal HPV infection
History of receptive anal intercourse (102) (106)
History of anal warts (107)
Younger age (108)
HIV infection (109) (107) (61) (110)
HIV infection with a lower CD4 count (102) (109) (110)
History of smoking tobacco (109)
Recreational rectal drug use (102)
2.8.2 DEMOGRAPHICS OF ANAL HPV
No comprehensive information is currently available on the demographics of anal
HPV in the general US population as HPV is not a notifiable sexually transmitted
infection.(82) Centres investigating anal HPV most commonly have study populations
ofMSM who tend to be between the ages of 30 and 50 years, live in urban American
centres, and have a high prevalence of HIV infection. However, a recent study has
reported a high prevalence of anal HPV infection in a population of HIV-negative
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urban MSM. This 4 site study of 1218 men between 18 and 89 years of age revealed a
near constant prevalence of 57% in all age ranges studied with no significant
differences noted in prevalence between urban centres.(111) (See Appendix 4)
2.8.3 ANAL HIV/HPV
In the context of HIV co-infection, most anal HPV research has been conducted in
MSM. Using PCR detection methods, one group identified 29 individual types and 10
HPV groups from the anal canal of MSM with concomitant HIV infection.(102)
Additionally, HIV-positive individuals with reduced CD4 counts have an over
representation of high-risk HPV,(112) (102) increased transcription of early HPV
genes,(112) and are more likely to shed HIV RNA from the anal canal in association
with detectable HPV DNA.(113)
In women, data from the Women's Interagency HIV Study showed that 76% of 223
HIV-positive women were found to have anal HPV infection, as did 42% ofhigh-risk
(commercial sex workers and injection drug users) HIV-negative women.(114) Anal
HPV infection appears to be at least as common as cervical HPV infection in HIV-
positive women,(62) with one study showing that anal infection was more common
than cervical infection, with two site concordance of HPV types reported as
50%.(115)
In adolescent women with HIV immunosuppression, as measured by reduced CD4
count, HIV was not a risk for HPV detection.(l 16)
2.8.4 TREATMENT OF ANAL HPV ASSOCIATED LESIONS
There is no current Food and Drug Administration (FDA) approved antiviral drug
with activity against HPV. However, therapeutic vaccines directed against HPV-
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infected cells are being explored as is prophylactic vaccination.(l 17) (118) (119)
(120) (121) The following treatment modalities have been used to treat anal HPV
associated lesions. Treatment of anal high-grade dysplastic lesions will be considered
in the following chapter.
2.8.4.1 PODOPHYLLIN/PODOPHYLLOTOXIN
Podophyllin is an extract of the rhizome of Podophyllum peltatum, commonly known
as American mandrake. (See Figure 2.1) It contains the antimitotic agent
podophyllotoxin, which arrests the cell cycle in metaphase and leads to cell death.
Podophyllin solution when used topically as a single agent once or twice a week has
limited success in clearing warts ranging from 20 to 50 percent at three months.(122)
It is usually employed as a 25 percent solution in combination with another treatment
method such as cryotherapy. The drug is teratogenic and must not be used in
pregnancy or suspected pregnancy and it is not indicated for internal use. Adverse
effects range from mild skin irritation to ulceration and pain depending upon the
concentration used and the length of time over which it is applied to the skin before
removal by washing.
More recently, podophyllotoxin, the active element of podophyllin has been available
as a solution or cream in concentrations of 0.15-0.5 percent. This preparation has the
advantage of less clinical adverse events,(123) (124) consistency of formulation,(125)
and improved efficacy when compared to podophyllin therapy.(126) (127)
22
Figure 2.1: American mandrake (Podophyllumpeltatum)
2.8.4.2 TRICHLOROACETIC ACID
Eighty percent trichloroacetic acid (TCA) physically destroys wart tissue by protein
coagulation. Clearance rates and adverse effects are similar to podophyllin and
repeated application may be required. In contrast to podophyllin TCA can be used for
internal lesions and in pregnancy.(128)
2.8.4.3 CRYOTHERAPY
Cryotherapy is performed by the application of liquid nitrogen spray, a swab soaked
in liquid nitrogen, or by placing a nitrous oxide cooled cryoprobe on the lesion to be
treated. This procedure is safe in pregnancy. Subjects usually experience mild pain
during application and a variable degree of localized inflammation afterwards.




Carbon dioxide laser therapy is carried out in an operating theatre and requires
anesthesia. The HPV infected tissue absorbs the laser energy, which is converted into
heat energy and the lesion is vaporized. This technique has rates ofwart clearance that
approach 100 percent over one year; however, recurrences can be up to 45
percent.(128) (129) Adverse events include scarring and pain.(130) It should be noted
that laser surgery of condylomata has been associated with laryngeal papillomatosis
developing in the operating surgeon.(131)
2.8.4.5 SURGERY
Surgical therapy may be considered when medical therapy has failed, when warts are
very large, or are amenable to surgical removal. Scissor excision requires anesthesia
and routine surgical risks such as infection and hemorrhage apply. The three-month
clearance rates are 36 percent.(128) Circumferential anal lesions are best treated in
two stages to reduce the risk of anal stricture and stenosis.
2.8.4.6 CIDOFOVIR
Cidofovir is an acyclic nucleotide analogue active against DNA viruses and licensed
for the treatment of cytomegalovirus (CMV) infection. It has shown clinical efficacy
in the treatment of external genital warts related to low-risk HPV infection,(132)
supporting previous in vitro evidence of the growth inhibitory effects of cidofovir on




This device is used in an outpatient setting and delivers infrared light in aliquots of
0.5 to 3 second intervals to previously anesthetized epithelium. The Infrared
coagulator (IRC) produces a focal shallow burn in millimeter depth that correspond to
the length of the light aliquot in seconds.(135, 136) The coagulated tissue is then
removed by debridement or by excision using baby Tischler forceps. Small studies
with encouraging results and response rates of 70% have reported to date.(137)
2.8.4.8 TOPICAL PHOTODYNAMIC THERAPY
Topical photodymamic therapy (PDT) employs the use of a photosensitizing
compound, such as 5-aminolaevulinic acid - a precursor in the heme biosynthetic
pathway, followed by subsequent exposure to a light source. The mechanism of action
relates to the release of highly reactive oxygen species with local tissue destruction
and inflammation. In one study 5-aminolaevulinic acid was used to treat urethral
warts with response rates of 95% at 6-24 months following the procedure.(138)
2.8.4.9 IMIQUIMOD
Imiquimod is a non-nucleoside heterocyclic amine and Toll-like receptor 7 agonist. It
is classified as an immune response modifier due to its ability to stimulate production
of cytokines such as interferon-gamma, tumor necrosis factor-alpha and interleukin-6
in monocytes/macrophages thus creating a T helper (Th) 1 like environment and
promoting a cell mediated immune response.(139) (140) Application of Imiquimod as
a 5% cream three times per week has shown efficacy in the treatment of external




Inferferons are a multigene family of proteins that can be divided into alpha (IF-a),
beta (IF-P), and gamma (IF-y), all of which have antiviral and immunoregulatory
properties which they exert by binding to cell surface receptors.(143) Interferons have
been used in HPV infection, usually by intralesional injection to genital warts
although they may be applied topically or given systemically, with proven
efficacy.(144) (145) The limiting factor for this therapy is high cost, and associated
flu-like symptoms.
2.8.4.11 GENE THERAPY
As HPV associated cancers rely on continuous presence of E6 and E7 proteins it is
theoretically possible that by abrogating the expression of E6 and E7 genes that the
malignant phenotype of the cell may be lost. Potential mechanisms for this include
use of antisense RNA, ribozymes, or short interfering RNA.(146)
2.8.4.12 HPV VACCINES
Both prophylactic and therapeutic vaccines are in Phase 3 clinical trials for the
prevention and treatment ofHPV associated lesions respectively.
2.8.4.12.1 THERAPEUTIC HPV VACCINATION
It is apparent that cell mediated immune responses are involved in the control of HPV
infection as demonstrated by the increased frequency of clinically apparent warts and
cervical/anal dysplasia in immunosuppressed individuals,(147) (148) (149) (150) the
presence of lymphocytic infiltrates in biopsy specimens of cervical tumour
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tissue,(l 51) and the presence of specific cytotoxic T lymphocyte (CTL) responses to
HPV viral epitopes.(120) Thus, therapeutic vaccines aim to augment the established
host cell-mediated immunological response and mount an enhanced, specific and
directed T-cell mediated attack on the HPV-infected cell with down-regulation of
viral reproduction or even viral clearance. Challenges in HPV associated cancer
vaccine development are compounded by the down-regulation of major
histocompatability class 1 (MHC1) antigen on tumour cells restricting opportunity for
antigen presentation, and the development of immune tolerance.(152)
The therapeutic vaccine preparation methods to produce a directed cell-mediated
response vary and include:
• Adaptive cellular transfer. This method involves collecting immune system
cells from a subject, or a histocompatible donor with HPV infection and
stimulating the cells ex vivo with recombinant IL-2. The cells, thus activated,
are returned to the donor. This method has been used in murine HPV-positive
tumour models with some effect.(120)
• Fusing HPV peptides to immunogenic moieties to enhance the existing
immune response. Heat shock proteins acting as natural adjuvants have been
shown to induce CTLs.(152) Phase 3 clinical trials are currently recruiting
using the E7 protein of HPV 16 fused to a Bacille Calmette-Guerin (BCG)
heatshock protein, Hsp 65, as this has shown promise in a murine model of
squamous cancer.(153)
• Expressing HPV 16 and 18 E6 and E7 epitope peptides in a recombinant
vaccinia viral particle. This method has been investigated in humans with
advanced cervical cancer with a demonstrable effector CTL response in one
out of eight patients, and no significant reported toxicity.( 121)
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• DNA vaccine. One Phase 1 clinical trial has reported the use of plasmid DNA
encoding for HLA-A2 restricted epitopes derived from HPV-16 E7 protein,
encapsulated in a biodegradable polymer, and formulated into microparticles.
Study subjects were HPV-16 positive with high-grade anal dysplasia and an
HLA-A2 haplotype. The vaccine was well tolerated and histological responses
were noted in 3 of 12 eligible subjects.(154)
2.8.4.12.2 PROPHYLACTIC HPV VACCINATION
Prophylactic HPV vaccines contain HPV sub-units that induce neutralizing antibody
prior to the host encountering natural HPV infection. The epitopes used in these
vaccines are the major capsid proteins of HPV (LI alone or in combination with L2),
which self-assemble into virus-like particles (VLP) with no enclosed DNA, and have
shown effect in animal models with concurrent induction of a CMI response.(155)
(34) The challenges of this vaccine are the potential that only type-specific restricted
responses are induced by each VLP.(118) Thus, to provide protection against the
occurrence of warts as well as anogenital dysplasia, LI capsid VLP from both highl¬
and low-risk HPV are being considered.
Koutsky et al reported findings from an HPV 16 LI virus like particle (VLP) vaccine
given in three intramuscular doses over six months to sexually active females not
previously exposed to HPV16 (negative cervical DNA analysis/cytology). The
vaccine efficacy was 100% in preventing HPV 16 and HPV 16-related cytological
abnormality.(156) Subsequently clinical trials have been performed with low- and
high-risk bivalent VLPs that have showed long lasting antibody responses.(157)
Furthermore a Phase 2 clinical trial reported high efficacy with a bivalent HPV 16 and
18 VLP vaccine in women.(158) While it is biologically plausible that these
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promising results will also occur in men, no prophylactic vaccine trial has yet reported
in this population.
There is no current FDA approved HPV prophylactic or therapeutic vaccine available
for clinical use. However this is likely to change in the near future when issues such
as age at time of vaccination, and pre-testing of minors for a sexually transmitted
infection will need to be addressed. This is particularly relevant given the high
reported rates of serological evidence of high-risk anogenital HPV infection in this
population that may potentially compromise vaccine efficacy.(159)
2.9 HPV DETECTION
There are a number of clinical and molecular methods ofHPV detection.
2.9.1 VISUAL INSPECTION
HPV associated lesions may have a condylomatous, flat, papular or keratotic
appearance on the anogenital epithelium, or may be undetectable to the naked eye.
(See Figure 2.2)
Figure 2.2: Perianal condylomata
04/27/2000 12:41 - (DYS-001-D4)
Image courtesy of UCSF Anal Neoplasia Study
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2.9.2 COLPOSCOPY
Colposcopy employs a binocular or video microscope with a focal length of between
300-350 mm that allows the clinician to observe the anogenital epithelium at
magnification. The magnifications commonly used are 10, 16 and 25 times normal.
HPV associated genital warts and high-grade dysplastic tissue has well-defined
appearances in the cervix that are similar to those present in the anal canal.(160) (161)
In addition to magnification, the use of stains such as 3% acetic acid and Lugols
Iodine are employed to better define lesions. Acetic acid characteristically causes
transient 'aceto-whitening' of abnormal epithelia, and despite being a non-specific
change, one study demonstrated the presence of HPV using the Hybrid Capture 2
(HC2) detection system in more that 85% of acetowhite cervical lesions.(162) Lugol's
iodine is taken up by normal glycogenated cells but not by dysplastic cells with
reduced glycogen content, and may be used to confirm clinical suspicion of dysplastic
tissue.(163) The use of the colposcope (high resolution anoscope (HRA) in the
context of anal disease) is user dependent and requires training and the development
of expertise prior to use. While no formal training exists for HRA, the American
Society for Cervical Colposcopy oversees accreditation of cervical colposcopists in
the US.
2.9.3 CYTOLOGY
Exfoliative cervical cytology has been employed since the 1950's in industrialized
countries to detect and predict the severity of cervical dysplasia before HPV was




Human serum has antibodies that react with HPV proteins.(165) Viral antigens in the
form of VLPs using LI expressed in eukaryotic systems have been produced that, in
enzyme-linked immunosorbent assays (ELISA), show type-specific antibodies that
correlate with a subject's clinical history ofHPV infection.(166) (167) (168) The time
interval between infection and seropositivity has been shown to vary by HPV type in
a cohort of university women with incident HPV infections, 59.5%, 54.1%, and
68.8% seroconverted for HPV 16, 18, or 6, respectively within 18 months of detecting
corresponding cervical HPV DNA.(169) It is unknown how long the HPV antibodies
remains detectable. Using antibody detection, investigators have reported that more
than 75% of women in the US are/will be exposed to anogenital HPV in their lives
with most infections occurring with high-risk HPV (HPV-16).(170) (171)
2.9.5 HPV DNA DETECTION
There are several methods available to detect the presence and type of HPV DNA
including in-situ hybridization (ISH), Southern transfer hybridization (STH), Hybrid
Capture (HC), dot blot (DB) and filter hybridisation (FH), and PCR.(172) HC
provides a semi-quantitative measure of HPV by the production of a
chemiluminescent signal, while more recently quantitative real-time PCR can also be
used to measure DNA levels.(173)
These tests can also be grouped according to their method of HPV DNA detection:
PCR by target amplification, HC by signal amplification, and ISH/FH/DB/STH
require no amplification.
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2.9.5.1 IN-SITU HYBRIDISATION (ISH)
The advantage of ISH is that it is performed directly on tissue with specific DNA
probes applied to de-natured DNA in permeabilized cells. Probes containing
radiolabelled nucleotides can then be detected following exposure to photographic
film. The process can also be performed with non-radiolabelled techniques, e.g.,
biotin. This process allows localisation of the target DNA sequences and correlation
with the cytopathological appearance of the tissue. This method requires five or ten
HPV genomes per cell to give a positive result, is less sensitive than PCR or HC, and
is more labor intensive. However, when augmented by PCR, the sensitivity can be
increased to one HPV genome copy per cell. There is currently no clinical indication
for the routine use of ISH.(172)
2.9.5.2 DOT BLOT AND SOUTHERN TRANSFER HYBRIDISATION
DB, FH, and STH all require binding, by hydrogen bonding and hydrophobic
interactions, of denatured target DNA to filter supports prior to blocking to prevent
non-specific binding. The target is then hybridized with a complimentary labeled
DNA probe, washed and then detected by differing methods depending on the probe
label used. STH differs from the other methods by the addition of an electrophoretic
separation step that increases the specificity of the test and may use restriction
endonucleases for each HPV type before applying the DNA probe. All of these tests
produce qualitative results and are occasionally used in research settings but are not
used in clinical practice.(172)
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2.9.5.3 FILTER IN-SITU HYBRIDISATION
This method combines aspects of both in-situ and dot blot hybridization with the
application of cells onto filters where they are treated to denature the DNA, then
hybridized and signals generated as for ISH. This method has poor sensitivity and
specificity and is of methodological interest only.(174)
2.9.5.4 HYBRID CAPTURE (SOLUTION HYBRIDISATION)
HC requires hybridisation of long single-stranded, or multiple oligonucleotide RNA
probes to the whole denatured HPV genome in solution. The solution is added to a
tube containing immobilised RNA-DNA antibodies conjugated to alkaline
phosphatase on the tube wall. The RNA-DNA hybrids then bind in a non-sequence
dependent fashion to the antibodies. The detection method uses a chemiluminescent
substrate that attaches to the hybrid and provides a semi-quantitative result. By using
RNA probes specific for either grouped high- or low-risk HPV types, both the
phenotype and viral quantitation can be related to other investigational parameters
such as HIV infection, immunosuppression, and partner number.(174) (See Figure
2.3)
HC, and specifically HC-2 produced by Digene Corp. (Gaithersburg, MD.
USA) is the only FDA approved method for cervical HPV DNA testing. Anal HPV
testing, or any form ofHPV testing in men is not FDA approved and is not in routine
clinical use.
The use of HPV typing is currently indicated in reflex testing of liquid cervical
cytology reported as ASC-US using the 2001 Bethesda terminology.! 175). In
particular HPV testing using the second generation Digene HC 2 kit which
33
differentiates high-risk (Group B) from low-risk (Group A) HPV by the use of
specific primer sequences has shown clinical efficacy in the triage of ASCUS
cytology to routine care or colposcopic referral.(176) HC is also used in conjunction
with cytology testing to screen women over the age of 30 years - if both tests are
negative subsequent testing may be performed every 3 years instead of annually.
Figure 2.3: Hybrid capture 2 methodology
A B C D E
From left to right the diagram shows DNA (dark blue) being denatured (A), the addition of an RNA
probe (light blue) that hybridizes with complementary sequences of DNA (B), capture of the
DNA/RNA hybrids to a solid phase RNA/DNA antibodies (C), labeling of the hybrids (D), and finally
production and detection of a chemiluminescent signal (E). Image adapted from Digene Corp.
2.9.5.5 POLYMERASE CHAIN REACTION
In this method, target DNA is selectively amplified by the action ofDNA polymerase
on specific primers that can then be detected by DB or STH or line blot as in the
Roche linear array assay test. PCR can detect between 10 and 100 DNA molecules in
a specimen and is the most sensitive method available.(177) By combining the
sensitivity of PCR with the use of specific primer sequences, individual HPV types
and type variants can be isolated from a variety of clinical specimens and correlated
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with the disease process present. This technique has provided evidence for the
etiologic role of HPV in the development of cervical/anal dysplasia and cancer. PCR
testing for HPV is not used in clinical settings, although PCR may prove useful in a
clinical setting similar to reflex HC testing above.(178) PCR testing shows extreme
sensitivity, although there are concomitant concerns related to false-positive results
due to possible specimen contamination. It is also unclear whether positive results
found by PCR technology indicate current productive, latent or resolved infection, or
all three.(174) (172) (179)
2.10 SUMMARY
The clinical manifestations of anogenital HPV infection have been apparent for
thousands of years, while more recent methods such as cytology and colposcopy have
been able to detect the presence of sub-clinical infection. Given the established
association of high-risk HPV infection and anogenital squamous cell cancer, DNA
testing technology may allow triage of those individuals who may be at highest risk of
developing cancer. Furthermore, there is hope that with the development and reported
efficacy of prophylactic HPV vaccines, there may be a decrease in anogenital
squamous cancers in the future.
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CHAPTER 3
ANAL SQUAMOUS INTRAEPITHELIAL LESIONS
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3.1 INTRODUCTION
Anal squamous intraepithelial lesions (ASIL) are the putative precursor to anal
squamous cell cancer (SCC). This chapter will discuss the classification,
epidemiology, pathology, and clinical management ofASIL.
3.2 THE EMBRYOLOGY OF THE ANAL CANAL
The anal canal develops from the embryological cloacal membrane that is the site of
endodermal and ectodermal fusion. As a result, the anal canal has a squamocolumnar
epithelial junction where rectal columnar epithelium meets the squamous epithelium
of the anal canal, and may normally display metaplastic change.(180) (See Figure 3.1)
These embryological, anatomical and histological characteristics are shared with the
cervical canal and extend to the cellular pathological response of both these tissues to
infection with HPV.(181)
3.3 HPV ASSOCIATED PATHOLOGY OF THE ANAL CANAL
The anal canal is prone to infection with genitotropic HPV that may result in the
development of ASIL.(182) (183) (184) Both high-risk and low-risk HPV's are
associated with ASIL. Low-risk HPV (predominantly types 6 and 11) and high-risk
HPV (predominantly types 16 and 18) may be found in association with low-grade
squamous intraepithelial lesions (LSIL) including condylomata, whereas high-risk
HPV such as 16 and 18 may be found associated with LSIL but are almost exclusively
associated with the presence of high-grade squamous intraepithelial lesions
(HSIL).(l 15) (58) (185)
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Image adapted from Ryan (186)
3.4 BETHESDA 2001 CYTOLOGY REPORTING SYSTEM
The Bethesda guidelines were originally developed for the classification of cervical
squamous intraepithelial lesions (CSIL).(187) In this system, cytological evaluation of
cellular material from the cervical canal, ideally including the squamocolumnar
transition zone, and staining of the cells by the Papanicolaou method (188) is used to
classify the degree of cervical cellular atypia. Exfoliative cytology and Papanicolaou
staining has also been validated for use in the anal canal and is also reported using the
2001 Bethedsa system.(189) (175)
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Table 3.1: The 2001 Bethesda system for reporting anal and cervical cytology
(Abridged) (190)
SPECIMEN ADEQUACY
Satisfactory for evaluation (note presence/absence ofendocervical/transformation zone component)
unsatisfactory for evaluation. . . (specify reason)
specimen rejected/not processed (specify reason)
specimen processed and examined, but unsatisfactory for evaluation of epithelial abnormality
because of (specify reason)
GENERAL CATEGORIZATION (Optional)




Negative for Intraepithelial Lesion or Malignancy
Organisms
Trichomonas vaginalis
Fungal organisms morphologically consistent with Candida species
Shift in flora suggestive of bacterial vaginosis
Bacteria morphologically consistent with Actinomyces species
Cellular changes consistent with herpes simplex virus
Other non-neoplastic findings (Optional to report; list not comprehensive)
Reactive cellular changes associated with
inflammation (includes typical repair)
radiation
intrauterine contraceptive device




Atypical squamous cells (ASC) ofundetermined significance (ASC-US) cannot exclude HS1L
(ASC-H)
Low-grade squamous intraepithelial lesion (LSIL) encompassing: human papillomavirus/mild
dysplasia/cervical intraepithelial neoplasia (CIN 1)
High-grade squamous intraepithelial lesion (HSIL) encompassing: moderate and severe dysplasia,
carcinoma in situ (CIN 2 and CIN 3)
Squamous cell carcinoma
Glandular cell
Atypical glandular cells (AGC) (specify endocervical, endometrial, or not otherwise specified)
Atypical glandular cells, favor neoplastic (specify endocervical or not otherwise specified)
Endocervical adenocarcinoma in situ (AIS)
Adenocarcinoma
Other (List not comprehensive)
Endometrial cells in a woman over 40 years of age
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3.4.1 THE CYTOPATHOLOGICAL CLASSIFICATION OF
SQUAMOUS INTRAEPITHELIAL LESIONS
Increasing degrees of squamous cytological abnormality are shown in Figure 3.2.
Figure 3.2 Normal, ASCUS, ASCH, LSIL, HSIL, and squamous cancer
cytology
HSIL Squamous cancer
Images reproduced with permission of the National Cancer Institute
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3.4.2 ANAL AND CERVICAL HISTOPATHOLOGY
Cervical and anal dysplasia are defined by the presence of abnormal cells with an
immature, basaloid appearance present in varying degrees of epithelial thickness from
the basement membrane towards the epithelial surface. These cells characteristically
exhibit an increased nuclear to cytoplasmic ratio, dark staining/polychromatic
chromatin, and may undergo mitosis in cell layers normally characterised by more
differentiated cells.
Low-grade dysplasia is diagnosed when abnormal cells replace the lower third of the
epithelium and is reported histologically as cervical intraepithelial neoplasia grade 1
(CIN 1) and anal intraepithelial neoplasia grade 1 (AIN 1). The cellular changes in
low-grade dysplasia include the presence of koilocytes, enlarged cells with a halo of
clear cytoplasm surrounding the nucleus that is associated with HPV infection.
High-grade dysplasia encompasses moderate and severe dysplasia and is defined
histopathologically as abnormal basaloid cells comprising up to two thirds (CIN
2/AIN 2) and between two thirds and the full thickness (CIN 3/AIN 3) of the
epithelium. CIN 3 and AIN 3 were previously referred to as carcinoma in situ
(CIS).(187)
High-grade CSIL, is now generally accepted to be the precursor lesion of cervical
cancer (11) and is causally related to infection with oncogenic types of HPV.(191)
Likewise it is thought considered that high-grade ASIL is the precursor of anal cancer.
Figure 3.3 shows a diagrammatic representation of anal and cervical dysplasia, and
Figure 3.4 shows increasing degrees of anal dysplastic change in anal biopsy
specimens.
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Figure 3.3: Diagrammatic representation of dysplasia
Schematic Representation of SI I
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Image adapted from Palefsky (192)
3.5 CLINICAL ASSOCIATIONS OF ASIL
Development of anal canal SCC is associated with both anal canal HPV infection
(193, 194) (185) (103) (195) and ASIL.(196) (197) (198) (91) Early SCC may present
with symptoms of anal pain, bleeding, and sometimes the presence of a palpable mass
lesion. These symptoms are common in the general population and may occur with
herpes simplex virus (HSV) infection, anal warts, anal fissure, and hemorrhoids - and
so may be ignored by the individual. This may particularly be the case in MSM who
commonly have anal symptoms related to the practice of receptive anal
intercourse.(199)
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Figure 3.4: Anal intraepithelial neoplasia grade 1, 2 and 3
AIN 1 AIN l" AIN 3 '
Images courtesy of Dr Galen Cortina, Department of Pathology, UCLA
3.6 EVIDENCE FOR ASIL AS A PRECURSOR OF ANAL
SQUAMOUS CELL CANCER
The progression of high-grade anal dysplasia to anal cancer has not been definitively
proven. However, considering the cervical paradigm of progression from high-grade
cervical dysplasia to cervical cancer, in addition to the associations below, it is
biologically plausible that this is also the case for high-grade anal dysplasia. The
observed parallels between anal and cervical epithelial dysplasia include:
ASIL and anal cancer are both associated with HPV, and similar HPV risk-
types as CSIL and cervical cancer. (185) (57, 200) (201) (202) (192) (203)
(204)(205)
• CSIL/ASIL and cervical/anal cancer are similar pathologically.(114)
• In populations known to be at risk of anal cancer there is a high incidence of
ASIL.(206) (59) (207)
Cervical/anal HSIL is frequently found overlying cervical/anal cancer.(57,
200)
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• There is documented evidence of progression from high-grade anal dysplasia
to anal cancer in both iatrogenic and HIV-induced immunosuppression.(208)
(209)
• There is documented progression of Bowen's disease (perianal AIN-3) to
cancer.(210)
Chromosomal abnormalities found in high-grade anal dysplasia are also found
in cervical cancer.(181)
Thus, analogous to treatment of cervical HSIL to prevent cervical cancer, ablation of
anal HSIL may be effective in reducing the incidence of anal cancer.
3.7 SCREENING FOR ASIL
The institution of routine cervical cytology screening has contributed to the dramatic
decrease in the incidence of cervical cancer in the US.(211) The similar etiology and
histopathology of ASIL and CSIL has led investigators to translate the screening
methods used for the cervix to the anal canal, and to assess the technique of anal
cytology as a screening tool. Palefsky et al reported the sensitivity of anal cytology to
detect biopsy-proven anal dysplasia in HIV-positive men to be equal to that of
cervical cytology for the detection of cervical dysplasia when ASCUS was included in
the 'abnormal' category.(196) The sensitivity of this technique was lower in HIV-
negative men (50 percent) compared with HIV-positive men (81 percent), possibly
reflecting the presence of less widespread disease than is seen in an HIV-positive
population^ 196) As in the cervix, histopathology is considered necessary to grade the
severity of the disease as this cannot be accurately established by cytology
alone.(196) Collection of specimens for histopathologic evaluation is accomplished
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through visualisation and sampling of lesions identified by high-resolution anoscopy
(HRA).
3.7.1 CERVICAL VERSUS ANAL CYTOLOGY SCREENING
There are important technical considerations that differ between anal and cervical
cytology. Cervical cytology using a spatula and endocervical brush can typically yield
more than 50,000 epithelial cells per sample (212) which is significantly more than
most anal samples.(213) This, combined with possible cellular artifact caused by air
drying prior to ethanol fixation are two of the main causes of anal samples being
inadequate for cytopathological interpretation.^ 13) Other factors that may increase
the difficulty of interpretation of anal cytology samples are faecal and bacterial
contamination^ 189)
There are two available methods for anal cytology sample collection. The first and
most established is that of alcohol fixation of the cytology sample and subsequent
staining by the Papanicolaou method.(196) The other more recent method uses cells
that are collected then released into a methanol containing fixative before being
processed and subsequently stained by the Papaniculaou method.(214) This liquid
cytology method has been shown to have greater diagnostic accuracy when used for
cervical cytology.(215) (212) (216) While liquid cytology reduces faecal and bacterial
contamination for anal samples, a comparative study showed no difference between
the two collection methods.(189) However, a potential research advantage of liquid
cytology is that the fluid may also be tested for HPV typing.(176)
As with cervical cytology, the experience of the clinician taking an adequate cytology
specimen and the pathologist's experience in interpreting the anal specimen is
essential to the diagnostic process.(217) Inter-observer differences in diagnosis also
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may occur with interpretation of histopathology samples. In one study by Colquhoun
et al there was only moderate agreement between three pathologists assessing 190
anal biopsy specimens.(218)
3.7.2 ASIL SCREENING GUIDELINES
Chin-Hong and Northfelt have published guidelines on screening for individuals at
risk of developing anal cancer.(l 14) (219) (See Table 3.2)
Table 3.2 High-risk groups for anal cancer
HIV negative men with a history of receptive anal intercourse (RAI)
HIV-positive men regardless of CD4 level
HIV-negative women with high-grade CSIL or high-grade vulval SIL
HIV-positive women regardless ofCD4 level
Solid organ transplant recipients
Individuals with perianal condylomata accuminata
The goal of screening for ASIL is ultimately to identify anal HSIL. An anal screening
program based on the cervical screening paradigm would rely on exfoliative cytology
as the initial screening test. The goal of screening at this stage would be to identify
individuals who need to undergo HRA. In this respect, anal cytology should be
classified as "normal" versus "abnormal", i.e. anyone with ASCUS, ASCH, LSIL or
HSIL should undergo anoscopy. It would also be inappropriate to depend on anal
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cytology grade as this is poorly predictive of anal histopathological diagnosis on
biopsy following HRA.(220)
3.7.3 COST EFFECTIVENESS OF SCREENING FOR ASIL
There have been two key papers published by the same group examining the cost-
effectiveness (CE) of anal cytology in screening HIV-positive and HIV-negative
MSM.
Goldie et al reported the CE of performing anal cytology screening in a male
homosexual and bisexual HIV-positive population. A state-transition Markov model
was developed to calculate lifetime costs, life expectancy, and quality adjusted life
expectancy for no screening versus several screening strategies. Strategic variables
included screening interval, stage of HIV infection, and progression or regression of
anal lesions. The results of this study showed that screening every 2 years beginning
in the early stages of HIV infection was associated with an incremental cost-
effectiveness ratio of approximately $13,000 per quality-adjusted life year (QALY)
saved. This compares well with the accepted use of trimethoprim-sulphamethoxazole
for Pneumocystis carinii pneumonia prophylaxis in HIV disease ($13,000/QALY) and
is considerably less expensive than triennial cervical cancer screening in HIV-
negative women ($180,000/QALY). Annual anal cytology screening was also cost-
effective and was recommended by the authors as the screening interval of choice for
HIV-positive MSM.(221)
A subsequent study by the same group again using a state-transition Markov model
showed that screening HIV-negative homosexual and bisexual men with anal
cytology every 2-3 years provided life expectancy benefits comparable with accepted
preventative health measures, and would be cost-effective.(222)
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3.7.4 SCREENING FOR ASIL IN PRIMARY CARE.
Current clinical practice at UCSF is shown in Figure 3.5.
Figure 3.5: Current suggested anal cytology screening practice
Adapted from Chin-Hong (114)
For negative cytology reports, as with cervical cytology, the sample should be
repeated due to the possibility of false-negative reporting.(196) The cytology sample
may be repeated on an annual or biannual basis depending on HIV status.
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3.8 OBTAINING AN ANAL CYTOLOGY SAMPLE
To obtain a sample for anal cytology, subjects should be advised to refrain from
placing anything in the anal canal for 24 hours before the anal cytology swab is taken.
This includes using an enema or douche, or having receptive anal sex. These
measures aim to increase the yield of exfoliated anal canal cells when the cytology
swab is taken. With the patient in the left lateral position, a tap water or 0.9% saline-
moistened Dacron™ swab (Baxter Healthcare Corporation, McGraw Park, Illinois,
USA) is gently inserted at least 2 inches beyond the anal margin, so as to be proximal
to the anorectal transition zone. Cotton swabs should not be used as it is more difficult
to release anal cells onto the glass slide although nylon brush endocervical swabs
have been used in some centres.(223) With firm lateral pressure and a spiral motion to
sample the entire anal circumference, the swab is withdrawn over 10 seconds. The
swab can either be smeared onto a glass slide and the slide immersed immediately in
ethanol fixative, or agitated vigorously in ThinPrep™ liquid collection media to
disgorge cellular material.(189) Regardless of collection method, anal cytology
grading follows the standard 2001 Bethesda system as above.(224)
3.9 HIGH-RESOLUTION ANOSCOPY EVALUATION OF THE
ANAL CANAL
Following a diagnosis of abnormal anal cytology, it is recommended that patients
undergo high-resolution anoscopy (HRA). The purpose of HRA is to identify the
source of the dysplastic cells and perform a biopsy to establish the histological grade
of the lesion(s).
With the patient in the left lateral position a visual inspection of the peri-anal area is
made, followed by a digital examination to define masses or tender areas. Lesions that
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are firm, immobile, and painful should raise suspicions of invasive cancer. A clear
plastic anoscope is lubricated and inserted into the anal canal. For patients with anal
discomfort the anoscope may be lubricated with xylocaine jelly. A gauze swab soaked
in 3 percent acetic acid and wrapped around a Q-tip is inserted through the anoscope.
Following this, the anoscope is withdrawn with the swab left inside in direct contact
with the anal mucosa for 1 minute before removal.(196) Abnormal squamous
epithelium will turn white in the presence of the acetic acid (hence the term 'aceto-
whitening'), although the change is transient requiring re-application of acetic acid.
Lugol's iodine solution may also be used to confirm suspicion of high-grade
dysplasia. Typically F1SIL does not take up the iodine stain and remains yellow, while
normal tissue turns a deep brown colour that relates to its glycogen content. This test
has not been verified for the anal canal but is used in assessing dysplasia in both the
cervix and oesophagus.(225) (226) (227) The colposcopic features of a high-grade
lesion in the anus correspond to those of high-grade lesions in the cervix, and thus the
established colposcopic criteria for identifying cervical HSIL may serve as a guide for
the clinician performing anal biopsies.(160) (See Figure 3.6) Intra-anal biopsies may
be performed with standard endoscopy forceps with a 2.3 mm non-serrated cup
without local anesthetic, the patient usually only being aware of a tugging sensation.
Flemostasis can then be achieved with ferrous subsulphate (Monsell's) solution or
local pressure applied with a cotton-tipped swab under direct visualisation. Following
any anal biopsy, the individual should be counseled with regard to the rare
complications of bleeding and infection. Subjects with a low granulocyte or platelet
count should not undergo anal biopsy, and patients taking acetylsalicylic acid (ASA)
or other platelet inhibitors should defer the biopsy until they have stopped therapy
long enough for the anti-platelet activity to abate. Standard antibiotic prophylaxis
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guidelines should be followed in subjects with prosthetic or abnormal heart valves.
Lesions overlying hemorrhoids are prone to significant bleeding and it is more
appropriate that anal surgeons, who can control haemostasis more aggressively,
perform biopsies of those lesion(s) in patients who cannot discontinue
anticoagulants.(206)
The external anal margin and peri-anal skin should also be carefully examined for
abnormality after the application of 3 percent acetic acid, however abnormal changes
in this site are less well characterised. When external biopsies are indicated, local
anesthesia with lignocaine is required before biopsy with baby Tischler forceps. The
subject should be counseled regarding local hygiene measures and the use of simple
analgesia if required.
Figure 3.6 High-resolution anoscopic appearances of normal anorectal
transition zone, condylomata/LSIL, HSIL, and squamous anal cancer




Images courtesy of the UCSF Anal Neoplasia Study
51
3.10 EVALUATION OF HRA
There are few published reports of the visual correlation of anal epithelium and
pathological grade. The first was published by Scholefield et al and showed a high
correlation for normal and high-grade changes, but was less accurate for low-grade
dysplasia and non-condylomatous HPV infection.(228) More recently Matthews et al
showed a sensitivity of 59% and specificity of 75% between visual criteria and anal
histopathological diagnoses using the categories of invasive carcinoma, HSIL, LSIL,
and other, with visual assessment of HSIL showing a positive predictive value of
74.7%.(229)
3.11 RISK FACTORS FOR ASIL
Risk factors for the development ofASIL in men are summarised in Table 3.3.
Table 3.3: Risk-factors for ASIL in men
HPV infection (197) (91) (206) (230)
HIV infection especially with a lower CD4 count (198) (230) (62) (91) (86) (109)
(58,59, 231)
Receptive anal intercourse (106)
History of rectal discharge (91)
History of genital warts (91)
History of injection drug use (230)
Current cigarette smoking (230) (109)
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The level of HPV in the tissue may also be important in the development of ASIL
(198) as a high level of HPV was significantly associated with ASIL in both HIV-
positive and HIV-negative men in one large study.(91) Additional risk factors for
ASIL in women include concomitant high-grade cervical or vulval lesions,(232) (209)
cervical cancer (233) (234), or vulval cancer (235). Iatrogenic immunosuppression
such as that required for solid organ transplantation has also been reported to increase
the prevalence of HPV-related anal disease.(235)
3.12 NATURAL HISTORY OF ASIL
Studies are ongoing to characterise the natural history of HPV related ASIL in both
HIV-negative and HIV-positive populations. To date, risk-factors for progression
from normal anal epithelium or low-grade dysplasia to high-grade dysplasia include
immunosuppression by HIV,(206) (102) detection of multiple HPV types,(206)
history of genital warts,(91) and history of rectal discharge.(91) Furthermore, several
authors have reported other factors that may indicate or increase the risk of
progression to cancer in susceptible individuals. Ogunbiyi at al suggested that
expression of the oncogene c-myc, and subsequent detection of c-myc protein may be
linked to progression of high-grade dysplasia as may the increasing presence of
nucleolar organiser region associated proteins.(236, 237) Xi et al reported that
infection with non-prototype (NPL) HPV 16 was a risk factor for the development of
carcinoma in situ (CIS) in MSM compared with prototype like (PL) HPV 16.(238)
This finding was supported by Da Costa at al who reported an increased risk of anal
HSIL with NPL HPV 16 after controlling for HIV infection.(53) Haga et al examined
the genetic changes in increasingly dysplastic anal epithelium by comparative
genomic hybridisation in HIV-positive and HIV-negative MSM. There was a
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significantly increased genetic change with increasing grades of anal dysplasia, most
commonly mapped to chromosome arm 3q. This finding is analogous to genetic
changes demonstrated in cervical cancers, suggesting a common pathway for the two
HPV associated squamous neoplasias.(181) (239)
Compared to the cervical literature, anal dysplasia as a clinical entity has only
relatively recently been the focus of research attention and there is only limited
information from the small number of natural history studies performed.
Consequently there has been little direct evidence documenting progression of high-
grade anal dysplasia to anal cancer that would help support the implementation of an
anal cytology screening program. However, a recent prospective observational cohort
study of HIV-positive MSM with biopsy proven high-grade anal dysplasia reported
that anal cancer developed in 3 of 40 men during follow-up.(208). In another cohort
study of individuals with high-grade anal dysplasia and median follow-up of 63
months, 3 of 6 individuals with non-HIV induced immunosuppression developed anal
cancer. There was no progression in the 29 immunocompetent individuals, 28 of
whom had received surgical treatment for high-grade dysplasia.(209)
3.13 DEMOGRAPHICS OF ASIL
No comprehensive information is currently available on the demographics ofASIL in
the general population, as centres investigating this condition have focused primarily
on populations ofMSM. The MSM studied tend to be in men between the ages of 30
and 50, are living in American cities, and have a high prevalence ofHIV infection.
The available literature reports that abnormal anal cytology is present more frequently
in HIV-positive MSM. Rates of any anal cytological abnormality range from 28 to 56
percent in HIV-positive MSM and 4.7 to 8 percent in HIV-negative MSM.(91) (109)
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(240) (241) (242) (230) In addition, natural history studies confirm an increased
prevalence of ASIL over time in HIV-positive MSM. In one study of MSM, 27
percent of subjects were diagnosed with ASIL at baseline and this figure increased to
65 percent after an average of 17 months.(242)
A recent study in HIV-negative North American MSM reported that the prevalence of
anal cytological abnormalities was constant in this population over a wide age
range.(243) Specifically the prevalence of LSIL was 15% and associated with reports
of more than five male receptive anal sex partners, any use of alkyl nitrites in the
previous 6 months, use of injection drugs two or more times per month during the
previous 6 months, older age at first receptive anal intercourse, and infection with a
greater number of HPV types.(243) The prevalence of HSIL was 5 % in this
population and associated with any HPV infection and infection with multiple HPV
types. (243)
ASIL is also more prevalent in HIV-positive women with prevalence ranging from 15
to 42 percent compared with HIV-negative women who have a reported prevalence of
1.4 to 12 percent.(62) (198) (244) (245) (116)
3.14 CONDYLOMATOUS LESIONS AND HIV INFECTION
There are differences in the clinical presentation of ASIL in an HIV-positive
population, compared to an HIV-negative population. Exophytic genital warts are
usually associated with infection with low-risk HPV (types 6 and 11) and a LSIL
cellular change. However, in an HIV positive population, high-risk HPV and
associated high-grade dysplastic change has been isolated from exophytic lesions
more frequently than in HIV-negative controls. This suggests that biopsy to define
histological grade of dysplasia should be considered in an HIV-positive population
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before standard destructive therapy of these lesions to exclude early HSIL or early
SCC.(246) (247) Additionally, at HRA the appearance of internal anal lesions (flat or
exophytic) have not been shown to correlate with detected HPV risk-type.(248)
3.14.1 HIV/HPV INTERACTIONS
As previously discussed, HIV/HPV interactions in the context of impaired cell
mediated immunity (CMI), altered mucosal cytokine patterns and the interaction of
HIV tat protein in increasing E6 and E7 HPV expression may explain the increased
incidence and progression of LSIL to HSIL in HIV-positive MSM.(115) There is
inadequate available data addressing this issue in women although it may be
reasonable to assume a similar mechanism.
3.14.2 ANAL DYSPLASIA AND HIGHLY ACTIVE ANTIRETROVIRAL
THERAPY
Recent advances in the management of patients with HIV infection, including the use
of potent combination antiretroviral therapy have been associated with decreased
mortality and morbidity in these individuals. As a consequence, HIV-positive
individuals are exposed for a greater period of time to high-risk HPV infection,(196)
(88) (110) high level HPV infection,(249) infection with multiple HPV types,(241)
and are experiencing a high prevalence of HSIL.(230) (250) Highly active
antiretroviral therapy (HAART) is associated with improvements in functional cell
mediated immunity as measured by increasing CD4 lymphocyte counts, improved
response to recall antigens, and decreased incidence of opportunistic infections. These
immunological changes may be postulated to have a beneficial effect on HPV
infection and so reduce the prevalence of anal dysplasia. The effect of HAART on
anal dysplasia has recently been investigated in a cohort of HIV-positive MSM. Anal
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cytology, anal biopsy, HPV typing and level of infection were collected at least six
months before, and at least six months after starting HAART. This study showed that
HPV isolation, level of HPV, and grade of ASIL was similar between the two
investigational points.(251)
Furthermore HAART therapy was associated with the presence of anal dysplasia in
multivariate analysis of a cohort of HIV-positive MSM in San Francisco, in addition
to detection of multiple HPV types.(252) Further investigation of variables such as
HAART efficacy, baseline CD4 counts and extended length of HAART treatment
(including HAART failure) are now necessary to more fully define the response of
anal HPV and abnormal anal cytology to combination antiretroviral therapy.
3.15 TREATMENT OF ASIL
Therapy for anal dysplasia is usually only considered for those individuals with AIN
2/3 since these lesions are thought more likely to progress to anal SCC. However,
many patients opt for therapy for a variety of other reasons including symptoms
(burning, itching, and bleeding) and psychological discomfort. Untreated patients with
LSIL, especially if HIV-positive, are followed approximately every six months
because of the high rate of progression to HSIL.(206) However, individuals with AIN
1 who desire therapy for treatment of symptoms or psychological discomfort should
also be considered for therapy. (See Chapter 2)
Experience is limited with current modalities of treatment. To date there has only
been one formal efficacy trial reported in the literature containing efficacy data for
treatment ofAIN 2/3 (see below).
57
3.15.1 TREATMENT OF LOW-GRADE ANAL DYSPLASIA/
CONDYLOMATA
This topic is covered in Chapter 2. It is noteworthy that, in the context of HIV
infection, there is an increased risk of clinical recurrence of condylomata when
compared to an HIV-negative population.(88)
3.15.2 TREATMENT OF HIGH-GRADE ANAL DYSPLASIA
3.15.2.1 COLD SCALPEL EXCISION/ELECTROFULGURATION
Cold-scalpel excision of dysplastic tissue under anesthesia has, until recently, been
the mainstay of therapy. This method is best utilized when there is discrete, limited,
non-circumferential disease. Extensive disease may require multiple staged operations
to clear the lesions and prevent anal stenosis. Although usual anaesthetic and surgical
complications such as haemorrhage and infection may occur, they are rare with this
procedure. Post-operative pain however has proved difficult to control and may be
significant for up to 2 weeks post-surgery, particularly with bowel movements. In
addition to cold-scalpel resection, electrofulguration may be carried out concomitantly
with similar side effects and complications.
Until recently there has been little information on the follow-up and efficacy of these
treatments for anal disease. A group working at UCSF published data on the efficacy
of excision/cauterization of anal HSIL identified by HRA in 37 HIV-positive and 8
HIV-negative MSM. Results showed that although this procedure was safe, there was
a persistence/recurrence in 79 percent of HIV-positive patients (23/29) treated with a
mean follow-up of 28.6 +/- 12.9 months. However, no HIV-negative patients (0/8)
developed recurrent HSIL during follow-up of 32.3 +/- 20.6 months. The authors
suggested multiple staged procedures may be appropriate for HIV-positive
patients.(253)
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3.15.2.2 LASER ABLATION/PHOTODYNAMIC THERAPY
Laser ablation of dysplastic tissue may be undertaken in the operating room, but
experience with this relatively new technique for this indication is limited, as is the
case with photodynamic therapy.(254)
3.15.2.3 INFRARED COAGULATION
The mechanism of action of the IRC is described in Chapter 2. The IRC (See Figure
3.7) has recently been used as an alternative to surgical excision in individuals with
HSIL. A retrospective review was undertaken in 68 HIV-positive MSM with biopsy
proven high-grade anal dysplasia that underwent IRC treatment. 165 lesions in 68
patients were treated and at follow-up only 46 lesions persisted. Subsequently 44
patients developed new or persistent high-grade lesions within a median time of 217
days. When these patients were re-treated the incidence of new or persistent high-
grade lesions fell from 58% to 40% respectively. No serious adverse events were
reported following the procedure and no patients developed anal cancer during
follow-up.(136)
Figure 3.7 The Infrared coagulator
IRC2100TM, Redfield Corp., Rochelle Park, NJ (with permission)
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3.16 EXTERNAL ASIL
Perianal HSIL has proven malignant potential.(255) In 1912 Bowen was the first to
describe the perianal lesions with intraepithelial keratinocytic atypia that bear his
name.(256) The lesions typically present as chronic, red or hyperpigmented, well-
defined scaly plaques. Histological examination shows AIN 3 but no invasion of the
dermis. The exact lifetime risk of progression from Bowen's disease to invasive SCC
is unknown but may be up to 6%.(257)
3.16.1 TREATMENT OF EXTERNAL ASIL
Treatment modalities for Bowen's disease include electrodessication and curettage
and excisional surgery with subsequent follow-up.(258) (259) More recently there
have been case reports of Bowen's disease responding to topical Imiquimod and 5-
fluorouracil.(260) (261) Other treatment modalities include the use of used include
cryotherapy,(262) laser ablation,(263) and photodynamic therapy.(264)
3.17 SUMMARY
The anal and cervical canal share many common features. They are both derived from
embryologically similar tissue, have a squamocolumnar epithelial transition zone, and
support anogenital HPV infection that may cause dysplastic change and lead to
squamous malignancy. For more than 50 years screening cervical cytology has been
performed in developed countries to detect cytological abnormalities that may
progress to cervical cancer. More recently cytological testing has been validated for
the anal canal to detect anal squamous intraepithelial lesions. Anal cytological
abnormalities may be defined histopathologically following high-resolution anoscopy
and anal biopsy, analogous to cervical colposcopy, with subsequent treatment of high-
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grade dysplastic lesions. It is yet unproven, although biologically plausible, that high-
grade anal lesions progress to anal cancer and that by treating high-grade lesions this
progression may be abrogated.
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CHAPTER 4
ANAL SQUAMOUS CELL CANCER DEVELOPING IN




Anal and cervical squamous intraepithelial lesions and cancer share many common
features as described in Chapter 3. In this chapter anal squamous cell cancer will be
considered in the context of anal dysplasia progression, and the demographics of
individuals who progressed from documented high-grade anal dysplasia to anal
cancer.
4.2 THE ANAL AND CERVICAL CANAL
Detection of CSIL by cervical cytology screening programs, followed by ablative
treatment of the lesions is considered to have contributed substantially to the decline
in incidence of cervical cancer in the United States from 35 per 100 000 to 8 per 100
000 since the introduction of this program over 50 years ago.(211) However,
concurrent with this drop in the incidence of cervical cancer, there has been a rise in
recent years in the incidence of anal cancer in both men and women.(265) (58) (12)
4.3 ANAL SQUAMOUS CELL CANCER (SCC)
4.3.1 ANAL SCC INCIDENCE
In the United States, the current incidence of anal squamous cell cancer (SCC) in the
general population is approximately 1.4 per 100,000.(266) However, there is evidence
of increased risk of anal cancer certain groups, specifically MSM. (267) (268) (269)
(270) (271) Considering a population of never married men, a surrogate for MSM,
prior to the clinical manifestations of the HIV epidemic, the rate of anal cancer was
estimated to be as high as 35 per 100,000.(272) Moreover, recent data indicates that
the incidence of anal cancer in HIV-positive MSM is approximately double that of
HIV-negative MSM, with Frisch et al reporting that the relative risk of anal cancer
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among HIV-positive men was 37 times higher than the general population.(273) (274,
275) (276) (277, 278) In San Francisco County, the incidence of anal cancer among
all men aged 40-64 years more than quadrupled from a pre-HIV epidemic period
(1973-1978) to during the HIV epidemic period (1996-1999).(279) The incidence of
anal cancer in both HIV-negative and HIV-positive MSM is therefore as high, or
higher than the current incidence of cervical cancer in the general female population
and is similar to the incidence of cervical cancer prior to the introduction of cervical
cytology screening.(115) Other groups at increased risk of anal cancer include women
with concurrent high-grade cervical disease or cervical cancer,(232) (228) high-grade
vulval dysplasia or vulval cancer,(280) and anal warts.(193) Recently HIV-positive
women were shown to be at increased risk of anal cancer compared to women in the
general population with a relative risk of 6.8.(198, 273) (62) The rate of anal cancer is
also increasing in the context of iatrogenic immunosuppression such as occurs with
solid organ transplantation (89, 281) and with additional significant morbidity from
other non-anogenital cutaneous and mucosal HPVs.(282)
4.3.2 ANAL SCC TUMOUR SITE
In 1987 the World Health Organization defined anal canal tumours as arising from the
area between the dentate line and the anal verge, with anal margin tumours defined as
arising distal to the anal verge.(283) There are however various definitions of the anal
canal:
• Classic anatomic definition of anal canal: between proximal and distal
margins of internal sphincter muscle, which includes part of rectum.
• American Joint Committee on Cancer definition of anal canal: begins
where the rectum enters the puborectalis sling at the apex of the anal sphincter
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complex (palpable as anorectal ring, but difficult for pathologists to identify),
and ends at the squamous mucocutaneous junction with perianal skin; includes
1-2 cm of rectal-type glandular mucosa and possibly transitional mucosa at the
dentate line.
• Histologic definition of anal canal: anal transitional zone and squamous
epithelium to the perianal skin.
4.3.3 ANAL SCC EPIDEMIOLOGY
Anal cancer is a rare tumour in the general population, accounting for 1-2% of all
large gastrointestinal malignancies in the US, and accounts for just 5% of anorectal
malignancies. (186) (284) (285) (286) The various histological types include
squamous cell (80% of tumours) and its variants (cloacogenic, basaloid and
transitional tumours) in addition to adenocarcinoma (5-10%),(287) melanoma,
leiomyosarcoma and carcinoid tumours.(288)
The increasing incidence of SCC (265) (270) has been related to the HIV pandemic
(265) and changing patterns of sexual behaviour, particularly the trend for increasing
numbers of sexual partners.(270)
4.3.4 ANAL SCC DEMOGRAPHICS
The Surveillance, Epidemiology, and End Results (SEER) program, a system of
population-based US tumour registries reported an increase in incidence of
predominantly squamous cell anal cancer in the general US population between the
years 1973-1979 and 1994-2000.(266) While there was previously a female
predominance in anal cancer diagnoses there is now sex equality with the largest
notable increase in incidence in Black males. In numerical terms, individuals with an
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anal cancer diagnosis are most commonly Caucasian and present in the sixth and
seventh decades of life.(286) (289) (290) (291) (292) (266)
4.3.5 ANAL SCC RISK-FACTORS
Published risk factors for anal cancer include immunosuppression (HIV, solid organ
transplant recipients, systemic corticosteroids), high-risk HPV infection, higher
numbers of sexual partners, cervical cancer in women, chronic anal fistula or fissure,
previous radiation, Crohn's disease, and cigarette smoking.(288) (186, 193) (209)
4.3.6 ANAL SCC CLINICAL PRESENTATION
Anal cancer may present with a palpable mass (100%), bleeding (78%), pain (70%),
change in bowel habits (29%), discharge (20%), and pruritus ani (20%).(288) (293)
However, no symptom is pathognomonic. Other anal conditions such as hemorrhoids,
fissures, leucoplakia and fistulas may be present concomitantly and share similar
symptomatology.
At presentation the majority of tumours have infiltrated through sphincteric muscle
into pelvic soft tissue,(294) (295) and 10-50% of patients have regional lymph node
spread,(294) (296) (297) (285) while 5-10% of patients have distant metastases.(298)
4.3.7 ANAL SCC TREATMENT
Previously, anal cancer was treated with radical surgery, often requiring an abdomino-
peroneal resection necessitating the fashioning of a colostomy. More recently, similar
treatment efficacy has been achieved by using combined chemotherapy and
radiotherapy, with the additional benefit of preserving anal sphincter function (85%
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versus 9%).(299) (300) (301) (302) (303) Although therapeutic regimes vary, the
elements are similar and include an infusion of 5-fluorouracil, a bolus of mitomycin
C, followed by megavoltage external beam radiotherapy.(288)
The mitomycin C component has been controversial due to additional hematological
toxicity and questionable efficacy particularly with larger tumours, but shows
improved responses in combination with radiotherapy and chemotherapy in smaller
tumours.(304) More recently cis-platinum is being used instead of mitomycin C with
similar efficacy and reduced toxicity.(305)
4.3.8 ANAL SCC STAGING
Anal cancer is staged by the tumour, node, and metastasis classification. (288) (See
Table 4.1)
4.3.9 ANAL SCC PROGNOSIS
The prognosis of anal cancer with treatment is dependent upon the depth of invasion
and the extent of spread of the tumour at diagnosis.(306) (290) (307) (308) (309)
(310) Five year survival rates vary from 91% (Tl), 80% (T2), 16% (T3) and 0%
(T4).(307) Additionally, recurrence rates when initial tumour has infiltrated muscle or
pelvic soft tissue is 60%.(306) There is no prognostic significance in the following
pathological and molecular factors: keratinization, HPV presence or absence, mitotic
rate, invasive margin, and cell pleomorphism.(311) (310) (312) HIV infection does
not appear to have a negative impact on prognosis.(313)
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Table 4.1: Tumour, node, metastasis staging of anal cancer
Abbreviation Definition
Primary tumour
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ (=AIN-3)
T1 Tumour 2 cm or less in the greatest dimension
T2 Tumour 2-5 cm in the greatest dimension
T3 Tumour exceeding 5 cm in the greatest dimension
T4 Tumour of any size invading adjacent organ
Regional Lymph Nodes
NX Regional Lymph nodes cannot be assessed
NO No regional lymph node metastases
N1 Metastases in the perirectal lymph node(s)
N2 Metastases in unilateral internal iliac and/or inguinal lymph
node(s)
N3 Metastases in perirectal and inguinal lymph nodes and/or
bilateral internal iliac lymph nodes and/or inguinal lymph
nodes.
Distant Metastases
MX Presence of distant metastases cannot be assessed
MO No distant metastases
Ml Distant metastases
T: tumour, N: node, M: metastasis
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4.4 STUDY AIM
The aim of this retrospective study was to investigate the demographics of individuals
diagnosed with anal cancer in the San Francisco Bay Area that had prior cytological
or pathological evidence of high-grade anal dysplasia.
4.5 METHODS
This study was performed with the approval of the University of California San
Francisco (UCSF) Committee on Fluman Research (CF1R). A chart review was
undertaken of all cases of anal SCC diagnosed or treated at UCSF that had prior anal
dysplasia documented by either cytology or biopsy. Subjects diagnosed with anal
cancer who had no prior pathological evidence of anal dysplasia were excluded from
the analysis. Referral sources included the UCSF Anal Neoplasia Study,(206) the
UCSF Dysplasia Clinic, and clinicians both at UCSF and elsewhere within the San
Francisco Bay Area. Charts were accessed at UCSF central records and also at
referring locations. All cytology and tissue specimens in this study were retrieved and
reviewed in the UCSF Department ofPathology (TD).
4.6 RESULTS
Eight subjects were found who met the criteria for inclusion in this case series.
Subject 1: Anal biopsies were performed consequent to a perianal abscess in January
1996 and showed internal AIN 3. In May 1996 anal fissures were biopsied and
showed AIN 3 at both perianal and internal anal sites. Anal cytology was not
obtained. In December 1996 an anal canal mass was biopsied and confirmed as
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invasive anal cancer with AIN 3 reported at other internal anal and perianal biopsy
sites. (See Table 4.2)





AIN 3 SCC + AIN 3
INTERNAL ANAL
BIOPSY
AIN 3 AIN 3 AIN 3
LSIL: low grade squamous intraepithelial lesion, HS1L: high-grade squamous intraepithelial lesion,
AIN-1: anal intraepithelial neoplasia grade 1 (equal to low-grade dysplasia), AIN 2 and 3: anal
squamous intraepithelial neoplasia grade 2 and 3 (equal to high-grade dysplasia), SCC: squamous cell
cancer.
Subject 2: Anal biopsy in March 1996 showed internal AIN 2 and 3 and external
circumferential AIN 3. Anal cytology was not obtained. He was followed without
treatment. Further internal anal biopsies in January 1997 showed internal AIN 2/3 at
three locations. In March 1999 he developed a gastric B cell lymphoma that was
treated by gastrectomy in May 1999, delaying further evaluation of his anal disease.
In June 1999 anal cytology showed HSIL, an internal anal biopsy showed high-grade
dysplasia and an external biopsy showed superficially invasive SCC. (See Table 4.3)
Table 4.3: Subject 2
3/96 1/97 6/99
ANAL CYTOLOGY HSIL
EXTERNAL ANAL BIOPSY AIN 3 SCC
INTERNAL ANAL BIOPSY AIN 2 and 3 AIN 2/3 AIN 2/3
Subject 3: Perianal AIN 3 was diagnosed by biopsy but untreated in March 1996.
Anal cytology showed HSIL in March 1997. In August 1997 an examination under
anesthesia with biopsies confirmed internal anal SCC and AIN 2/3. (See Table 4.4)
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Table 4.4: Subject 3
3/96 3/97 8/97
ANAL CYTOLOGY HSIL
EXTERNAL ANAL BIOPSY AIN 3
INTERNAL ANAL BIOPSY SCC + AIN 2/3
Subject 4: Anal cytology showed HSIL in May 1996. The subject reported a new
internal anal nodule in August 1996, when cytology showed HSIL and nodule biopsy
showed AIN 2/3. He was referred for a surgical opinion where biopsy of an ulcerating
internal anal mass in November 1996 confirmed moderately differentiated SCC. (See
Table 4.5)
Table 4.5: Subject 4
5/96 8/96 11/96
ANAL CYTOLOGY HSIL HSIL
EXTERNAL ANAL BIOPSY
INTERNAL ANAL BIOPSY AIN 2/3 SCC
Subject 5: Anal cytology in August 1999 showed HSIL with internal biopsies
showing AIN 1 (indicating the biopsy missed the high-grade lesion). He was seen in
December 1999 with a superficial anal ulcer when cytology again showed HSIL and
an internal anal biopsy confirmed SCC. (See Table 4.6)
Table 4.6: Subject 5
8/99 12/99
ANAL CYTOLOGY HSIL HSIL
EXTERNAL BIOPSY
INTERNAL BIOPSY AIN 1 SCC
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Subject 6: Anal cytology taken in December 1997 showed LSIL. Subsequent
cytology showed: ASCUS in May 1998; LSIL in August 1998; HSIL in December
1998; and HSIL in June 1999 when the first internal anal biopsy was taken and
showed AIN 2. He presented in April 2000 with a two-month history of bleeding per
rectum, tenderness and a protruding mass. SCC was diagnosed by cytology and
internal anal biopsy. (See Table 4.7)
Table 4.7: Subject 6
12/ 97 5/ 98 8/98 12/ 98 6/ 99 4/00
ANAL CYTOLOGY LSIL ASCUS LSIL HSIL HSIL SCC
EXTERNAL BIOPSY
INTERNAL BIOPSY AIN 2 SCC
Subject 7: Circumferential Bowen's disease was diagnosed in March 1994 and
treated with 5-fluorouracil cream. He subsequently had circumferential Bowen's
disease diagnosed on biopsy in 1995 and 1997 and was treated with tri-weekly
Imiquimod from February 1999 to August 1999. In March 1999 anal cytology showed
LSIL. In May 2000 an internal anal biopsy showed AIN 2, and in February 2000
cytology showed HSIL. He was seen with anal pain in May 2000 and surgery was
recommended. Surgical biopsies taken in June 2000 confirmed invasive well-
differentiated SCC at 3 sites in the anal canal. (See Table 4.8)
Table 4.8: Subject 7
3/94 95 97 3/ 99 5/ 00 2/ 00 6/ 00
ANAL CYTOLOGY LSIL HSIL
EXTERNAL BIOPSY AIN 3 AIN 3 AIN 3
INTERNAL BIOPSY AIN 2 SCC
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Subject 8: Anal cytology taken in February 1997 showed HSIL, confirmed by
biopsies in April 1997, which showed extensive internal AIN 2/3 and external anal
AIN 2/3 with a Bowenoid appearance. At that time she underwent a simple
vulvectomy for vulval intraepithelial neoplasia (VIN), followed by laser treatment to
the vulva/perineum and perianal area in July 1997. Further anal cytology showed
ASCUS in December 1997 and squamous metaplasia in July 1998. AIN 2/3 was
reported on internal anal biopsy in August 1998 and perianal superficially invasive
SCC and AIN 2/3 with introital VIN 1 in March 1999. (See Table 4.9)
Table 4.9: Subject 8
2/ 97 4/97 12/97 7/98 8/98 3/ 99
ANAL CYTOLOGY HSIL ASCUS SQ MET
EXTERNAL BIOPSY AIN 2/3 SCC
INTERNAL BIOPSY AIN 2/3 AIN 2/3
Sq met.: Squamous metaplasia. (Laser treatment to perineum/perianal was performed at the time of a
simple vulvectomy for VIN in July 1997)
Seven of the eight subjects (83%) were male. The mean age of the subjects at the time
of anal cancer diagnosis was 45.1 years with a range of 39 to 54 years. Accurate CD4
counts and HIV viral loads at time of diagnosis were not available. The mean time
from first diagnosis of high-grade dysplasia by anal cytology or biopsy to the
diagnosis of anal cancer was 14.4 months, with a range of 3 to 23 months. Five of
eight subjects (63%) had a history of anal warts, three (37.5%) had history of
recreational drug use, two (25%) had not used recreational drugs, and recreational
drug history was unknown for three (37.5%) subjects. Three (37.5%) subjects were
current smokers, two (25%) were former smokers, one (12.5%) subject had no history
of smoking and the smoking history was unknown for two (25%) subjects. All male
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subjects were MSM, had been HIV-positive for over 10 years and were taking highly
active antiretroviral therapy (HAART) at the time of diagnosis. The one female
subject was heterosexual and HIV-negative. (See Table 4.10)













1 POS 0 NO PREVIOUS YES NO 44y 11 months
2 POS 119 YES PREVIOUS YES YES 54y 37 months
3 POS 176 YES CURRENT YES YES 39y 5 months
4 POS 143 UNK CURRENT UNK YES 44y 6 months
5 POS 241 YES NO NO NO 40y 3 months
6 POS UNK UNK UNK UNK YES 54Y 17 months
7 POS 130 UNK UNK UNK YES 42y 13 months
8 NEG NA NO CURRENT NO NO 44y 23 months
Pos: positive, Neg: negative, NA: not applicable, UNK: unknown, Hx: history, Diag: diagnosis, Rec:
recreational, STI: sexually transmitted infection
4.7 DISCUSSION
4.7.1 PROGRESSION OF HIGH-GRADE ANAL DYSPLASIA TO
ANAL SCC
These cases demonstrate that anal SCC develops in the presence of high-grade
squamous intraepithelial lesions diagnosed by either anal cytology or anal biopsy, and
is consistent with the hypothesis that high-grade anal dysplasia may be a precursor
lesion to the development of anal cancer. Three cases also confirm the previously
reported progression of external high-grade anal dysplasia to anal SCC.(314)
AIN 2/3 likely takes several years to progress to invasive anal cancer, as is known to
be true of the temporal relationship between high-grade cervical dysplasia and the
development of cervical cancer.(315) The data in this study show that the mean time
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from first diagnosis of high-grade dysplasia by anal cytology or biopsy to the
diagnosis of cancer was 14.6 months. However this figure likely underestimates the
true transition time to cancer as incident high-grade disease was only captured in 2
cases. In these cases the incident high-grade dysplasia diagnosis was made on anal
cytology which although sensitive for detection of anal dysplasia is poorly predictive
of anal dysplasia grade, with most cytology samples indicating lower grades of
dysplasia than are confirmed by anal biopsy. Thus, it is feasible that high-grade
dysplasia was present prior to its' cytological diagnosis. All other subjects had high-
grade dysplasia at first cytological or pathological diagnosis. In the two incident cases
the interval from first high-grade dysplasia diagnosis to cancer was 29 months and 13
months. Clinical experience in the Anal Neoplasia Study suggests that this is an
unusually short timeframe for progression, as many subjects have been observed with
high-grade anal dysplasia without treatment for many years. Thus it is unlikely that
the data permit an accurate estimation of time to progression to anal cancer from first
developing high-grade dysplasia. They do show, however that in this high-risk
population of predominantly HIV-positive MSM, anal cancer can occur within a
relatively short period of time after first clinical detection of high-grade dysplasia.
4.7.2 DEMOGRAPHICS OF STUDY SUBJECTS
The demographics of subjects with anal cancer in the general population differ from
those described in this study by having a female predominance and a peak incidence
of anal cancer diagnosed in the seventh decade.(288) (316) At diagnosis, study
subjects were predominantly male, with an average age of 45 years. All male subjects
were HIV-positive with an average known seropositivity of 13 years. It is noteworthy
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that previous reports of anal cancer incidence including the SEER database do not
include HIV serostatus in the demographic analysis.(279)
4.7.3 EFFECT OF HIV INFECTION AND HAART
Although HIV infection in MSM may have been expected to lead to an increase in the
risk of anal cancer, an increase beyond that observed in HIV-negative MSM was not
detected during the early years of the HIV epidemic.(275) This may have been due to
individuals succumbing to opportunistic infections or other HIV-related malignancies
before anal cancer had time to develop. Consistent with this postulate, subjects in this
study developed anal cancer at a mean of 13 years after the first documented positive
HIV test while median time interval to an AIDS diagnosis from HIV seroconversion
in an untreated population is on average 10 years.(317)
All of the HIV-positive subjects reported having taken HAART at some time prior to,
or at the time of, the diagnosis of anal cancer. Little is known about the effect of
HAART on the incidence of anal cancer, although recent studies in San Diego and
San Francisco showed an increased incidence in the post HAART era.(278) (279) In
Europe, Bower et al concluded that since the introduction of HAART there had been
no significant change in the incidence of anal cancer at a central London teaching
hospital cohort ofHIV infected individuals.(277)
If progression from anal HSIL to anal cancer takes many years, individuals taking
HAART with its positive impact on survival may now have sufficient time for
progression to occur. Thus, in the absence of routine screening and treatment of anal
HSIL, individuals taking HAART may paradoxically be at increased risk of
developing anal cancer.
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4.7.4 PROGRESSION OF INDIVIDUAL HIGH-GRADE DYSPLASTIC
LESIONS
It is clear from studies in San Francisco and elsewhere that there is a higher
prevalence of high-grade anal dysplasia diagnosed than anal cancer, similar to high-
grade cervical dysplasia and cervical cancer.(315) Assuming high-grade dysplasia is
the precursor lesion to anal SCC, there is no current method of detecting exactly
which area of high-grade dysplasia will progress to cancer. Thus, the detection of
high-grade anal disease should lead to consideration of ablative treatments or close
clinical monitoring.
4.7.5 STUDY LIMITATIONS
This study has several noteworthy limitations. The study was performed as a
retrospective chart review and so was limited to available charts and documentation
with the potential that cases were missed that were not present in the UCSF pathology
database. Additionally data available were often sparse and did not include a
comprehensive medical history and investigation with chronological details of
antiretroviral therapy, sexual history, smoking start and stopping dates, in addition to
those parameters shown in Table 4.10.
The awareness of anal dysplasia screening and availability of both studies and
services was likely to be more apparent to the MSM community in the San Francisco
Bay area and so may have biased the sex ratio. However, initial data from the UCSF
pathology database prior to exclusion of subjects without prior documentation of anal
high-grade dysplasia also showed a male predominance.
It cannot be certain that the anal cancers arose in the exact site where the high-grade
dysplasia was diagnosed when anal biopsy data was present, as dysplasia may have
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been multi-focal. Additionally some biopsy locations were simply documented
empirically as internal or external. However, even if there is no direct relationship
between previously identified high-grade dysplasia and the subsequent development
of anal cancer, detection of high-grade dysplasia may at least represent a marker for
an individual at risk of developing cancer.
4.8 SUMMARY
This study indicates that anal cancer may be diagnosed subsequent to previous
documentation of high-grade anal dysplasia. HIV-positive MSM subjects developed
anal cancer at a younger age than the general population.
Large prospective cohort studies are required to determine the efficacy of anal
cytology screening to identify anal dysplasia, and treatment of high-grade dysplasia to
prevent anal cancer. However, these studies will be difficult to perform because of the
large numbers of patients required, the length of time required for follow-up, and the
complex ethical issues involved. It is noteworthy that implementation of cervical
cancer screening programs preceded unequivocal evidence that a cytolopathological
diagnosis of dysplasia and its' ablation led to a reduction in cervical cancer incidence.
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CHAPTER 5
THE SENSITIVITY AND SPECIFICITY OF SELF-TAKEN
ANAL CYTOLOGY SAMPLES FOR THE DIAGNOSIS OF
ANAL SQUAMOUS INTRAEPITHELIAL LESIONS IN
MEN WHO HAVE SEX WITH MEN
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5.1 INTRODUCTION
The incidence of anal cancer in the United States is rising. To address this,
investigators have used anal canal cytology screening as a means of detecting anal
dysplasia, with subsequent ablation of high-grade dysplasia similar to the screening
and treatment paradigm utilized for the female cervix as has previously been
discussed in Chapter 2 and 3. Several barriers currently exist to the implementation of
an anal cytology screening program for high-risk individuals. One obstacle is the lack
of studies to document that treatment of HSIL reduces the incidence of anal cancer.
Performance of such studies is hampered by the large number of subjects needed,
difficulties in assembling an appropriate control group and the long follow-up time
needed to assess the impact on cancer incidence as discussed in Chapter 4. Other
obstacles include a paucity of clinicians trained in collecting anal cytology and trained
in HRA, the potential reluctance of clinicians to address the issue of ASIL with their
patients, and patients' feelings of embarrassment and fear of potential discomfort
associated with the collection of anal specimens. Collection of anal cytology samples
by patients themselves has the potential to obviate some of these concerns. It has
previously been shown that women can successfully obtain samples of cervicovaginal
fluid at home for HPV testing.(318) This method was not adapted to cervical cytology
screening because of the anatomic challenges in blindly directing the sample
collection devices precisely where they are needed in the cervix. However, the anal
canal is an easier anatomic site for self-directed collection of cells.
The purpose of this study was to assess the performance of results from anal cytology
samples collected by study participants at home compared to samples collected by
experienced research clinicians in a clinic of MSM with a high prevalence of ASIL.
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Anal histopathology was used as the gold standard for this research comparison. The
published paper is presented in Appendix 1.
5.2 METHODS AND MATERIALS
5.2.1 SUBJECTS
The study was performed with the approval of the UCSF Committee on Human
Research. Informed consent was obtained from all subjects. Participants were
recruited from 505 HIV-positive and 364 HIV-negative MSM in the UCSF Anal
Neoplasia Study.(196)
5.2.2 CLINIC ANAL CYTOLOGY AND BIOPSY SAMPLING
Study participants were examined every 3-6 months with anal cytology and HRA with
biopsy of any lesion suspicious for dysplasia. Demographic information was collected
and blood samples were obtained for HIV antibody testing.
One hundred twenty five study participants from the ongoing Anal Neoplasia Study
population were sequentially invited to participate in this study. Criteria for study
eligibility included having had an anal cytology sample taken using glass-slide smears
and ethanol fixation, and a simultaneous biopsy of any visible anal lesion that
appeared dysplastic using HRA. The study participants had previously had anal
cytology samples collected by their practitioner. The men were consecutively chosen
for participation during the study period, and neither the cytology nor the biopsy
results were known at the time of enrollment. A clinician provided an explanation of
the study, and informed consent was obtained from study subjects. Cytology
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specimen collection and HRA were performed as described previously with standard
glass slide and ethanol fixation technique used for clinician-collected samples.(196)
5.2.3 HOME ANAL CYTOLOGY SAMPLING
The study participants used the liquid cytology method to collect their specimens at
home, as they have similar performance characteristics to glass-slide cytology (189)
but are substantially easier to handle. The men were given written instructions on how
to take an anal cytology sample. The collection kit consisted of: one bottle of Cytyc
ThinPrep (Cytyc Corp., Boxborough, MA) sample collection medium, one Dacron
swab, two sealable plastic bags for disposal and a pair of latex gloves. To allow for
healing of the initial anal biopsy site, subjects were requested to wait one month from
the time of the original anal cytology and biopsy prior to collecting their cytology
sample.
While wearing latex gloves, the men were instructed to remove the Dacron swab from
its sterile package and moisten it with tap water before inserting it two inches into the
anal canal. Applying gentle lateral pressure to the walls of the anal canal, participants
were instructed to remove the swab with a spiral motion over ten seconds. The swab
was to be immediately placed into an open Cytyc bottle containing Cytyc ThinPrep
media and agitated vigorously to disgorge the cells from the swab before it was
removed from the bottle. Participants were instructed to close the Cytyc bottle tightly,
store it at room temperature and return it to the clinic in a sealed plastic bag within
one week of specimen collection.
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5.2.4 CYTOLOGY SAMPLE ANALYSIS
The same pathologist analysed all clinician collected cytology and biopsy samples.
Because of the different sampling method used, the pathologist knew whether the
specimen was clinician-collected or self-collected. However, all specimen findings
were interpreted without reference to the paired specimen. Cytology findings were
classified according to the Bethesda classification system as inadequate for
interpretation (sample contained less than 2000 to 3000 nucleated squamous cells),
negative for squamous intraepithelial lesion, ASCUS, LSIL, or HSIL. At the time of
this study, the new Bethesda 2001 terminology of ASCH had not been developed and
so does not appear in any diagnostic category.
5.2.5 STATISTICAL ANALYSIS
Statistical analysis was performed using Version 8 of the Statistical Analysis System
(SAS Inc., Cary, NC). The sensitivity of anal cytology to detect LSIL and HSIL was
defined as the number of specimens with abnormal cytology divided by the number of
individuals with AIN. The Fishers exact test was used to compute p values for
comparing sensitivities or other proportions across groups.
The Fishers exact test is an eponymous statistical significance test used in the analysis
of categorical data. The test is used to examine the significance of the association
between two categorical variables in an r x c contingency table, where one variable
has "r" categories and the other has "c" categories. A special case is a 2 x 2 table
(r=c=2). With large samples or well-balanced tables, a chi-square test p value is a
good approximation for the exact Fisher p value. However, the chi square
approximation is no longer accurate when the sample size is small or the expected
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frequencies in any cell of the table is below 5 or the expected frequency is below 10
in a 2 x 2 table.
In the context of the above study, the Fishers test was chosen, as this is the exact
method for computing a p value when comparing two independent
proportions/percentages for a binary outcome. For example, the Fisher procedure is
the correct way to compute a p value for comparing the 3/15 = 20% response in 15
HIV negative patients versus the 56/73 = 77% response in 73 HIV positive patients as
these are clearly two independent groups. A patient must be HIV negative or HIV
positive and cannot be both. If one is comparing percentages/proportions where two
different medical tests or determinations are compared on the same (paired) samples
or patients, then the Fisher test is not the appropriate way to compute a p value.
The observed p value is a function of the data. Using p < 0.05 (where 0.05 is the
alpha level) is a generally accepted criterion for deciding whether the p value is
'statistically significant'.
5.3 RESULTS
One hundred and six MSM subjects who had a clinician-collected anal cytology and
HRA examination with anal biopsy were enrolled from the UCSF Anal Neoplasia
Study. Nineteen subjects either declined to take part in the study or did not return the
cytology samples in a timely manner. Four subjects without complete self-collected
cytology, clinic collected cytology and biopsy results were excluded from the
analysis. Of the 102 remaining subjects, 82 were HIV-positive and 20 were HIV-
negative. The mean age at time of sampling was 45 years (range 29-72 years). Most
of the subjects were white non-Hispanic, n = 89 (87%); the rest were white-Hispanic,
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n = 2 (2%); African American, n = 3 (3%); Native American n = 1 (1%); Asian, n = 3
(3%); and other, n = 4 (4%).
5.3.1 RESULTS OF CLINICIAN-COLLECTED AND SELF-
COLLECTED ANAL CYTOLOGY, AND CORRESPONDING
ANAL HISTOLOGY
The results of clinician-collected anal cytology and the corresponding histopathology
are shown in Table 5.1. The results of the self-collected anal cytology and the
corresponding histopathology are shown in Table 5.2. Specimen adequacy was high
in both the clinician-collected (101/102, 99%) and the self-collected cytology (93/102,
91%) with a significantly higher rate of adequacy seen in the clinician-collected
samples (p=0.02). The adequacy rate of self-collected samples was similar for HIV-
positive (93%) and HIV-negative (85%) men (p=0.37).





Normal Atypical AIN 1 AIN 2 or 3 Insufficient Total (%)
Normal 4 1 10 18 0 33 (32%)
ASCUS 1 0 0 2 0 3 (3%)
LSIL 0 1 13 22 0 36 (35%)
HSIL 0 0 2 27 0 29 (28%)
Insufficient 0 0 1 0 0 1 (1%)
Total (%) 5 (5%) 2 (2%) 26 (26%) 69 (68%) 0 (0%) 102
Insufficient: insufficient cellular material for interpretation, A1N 1: low-grade anal intraepithelial
neoplasia, AIN 2 or 3: high-grade anal intraepithelial neoplasia)
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Normal Atypical AIN 1 AIN 2 or 3 Insufficient Total (%)
Normal 3 1 8 20 0 32 (31%)
ASCUS 0 0 1 3 0 4 (4%)
LSIL 0 1 10 22 0 33 (32%)
HSIL 0 0 1 23 0 24 (24%)
Insufficient 2 0 6 1 0 9 (9%)
Total (%) 5 (5%) 2 (2%) 26 (26%) 69 (68%) 0 (0%) 102
5.3.2 SENSITIVITY OF CLINICIAN-COLLECTED AND SELF-
COLLECTED ANAL CYTOLOGY TO DETECT ANY BIOPSY
PROVEN ABNORMALITY
The sensitivity of any grade of anal cytology abnormality for detection ofAIN 1, AIN
2, or AIN 3 was comparable between the clinician-collected (70%) and self-collected
(68%) samples. The sensitivity of any grade of anal cytology abnormality for
detection of a high-grade lesion (i.e., AIN 2 or 3) was also compared between the
clinician-collected (74%) and self-collected (71%) samples.
5.3.3 THE EFFECT OF HIV SEROSTATUS ON COLLECTION OF
ANAL CYTOLOGY SAMPLES
The sensitivity of anal cytology to detect AIN in self-collected samples was higher
among HIV-positive men than among HIV-negative men. Three (20%) of the 15
HIV-negative men with AIN had abnormal cytology compared with 56 (77%) of 73
HIV-positive men (p<0.01). The sensitivity for detection of AIN 2 or 3 specifically in
self-collected specimens was also higher among HIV-positive men than among HIV-
negative men. Among the 57 HIV-positive men with biopsy proven AIN 2 or 3, anal
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cytology was abnormal in 43 (75%), compared with 4 (40%) of 10 HIV-negative men
(p=0.05). The sensitivity of anal cytology to detect either AIN overall or AIN 2 or 3
specifically was also higher for HIV-positive men in the clinician-collected samples,
and the magnitude of these differences in sensitivity was similar to those seen in self-
collected samples (p=0.15 for AIN overall; p=1.0 for AIN 2 or 3). Overall cytologic
results did not differ by grade between clinician-collected and self-collected samples.
Among men diagnosed with AIN 2 or 3 by biopsy, 39% with AIN 2 and 33% with
AIN 3 had HSIL by cytology.
5.4 DISCUSSION
In this study, we compared overall rates of abnormality between samples collected by
clinicians and study participants. The results of this study strongly suggest that in this
population of MSM, with previous experience of having had anal swabs used to
collect cytology specimens and anal biopsies of lesions clinically suspicious for anal
dysplasia taken by a clinician, are capable of self-collecting samples with sensitivity
comparable to experienced clinicians. This was accomplished with only written
instructions on how to self-collect an anal cytology specimen in this experienced
population.
5.4.1 ANAL CYTOLOGY SCREENING
Recent guidelines from the United States Public Health Service for the treatment of
opportunistic infections in HIV-positive individuals indicate that although anal
cytology screening has not yet been formally recommended, anal cytology screening
should be considered for HIV-positive men and women. Anal cytology should be
used as a screening tool to identify individuals who would benefit from HRA to detect
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and treat HSIL.(196) The current UCSF recommendation is to refer patients with any
grade of anal cytologic abnormality for HRA.(114) Moreover the UCSF group
previously showed that detection of HSIL on anal cytology had a high positive
predictive value for detection of biopsy-proven high-grade dysplasia. (196) Thus,
inability to confirm high-grade dysplasia on FIRA-directed biopsy in a patient with
HSIL cytology should prompt a repeat examination.
5.4.2 ANAL CYTOLOGY SENSITIVITY
The primary goal of anal cancer prevention is to detect and treat HSIL before it
progresses to cancer. To this end, we also compared the sensitivity of cytology
collected by clinicians and subjects to detect AIN 2 or 3 by biopsy and found that the
sensitivity of the two groups was comparable. This ability to self-collect anal cytology
may allow high-risk populations to be screened outside of a medical setting, and allow
for subsequent evaluation with HRA and treatment of lesions in individuals with
abnormal cytology. It could also provide a useful tool for epidemiologic studies of
anal cytology and possibly anal HPV in large population-based cohorts.
5.4.3 ANAL CYTOLOGY SPECIMEN ADEQUACY AND HIV
The rates of clinician-collected and self-collected anal cytology specimen adequacy
were similar to those seen in a previous study that validated anal cytology as a
screening test for ASIL.(196) In the present study, the adequacy of specimens
collected by clinicians was slightly higher than those collected by study subjects.
However, this should not affect the role of self-screening since patients with
inadequate specimens could be informed of the need to repeat the test. Notably the
sensitivity of anal cytology to detect anal dysplasia overall and AIN 2 or 3 specifically
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was significantly higher among HIV-positive men than HIV-negative men, a finding
consistent with an earlier study.(196) We speculate that this reflects the larger size of
lesions typically found in HIV-positive men, leading to a higher likelihood of
detection. Another explanation is that HIV-negative men were not as vigorous in
obtaining specimens as the HIV-positive men. This is less likely because adequacy
rates for specimens were similar between the HIV-positive and HIV-negative men.
Further, the clinician-collected specimens were less sensitive among the HIV-negative
men than the HIV-positive men, similar to our findings for the self-collected
specimens. Because participants were enrolled in the study only if they had undergone
anal biopsy, the prevalence of ASIL in the study was very high, and there were too
few participants with normal anoscopic examination findings to assess differences in
other measures of screening validity (eg, specificity and positive and negative
predictive values) between sample specimens. In a predominantly HIV-negative
population we would expect fewer abnormal anal cytology results, consistent with the
less frequent diagnosis of anal dysplasia in this population. However, despite the
statistically insignificant differences in specimen adequacy between the HIV-positive
and HIV-negative subjects, there were fewer HIV-negative participants in this study
and further investigation of this population would be appropriate.
5.4.4 FALSE NEGATIVE ANAL CYTOLOGY
As with previous studies of anal and cervical cytology, a substantial proportion of
normal cytology specimens were false negative. In this study approximately 30% of
subjects with biopsy-proven ASIL had normal cytology suggesting that, similar to
cervical screening, sequential anal cytology screening may be necessary to detect
ASIL in this population. In this context, the role of testing for high-risk HPV as an
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adjunct to anal cytology has not been characterised. Previous studies have shown that
detection of multiple HPV types is a risk factor for progression of LSIL to HSIL,
although the risk of progression associated with individual high-risk HPV types has
not been fully addressed.(206)
5.4.5 STATISTICAL CONSIDERATIONS
Fishers exact test is used for computing p values when comparing proportions
(sensitivity is an example of a proportion) in different categories. All of the above
data is categorical and is expressed as two way categorical cross tabulations. Before
the advent of easy to use computational software, approximate p values for comparing
proportions in different categories were computed with the chi-square test method.
However, computer software such as SAS has been available for the last 10 years or
so that performs the exact p value computation using Fishers method, making the chi-
square approximation no longer necessary.
The statistical power/sample size in the above study may be too low, however, this
does not invalidate the Fisher p value computation method but is a separate criticism
of inadequate sample size, a criticism that could be made regardless of the statistical
computation procedure. Additionally, examining many associations by doing many p
value calculations for many statistical tests is a problem in any exploratory
study. Again, this is not a shortcoming of the Fisher test; it is a shortcoming in any
exploratory study where many potential associations are examined. The problem with
examining many potential associations or retesting after changing the definitions is
that one of the tests may come out "significant" as an artifact of the multiple testing,
that is a "false positive". In the above study we compared physician collected vs self
collected and HIV positive vs HIV negative and we considered both AIN overall and
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AIN 1 vs AIN 2-3 separately. Since we examined less than a dozen associations or
redefinitions, multiple significance testing is a not a major problem in this study.
Further, observational studies frequently tend to be exploratory in nature and results
usually are reported without an alpha correction.
Additionally, the above study did not investigate the efficacy of anal cytology
sampling by clinicians or subjects with no previously diagnosed anal pathology, and
was therefore unable to report specificity of anal cytology sample in the two groups
studied.
5.4.6 STUDY LIMITATIONS
The results of self-collected anal cytology were encouraging in this study, although
the results should be interpreted with caution. The study participants in this study had
experienced the collection ofmultiple anal cytology samples by clinicians in the past
and were aware of how an adequately collected sample felt while being taken. This
experience may have enhanced their ability to take an adequate specimen. Self-
collected samples were taken one month following clinic anal cytology and anal
biopsy. It is possible, although unlikely given the slow progression of dysplastic
lesions in the cervical and anal canal that the degree of dysplasia may have changed
during this time. It is possible, although also unlikely, that taking an anal biopsy could
have completely removed the dysplastic lesion or changed the natural history of the
lesion. Clinician-collected cytology specimens were obtained using a glass slide and
were preserved in ethanol, whereas self-collected specimens were processed using
liquid cytology methods. The liquid method may have facilitated improved specimen
adequacy by reducing processing problems associated with faecal contamination and
low cell count. However, when previously assessed using a split-sample technique,
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both methods were shown to be comparable, although this may not have been the case
in this study.(189)
One of the strengths of this study was that the same pathologist analysed all of the
cytology and biopsy specimens, facilitating comparison of the results. The pathologist
was also aware if the cytology was clinician or subject collected because of the
different sampling methods used. Therefore, a potential bias may have been
introduced into the interpretation of cytology results. However, we do not believe that
this affected the results in a substantive way because the pathologist interpreted the
samples at least 1 month apart and would not know the findings for the other samples
collected from the same participant.
5.5 SUMMARY
In summary, these data indicate that self-collected anal cytology specimens, when
adequate for interpretation, had similar sensitivity to specimens collected by
experienced clinicians. The sensitivity of anal cytology to detect AIN 2 and 3 is good
among HIV-positive men, but further effort is needed to improve sampling among
HIV-negative men. If successful, this technique could greatly facilitate institution of
anal cytology screening to prevent anal cancer among at-risk individuals and would
be a useful tool to define the prevalence of abnormal anal cytology in large
populations. Further research is needed to determine whether this technique works as
well when performed by individuals with no prior experience with anal cytology and
among a population with a lower prevalence of AIN. In addition, the sensitivity,
specificity, and positive and negative predictive values should be studied for








This chapter will discuss the biological properties of selected cytokines and their
involvement in infectious and neoplastic disease with particular reference to HPV
associated disease in the cervical canal, in the absence of current data for the anal
canal.
6.2 CYTOKINES
Cytokines are transcriptionally regulated proteins secreted by T helper (Th) cells and
other cell types in response to a variety of stimuli, and function by acting on specific
cell receptors to regulate the host immune response. They may act in an autocrine or
paracrine manner, binding to cell receptors on the cell of origin or those in the
immediate vicinity respectively. Cytokines may additionally act on cells distant to the
cells of origin analogous to the action of a hormone.
6.2.1 Th1/Th2 PARADIGM
The T helper type 1 (Thl) and Th type 2 (Th2) nomenclature of cytokines was first
used by Mosmann and Coffman in 1986 when reporting that murine Th lymphocyte
clones could be divided into two subsets based on the function of the
immunoregulatory cytokines secreted by these cells; Thl cells (interferon gamma (IF-
y), interleukin 2 (IL-2), granulocyte macrophage colony stimulating factor (GM-CSF)
and interleukin 3 (IL-3)) and Th2 cells (interleukin 4 (IL-4), interleukin 5 (IL-5),
interleukin 6 (IL-6), interleukin 10 (IL-10) and GM-CSF)).(319) Thl cytokines are
pro-inflammatory and stimulate cell-mediated immunity (CMI) that is effective in the
host defense against viral infections and tumour development. Th2 cytokines
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stimulate B-lymphocyte development and antibody production against extracellular
pathogens.(320) Th2 cytokines are anti-inflammatory or immunoinhibitory and may
facilitate tumour growth.(321) This classification was extended to humans in 1991
(322) and following this observation the pathogenesis of infectious, inflammatory and
neoplastic disease has been classified by predominant cytokine phenotype.(323) (324)
(325) (320)
More recently it has been established that T cells may secrete both Thl and Th2
cytokines and are labeled ThO (or Th0-like).(326) (327) Early cytokine contact and
the nature of the antigen signal influence differentiation of ThO cells into either Thl or
Th2 effectors.
There is one further immunoregulatory T cell type that co-expresses CD4 and CD25
(the IL-2 receptor alpha chain) on the cell surface and are phenotypically
immunosuppressive.(328) These cells have been labeled Treg although this function
is not limited to this particular cell type. It is apparent that Treg cells are critical in the
development of the immune response in autoimmune disease and hypothetically, if
down regulated, may function to augment tumour development.(329)
6.2.2 CYTOKINE NOMENCLATURE
Thl and Th2 cytokines are produced by a diverse lineage of cell types that include
CD4 T cells, CD8 T cells, monocytes, NK cells, B cells, eosinophils, mast cells,
basophils and epithelial cells.(330) (331) More recently the terms 'Thl-like' and
'Th2-like' are being used to reflect the diversity of cell types that can produce
cytokines.(330) For simplicity, the following two chapters will use Thl to represent




The IF-y gene is located on chromosome 12. IF-y is the dominant Thl cytokine
secreted by activated T lymphocytes and NK cells.(332, 333) IF-y increases cell
surface expression of major histocompatability complex (MHC) class I antigens,
increases cell surface expression ofMHC class II antigens on antigen presenting cells,
augments tumour necrosis factor (TNF) cytotoxicity, and activates macrophages
resulting in enhanced killing of intracellular pathogens.(334) (335) (336) There is
minimal homology between IF-y and the two other interferons (IF-a and IF-p) as IF-y
binds to a separate cell receptor. (3 37)
The IL-2 gene is located on chromosome 4.(338) IL-2 is a Thl cytokine secreted by
activated T lymphocytes and was first identified as a T cell growth factor in
1976.(339) (332) IL-2 stimulates proliferation and differentiation of T lymphocytes
by autocrine and paracrine up-regulation of the high-affinity a/p IL-2 receptor. It also
enhances B cell growth and the cytolytic effect ofNK cells in addition to increasing
IL-4 and IF-y production by other lymphocytes.(340) (341)
IL-4 is a Th2 cytokine secreted by T lymphocytes, macrophages, mast cells,
basophils, B lymphocytes, bone marrow and epithelial stromal cells.(332) Its' action




differentiation. It also induces the proliferation and differentiation of B lymphocytes,
and the production of immunoglobulin (Ig) E.(341, 342)
6.2.3.4 IL-10
IL-10 is a Th2 cytokine secreted by T lymphocytes, macrophages, keratinocytes, B
lymphocytes, and epithelial cells.(332) (343) It acts to suppress the functional activity
of macrophages, and inhibits both macrophage and monocyte production of pro¬
inflammatory cytokines. It also increases B lymphocyte proliferation, MHC class II
expression and immunoglobulin (Ig) secretion.(344) IL-10 inhibits IL-12 production
by dendritic cells and monocytes.(345) IL-10 m-RNA and protein has been found in
excess in several cancers, and been shown to be produced by tumour infiltrating
lymphocytes and tumour cells.(346-349)
6.2.4 CYTOKINES AND THE MAJOR HISTOCOMPATABILITY
COMPLEX
The MHC determines the body's response to antigen in that the peptide/MHC
complex presented to the T-cell will help determine the Thl or Th2 response to
antigenic stimulation. This has been demonstrated in both human and murine studies
and may be particularly important in the context of chronic infections where the
response to the pathogen is vital to host defense and prognosis.(350) A Th2 response
is associated with down-regulation of MHC class I and Pi-microglobulin expression
and so reduces antigen presentation to antigen presenting cells, whose function is
concomitantly impaired in this environment.(351) (352) (353) (354)
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6.2.5 CYTOKINE GENE EXPRESSION IN THE FEMALE GENITAL
TRACT
Cytokine gene expression has been detected by RT-PCR in the female genital tract
from cervico-vaginal secretions that, in health, exhibit a predominantly Thl type
environment.(355) This is not the case in the cervix of HIV-positive women in the
absence of detectable HPV or CSIL who show a predominantly Th2 type cytokine
gene expression pattern.(356)
Female genital tract cytokine gene expression has been investigated in the context of
HPV infection. Female subjects with cervical intraepithelial neoplasia
(CIN)/anogenital HPV and a predominantly Thl type cytokine response from in vitro
stimulated PBMC's have more contained HPV disease than subjects with a
predominantly Th2 type cytokine response.(321) This finding was also demonstrated
by Stellato et al who reported that high serum IL-2 levels may predict a better
prognosis in women treated for genital HPV associated lesions.(357) The mechanism
of this finding may in part relate to the in vitro finding that IL-10 increases the
transcription ofHPV E7 in HPV 16-positive cervical cancer cell lines.(358)
Local cervical cytokine gene expression has also been investigated by RT-PCR from
material collected by cervical swabs in subjects infected with HPV. This study by
Scott et al demonstrated that all subjects who cleared HPV infection, as evidenced by
a negative HPV PCR, had a preceding Thl cytokine gene expression pattern and
subjects with persistent HPV lacked a Thl response.(359)
A comparison was reported between Thl and Th2 cytokine production in women with
cervical LSIL and HSIL, using matched controls. PBMC and whole blood culture
cytokine levels of IL-4 and IF-y showed no significant difference between the two
groups, however, an inverted relationship of IL-12 and IL-10 with a Th2
predominance was found in subjects with cervical HSIL.(360)
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The cytokine milieu of cervical tissue has been less frequently reported in the
literature. Al-Saleh et al analysed transition zone and ectocervical biopsy specimens
from normal and dysplastic cervices. Immunohistochemistry was used to detect cells
secreting IL-2, IF-y, IL-4, and IL-6. Higher densities of Thl cytokines were found in
normal tissue and higher densities of Th2 cytokines were found in CSILs. The authors
suggested that this immunomodulation may participate in cervical
carcinogenesis.(361) Similar findings were reported by El-Sherif et al using
quantitative RT-PCR from paraffin embedded cervical specimens.(333)
6.2.6 CYTOKINE GENE EXPRESSION IN CERVICAL CANCER
Cytokine gene expression is considered part of the host defense to injury or disease,
and as such may reflect disease activity.(362) Serum IL-2 and production of IF-y by
activated PBMC's is reduced in subjects with invasive cervical cancer, and
additionally may be reduced at the tumour site in poor prognosis cases. (363-365) IF-y
has been shown to suppress expression ofHPV E6 and E7 genes in both immortalized
and cervical cancer cell lines, as well as enhancing peptide presentation to cytotoxic
T-cells.(366) (367) Although a reduction of Thl and enhancement of Th2 activity had
been suggested as a response to, or mediator of, the progression of cervical dysplasia
to cancer, not all investigators have demonstrated this, with one study reporting a
generalised impairment of cervical cancer T cells and down-regulation of both
cytokine classes.(368)
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6.2.7 CYTOKINE GENE EXPRESSION AND CONCURRENT
SEXUALLY TRANSMITTED INFECTION
The anogenital tract is prone to both sexually transmitted and non-sexually
transmitted infection (STI). The cytokine environment of the cervical canal, with
particular reference to IL-10 gene expression, has been studied in women with STI's
with conflicting findings. Hedges et al report that infection with T. vaginalis, C.
trachomatis and N. gonorrhoea have no influence on IL-10 gene expression (369),
whereas Cohen et al reported that IL-10 was isolated more frequently in women with
concurrent STI.(370)
6.2.8 CYTOKINE GENE EXPRESSION IN THE ANAL CANAL
The cytokine environment of the anal canal has not previously been investigated.
Sampling techniques that have been used to investigate the cervix include biopsy and
exfoliative cytology. Collection of anal cytology specimens is less invasive when
compared to anal biopsy, although the collected material is hypocellular and
predominantly composed of anal squamous cells although immune cells such as T
lymphocytes may also be present (S. Hirschowitz - personal communication).
6.2.9 CYTOKINE GENE EXPRESSION AND HIV INFECTION
Infection with HIV-1 results in a progressive destruction of the cell-mediated immune
system with profound loss of CD4 lymphocytes resulting in increased risk of
opportunistic infection and the development of certain malignancies. The immune
milieu during chronic HIV infection and progression to AIDS has been studied with
particular reference to Thl and Th2 cytokine gene expression, and various theories
presented to better understand the clinical decline of these patients. Clerici and
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Shearer have proposed a dysregulation of cytokine gene expression with a shift from
Thl to Th2 predominance to predict clinical decline.(324, 371) There was pre¬
existing evidence suggesting an impairment in T-cell proliferation and IL-2
production in vitro using PBMC's from immunocompetent HIV-positive patients with
normal CD4 counts.(372) The Th2 predominance does not appear to be restricted to
HIV subtype B. the type most commonly seen in Western infections, with a Th2
predominance also demonstrated in other parts of the world with predominant
infection with HIV subtype C and is also seen in HIV-2 infection.(373)
The Th type of immune response may be modulated by the ratio of circulating
antibody/antigen complexes. Berger et al described a Thl to Th2 type shift when ex-
vivo peripheral blood mononuclear cells (PBMC) were challenged with antibody-
excess immune complexes, as occurs frequently in HIV disease in the form of
polyclonal hypergammaglobulinemia.(374)
In the era of highly active antiretroviral therapy (HAART), response to therapy as
measured by decreasing HIV RNA in plasma and concomitant increase in CD4
lymphocyte count has been shown to increase levels of IL-2 and IF-y while also
showing a decrease in IL-10 by RT-PCR. This was reported in an antiretroviral
exposed cohort commencing a new antiretroviral regime that included a class of drug
to which the patient had not been previously exposed, so increasing the probability of
treatment efficacy and immunological response.(375)
Long-term non-progressors are HIV patients who do not show a reduction in CD4 cell
numbers over time and usually have very low or undetectable steady state untreated
plasma HIV viral load. This population showed a balance in Thl/Th2 profiles without
a Th2 predominance.(376) This paradigm does not appear to be limited to adults with
HIV infection, with vertically HIV-infected long term non-progressing children also
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displaying increased Thl compared to Th2 cytokines, while as with adults, clinically
progressing children have a Th2 predominance.(377)
6.3 SUMMARY
Cytokines are transcriptionally regulated proteins secreted by a variety of cells that
orchestrate the body's immune response to infection and may influence tumour
development. The cytokine phenotypes are broadly classified into a pro-inflammatory
Thl type that facilitates antigen presentation and T cell proliferation, and an
immunoinhibitory Th 2 type that decreases macrophage function and promotes B cell
differentiation.
In the normal cervicovaginal environment there is a predominantly Thl type milieu
that may change following infection although bacterial sexually transmitted infections
do not appear to promote a consistent response. Infection with anogenital HPV is
more likely to be contained when a Thl response is detected, with the development of
HPV associated dysplasia facilitated by a Th2 environment. Similarly HIV infection
is predominantly associated with a Th2 type response, clinical decline and disease
progression. This may be reversed to a predominantly Th 1 response when HAART is
instituted. Thus the local or generalised cytokine environment may be essential to
successful containment of infection and may influence tumourogenesis.
It remains unknown, given the anatomical, histological and pathological homology, if
the cervical canal cytokine response is similar in the anal canal.
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CHAPTER 7
DETECTION OF ANAL CANAL CYTOKINES USING THE




HPV infection is confined to stratified squamous epithelium. The host cell mediated
immune response to HPV and HPV associated lesions is critical to viral clearance, or
to suppress viral replication to undetectable levels, as has been demonstrated in the
female cervix.(378, 379) To date there have been no reports on cytokine gene
expression in the anal canal of either male or female subjects with HPV-associated
lesions.
High-grade anal dysplasia is the putative precursor of anal cancer. Currently, there is
no method available to predict which individual is more likely to progress to a higher
level of dysplasia or to develop anal cancer. Assuming similarity to the female cervix,
it was hypothesised that detection of high-grade anal cytological abnormality would




1. To confirm that cytokine gene expression is detectable by RT-PCR from
material collected from anal swabs.
2. To compare cytokine gene expression in MSM subjects with high-grade and




Subjects were recruited sequentially from the Anal Neoplasia Study at UCSF. The
UCSF Committee on Human Research approved participation in the research study,
and each study subject received written and verbal explanations of study procedures
before signing informed consent.
The Anal Neoplasia Study is funded by the National Institute of Health and has been
established at UCSF, San Francisco since 1992. The study comprises 658 MSM (407
HIV-positive and 251 HIV-negative), who are seen at 3-6 monthly intervals
depending on their grade of anal dysplasia.
Prior to each clinic visit, subjects were advised to refrain from placing anything in the
anal canal for at least 24 hours. An anal examination was performed which comprised
taking an anal cytology swab, an anal swab for human HPV detection (typing by
PCR), and high-resolution anoscopy with or without anal biopsy.
7.4.2 EXPERIMENTAL PROCEDURES
Anal swabs were collected as described above. RNA was purified from the anal swab
material, and reverse transcribed to complementary DNA (cDNA). This was followed
by optimised PCR amplification using primers for IF-y, IL-2, IL-4, and IL-10. The
housekeeping gene Glyceraldehydes-3-phosphate dehydrogenase (GAP-DH) was
used to verify sample and cDNA integrity. To verify the authenticity of the cytokine
PCR gel electrophoretic product, a Southern transfer was performed, and cytokine
amplified product detected by enhanced chemiluminescence.
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7.4.2.1 SPECIMEN COLLECTION
This study employed a Dacron™ (Baxter Healthcare Corporation, McGraw Park, IL.
USA) swab to obtain an anal canal sample. With the patient in the left lateral position,
the swab was inserted 2 inches beyond the anal margin. With firm pressure, and a
spiral motion to sample the entire anal circumference, the swab was withdrawn over
10 seconds and placed immediately in 1000 pL of denaturing solution. This swab was
taken following the anal cytology and HPV swabs. Any swab with evidence of frank
blood on visual inspection was discarded.
7.4.2.2 DENATURING SOLUTION
A base solution was made by dissolving 250 g guanidinium thiocyanate (Roche
Diagnostics Corporation. Indianapolis, IN. USA) in 293 mL molecular grade water
(UCSF) and adding 17.6 mL 0.75M sodium citrate pH 7 (Fisher Scientific. Fairlawn,
NJ. USA) and 26.4 mL 10% sarcosyl (Sigma Molecular Biology. St. Louis, MO.
USA).(380) The solution was dissolved in a waterbath set at 60 °C for one hour then
stored at room temperature. The base solution was discarded if unused after 3 months.
To create the final denaturing solution, 0.36 mL of 2mercaptoethanol (Sigma
molecular biology. St. Louis. MO. USA) was added to 50 mL of the base solution.
The denaturing solution was divided into 1000 pL aliquots and stored at 4 °C until
required. The aliquots were discarded if not used within one month.(381)
7.4.2.3 STORAGE AND TRANSPORT OF SAMPLES
Anal swabs were collected from subjects at the General Clinical Research Clinic
(GCRC) at UCSF Mount Zion hospital, San Francisco and placed immediately in
denaturing solution and stored at -80 °C for no more than two days. The swabs were
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collected from Mt Zion hospital and transported in a sealed polystyrene container to
UCSF Parnassus, San Francisco, a journey of fifteen minutes. On arrival at UCSF
Parnassus the swabs were immediately placed in a -80 °C freezer for no more than
seven days before processing.
7.4.2.4 PRECAUTIONS TAKEN TO AVOID RIBONUCLEIC ACID
DEGRADATION
A laminar airflow sterile cabinet was cleaned with 75% ethanol (Quantum Chemical
Co. Tuscola, IL. USA) and RNase-Erase™ (Krackeler Scientific Inc. Albany, NY.
USA). All Gilson pipettes and Eppendorf tube racks were then placed in the cabinet
and exposed to UV light for at least 15 minutes before use. Latex gloves were worn
and washed in 75% ethanol prior to working in the sterile cabinet. Sterile
microcentrifuge tubes and micropipette tips were used at all times, as were dedicated
Gilson pipettes.
7.4.2.5 RIBONUCLEIC ACID EXTRACTION
The specimens were taken out of the -80 °C freezer, placed in the laminar air-flow
sterile cabinet and allowed to thaw at room temperature for 15 minutes. Ribonucleic
acid (RNA) extraction was subsequently performed by the phenol:chloroform
method.(381)
Working in the sterile cabinet, the swab and denaturing solution were vortexed for 10
seconds then 900 pL of swab lysate was transferred to a labeled 2 mL Eppendorf
microcentrifuge tube. One tube was filled with un-inoculated denaturing solution to
serve as a negative control. 90 pL of 2M Sodium acetate pH4, and 900 pL of
phenol:chloroform:isoamyl alcohol (IAA) (25:24:1) (Roche Diagnostics Corporation.
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Indianapolis, IN. USA) were added to each tube. The tubes were mixed by inversion 5
times, vortexed for 2 minutes, then chilled on ice for 15 minutes. The tubes were then
centrifuged at 8000 rpm for 20 minutes at 4 °C. Avoiding the interface, the upper
aqueous phase was transferred to a new Eppendorf microcentrifuge tube. 800 pL of
stock isopropanol 99% (Sigma Molecular Biology. St. Louis, MO. USA) was added
to each sample, vortexed for 10 seconds and incubated at minus 20 °C for at least 2
hrs. The tubes were then centrifuged at 8000 rpm for 20 minutes at 4 °C and the
supernatant poured off. 1 mL of 70% ethanol was added and the tubes were vortexed
for 2 minutes to dissolve the pellet. The tubes were centrifuged at 8000 rpm for 20
minutes at 4 °C and the supernatant was poured off. The pellet was air dried in the
sterile cabinet before re-suspending in 25 pL diethylpyrocarbonate (DEPC) (Sigma
Molecular Biology. St. Louis, MO. USA) treated water and vortexed until dissolved.
The RNA was stored at -80 °C until quantified by spectrophotometry and
subsequently reverse transcribed.
7.4.2.5.1 OPTIMISING RNA EXTRACTION
To investigate whether the number of phenol:chloroform:IAA extractions had any
impact on either the amount, concentration or purity of RNA, this step was repeated
with groups of 6 randomly chosen specimens for 1 to 5 rounds of extractions.
7.4.2.6 SPECTROPHOTOMETRY
RNA was quantified by spectrophotometic determination at wavelengths of 260 nm
and 280 nm. Optical density (OD) at 260 allowed calculation of RNA concentration.
An OD 260 of 1 corresponds to 0.04 pg/pL of RNA. The ratio of OD 260/280
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provides an estimate of purity of the nucleic acid. Ideally, the nucleic acid OD
260/280 ratios should fall between 1.8 and 2.0.
To measure the OD 260/280 ratio, 5 pL of RNA solution (from a total of 25 pL) was
diluted in 495 pL DEPC treated water in a quartz cuvette. The cuvette was placed in
the spectrophotometer and the measurement was taken. The quartz cuvette was
washed in DEPC treated water and shaken dry between samples. The
spectrophotometer used was an Amersham GeneQuant Pro (Amersham Biosciences.
Piscataway, NJ. USA).
Total RNA was calculated using the equation:
Total RNA (pg/pL) = OD 260 x dilution factor x 0.04
7.4.2.7 REVERSE TRANSCRIPTION
Single stranded cDNA is manufactured by reverse transcription of messenger RNA
(mRNA) that can then be used as a template for PCR amplification. In order to limit
transcription to mRNA, primers are used (random hexamers) that hybridize to the 3'
polyadenylated tail of mRNA and allow the enzyme reverse transcriptase to initiate
cDNA synthesis. Reverse transcriptase is derived from cloned Moloney murine
leukaemia virus (MMLV). RT-PCR allows investigators to work with much smaller
quantities of RNA than was previously possible using experimental methods such as
the Northern blot procedure.
7.4.2.7.1 REVERSE TRANSCRIPTION REACTION
All reagents were stored at -20 °C in a designated PCR room with designated
instruments and no contact with post PCR product.
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The quantities for 1 reaction were: 0.2 pL of random hexamers (Promega. Madison,
WI. USA) were diluted 1:5 in molecular grade water (UCSF) to give a final volume of
1 pL and kept on ice. The RT reaction mix was prepared with 4 pL 5X MMLV RT
buffer (Promega. Madison, WI. USA), 3 pL 10 mM 4 dNTP mix (final concentration
1.5 mM) (Promega. Madison, WI. USA), 1.75 pL molecular grade water, 0.25 pL
RNAsin Ribonuclease inhibitor 40 u/pL (Promega. Madison, WI. USA), and 1 pL
MMLV 40 u/pL (Promega. Madison, WI. USA) to make a final volume of 10 pL and
kept on ice.
For the primer annealing step 2 pg of total RNA were combined with 1 pL diluted
random primer and a variable volume of molecular grade water (depending on RNA
volume to give 2 pg of total RNA) to a final volume of 10 pL. The mix was heated to
95 °C for one minute in a Biometral thermal cycler, cooled to 4 °C and kept on ice.
For the RT reaction, 10 pL of RT reaction mix was added to the hexamer mix and
incubated at 37 °C in the Biometra thermal cycler for 1 hour before heat inactivating
the reverse transcriptase at 95 °C for 5 minutes and cooling to 4 °C. The 20 pL
volume product was stored at -20 °C until used.(382)
7.4.2.7.2 REVERSE TRANCRIPTION AND PCR NEGATIVE CONTROL
CONTROL
In every round of reverse transcription, one negative control was included which
contained no RNA template. This sample was reverse transcribed, PCR performed
and PCR product was run with all other samples on the final agarose gel.
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7.4.2.8 AGAROSE GEL MANUFACTURE
1.5 percent agarose gels were made by adding 0.75 g of electrophoresis grade agarose
(GibcoBRL. Gaithersburg, MD. USA) to 50 mL 10X Tris-Acetate-EDTA (TAE). 10X
TAE was made with TRIS (Fisher Scientific. Fairlawn, NJ. USA) (48.46 g/L (0.4M),
ethylenediaminetetraacetic acid (EDTA)-Na2-salt (Invitrogen Life Technology.
Carlsbad, CA. USA) 3.72 g/L (0.01 M), and acetic acid (Fisher Scientific. Fairlawn,
NJ. USA) 12.01 g/L (0.2 M). The mixture was heated to boiling point in a microwave
oven then 2.5 pL of ethidium bromide (Sigma molecular biology. St. Louis, MO.
USA) 10 mg/mL was added to give a final concentration of 0.5 pg/mL. Two 12-
toothed combs were inserted and the agarose was allowed to solidify at room
temperature. The gel was used when it had cooled to room temperature.
7.4.2.9 AGAROSE GEL ELECTROPHORESIS
Each gel was submerged in an electrophoresis tray filled with 10X TAE. Each well
was loaded with 10 pL of PCR product and 2 pL of 6X loading buffer (BioVentures
Inc. Murfreesboro, TN. USA) per sample. A negative PCR control as defined above
and positive cytokine control (see below) were also loaded on each gel in addition to
4 pL of 100 base-pair ladder (BioVentures Inc. Murfreesboro, TN. USA) with 2 pL of
6X loading buffer. The gel was run at 80 Volts for 30 minutes and then viewed and
photographed with Polaroid film on an ultraviolet viewing box.
7.4.2.10 POLYMERASE CHAIN REACTION AMPLIFICATION
The basic features of the polymerase chain reaction (PCR) reaction are illustrated in
Figure 7.1. PCR is a means of amplifying specific DNA sequences by the use of
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complementary primer sequences and a DNA polymerase. Firstly the double stranded
DNA is denatured at high temperature then cooled to allow annealing of primer
sequences, present in excess, to their complementary sequences on the dissociated
double stranded DNA template. After a further temperature change the DNA
polymerase facilitates extension of the primer sequence in the 5' to 3' direction. The
primer sequences are designed so that the extension phase will allow synthesis of
regions complementary to the original primer sequences. Thus, the newly synthesized
DNA can then act as a template for further cycles of amplification. The discovery of
Thermus aquaticus (Taq) polymerase,(383) which has a half-life of 20 minutes at
94 °C, facilitated the development of automated PCR sequencing technology.
Under optimal conditions, PCR technology allows for the amplification ofDNA from
a single cell with an error rate calculated as 1:9000 for single base pair
substitutions.(384) (385)




















All primer sequences were designed so that they that spanned at least one intron/exon
boundary.(See Table 7.1) An intron is a nucleotide sequence intervening between
exons (coding regions) that are excised from a gene transcript during RNA
processing. Thus, PCR products amplified from genomic DNA rather than cDNA
could be recognised as they would be larger than the predicted size of the cDNA
product. PCR product size was between 200 and 600 base pairs that allowed for clear
resolution of PCR product on agarose gels without the prolonged optimization that is
required for larger PCR products. Primer sequences for GAP-DH, IF-y and IL-4 were
manufactured by Operon Technologies (Alameda, CA. USA) and diluted to stock
solutions of 5 pM per pL in tris[hydroxymethyl] aminomethane (TRIS) pH 8.4.
Table 7.1: Positive control and cytokine DNA primer sequences
Sequence
name





5'-C CAA AAG GGT CAT CAT CTC T-3'
5'CCT GCT TCA CCA CCT TCT TG-3'
446
IF-y (386)
5'-AAT GCA GGT CAT TCA GAT GTA GCG G-3'
5'-GGA TGA GTT CAT GTA TTG CTT TGC G-3'
298
IL-2*
5'-CAT TGC ACT AAG TCT TGC ACT TGT CA-3'
5'-CGT TGA TAT TGC TGA TTA AGT CCC TG-3'
305
IL-4 (387)
5'-CAA CTT TGT CCA CGG ACA C-3'
5'-TCC AAC GTA CTC TGG TTG G-3'
344
IL-10*
5'-AAG CTG AGA ACC AAG ACC CAG ACA TCA AGG CG-3'
5'- AGC TAT CCC AGA GCC CCA GAT CCG ATT TTG G-3'
328
*Primer sequences supplied by Dr. Mark Scott
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7.4.2.10.2 PCR REACTION CONSTITUENTS
All reagents were stored at -20 °C in a designated PCR room with designated
instruments and no contact with post-PCR product.
The quantities given are for 1 reaction: The PCR reaction mixture consisted of 5 pL
10X PCR buffer (Mg free) (Promega. Madison, WI. USA), 5 pL MgCf (various
concentrations according to primer) (Perkin Elmer. Madison, WI. USA), 1 pL 10 mM
4 dNTP's (dATP, dGTP, dTTP, dCTP) (Roche Diagnostics Corporation. Indianapolis,
IN. USA), 5 pL each of the 5 pM sense and anti-sense primers (Operon technologies.
Alameda, CA. USA) and 24 pL molecular grade water. The total volume was 45 pL
and the PCR mixture was kept on ice.(382)
The Taq reaction mixture was made with 0.2 pL Taq 5u/pL (Promega. Madison, WI.
USA), 0.25 pL 10X PCR buffer (Mg free) (Promega. Madison, WI. USA) and
2.05 pL molecular grade water to a total volume of 2.5 pL and kept on ice.
The PCR reaction consisted of 45 pL of reaction mix, 2.5 pL of sample cDNA and
2.5 pL diluted Taq polymerase, to a total of 50 pL.(382)
7.4.2.10.3 PCR CYCLING PROFILE
PCR was performed on a Biometra 1 programmable thermal cycler (Whatman.
Gottingen, Germany). Amplification was performed over 30 cycles (see below)
consisting of denaturation at 94 °C for 30 seconds, primer annealing at 50 °C for 45
seconds, primer extension at 72 °C for 60 seconds, with the final primer extension at
72 °C for 360 seconds before cooling to hold at 4 °C. The cycling protocol was
generously shared by Dr. Mark Scott.
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7.4.2.10.4 PCR OPTIMISATION
7.4.2.10.4.1 RNA CONCENTRATION AND LOWER LIMIT OF DETECTION
Previous experiments performed by Dr. Mark Scott with cervical samples had
suggested that a starting RNA concentration of 2 pg was adequate for RT. It was
considered appropriate to confirm this for the anal samples and assess the limit of
detection of the PCR. Anal swabs had RNA extracted in the usual manner and
quantified by spectrophotometry. Reverse transcription was performed according to
protocol on 2pg of RNA and serial dilutions were made of the cDNA to represent
starting RNA concentrations of 2000 ng, 1000 ng, 500 ng, 100 ng, 50 ng, 10 ng, 2 ng.
7.4.2.10.4.2 MAGNESIUM CONCENTRATION
PCR was performed to optimise magnesium chloride concentrations with positive
controls for GAP-DH, IF-y, IL-2, IL-4, IL-10, and molecular grade water as a
negative control. Magnesium chloride concentrations of 25, 20, 15, 10, and 5 mmol/L
were used.
7.4.2.10.4.3 OPTIMUM THERMUS AQUATICUS CONCENTRATION
To ensure that the concentration of Thermus Aquaticus (Taq) was adequate for the
PCR amplification, a PCR was performed using GAP-DH positive control and GAP-
DH primers with Taq concentrations of 10 u, 1 u, 0.1 u, 0.01 u and 0.001 u.
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7.4.2.10.4.4 PCR CYCLING PARAMETERS
Experiments were undertaken to investigate the optimum cycle number for the PCR
reaction. These experiments were undertaken with GAP-DH positive control and
GAP-DH primers, and used cycle numbers of 22, 24, 26, 28, 30, 32, and 34.
7.4.2.10.4.5 UNIFORMITY OF PCR AMPLIFICATION
In order to compare different cDNA samples, it was essential to ensure uniformity of
amplication between samples. To ensure the Biometra 1 programmable thermal cycler
performed in this way all 96 wells were loaded with GAP-DH positive control and
amplified with GAP-DH primers. The PCR products were then run on an agarose gel.
7.4.2.10.4.6 PCR POSITIVE CONTROLS
GAP-DH is a catalytic enzyme involved in glycolysis that is constitutively expressed
in almost all mammalian tissues at high levels. Reverse transcription and
amplification of GAP-DH m-RNA was included in every assay as an endogenous
standard. Cytokine and GAP-DH positive controls were provided by Dr Mark Scott
and were derived from gel purified RT-PCR product of cervical swab material. To
assess the optimal concentration of positive control for PCR, serial dilutions were
made and ran on Agarose gel. (See Figure 7.2 for an example using IL-10) The
clearest band with least accessory bands was chosen for each positive control, and
stock solutions of this concentration were made and kept at 4 °C.
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Figure 7.2: PCR of IL-10 positive control logarithmic dilutions
12345678 9









9 100 base-pair ladder
* Dilution chosen for stock solution
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7.4.2.10.4.7 VERIFICATION OF GAP-DH AND CYTOKINE PCR POSITIVE
CONTROLS
Positive controls for GAP-DH, IF-y, IL-2, IL-4, and IL-10 were amplified and the
PCR product ran on an agarose gel. The gel product band for each control was excised
and concentrated using a gel purification method (Quiagen Inc., Valencia, CA, USA)
and subsequently sequenced by the DNA sequencing lab at UCSF.
7.4.2.11 SOUTHERN TRANSFER AND DETECTION OF PCR
PRODUCT
As the PCR electrophoretic product from the anal swab samples often contained
several bands in the region of the expected base-pair band, a Southern transfer was
performed for cytokine band confirmation. This technique was first described by
Southern in 1971 and involves transfer of electrophoretically separated fragments of
DNA, after denaturation, from a gel to an absorbent sheet of material, such as
nitrocellulose, to which the DNA binds. The sheet is then immersed in a solution
containing a labeled probe that will hybridize to the DNA fragment.(388) Southern
transfer and enhanced chemiluminescent (ECL) were performed as described below.
7.4.2.11.1 METHOD
Southern transfer was undertaken using the Trans-BlotR SD Semi-Dry Electrophoretic
Transfer Cell (Bio-Rad laboratories. Hercules, CA, USA).
7.4.2.11.2 SOUTHERN TRANSFER
Eighteen samples of PCR product with evidence of bands corresponding to positive
control for both IF-y and IL-4 were investigated. PCR product was run with 10 pL
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PCR product and 2 pL 6X running buffer on a 1.5 percent 50 mL agarose gel with
2 pL ethidium Bromide over 60 mins at 80 volts as previously described. A Polaroid
phototograph was taken.
A 3 mm thick blotting paper, a nitrocellulose membrane cut slightly smaller than the
agarose gel, and the agarose gel was soaked in 0.5X TAE for 15 minutes. An
electrophoresis gel sandwich was assembled in an electrophoresis box as shown
below. See Figure 7.3.
Figure 7.3: Southern transfer electrophoresis diagram
Cathode
2x3 mm blotting paper
Agarose gel
Nitrocellulose membrane
2 x 3 mm filter paper
Anode
Any air bubbles were removed by expression, as they would impair transfer of the
DNA from the gel to the nitrocellulose membrane. The cathode was set in place and
the cover closed. The 50 mL gel transfer was performed at 10 volts for 30 minutes.
The current calculation used was 5.5 mA/cm" for the 50 mL gel used.
Following transfer the membrane was rinsed briefly in 0.5X TAE buffer. DNA was
fixed to the membrane by placing it on filter paper pre-soaked with 0.4 M NaOH
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(Fisher Scientific. Fairlawn, NJ. US) for 10 mins. Thereafter, the membrane was
rinsed in 2X standard sodium citrate (SCC) (Fisher Scientific. Fairlawn, NJ. US) for
10 mins and vacuum baked for 2 hrs at 80 °C. The membrane was then stored in a
sealed plastic bag at room temperature.
7.4.2.11.3 PEROXIDASE BLOCK
The membrane was soaked in 3 % hydrogen Peroxide solution. (Fisher Scientific.
Fairlawn, NJ. US) at room temperature for 15 minutes, then washed in 0.1X saline,
sodium phosphate, EDTA (SSPE) (Fisher Scientific. Fairlawn, NJ. US)/0.5% Sodium
dodecyl sulphate (SDS) (BioRad, Flercules, CA, USA) for 30 mins at 65°C. The
membrane was then either hybridised or stored in 2X SSPE at 4°C.
7.4.2.11.4 HYBRIDISATION
The membrane was placed in a sealed plastic bag with 10 mL of the hybridization
solution (5X SSPE/0.1% SDS) that had been previously warmed in a water bath to
50 °C, and 2 pL of the cytokine probe (IF-y and IL-4 (both 5 pmol/pL) were used
separately) (Operon Technologies. Alameda, CA, USA). All air bubbles were
removed from the bag, it was heat sealed, and hybridisation was allowed to take place
overnight at 50 °C. See Table 7.2 for details of cytokine probe sequences.
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Table 7.2: Cytokine probe sequences used for hybridisation after Southern
transfer
Cytokine probe Probe sequence TM (°C)
IF-y 5'XTCTGTCACTCTCCTCTTTCCAATT3' 61.5
IL-4 5'XGGTGCACAGAGTCTTCTGCTCTGTG3' 67.75
X= biotin, Tm = melting temperature.
7.4.2.11.5 ENHANCED CHEMILUMINESCENT DETECTION
The membrane was removed from the hybridisation bag, immersed in a biotin wash
and shaken for 30 minutes at 55 °C. A second biotin wash was performed for 30 min
at 55 °C. The membrane was then immersed in a horseradish peroxidase (HRP)
(Vector Laboratories, Burlingame, CA, USA) wash (5 pL of HRP added to 200mL of
37 °C wash), and shaken at room temperature for 30 min. This step was then repeated
once. The membrane was removed from the HRP wash and blotted dry. The ECL was
performed by adding equal quantities of each reagent and incubating the membrane
for 1 minute. The membrane was then again blotted dry.
In a dark-room the dry membrane was placed next to an unexposed X-ray plate for 3
minutes and then the X-ray film was exposed using a Hope Micro-Max Model 319




Spectrophotometric analysis indicated that RNA quality was less than optimal for
subsequent RT-PCR. An ideal 260/280 ratio is above 1.8, and most specimen ratios
averaged 1.4 (See Table 7.3). This is most likely related to the nature of the
specimens, and faecal protein contamination in particular. Repeated rounds of
phenol:chloroform:IAA RNA extraction did not improve specimen purity. (See Table
7.4 and Table 7.5)
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Table 7.3: Sample of RNA spectrophotometry results
Sample OD 260 OD 280 RNA concn.
(pg/pL)
260/280 OD
1 0.025 0.015 0.100 1.667
2 0.032 0.019 0.128 1.684
3 0.101 0.168 0.404 1.485
4 0.413 0.281 1.652 1.470
5 0.243 0.221 0.972 1.100
6 0.220 0.141 0.880 1.560
7 0.327 0.211 1.308 1.550
8 0.225 0.151 0.900 1.490
9 0.264 0.179 1.056 1.475
10 0.434 0.298 1.736 1.456
11 0.116 0.082 0.464 1.415
12 0.192 0.130 0.768 1.477
13 0.439 0.280 1.756 1.568
14 0.277 0.182 1.108 1.522
15 0.110 0.071 0.440 1.549
16 0.354 0.236 1.416 1.500
17 0.114 0.080 0.456 1.425
18 0.129 0.086 0.516 1.500
19 0.554 0.331 2.216 1.674
20 0.975 0.668 3.900 1.460
21 0.881 0.578 3.524 1.524
22 0.712 0.489 2.840 1.456
23 0.315 0.242 1.260 1.302
24 1.277 0.867 5.108 1.473
25 1.002 0.669 4.008 1.498
26 1.432 0.914 5.728 1.567
27 2.076 1.249 8.304 1.662
28 1.193 0.806 4.772 1.480
29 1.215 0.821 4.860 1.480
30 0.715 0.504 2.860 1.419
31 1.630 1.023 6.520 0.586
32 0.914 0.636 3.656 0.437
33 0.890 0.624 3.560 1.426
34 1.642 1.048 6.568 1.567
water 0.004 0.001 0.0 4
average 0.631 0.421 2.522 1.438
OD: optic density
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Table 7.4: Spectrophotometric analysis of 1-5 RNA extractions from batches
of 6 anal swabs using the phenol:chloroform:IAA method
Number of OD 260 OD 280 RNA concn. 260/280 OD
extractions (HS/HL)
1 0.092 0.064 0.368 1.437
1 0.064 0.040 0.256 1.600
1 0.204 0.136 0.816 1.500
1 0.090 0.059 0.360 1.525
1 0.042 0.021 0.168 2.000
1 0.079 0.057 0.316 1.386
2 0.075 0.053 0.300 1.415
2 0.002 0.001 0.008 2.000
2 0.088 0.059 0.352 1.492
2 0.078 0.051 0.312 1.529
2 0.042 0.027 0.168 1.556
2 0.031 0.017 0.124 1.824
3 0.019 0.012 0.076 1.583
3 0.094 0.062 0.376 1.516
3 0.070 0.045 0.280 1.556
3 0.089 0.064 0.356 1.391
3 0.065 0.044 0.260 1.477
3 0.161 0.118 0.644 1.364
4 0.094 0.067 0.376 1.403
4 0.040 0.031 0.160 1.290
4 0.078 0.060 0.312 1.300
4 0.100 0.061 0.400 1.639
4 0.119 0.079 0.476 1.506
4 0.089 0.062 0.256 1.435
5 0.202 0.137 0.808 1.474
5 0.038 0.026 0.152 1.462
5 0.103 0.066 0.412 1.561
5 0.050 0.033 0.200 1.515
5 0.018 0.011 0.072 1.636
5 0.041 0.027 0.264 1.519
water 0.001 0.000 0.004 0.001
Table 7.5 Summary of mean RNA OD 260, RNA concentration, and RNA
purity from samples in Table 7.4
No. of Mean OD 260 Mean RNA cone. Mean 260/280
extractions Hg/fiL OD
1 0.095 0.380 1.575
2 0.053 0.212 1.636
3 0.083 0.332 1.481
4 0.087 0.348 1.429
5 0.075 0.300 1.528
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7.5.2 PCR OPTIMISATION
7.5.2.1 RNA CONCENTRATION AND LOWER LIMIT OF DETECTION
The lower limit of detection for GAP-DH using GAP-DH primers for both samples
was 2 ng of starting RNA. (See Figure 7.4) As GAP-DH is expressed in high
concentration in human cells, it was elected to maintain the starting RNA
concentration at 2 pg for the cytokine studies as it was assumed that they would be
present in much lower concentrations.
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Figure 7.4: GAP-DH lower limit of detection













7.5.2.2 PCR REACTION MAGNESIUM CONCENTRATION
Results are shown in Figure 7.5.1, Figure 7.5.2, Figure 7.5.3, Table 7.6, and Figure
7.6 for optimum magnesium chloride concentration in PCR reactions using primers
for GAP-DH, IF-y, IL-2, IL-4, and IL-10. (* indicated the MgCl2 concentrations
chosen for PCR reaction mixtures).
Figure 7.5.1: Optimising PCR MgCI2 concentration for A: IL-4 and B: IL-2
A B
123456789 10 11
1 2 3 4 5 6 7 8 9 10 11 12
13 14 15
Lane Number MgCL cone. Lane Number MgCL cone.
(A) (mmol/L) (B) (mmol/L)
1,2 25 1,2 25
4,5 20 4,5 20
7,8 15* 7,8 15*
12, 13 10 10, 11 10
15, 16 5 13, 14 5
3,6, 9, 14, 17 Negative controls 3,6, 9, 12, 15 Negative controls
11, 18 100 base-pair ladder
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Figure 7.5.2: Optimising PCR MgCI2 concentration forC:IF-Y, and D:GAP-DFI
Lane Number MgCL conc. Lane Number MgCh conc.
(C) (mmol/L) (D) (mmol/L)
1,2,3 25 1,2 25
4, 5,6 20 4,5 20
7, 8,9 15* 7,8 15
11, 12, 13 10 12, 13 10*
14, 15, 16 5 15, 16 5
10, 17 100 base-pair ladder 11, 18 100 base-pair ladder
3,6, 9, 14, 17 Negative controls
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Figure 7.5.3: Optimising PCR MgCI2 concentration for E: IL-10
E






11, 18 100 base-pair ladder
Table 7.6: Optimum magnesium chloride concentration for cytokine and GAP-
DH PCR reactions








Figure 7.6 Agarose gel of optimum PCR magnesium chloride concentration
for cytokine and GAP-DH positive control PCR reactions






6 100 base-pair ladder
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7.5.2.3 OPTIMUM THERMUS AQUATICUS CONCENTRATION
The optimum Taq concentration chosen for all PCR reactions was lu as shown in
Figure 7.7.
Figure 7.7 Optimum Taq concentration for PCR using GAP-DH positive
control primer sequences






10 100 base-pair ladder
11 Negative control
12 Positive control
* 1 unit of Taq was chosen for the PCR reactions
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7.5.2.4 OPTIMUM PCR CYCLING PARAMETERS
The PCR signal for GAP-DH that was most clear with the least number of accessory
bands present was seen at 30 cycles of amplification. (See Figure 7.8)
Figure 7.8 Optimum PCR cycle number
12 34 56 789
10 11 12 13 14 15 16








9, 16 100 base-pair ladder
30 cycles of PCR were chosen for the PCR reaction
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7.5.2.5 UNIFORMITY OF PCR AMPLIFICATION
The Biometra 1 PCR thermal cycler showed equal amplification performance in each
well using GAP-DH positive control. (See Figure 7.9)
Figure 7.9: Uniformity of PCR amplification using GAP-DFI positive control
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7.5.2.6 VERIFICATION OF GAP-DH AND CYTOKINE PCR POSITIVE
CONTROLS
DNA sequence analysis using the basic local alignment search tool (BLAST) that
provides a method for rapid searching of nucleotide and protein databases confirmed
the identity of DNA sequence fragments as IF-y, IL-2, IL-4, IL-10, and GAP-DH.
(Data not shown)
7.5.3 PCR GEL ELECTROPHORESIS
Each 50 mL agarose gel was made with two 12-slot combs per anal swab batch. Each
row had a positive control, and graduated 100 base-pair ladder with remaining spaces
for PCR product. A single negative control was run per batch. Typically when gels
were run GAP-DH was mostly positive but cytokine analysis frequently showed
absent bands, or numerous accessory bands and very few visible bands that
corresponded to the size of the cytokine positive control. (See Figure 7.10 as an
example with positive controls for IL-10). The accessory bands were considered to
reflect impurity ofRNA obtained after phenol:chloroform:IAA extraction. To confirm
that bands corresponding to the positive control, and to identify possible bands that
may not have been visible, Southern transfer was carried out with probes for IF-y and
IL-4, representing a Thl and Th2 cytokine.
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Figure 7.9: Typical agarose gel from anal specimens using primers and
positive controls for IL-10
Lane Number Contents Lane Number Contents
(A) (B)
1-10, 13-22 Anal swab samples 1-10, 13,14 Anal swab samples
11,23 Positive control 11,23 Positive control
12, 24 100 base pair ladder 12,24 100 base pair ladder
22 Negative control
Anal swabs were typically processed in batches of 35. Depending on RNA
concentration, RT-PCR was performed on average between 25 and 30 samples. These
samples were subsequently amplified by PCR and ran on agarose gels as above.
7.5.4 SOUTHERN TRANSFER
Southern transfer of PCR gels that showed bands corresponding to the base pair size
of both IF-y and IL-4 had no corresponding bands when probed by the Southern
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transfer method. Positive and negative controls were intact. It was concluded after this
analysis that there was either no anal sample cytokine mRNA present, or it was
present in very low concentration and beyond the sensitivity of the experimental
method used.
7.6 DISCUSSION
There is increasing interest in the immunopathogenesis of various diseases within
gastrointestinal tissue.(389) Consequently, there has been a need to develop assays to
quantify immunological parameters such as cytokine gene expression in these
compartments. This is particularly relevant to the field of HIV mucosal pathogenesis
as the gastrointestinal epithelium is the site in Western societies where HIV
transmission most frequently occurs and where HIV infection is established. It is
critical to understand these early events, particulary as the prevention strategy for HIV
expands to include mucosal immune responses to preventative or therapeutic
vaccination and the local immune response to candidate rectal microbicides. Within
this context, and due to the amost ubiquitous presence of sexually transmitted HPV in
HIV-positive MSM, it is vital to understand the local influence both of this infection
and ofHPV associated anal dysplasia.
To date, most studies have used tisssue samples derived from surgical resection
specimens or endoscopic biopsies to describe cytokine responses in gut. However it
would be clearly advantageous to develop assays based on less invasive procedures
such as the collection of anal swabs. As discussed earlier this approach has been used
to characterise cytokine gene expression using endocervical brush sampling.(359)
Unfortunately in the above study this did not prove possible for the anal canal.
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Reasons for this failure to detect cytokine gene expression may be due to a number of
different reasons that are discussed below.
7.6.1 CYTOKINE DETECTION BY RT-PCR FROM ANAL
CYTOLOGY SWAB SAMPLES
In the above study anal canal samples were taken and immediately placed in
denaturing solution and stored at -80 °C. RNA was subsequently extracted by the
phenol-chloroform method, quantified and reverse transcribed. PCR was then
undertaken with primers specific for GAP-DH, IF-y, IL-2, IL-4 and IL-10. Lastly,
Southern transfer was performed and did not confirm the presence of any cytokine
signal. Potential factors associated with the failure to detect cytokine m-RNA with
this methodology are discussed below.
7.6.1.1 ANAL SWABS
7.6.1.1.1 CELLULARITY
Anal swabs are hypocellular compared to both cervical cytology material that has at
least 2000-3000 squamous cells, and anal biopsies that contain approximately 1
million cells when obtained using endoscopic forceps (J Elliott - personal
communication). In this study the subjects had previous anal cytology and a further
anal swab taken for HPV detection making it likely that the third study swab taken for
the cytokine study contained decreased amounts of cellular material.
The cells present in anal cytology specimens are predominantly squamous cells, with
T lymphocytes present in much reduced numbers. While epithelial cells are capable of
producing cytokines, Th cells are more likely to secrete both Thl and Th2 cytokine
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mRNA. Additionally, most cytokine secreting Th cells are predominantly found in the
sub-epithelial compartment that is not accessible to cytological sampling.
Thus, using the above sampling technique in the anal canal there was likely to be a
low starting cell count with cells that were present less likely than PBMCs to secrete
cytokines.
7.6.1.1.2 COMPARISON OF ANAL AND CERVICAL SWABS
The previously demonstrated detection of cervical canal cytokines by Scott et al using
similar methodology to that used above was encouraging although the cervical and
anal canals have significant differences from a sampling perspective.(359) Cervical
samples are obtained using both an endocervical brush in addition to an ectocervical
spatula, wheras the anal samples were taken using only a water moistened Dacron
swab because of issues related to subject acceptability. By using the bimodal cervical
sampling technique, and because of limited cervical subjective sensation, the ability
of clinicians to be more vigorous when sampling the cervix may in part explain the
cervical hypercellularity compared to the anal canal. Additionally the anal canal is
subject to abrasion with the passage of stool that may remove surface cells that is not
an issue in the cervical canal.
Furthermore, the cervix has been shown to be immunologically active with
lymphocyte shedding detected in almost 40% of HIV-positive women in one
study.(390) This may also be the case in HIV-negative women and so have had an
impact on the ability of Scott et al to detect cytokines in samples from cervical swabs.
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7.6.1.1.3 FAECAL CONTAMINATION OF SWABS
The reduced RNA purity was likely due to the presence of protein in the sample and
related to faecal contamination of the anal swab specimens. Anal specimens were
rarely grossly faecally contaminated, despite their nature, so discarding swabs based
on visual appearance would not have obviated this concern.
Normal faecal volume is partially comprised of gastrointestinal cellular material. It is
likely that total anal swab RNA was derived from both anal epithelial cells and other
cellular material such as sloughed gastrointestinal luminal cells and may explain the
robust signals demonstrated for GAP-DH so giving false reassurance as to the
adequacy of the experimental methods.
7.6.1.2 RNA
7.6.1.2.1 RNA DEGRADATION
While every effort was made to reduce the possibility of RNA degradation, it is
possible that cytokine RNA degradation may have occurred prior to reverse
transcription to cDNA. The management of anal samples following collection was
similar to that performed by Dr. Mark Scott with cervical specimens. It is possible
that RNAse exists in the anorectum that is not present in the cervical canal, or that the
degradation of the likely smaller concentrations of cytokine mRNA was enough to
limit its detection when compared to a housekeeping gene such as GAP-DH.
7.6.1.2.2 RNA PURITY
Phenol:chloroform RNA extraction provided less than optimal RNA quality based on
spectrophotometric analysis of 260/280 nm light absorption. This problem was
addressed by performing repeated rounds of phenokchloroform extraction that had
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little or no effect on quality. In addition, great care was taken to avoid any cellular
debris at the phenol:chloroform interface when processing the specimens as capturing
the interface would also increase protein content of samples. The poor quality of the
RNA was likely again related to the nature of the specimens and in particular protein
contamination as discussed above. The use of other RNA isolation methods such as
commercially available kits (e.g. RNAeasy.(Quiagen Inc., Valencia, CA, USA)), may
have yielded a better quality product, although all isolation systems are highly user
dependent.
7.6.1.2.3 RNA QUANTITY
Using the phenol:chloroform method mostly modest amounts ofRNA were extracted,
however these amounts were sufficient to allow RT-PCR within the volume and
concentration limits of the experimental method described above. Repeated rounds of
RNA extraction did not alter the amounts of RNA extracted. It should be noted that a
typical RNA yield is approximately 1-2% of all RNA in the sample, thus only
considering RNA samples of higher quantity (e.g. a 260 nm reading greater than 0.1),
or increased specimen purity with a 260/260 ratio over 1.8 for RT-PCR may have
yielded an increased chance of cytokine detection.
7.6.1.3 PCR
7.6.1.3.1 PCR CYCLING PARAMETERS
PCR cycling parameters were optimised for several variables including cycle number
and Taq concentration for GAP-DH, and each primer pair had optimum Magnesium
concentration established. In addition, the PCR machine used was shown to
consistently amplify DNA in each individual well.
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Due to the presence of highly visible positive control bands on agarose gel
electrophoresis using an empirical PCR protocol it was not considered necessary to
establish individual denaturing, annealing and extension temperatures for each primer
pair. Additionally, using the above method RT-PCR was capable of detecting 2 ng of
target mRNA with visualisation of PCR product on an agarose gel for GAP-DH.
Despite this optimisation of PCR cycling parameters no verifiable cytokine mRNA
was detectable. Reasons for this likely included low starting concentration of cytokine
cDNA after RT, and the presence of PCR inhibitors. Increasing the number of PCR
cycles was discounted as a means of increasing detectable PCR product as it was
considered that this would also increase the already frequent accessory bands visible
on the agarose gels and make specific band detection more difficult. This problem
would, however, have been abrogated if initial experimental design had included
plans to perform a Southern transfer on each specimen. The use of quantitative real¬
time PCR may have resolved the issue with low starting mRNA concentrations as is
discussed above.
7.6.2 ALTERNATE METHODOLOGY FOR CYTOKINE DETECTION
IN THE GASTROINTESTINAL TRACT AND GENITAL TRACT
A number of alternate methodologies exist to increase cytokine m-RNA detection and
are outlined above. Although the initial intent of the experiment was to demonstrate
cytokine gene expression in material collected by minimally invasive anal swabs, the
most effective change in experimental design may have been to transfer the sampling
technology from anal swab cytology to anal tissue biopsy collection. This change
would have increased cell yield, captured the cell rich submucosa, and if successful
allowed the investigator to assess cytokine gene expression in tissues with both
normal and dysplastic appearances using high-resolution anoscopy.
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Tissue biopsy has been used to obtain samples from the cervix with subsequent
detection of cytokines as described above.(361) (333) (391) This methodology is also
used at the University of California Los Angeles (UCLA) Mucosal Immunology Core
of the UCLA AIDS Instuitute to detect cytokines from rectal and colonic samples
taken at colonoscopy or flexible sigmoidoscopy.(392) UCLA investigators have
published data on cytokine gene expression by Real Time RT-PCR in rectal and
colonic biopsies in HIV-negative and HIV-positive individuals that qualifies the
methodology and has also demonstrated quantitative differences in cytokine gene
expression in both gastrointestinal sites, and also in individuals with treated and
untreated HIV disease.(392) Preliminary data has more recently also demonstrated the
feasibility of detecting cytokines using the same methodology from anal biopsy
material (I. McGowan - personal communication).
7.6.2.1 QUANTITATIVE REAL TIME PCR
Real-time polymerase chain reaction, also called quantitative real time polymerase
chain reaction (QRT-PCR) or kinetic polymerase chain reaction, is a laboratiory
technique used to simultaneously quantify and amplify a specific part of a given DNA
molecule. It is used to determine whether or not a specific DNA sequence is present in
the sample; and if it is present, what the numbers of copies in the sample are. The
procedure follows the general pattern of polymerase chain reaction, but DNA is
quantified after each round of amplification; this is the "real-time" aspect. Two
common methods of quantification are the use of fluorescent dyes that intercalate with
double-stranded DNA, and modified DNA oligonucleotide probes that fluoresce when
hybridised with a complementary DNA. While this technology was not available in
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the Palefsky lab, its use combined with RT may have allowed quantification of low
abundance cytokine mRNA at higher cycle numbers.
7.6.2.2 ENZYME LINKED IMMUNOSORBENT ASSAY
Investigators in the female genital tract have used cervical cytology to detect
cytokines but instead of RT-PCR have used an enzyme-linked immunosorbent assay
(ELISA).(393) These investigators demonstrated that levels of Thl-cytokines IFN-y
and TNF-a were negatively correlated with Th2-cytokines IL-6 and IL-10 in HPV-
positive normal and LSIL subjects. No correlation was observed for subjects with
HSIL.
7.6.2.3 IMMUNOASSAY
As an alternative to the use of biopsy tissue, Lettesjo et al have demonstrated the
presence of cytokines in stool from subjects with irritable bowel syndrome (IBS) and
collagenous colitis (CC) using a method that used immunoassays of faecal fluid
homogenate supernatant.(394) However, in these samples only 2 of 11 CC subjects
had detectable Interleukin 1 beta, and no IBS or CC subject had detectable tumour
necrosis factor alpha. This may indicate, similar to the methodology presented above,
that only small and mostly undetectable amounts of cytokine are present.
7.6.2.4 IN-SITU HYBRIDISATION (ISH)
Inflammatory bowel disease (IBD) encompasses Crohns Disease that typically
displays a Thl type response and Ulcerative Colitis that typically displays a Th2 type
response. Investigators have shown that cytokines may be detected by ISH of both




With over 100 cytokines/chemokines of clinical interest, investigators need to analyse
each sample for multiple cytokines order to correlate a specific disease process with
changes in cytokine levels. Using traditional methodologies, limited sample sizes or
budget restrictions can often prohibit this kind of testing. Luminex™ technology
offers rapid and sensitive testing of multiplexed cytokine measurements with
sensitivity comparable to traditional ELISA-based systems but with smaller sample
size requirements.(396) This methodology has been used with success in situations
where gastrointestinal tissue explants have been maintained in the laboratory and
functional assays performed on fluids supernantants.
7.6.3 ANORECTAL CO-INFECTION WITH STI
No testing for sexually transmitted infection (STI) was made prior to anal swab
collection, neither was anal symptoms noted. While it is likely that any
STI/inflammation would increase cytokine gene expression, this omission was of
academic interest only in the context of absent cytokine detection. However, of
interest Scott et al has recently published data that showed increased levels of IF-y,
IL-10, and IL-12 by RT-PCR of specimens collected by cervical swabs in women
with current C. trachomatis infection. (397)
7.6.4 AIM 2
As the RT-PCR for GAP-DH was almost always positive, and considering the strong
signals detected for each positive control it is unlikely that the RT-PCR reactions
were inadequate, and more likely that cytokine mRNA was not present in detectable
quantity using the above technique. Thus, it was not possible to progress with Aim 2.
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7.7 FUTURE CONSIDERATIONS
The anal canal has largely been ignored scientifically as a potentially
immunologically active site. More recently, and in the context of HPV associated
disease, statistics indicate that HIV-positive individuals have an increasing incidence
of anal cancer. Empirical translation of cervical cytological screening techniques are
being used to detect these potentially precancerous lesions but very little information
has been presented addressing the immunological impact of HPV and the
development of anal dysplasia. The above study failed to demonstrate the presence of
cytokines using the methodology described, however, as discussed above the most
appropriate change in methodology would have been to use biopsy tissue instead of
exfoliative cytology material. This would have likely abrogated issues related to
hypocellularity and faecal contamination, and additionally by using technologies such
as real-time PCR may have allowed manipulation of cycling parameters in response to
cytokine signal.
Ultimately despite the considerable challenges involved, the investigation of the anal
canal remains vital to both inform the pathogenesis of HPV associated anal dysplasia
and also to provide methods of assessing anal immune signal in the context of HIV
infection prevention strategies such as anorectal microbicide development.
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CHAPTER 8




What follows is a description of the development, set-up and initiation of a US multi-
site clinical study. An abridged study protocol is presented, and study results
published by Chin-Hong et al briefly presented and discussed.
8.2 PROJECT EXPLORE
Project EXPLORE (also known as HIV-NET 015) was a randomised controlled Phase
lib trial of a behavioral intervention to prevent HIV infection in a cohort of 4295
HIV-negative MSM funded by the National Institute of Allergy and Infectious
Disease (NIAID) Division of AIDS, HIV Network. The study was conducted in six
US metropolitan areas (New York City, San Francisco, Denver, Seattle, Boston and
Chicago) and employed counseling sessions and STD testing over a 3-year period.
The intervention arm received ten counseling sessions followed by maintenance
sessions every 3 months while the standard of care arm received twice-yearly
counseling. The design of the study allowed enrollment of ethnically and socio-
economically diverse HIV-negative MSM with a wide age range in US urban centers.
The assessments over a three-year period provided HIV incidence and prevalence
data, in addition to demographic, behavioural, medical (sexually transmitted
infection) data at each 3-6 month study visit. The published report for EXPLORE can
be found in Appendix 2.
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8.3 HPV SUB-STUDY
The HPV sub-study to EXPLORE was conceived and subsequently implemented at
UCSF with the goal of detecting the prevalence and incidence of HPV and anal
cytological abnormality in a population of HIV-negative MSM, in addition to
assessing the relationship of these parameters to HIV incidence.
8.3.1 BACKGROUND
The anal neoplasia study (ANS) at UCSF is the largest natural history study of anal
dysplasia in HIV-positive and -negative MSM in the US. Most of the ANS subjects
were initially recruited from the San Francisco Men's Health Study (SFMHS) - a
prospective epidemiological study designed to learn more about the natural history of
HIV/AIDS that was funded by the NIAID in 1983. Men 25-54 years old were
recruited then interviewed and tested for HIV infection at six-month intervals. To date
this study has provided invaluable information on sexual risk behaviour and HIV
incidence in this population.
The men subsequently recruited to the ANS were already at least 35 years old if
drawn from the first wave of SFMHS participants, and most other participants were
aged from their mid-thirties to mid-forties at study entry. This older population had
likely already been exposed to and acquired anal HPV and subsequently developed
anal cytological abnormalities. Thus, the study was unable to fully address incident
anal HPV and anal cytological abnormalities particularly in an HIV-negative
population as the study predominantly recruited HIV-positive men. The study also
had too few elderly men to adequately address the effects of age on anal HPV and
anal cytological abnormalites.
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The EXPLORE study provided a unique opportunity to address age-related anal HPV
and anal cytological abnormality incidence, prevalence and the effect of these
parameters on HIV seroincidence in an HIV-negative population ofMSM.
The evolution of the HPV sub-study study to EXPLORE may be divided into three
parts; Protocol Development and Site-Preparedness, Regulatory Considerations and
Communication Strategy as discussed below.
8.3.2 PROTOCOL
8.3.2.1 PROTOCOL TEAM
The protocol was developed by Dr. Cranston and Dr. Palefsky with consultation and
input from Dr. Darragh (anal cytopathologist) and Ms. Da Costa (Palefsky laboratory
manager), and latterly the four sub-study site Pis.
8.3.2.2 PROTOCOL DEVELOPMENT
The protocol was divided into sections devoted to Background, Objectives, Study
Design, Participant Eligibility, Study Procedures, Laboratory Specimens, Evaluation
of Outcomes, Data Collection, Statistical Considerations, Human Subjects, and
Administrative Procedures.
Dr. Cranston wrote initial drafts of each section that were then modified after review
by Dr. Palefsky, with the exception of the Statistical Considerations section that was
authored by Dr. Eric Vittinghoff, the biostatistician for the EXPLORE study.
Dr. Teresa Darragh (cytopathologist) and Ms. Maria DaCosta (laboratory manager)
were involved in discussions at the study concept and protocol development stage to
allow for forward planning of time/personnel management that facilitated processing
the specimens at UCSF. This was particularly important for anal cytology as this
influenced results reporting and time to clinical care for participants with abnormal
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anal cytology results. HPV specimen results were not made available to study
participants, as anal HPV testing is neither FDA approved nor standard of care and
were stored and batch tested according to laboratory personnel availability.
The final protocol appears in Appendix 3 and an abridged form of this protocol
appears below in section 8.2. The flow chart representing the study process is shown
in Figure 8.1.
Figure 8.1: The HPV sub-study development process
8.3.2.3 SITE PREPAREDNESS
8.3.2.3.1 STUDY SITES
Following HIV-NET approval of the study concept, the six EXPLORE study sites
were contacted and asked to consider taking part in the HPV sub-study. Four sites and
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Pis were willing to participate; San Franscisco CA (Grant Colfax), New York NY
(Beryl Koblin), Denver CO (Franklyn Judson), and Boston MA (Kenneth Mayer).
Two sites (Seattle and Chicago) declined to take part in the study as they did not
consider it would be feasible to implement the study due to the demands of
EXPLORE.
8.3.2.3.2 TRAINING MATERIALS
The HPV sub-study had a limited budget that did not include travel, and thus no on-
site training of study investigators or clinical staff was possible (with the exception of
the San Francisco site training that was undertaken by Dr. Cranston). Thus, most
training was accomplished remotely by creating video presentations of the anal
cytology testing method and common counseling messages relevant to each possible
anal cytology diagnosis (e.g. ASC-US, LSIL, HSIL).
Dr. Cranston scripted, set up filming with the assistance of the media department at
UCSF, and appeared in both videos entitled 'How to take an anal cytology specimen',
and 'Counseling messages for providers and study subjects regarding anal cytology
and HPV testing'. Scripts for both video presentations appear in Appendix 4 and
Appendix 5.
8.3.2.3.3 SUPPLIES
Dr. Cranston supplied all study sites with Cytyc™ ThinPrep anal cytology vials,
Dacron™ swabs, packaging and labeling materials that were appropriate for safely
transporting biological specimens by air according to Federal Airline Association
guidelines, and set up a dedicated shipping account.
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8.3.2.3.4 REFERRAL RESOURCES FOR ABNORMAL ANAL
CYTOLOGY RESULTS
Prior to study initiation Dr. Cranston provided all sites with the names and contact
information of local medical providers that were appropriate referral resources for
subjects with abnormal anal cytology.
8.3.2.3.5 REAL-TIME SITE PROBLEM RESOLUTION
At study commencement Dr. Cranston provided a 'hot-line' pager for any urgent real¬
time clinical care questions that arose relating to participant questions on HPV or anal
cytology interpretation or counseling, or any other pressing clinical site issue. This
allowed problem resolution while the participant was in the clinic and did not require
additional unscheduled return visits or impact clinic staff time.
8.3.3 CLINICAL TRIAL REGULATION
8.3.3.1 INSTITUTIONAL REVIEW BOARD (IRB)
Most large healthcare institutions in the US have an institutional review
board/independent ethics committee (IRB/IEC) whose membership is drawn from a
pool of individuals working in the same institution and community representatives.
This group is formally designated to review and monitor biomedical and behavioural
research involving human subjects that historically were initially developed in direct
response to research abuses earlier in the twentieth century. In accordance with FDA
and Health and Human Services (HHS) regulations, an IRB has the authority to
approve, require modifications in (to secure approval), or disapprove research. An
IRB performs critical reulatory oversight functions to ensure that research conducted
on human subjects is ethical. In the US, IRBs are mandated by the Research Act of
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1974, and are themselves regulated by the Office for Human Research Protections
(OHRP) within HHS.
As UCSF was not a study site, no IRB documentation was submitted to this site and it
was the responsibility of the site PI to submit the IRB request as an ammendment to
the EXPLORE protocol. Issues that were relevant to the IRB application that formed
an integral part of the protocol related to the Human Subjects section was concerned
with; risk of taking an anal cytology specimen, impact of an abnormal anal cytology
diagnosis both psychologically and in terms subsequent medical referral, and
protection of confidential medical information. At all clinical sites the IRB
ammendments were approved without difficulty.
8.3.3.2 EVOLUTION OF CLINICAL TRIAL REGULATION
The current regulatory environment in the US has evolved considerably since the
HPV sub-study was conceived and implemented. All studies now require Health
Insurance Portability and Accountability Act (HIPAA) documentation that ensures the
security and privacy of health data. Certificates of Confidentiality are required to limit
the availability of sensitive personal information such as illicit drug use/sexuality to
external investigators such as the Federal Government. Studies may additionally be
subject to external audit review during the study by the Federal funding body. While
all these regulations have been implemented to safeguard the wellbeing of the study
participant and their personal information they have significant consequences for
study costs and time to study implementation.
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8.3.4 COMMUNICATION STRATEGY
8.3.4.1 CONTRACT RESEARCH ORGANISATION (CRO)
Abt Associates Inc. (Cambridge, MA) functioned as the CRO with specific remit for
the HPV sub-study in addition to their responsibilities as CRO to EXPLORE. This
for-profit company applies research and consulting techniques to a wide range of
issues in social, economic, and health policy; international development; business
research and consulting; and clinical trials and registries. One of the strengths of this
company is that they employ experts in the specific field of research that in this case
included persons with extensive experience in the field of HIV/AIDS both for
EXPLORE and the HPV sub-study.
Abt Associates were responsible for suggesting that the initialisation of the sub-study
be delayed until after the initiation of EXPLORE due to the intensity of EXPLORE
set-up, and the use of study site resources for recruitment and retention. Thus the
HPV-sub-study initiation, with the full support of site Pis, was delayed approximately
8-12 months. Subsequently, after initiation of the parent study the first sub-study
subjects were recruited at the month 12 EXPLORE visit and offered study entry at
each 6-month visit subsequently. This delay had clear implications for recruitment
and in particular the number of longitudinal data points for subjects entering the sub-
study at later visits for incidence analysis of HPV, anal cytological abnormalities and
HIV infection.
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Figure 8.2: Organogram of the EXPLORE HPV sub-study
8.3.4.2 TELECONFERENCES
Teleconferences were the mainstay of study communication. Initial conference calls
were designated every four weeks when the study was being set up, and after the
hiatus due to EXPLORE start-up prior to study initiation. The conference calls were
coordinated by Abt Associates, led by Dr. Cranston and Dr. Palefsky and attended by
each PI or designated study site personnel. Initial calls were concerned with the
protocol, IRB applications and timelines around this process. Later conference calls
concentrated on issues of training study-site personnel to obtain anal cytology
samples, ability of study site personnel to counsel subjects on normal or abnormal
anal cytology results, adequacy of supplies to conduct the study and ensuring that
specimens were shipped according to study protocol.
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8.3.4.3 STUDY DOCUMENTATION
Due to the length of the start-up period and complexity of maintaining four clinical
sites all study-associated material was collated and kept at UCSF. This included the
final protocol, regulatory information, teleconference action items, Federal shipping
regulations for biological specimens, and contact information for the FedEx account,
vendors of study supplies, all study sites Pi's and associated personnel, and abnormal
anal cytology referral sources. This, along with a short period of overlap between Dr.
Cranston and Dr. Chin-Hong facilitated smooth transition of the medical management
of this multi-site study.
8.3.5 STUDY COMMENCEMENT
Dr. Cranston was present at UCSF for the first few weeks of study enrollment prior to
transferring responsibility to Dr. Chin-Hong.
8.3.6 ANAL CYTOLOGY ADEQUACY
This was the first time that many study-site personnel had taken an anal cytology
specimen and there was concern as to specimen quality. Dr. Darragh was asked to
perform rapid quality control on the initial 20 specimens from each site in order to
provide timely feedback to personnel.
8.4 THE ABRIDGED EXPLORE HPV SUB-STUDY PROTOCOL
HPV infection is one of the most common sexually transmitted agents among both
men and women, and HPV-associated anal condyloma are one of the most common
sexually transmitted diseases among MSM practicing receptive anal intercourse. HPV
has received much attention in the last decade due to its causal association with
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anogenital squamous cell cancer, including cancer of the cervix, vulva, vagina, penis
and anus.
There are two important reasons to study anal HPV infection and HPV-related lesions
in the anal canal of MSM. The first is that anal HPV infection may lead to
development of anal cancer and its putative precursors, ASIL. An understanding of
the biology of HPV infection and ASIL is critical to the development of an effective
strategy for prevention of potentially preventable anal cancer in MSM. The second
reason is perhaps even more important, which is that anal HPV infection and ASIL
may represent important risk factors for the acquisition ofHIV infection among HIV-
negative men, as well as new strains of HIV among men who are already HIV-
positive.
8.4.1 ANAL HPV INFECTION AND ASIL AS RISK FACTORS FOR
ANAL CANCER
The primary reason to expand our knowledge about anal HPV infection and ASIL is
their putative relationship with invasive anal cancer. Historically, most anal cancers in
men and women occur after the age of 50 years but anal cancer has recently been
increasing among younger men. The relationship between anal cancer incidence and
the HIV epidemic is not yet clear. One study suggested that the increase in anal cancer
among single, never-married men in San Francisco between the ages of 25 and 44
years predated the HIV epidemic.(267) In contrast, others have shown that the rate of
invasive anal cancer increased with increasing proximity to an AIDS diagnosis,
suggesting an association between anal cancer and HIV-related
immunosuppression.(276)
Since development of cervical cancer is preventable through detection and treatment
of CSIL before it progresses to cancer, it is highly likely that treatment of ASIL will
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prevent development of anal cancer. Anal cancer is thus one of the few preventable
malignancies in either HIV-positive or HIV-negative men, and an understanding of
the natural history of ASIL and associated risk factors is clearly needed to develop
appropriate prevention strategies.
For the last five years, the UCSF ANS has performed studies on the prevalence of
anal HPV infection and ASIL in a cohort of 346 HIV-positive and 242 HIV-negative
men, as well as changes in infection and disease over a 4-year follow-up period.(102,
206) The subjects were enrolled primarily from the SFMHS and the mean age at
enrollment of the HIV-positive men was 42 years (range, 24-64). The mean age of the
HIV-negative men was 45 years (range, 26-73). A high proportion of HIV-positive
and HIV-negative men had anal HPV infection and ASIL at baseline and after 4 years
of follow-up; the projected incidence ofHSIL was 49% among HIV-positive men and
17% among HIV-negative men. These data indicate that a significant proportion of
both HIV-positive and HIV-negative men are at risk of developing anal cancer.
This EXPLORE sub-study study was performed in HIV-negative men, but its results
have important implications for HIV-positive men. Since a high proportion of HIV-
negative men had anal HPV infection at baseline, we believe that many HIV-positive
men will have acquired HPV infection and possibly ASIL prior to acquisition ofHIV
infection. An understanding of anal HPV infection and ASIL among HIV-positive
men is therefore dependent on understanding the dynamics of infection and disease
prior to seroconversion.
Risk factors for acquisition of HPV infection and development of ASIL also remain
poorly understood. In the UCSF cohort study described above, we did not have a
sufficient number of HIV-negative men to perform multivariate analyses of risk
factors. Even more importantly, since most of the men were in their forties, we
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believe that they may have acquired HPV infection too long ago to provide
meaningful data. For this reason, studies of HIV-negative men younger than age 26
provides an ideal opportunity to better understand risk factors for HPV infection and
ASIL. To illustrate this point, we have been studying anal HPV infection in high-risk
HIV-positive and HIV-negative women, mostly age 35 or older. When queried about
receptive anal intercourse as a risk factor for HPV infection and ASIL, there was no
clear association. However, when we repeated this study among adolescent women
who had recently initiated sexual activity, we found anal HPV infection in nearly
30%, and there was a clear correlation with receptive anal intercourse in this group.
8.4.2 ANAL HPV INFECTION AND ASIL AS RISK FACTORS FOR
HIV SEROCONVERSION
Several studies have documented the role of sexually transmitted diseases (STD) as
cofactors for HIV acquisition.(398-401) To date there have not been any rigorous
studies on the role ofHPV infection or ASIL in potentiating HIV acquisition. The role
that STDs play in HIV acquisition may be twofold. Firstly, STDs are often associated
with mucosal friability and the increased possibility of body fluid exchange, including
blood, may enhance HIV transmission. Men who have internal anal lesions, whether
low-grade or high-grade, bleed very easily when a swab is passed into the anal canal
to obtain specimens for HPV testing or cytology. Insertion of objects into the anal
canal, as in receptive anal intercourse, may similarly lead to more frequent and larger
volumes of bleeding if ASIL is present. Secondly, STDs may lead to inflammatory
responses, and the increased presence of lymphocytes prone to HIV infection may
also potentiate HIV acquisition. HPV-related diseases may lead to HIV acquisition for
both of these reasons. Biopsies of ASIL frequently show a lymphocytic infiltration,
similar to cervical SIL lesions in which the majority of the lymphocytes in cervical
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lesions are CD4 cells. Therefore it is likely that cells susceptible to HIV infection are
present in larger quantities in ASIL lesions, at sites that are also likelier to bleed. For
both these reasons, we believe that HPV infection and ASIL increase the risk ofHIV
acquisition among HIV-negative men.
Additionally, HIV-positive men who have ASIL at the time of engaging in receptive
anal intercourse may be at risk of exposure to new HIV strains and may also be
likelier to transmit HIV to active partners. Since women have been shown to acquire
cervical HPV infection soon after initiation of sexual activity, we hypothesise that
MSM also acquire HPV infection soon after initiating receptive anal intercourse. If so,
then they may have HPV infection and possibly ASIL at a time of their lives when
they may be most likely to practice unsafe sex with a large number of partners. If data
do show that ASIL is a risk factor for HIV acquisition, this may have important
implications for development of new strategies to prevent HIV transmission.
Specifically, detection and treatment ofASIL in high-risk HIV-negative MSM may be
useful to lower the risk ofHIV acquisition.
In summary, more information is needed on the biology of anal HPV infection and
ASIL among MSM. These data are needed to better understand HPV infection and
ASIL as risk factors for anal cancer in both HIV-negative and HIV-positive men.




Anal cancer is a relatively common malignancy among MSM and may be even more
common among HIV-positive MSM. Data on anal HPV infection and ASIL from a
cohort of 346 HIV-positive and 262 HIV-negative MSM at UCSF show that anal
HPV infection and ASIL are very common among men in the 35-45 year age
range.(91, 102) Our follow up of the cohort showed that the 4-year projected
incidence of the putative anal cancer precursor lesion HSIL was 49% among HIV-
positive men and 17% among HIV-negative men. While men with anal HPV infection
and ASIL are probably at increased risk of anal cancer, little is known about the
prevalence or incidence of HPV infection and ASIL in men at either end of the age
spectrum, i.e., men over the age of 50 years and men aged 25 years or less. Although
these studies will be performed in HIV-negative men, they will also have important
implications for HIV-positive men, since we believe that many HIV-positive men will
have acquired HPV infection and possibly ASIL prior to acquisition ofHIV infection.
An understanding of anal HPV infection and ASIL among HIV-positive men is
therefore dependent on understanding the dynamics of infection and disease prior to
seroconversion. Knowledge of the natural history of anal HPV infection and ASIL in
the early years after sexual activity begins will therefore be very important. Like
cervical cancer, anal cancer may be preventable through screening for and treatment
of ASIL, and data collected in this study could have important implications for




The following objectives were addressed:
• To define the prevalence, incidence and risk factors for anal human
papillomavirus infection in a cohort of sexually active HIV-negative MSM.
• To define the prevalence, incidence and risk factors for anal cytologic
abnormalities in a cohort of sexually active HIV-negative MSM.
• To determine the association between HIV seroconversion and detection of
anal cytologic abnormalities or anal HPV infection in a cohort of sexually
active HIV-negative MSM.
8.4.5 STUDY DESIGN
The study characterised HPV infection and anal cytologic abnormalities in
approximately 1300 MSM chosen from among 2900 (four out of six sites) men
recruited into EXPLORE. All eligible participants were offered enrollment over a
maximum of a two-year accrual period until a total of 1400 - 2000 men were enrolled
to July 31, 2002.
EXPLORE participants were offered enrollment in the HPV study at the Month 12
study visit, unless the participant had been on study more than 486 days (closing date
of the Month 12-visit window) when the study was implemented. Thus some
participants were offered enrollment at the Month 18 study visit, and a few were
offered enrollment at the Month 24 study visit and Month 30 study visit.
At HPV study enrollment and at three 6-month interval visits (or two 6-month interval
visits for Month 30 enrollees) and for the duration of this HPV study, a minimum of
one anal swab was obtained from each participant. The swab was used for anal
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cytology (per our standard protocol) using the Thinprep method as well as for HPV
testing.
8.4.6 PARTICIPANT ELIGIBILITY
This study included men at high-risk for HIV infection enrolled in the EXPLORE: A
Randomized Clinical Trial of the Efficacy of a Behavioral Intervention to Prevent
Acquisition ofHIV Among Men who have Sex with Men.
8.4.6.1 INCLUSION CRITERIA
Persons were included in the study if they met the following criteria
• Enrolled in the EXPLORE
• Willing and able to provide written informed consent.
8.4.6.2 EXCLUSION CRITERIA
Persons were excluded from the study if they:
• Had an obvious psychological/psychiatric disorder that would invalidate the
informed consent process, or otherwise contraindicate participation in the study.
• Had any other condition that in the opinion of the study site Principal Investigator
will interfere with achieving the study objectives.
8.4.6.3 CONDITIONS FOR WITHDRAWAL
Participants could withdraw from study participation at any time, for any reason,
without loss of other benefits or services to which they were entitled. Withdrawal
from the HPV ancillary study did not affect participation in the EXPLORE trial.
Participants could be withdrawn from the study due to inability to comply with study
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procedures. Participants could be withdrawn at the request of the study site
investigator, following review with the co-chairs, protocol bio-statistician, and the
Protocol Coordination Team (PCT) Project Officer.
8.4.7 STUDY PROCEDURES
An overview of the study visit and procedure schedule is presented in Table 8.1.
Table 8.1: Schedule for visits and procedures during the HPV sub-study.
Study Month - hivnet 015 12 15 18 21 24 27 30 33 36 39 42
Enrollment in hpv Study d, d2 d3 d4
Laboratory tests
Anal Cytology d, d d d d2 d3
d3 d4
d4
Anal HPV Testing dj d d d d2 d3
d3 d4
d4
D = HPV study visits for all enrolled participants
Dj= HPV study visits for those who enroll at the Month 12 HIVNET 015 visit only
D2= HPV study visits for those who enroll at the Month 18 HIVNET 015 visit only
D3= HPV study visits for those who enroll at the Month 24 HIVNET 015 visit only
D4= HPV study visits for those who enroll at the Month 30 HIVNET 015 visit only
8.4.8 CONSENT
Each participant had to sign a consent form prior to participating in the HPV study.
8.4.9 SPECIMEN COLLECTION
Once the study was discussed with the subject and the consent form signed, anal
cytology specimens were collected using the ThinPrep method as previously
described above.
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8.4.10 FOLLOW-UP OF ANAL CYTOLOGY RESULTS
Anal cytology results were usually made available to subjects within 2 months (and
no longer than 4 months after collection) of their visit. If the cytology showed HSIL
or cancer, the subject was notified as soon as those results were available.
8.4.11 LABORATORY SPECIMENS
Specimens were collected and sent to the Department of Pathology, UCSF (cytology
samples) and the Department of Laboratory Medicine, UCSF (HPV samples).
8.4.11.1 ANAL CYTOLOGY TESTING
Thinprep anal cytologic smears were prepared according to the manufacturer's
instructions. Dr. Teresa Darragh, an expert in gynecologic pathology and is one the
most experienced pathologists in the world in interpreting anal cytology and
histopathology, read each slide. Slides were interpreted independently and without
knowledge of the results of anal HPV DNA testing. The criteria for grading anal
cytologic smears were identical to those for cervical cytology as discussed above.
8.4.11.2 HPV TESTING PROTOCOLS
HPV testing was performed using PCR, and provided information on the presence of
39 different HPV types. This test detects both high and low level infections. By
determining the presence of each type individually, it was possible to analyze other
combinations such as HPV 16 and 18 together. We determined how often these
individual types persist and whether we could detect new types over time.
To perform PCR, an aliquot of the Cytyc fixative was removed from each specimen
when the bottle was opened for the first time. The specimens were heated at 56 °C for
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one hour to inactivate HIV and digested with 10 mg/mL proteinase K. The PCR
protocol that we used was adapted from a method by Ting et al and has been used by
others for many different studies (16). The sample for PCR was added to a tube
containing one ml ammonium acetate/EtOH solution, and the DNA allowed to
precipitate at -20 °C overnight or at -70 °C for one hour. Thirty-five cycles of
amplification were performed. Detection of the PCR products was performed using a
non-radioactive enhanced chemiluminescence (ECL) dot blot technique. Each
membrane contained a set of negative LI hybridization controls that include human
HPV-negative cells and specimens containing all the components of the reaction
except target DNA. Positive controls consisted of plasmid amplifications of the
different HPV types. Each membrane also contained five specimens chosen at random
to be amplified and probed in duplicate, and therefore 5 % of our specimens were
tested twice as a check for assay reliability. The PCR product was fixed to the
membrane in a UV-crosslinker. ECL detection was performed according to the
manufacturer's (Amersham, Piscataway, NJ) instructions, and the blots exposed to X-
ray film at room temperature for 15 minutes and two hours. The blots were probed
with a generic probe mix consisting of biotinylated HPV LI PCR products from HPV
11, 16, 18, and 51. A second membrane was probed with B-globin oligonucleotide
probe to detect the presence of human DNA and confirm the integrity of the
amplification reaction. Ten more membranes containing specimens positive with the
generic probe were made and probed with each of the following types individually: 6,
11, 16, 18, 26, 31, 32, 33, 35, 39, 40, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 66, 68, 69,
70, 73, AE2, Pap 155, Pap 291, and the following types together in a probe mixture:
HPV 2, 13, 34, 42, 57, 62, 64, 67, 72, W13B. The presence of a dot on the membrane
with a probe for a given HPV type indicated positivity for that type. If a specimen was
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negative for B-globin, this implied that the specimen contained an inadequate number
of cells or an inhibitor of the amplification reaction. HPV results from these
specimens were excluded from analysis.
Specimens that were positive with the generic probe, but negative for the 39 specific
types were considered to have an "unknown" HPV type. Because of its high
sensitivity, PCR by definition must be performed with great care to avoid the
possibility of contamination. We took all possible precautions in handling our
samples, including separation of pre- and post-amplification products in different
parts of our research building. If any of the above negative and positive controls did
not work, the reaction was repeated. The UCSF lab performed a large volume ofHPV
testing for this study and other studies and to date we have not have problems with
contamination.
8.4.12 EVALUATION OF OUTCOMES
The outcomes measured were incidence of anal HPV infection, incidence of anal
cytological abnormality, prevalence of anal HPV infection, prevalence of anal
cytological abnormality, incidence of HIV infection, demographics of subjects with
anal HPV infection/HIV infection/anal cytological abnormality, and retention in the
study.
8.5 RESULTS OF THE HPV SUB-STUDY PUBLISHED BY CHIN-
HONG ET AL
Following Dr Cranston's departure from UCSF the study was handed over to Dr.
Peter Chin-Hong who was responsible for its management and subsequent data
collection, analysis and publication of results. In the interests of completeness the
results presented in the papers and abstract published by Chin-Hong et al (Appendices
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6, 7, and 8) are included below in addition to a brief disussion of the relevance of this
study's findings to the field of anal dysplasia and anal cancer.
8.5.1 PREVALENCE OF ANAL HPV
There is a high prevalence at first study visit of anal HPV of both high-risk and low-
risk types through all age ranges studied. (See Figure 8.2) The overall prevalence of
anal HPV was 57%, with 26% prevalence of high-risk HPV.




HPV: human papillomavirus; HPV HR: high-risk human papillomavirus; HPV LR: low-risk human
papillomavirus. Figure reproduced courtesy ofChin-Hong (111)
8.5.2 HPV TYPE
HPV-16 was the most commonly identified HPV type. Multiple HPV infections were
detected in 45% of participants.
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8.5.3 RISK FACTORS FOR ANAL HPV
Risk factors identified for the presence of anal HPV were: history of receptive anal
intercourse (Odds ratio (OR), 2.0; P<0.0001), and having more than 5 sex partners
within the previous 6 months (OR, 1.5; PO.OOOl).
8.5.4 PREVALENCE OF ANAL CYTOLOGICAL ABNORMALITIES
Anal cytological abnormalities were common in all age groups with an average
prevalence of 20% (See Figure 8.3)
Figure 8.4: Prevalence of ASIL in men by age group
ASIL: anal squamous intraepithelial lesion; LSIL: low-grade squamous intraepithelial lesion;
HSIL: high-grade squamous intraepithelial lesion. Figure reproduced courtesy ofChin-Hong (243)
8.5.5 RISK FACTORS FOR ANAL CYTOLOGICAL ABNORMALITIES
Using multivariate analyses the risk factors for LSIL was associated with having >5
male receptive anal sex partners (P = .03), use of alkyl nitrites in the previous 6
months (OR=1.6 95% confidence interval (CI) = 1.1-2.5; P = .03) or use of injection
drugs two or more times per month in the previous 6 months (OR = 19, 95% = 1.3 -
277; P = 0.03), older age at first receptive anal intercourse (P = .004), and infection
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with a greater number ofHPV types (P = .001 for linear trend). The risk ofHSILs was
associated with any anal HPV infection (OR 3.2, 95% CI = 1.1 - 9.4; P = .039) and
infection with an increasing number ofHPV types (P < 0.001 for linear trend).
8.5.6 RISK FACTORS FOR INCIDENT HIV INFECTION
Risk factors for incident HIV infection using univariate analysis showed evidence (P
< 0.05) for an association between anal HPV infection (hazard ratio (HR) 2.7, 95% CI
1.0-7.3) and detection of 3 HPV types (HR 3.7, 95% CI 1.4-10.3) in predicting HIV
seroconversion and moderate evidence (P < 0.10) for ASCUS (HR 2.4, 95% CI 0.9-
6.1). After adjustment for sexual activity, substance use and demographics, there was
evidence (P < 0.05) for the effect of 3 HPV types isolated (HR 3.3, 95% CI 1.1-9.9)
and ASCUS (HR2.8, 95% CI 1.1-7.8).
8.6 DISCUSSION OF RESULTS OF THE HPV SUB-STUDY
PUBLISHED BY CHIN-HONG ET AL
The epidemiology of cervical HPV infection and cervical cancer precursors has
already been established. In the female cervix the prevalence of both HPV infection
and cytological abnormality rises sharply in the late teenage years after sexual debut
and then decreases over time, with a slight rise in HPV prevalence in the over 55 year
old age group.(402) This late peak may be due to new infection related to a new
sexual partnership or age related attenuation of immune response and detection of
previous latent HPV infection. Cervical HPV infection is most commonly transient
with over 90% of infections becoming undetectable by PCR at 2 years.(403, 404)
Most cervical infections are with high-risk HPV, particularly HPV 16 and persistence
of this and other phenotypically high-risk infections are related to the development of
cervical cytological abnormalities. (405) (406)
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This study illustrated the epidemiology of anal HPV infection and anal cancer
precursors in urban HIV-negative MSM. The epidemiology of HPV infection in the
EXPLORE study differed greatly from that described in the cervix. There were high
prevalence rates of both high-risk and low-risk HPV throughout all age ranges
sampled with no diminution of prevalence over time. Likewise, and again in contrast
to the cervix, the prevalence of both high- and low-grade anal dysplasia was constant
over all age range samples at 5% and 15 % respectively.
In this population the high rates of both HPV infection and anal cytological
abnormality were most likely related to the higher numbers of new sex partners
consistently reported in all the age-groups sampled. The median number of new sex
partners in the 6 months preceding anal sampling was 8 while, by comparison,
sexually active females over age 30 years are much less likely to have similar
numbers of new sexual partners.(402, 407)
As there was no increase in anal HPV prevalence over time it is likely that, similar to
the cervix, anal infections are also transient with the constant prevalence rates
indicating frequent re-infections. Additionally, although HPV type-specific antibodies
have been previously shown to develop following HPV infection, the development of
protective type-specific immunity is unlikely as the same infection types were
detected in both younger and older men, assuming that all men had been exposed to
the same HPV types over time.
Although the prevalence of anal dysplasia in this study was 20%, this may be an
underestimate based on the limited sensitivity of anal cytological testing with Dacron
swabs of 50% for detection of high-grade dysplasia in a population of HIV-negative
MSM.(196) Thus, higher numbers of HIV-negative MSM may be at risk for the
development of anal cancer.
171
HPV infection and an atypical squamous cell diagnosis on anal cytology are
significantly associated with incident HIV infection. Prevention of anal HPV
onfection through vaccination or prompt treatment of HPV-associated lesions may
reduce the risk ofHIV transmission.
8.7 SUMMARY
8.7.1 HPV SUB-STUDY RESULTS
Although the anal canal and cervix share many embryological, histological and
pathological features, particularly in their response to infection with genitotropic HPV
infection - there are significant differences in the epidemiology of this infection and
subsequent cytological response in the cervical and anal canal of sexually active
adults. Likely related to frequent sexual exposure over many decades of life HIV-
negative MSM have persistent high prevalence of anal HPV and HPV associated
cytological abnormalities. This finding may be a factor contributing to the increased
rates of anal cancer in this population compared to the general population.
Additionally the presence of HPV and HPV associated anal cytological change may
increase risk ofHIV infection.
8.7.1 HPV SUB-STUDY SET-UP
The study provides an example of the potential benefits of collaborative research in
the context of a multi-site sub-study. Structured and facilitated communication
between all groups involved in this type of study at all levels is critical from planning
to study execution.
The most significant issue that arose in the initiation of the sub-study was the delay in
commencement due to the demands of EXPLORE. However, when the sub-study
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commenced, the study-site staff were in a position to both engage participants and to
enroll them rapidly. This enthusiastic enrollment allowed final subject numbers to be
similar to those projected with the full time allocation. Close liason at all levels from
study site to UCSF to the laboratory and cytopathology departments allowed rapid
responses to problem as they arose that may have delayed either study enrollment or
compromised study samples and data points.
Translational clinical research provides a critical role in bridging basic science to
clinical practice. This development has nescessitated increasing regulatory oversight
of such studies and whilst this is critical to protect the interests of study participants it
may have a significant impact on both study costs and initiation of studies in a timely
fashon. The above study was completed prior to federally mandated HIPAA
regulation that adds further complexity to the regulatory process.
By definition, translational clinical research requires a multilayered organisation of
complementary groups consisting of clinicians, basic scientists, and regulatory
groups. This is apparent not only in individual studies but in entire research networks
that have evolved to address particular research goals. Only by embracing these
challenges in current research can we hope to pursue the goals of the projects while




1. Saunders NA, Frazer IH. Simplifying the molecular mechanisms of
human papillomavirus. Dermatol Clin. 1998 Oct;16(4):823-7, xv.
2. Sailaja G, Watts RM, Bernard HU. Many different papillomaviruses
have low transcriptional activity in spite of strong epithelial specific enhancers.
J Gen Virol. 1999 Jul;80 ( Pt 7):1715-24.
3. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J
Clin Virol. 2005 Mar;32 Suppl 1:S59-66.
4. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, et
al. The LI major capsid protein of human papillomavirus type 11 recombinant
virus-like particles interacts with heparin and cell-surface glycosaminoglycans
on human keratinocytes. J Biol Chem. 1999 Feb 26;274(9):5810-22.
5. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. Human
papillomavirus infection requires cell surface heparan sulfate. J Virol. 2001
Feb;75(3):1565-70.
6. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky
K, Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular
receptors for human papillomaviruses. J Virol. 2003 Dec;77(24): 13125-35.
7. Patterson NA, Smith JL, Ozbun MA. Human papillomavirus type 31b
infection of human keratinocytes does not require heparan sulfate. J Virol.
2005 Jun;79(11):6838-47.
8. Day PM, Lowy DR, Schiller JT. Papillomaviruses infect cells via a
clathrin-dependent pathway. Virology. 2003 Mar 1 ;307(1): 1 -11.
9. Tilston P. Anal human papillomavirus and anal cancer. J Clin Pathol.
1997;50(8):625-34.
10. Favre M. Structural polypeptides of rabbit, bovine, and human
papillomaviruses. J Virol. 1975 May;15(5):1239-47.
11. Palefsky JM, Holly EA. Molecular virology and epidemiology of human
papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev.
1995;4(4):415-28.
12. Palefsky JM. Anal human papillomavirus infection and anal cancer in
HIV-positive individuals: an emerging problem. Aids. 1994;8(3):283-95.
13. Schneider A, Oltersdorf T, Schneider V, Gissmann L. Distribution
pattern of human papilloma virus 16 genome in cervical neoplasia by
molecular in situ hybridization of tissue sections. Int J Cancer. 1987 Jun
15;39(6):717-21.
14. Stoler MH, Broker TR. In situ hybridization detection of human
papillomavirus DNAs and messenger RNAs in genital condylomas and a
cervical carcinoma. Hum Pathol. 1986 Dec;17(12):1250-8.
15. Jenson AB, Rosenthal JD, Olson C, Pass F, Lancaster WD, Shah K.
Immunologic relatedness of papillomaviruses from different species. J Natl
Cancer Inst. 1980 Mar;64(3):495-500.
16. Chow LT, Broker TR. Papillomavirus DNA replication. Intervirology.
1994;37(3-4): 150-8.
17. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR,
et al. In vitro generation and type-specific neutralization of a human
papillomavirus type 16 virion pseudotype. J Virol. 1996 Sep;70(9):5875-83.
18. Meyers C, Mayer TJ, Ozbun MA. Synthesis of infectious human
papillomavirus type 18 in differentiating epithelium transfected with viral DNA.
J Virol. 1997 Oct;71(10):7381-6.
175
19. Fields BN. Field's Virology. Knipe DM, Flowley, P.M., editor.; 2001.
20. Mohr IJ, Clark R, Sun S, Androphy EJ, MacPherson P, Botchan MR.
Targeting the E1 replication protein to the papillomavirus origin of replication
by complex formation with the E2 transactivator. Science. 1990 Dec
21 ;250(4988): 1694-9.
21. Tsao YP, Li LY, Tsai TC, Chen SL. Human papillomavirus type 11 and
16 E5 represses p21 (Wafl/Sdil/Cipl) gene expression in fibroblasts and
keratinocytes. J Virol. 1996 Nov;70(11):7535-9.
22. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein
of human papillomavirus type 16 transforms fibroblasts and effects the
downregulation of the epidermal growth factor receptor in keratinocytes. J
Virol. 1993 Aug;67(8):4521-32.
23. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B,
Stremlau A, et al. Structure and transcription of human papillomavirus
sequences in cervical carcinoma cells. Nature. 1985 Mar 7-13;314(6006): 111-
4.
24. Luft F, Klaes R, Nees M, Durst M, Heilmann V, Melsheimer P, et al.
Detection of integrated papillomavirus sequences by ligation-mediated PCR
(DIPS-PCR) and molecular characterization in cervical cancer cells. Int J
Cancer. 2001 Apr 1 ;92(1):9-17.
25. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and
E7 genes of the human papillomavirus type 16 together are necessary and
sufficient for transformation of primary human keratinocytes. J Virol. 1989
Oct;63(10):4417-21.
26. Barbosa MS, Schlegel R. The E6 and E7 genes of HPV-18 are
sufficient for inducing two-stage in vitro transformation of human
keratinocytes. Oncogene. 1989 Dec;4(12): 1529-32.
27. Halbert CL, Demers GW, Galloway DA. The E7 gene of human
papillomavirus type 16 is sufficient for immortalization of human epithelial
cells. J Virol. 1991 Jan;65(1):473-8.
28. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the
retinoblastoma protein correlates with the transforming capacity of the E7
oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA. 1992
May 15;89(10):4442-6.
29. Sang BC, Barbosa MS. Single amino acid substitutions in "low-risk"
human papillomavirus (HPV) type 6 E7 protein enhance features
characteristic of the "high-risk" HPV E7 oncoproteins. Proc Natl Acad Sci U S
A. 1992 Sep 1 ;89(17):8063-7.
30. Werness BA, Levine AJ, Howley PM. Association of human
papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990 Apr
6;248(4951):76-9.
31. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC,
Nakamura Y, et al. Allelotype of colorectal carcinomas. Science. 1989 Apr
14;244(4901):207-11.
32. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. Rearrangement
of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA.
1987 Nov;84(21):7716-9.
33. Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53
gene for cooperation with the ras oncogene and transformation. J Virol. 1989
Feb;63(2):739-46.
176
34. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P.
Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles.
Microb Pathog. 1997 Apr;22(4):219-25.
35. Pagano M, Durst M, Joswig S, Draetta G, Jansen-Durr P. Binding of
the human E2F transcription factor to the retinoblastoma protein but not to
cyclin A is abolished in HPV-16-immortalized cells. Oncogene. 1992
Sep;7(9):1681-6.
36. Tommasino M, Adamczewski JP, Carlotti F, Barth CF, Manetti R,
Contorni M, et al. HPV16 E7 protein associates with the protein kinase
p33CDK2 and cyclin A. Oncogene. 1993 Jan;8(1):195-202.
37. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA. The
retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci.
1992 Aug;17(8):312-5.
38. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16
induces degradation of retinoblastoma protein through the ubiquitin-
proteasome pathway. Cancer Res. 1996 Oct 15;56(20):4620-4.
39. Greider CW. Telomerase is processive. Mol Cell Biol. 1991
Sep;11(9):4572-80.
40. Greider CW. Telomeres. CurrOpin Cell Biol. 1991 Jun;3(3):444-51.
41. Pandita TK. ATM function and telomere stability. Oncogene. 2002 Jan
21 ;21 (4):611-8.
42. Collins K. Structure and function of telomerase. Curr Opin Cell Biol.
1996 Jun;8(3):374-80.
43. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the
E6 gene product of human papillomavirus type 16. Nature. 1996 Mar
7;380(6569):79-82.
44. Nowak R, Sikora K, Pietas A, Skoneczna I, Chrapusta SJ. Germ cell¬
like telomeric length homeostasis in nonseminomatous testicular germ cell
tumors. Oncogene. 2000 Aug 17;19(35):4075-8.
45. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia
recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for
assembly of HPV virion-like particles. Virology. 1991 Nov;185(1):251-7.
46. Thierry F, Yaniv M. The BPV1-E2 trans-acting protein can be either an
activator or a repressor of the HPV18 regulatory region. Embo J. 1987
Nov;6(11):3391-7.
47. Delius H, Hofmann B. Primer-directed sequencing of human
papillomavirus types. Curr Top Microbiol Immunol. 1994;186:13-31.
48. zur Hausen H. Roots and perspectives of contemporary papillomavirus
research. J Cancer Res Clin Oncol. 1996; 122(1 ):3-13.
49. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, zur Hausen H,
et al. Specific types of human papillomavirus found in benign proliferations
and carcinomas of the skin in immunosuppressed patients. Cancer Res. 1994
Sep 1 ;54(17):4610-3.
50. de Villiers EM. Human pathogenic papillomavirus types: an update.
Curr Top Microbiol Immunol. 1994;186:1-12.
51. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A,
Jenison SA. Human papillomavirus type 16 variant lineages in United States
populations characterized by nucleotide sequence analysis of the E6, L2, and
L1 coding segments. J Virol. 1995 Dec;69(12):7743-53.
177
52. Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, Allan B, Williamson
AL, et al. Worldwide genomic diversity of the high-risk human papillomavirus
types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16.
J Virol. 2005 Nov;79(21):13630-40.
53. Da Costa MM, Hogeboom CJ, Holly EA, Palefsky JM. Increased risk of
high-grade anal neoplasia associated with a human papillomavirus type 16 e6
sequence variant. J Infect Dis. 2002 May 1; 185(9): 1229-37.
54. Stoppler MC, Ching K, Stoppler H, Clancy K, Schlegel R, Icenogle J.
Natural variants of the human papillomavirus type 16 E6 protein differ in their
abilities to alter keratinocyte differentiation and to induce p53 degradation. J
Virol. 1996 Oct;70(10):6987-93.
55. zur Hausen H. Condylomata acuminata and human genital cancer.
Cancer Res. 1976 Feb;36(2 pt 2):794.
56. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman
RJ. Human papillomavirus infection of the cervix: relative risk associations of
15 common anogenital types. Obstet Gynecol. 1992 Mar;79(3):328-37.
57. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et
al. Prevalence of human papillomavirus in cervical cancer: a worldwide
perspective. International biological study on cervical cancer (IBSCC) Study
Group. J Natl Cancer Inst. 1995 Jun 7;87(11):796-802.
58. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ,
Walboomers JM, et al. Sexually transmitted infection as a cause of anal
cancer. N Engl J Med. 1997;337(19):1350-8.
59. Kiviat NB, Critchlow CW, Holmes KK, Kuypers J, Sayer J, Dunphy C, et
al. Association of anal dysplasia and human papillomavirus with
immunosuppression and HIV infection among homosexual men. Aids.
1993;7(1):43-9.
60. Caussy D, Goedert JJ, Palefsky J, Gonzales J, Rabkin CS, DiGioia RA,
et al. Interaction of human immunodeficiency and papilloma viruses:
association with anal epithelial abnormality in homosexual men. Int J Cancer.
1990;46(2):214-9.
61. Critchlow CW, Holmes KK, Wood R, Krueger L, Dunphy C, Vernon DA,
et al. Association of human immunodeficiency virus and anal human
papillomavirus infection among homosexual men. Arch Intern Med.
1992;152(8):1673-6.
62. Williams AB, Darragh TM, Vranizan K, Ochia C, Moss AR, Palefsky
JM. Anal and cervical human papillomavirus infection and risk of anal and
cervical epithelial abnormalities in human immunodeficiency virus-infected
women. Obstet Gynecol. 1994;83(2):205-11.
63. Wallin KL, Wiklund F, Luostarinen T, Angstrom T, Anttila T, Bergman
F, et al. A population-based prospective study of Chlamydia trachomatis
infection and cervical carcinoma. Int J Cancer. 2002 Oct 1; 101 (4):371 -4.
64. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass
AG, et al. A prospective study of high-grade cervical neoplasia risk among
human papillomavirus-infected women. J Natl Cancer Inst. 2002 Sep
18;94(18):1406-14.
65. Tamim H, Finan RR, Sharida HE, Rashid M, Almawi WY.
Cervicovaginal coinfections with human papillomavirus and Chlamydia
trachomatis. Diagn Microbiol Infect Dis. 2002 Aug;43(4):277-81.
178
66. Coker AL, Bond SM, Williams A, Gerasimova T, Pirisi L. Active and
passive smoking, high-risk human papillomaviruses and cervical neoplasia.
Cancer Detect Prev. 2002;26(2):121-8.
67. Giulian AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MR, et al.
Clearance of oncogenic human papillomavirus (HPV) infection: effect of
smoking (United States). Cancer Causes Control. 2002 Nov;13(9):839-46.
68. Dating JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA,
Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in
the etiology of anal cancer. Cancer. 2004 Jul 15;101 (2):270-80.
69. Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV
carcinogenesis. Virus Res. 2002 Nov;89(2):191-9.
70. Handsfield HH. Clinical presentation and natural course of anogenital
warts. Am J Med. 1997 May 5;102(5A):16-20.
71. Nagle D, Rolandelli RH. Primary care office management of perianal
and anal disease. Prim Care. 1996 Sep;23(3):609-20.
72. Maw RD, Reitano M, Roy M. An international survey of patients with
genital warts: perceptions regarding treatment and impact on lifestyle. Int J
STD AIDS. 1998 Oct;9(10):571-8.
73. Reitano M. Counseling patients with genital warts. Am J Med. 1997
May 5;102(5A):38-43.
74. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et
al. Genital human papillomavirus infection in female university students as
determined by a PCR-based method. Jama. 1991 Jan 23-30;265(4):472-7.
75. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual
behavior and partner characteristics are the predominant risk factors for
genital human papillomavirus infection in young women. J Infect Dis. 1996
Oct;174(4):679-89.
76. Oriel JD. Natural history of genital warts. Br J Vener Dis. 1971
Feb;47(1):1-13.
77. Baken LA, Koutsky LA, Kuypers J, Kosorok MR, Lee SK, Kiviat NB, et
al. Genital human papillomavirus infection among male and female sex
partners: prevalence and type-specific concordance. J Infect Dis.
1995; 171 (2):429-32.
78. Schneider A, Sawada E, Gissmann L, Shah K. Human
papillomaviruses in women with a history of abnormal Papanicolaou smears
and in their male partners. Obstet Gynecol. 1987 Apr;69(4):554-62.
79. Palefsky JM, Barrasso R. HPV infection and disease in men. Obstet
Gynecol Clin North Am. 1996;23(4):895-916.
80. Becker TM, Stone KM, Alexander ER. Genital human papillomavirus
infection. A growing concern. Obstet Gynecol Clin North Am. 1987
Jun;14(2):389-96.
81. Koutsky L KN. Genital human papillomavirus. In: K HK, editor. Sexually
Transmitted Diseases. 3rd ed: McGraw-Hill; 1999. p. 347-59.
82. Koutsky L. Epidemiology of genital human papillomavirus infection. Am
J Med. 1997;102(5A):3-8.
83. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human
papillomavirus infection. Epidemiol Rev. 1988;10:122-63.
84. Kiviat NB, Koutsky LA, Paavonen JA, Galloway DA, Critchlow CW,
Beckmann AM, et al. Prevalence of genital papillomavirus infection among
179
women attending a college student health clinic or a sexually transmitted
disease clinic. J Infect Dis. 1989;159(2):293-302.
85. Martinez J, Smith R, Farmer M, Resau J, Alger L, Daniel R, et al. High
prevalence of genital tract papillomavirus infection in female adolescents.
Pediatrics. 1988 Oct;82(4):604-8.
86. Palefsky JM. Cutaneous and genital HPV-associated lesions in HIV-
infected patients. Clin Dermatol. 1997;15(3):439-47.
87. Vernon SD, Holmes KK, Reeves WC. Human papillomavirus infection
and associated disease in persons infected with human immunodeficiency
virus. Clin Infect Dis. 1995Aug;21 Suppl 1:S121 -4.
88. Chopra KF, Tyring SK. The impact of the human immunodeficiency
virus on the human papillomavirus epidemic. Arch Dermatol. 1997
May;133(5):629-33.
89. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al.
Cancer risk following organ transplantation: a nationwide cohort study in
Sweden. Br J Cancer. 2003 Oct 6;89(7):1221-7.
90. Anderson CA, Boiler AM, Richardson CJ, Balcos EG, Zera RT. Anal
condyloma: a comparison between HIV positive and negative patients. Am
Surg. 2004 Nov;70(11):1014-8.
91. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Jay N, Berry JM, et al.
Anal squamous intraepithelial lesions in HIV-positive and HIV-negative
homosexual and bisexual men: prevalence and risk factors. J Acquir Immune
Defic SyndrHum Retrovirol. 1998;17(4):320-6.
92. 1993 revised classification system for HIV infection and expanded
surveillance case definition for AIDS among adolescents and adults. MMWR
Recomm Rep. 1992 Dec 18;41 (RR-17): 1 -19.
93. Palefsky JM. Cervical human papillomavirus infection and cervical
intraepithelial neoplasia in women positive for human immunodeficiency virus
in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2003
Sep;15(5):382-8.
94. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early
regression of cervical lesions in HIV-seropositive women receiving highly
active antiretroviral therapy. Aids. 1998 Aug 20; 12(12): 1459-64.
95. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, et al.
Human papillomavirus infection and associated cervical disease in human
immunodeficiency virus-infected women: effect of highly active antiretroviral
therapy. J Infect Dis. 2001 Sep 1 ;184(5):547-51.
96. Moore AL, Sabin CA, Madge S, Mocroft A, Reid W, Johnson MA.
Highly active antiretroviral therapy and cervical intraepithelial neoplasia. Aids.
2002 Apr 12;16(6):927-9.
97. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et
al. The effect of highly active antiretroviral therapy on cervical cytologic
changes associated with oncogenic HPV among HIV-infected women. Aids.
2001 Nov 9;15(16):2157-64.
98. van der Snoek EM, Niesters HG, Mulder PG, van Doornum GJ,
Osterhaus AD, van der Meijden Wl. Human papillomavirus infection in men
who have sex with men participating in a Dutch gay-cohort study. Sex Transm
Dis. 2003 Aug;30(8):639-44.
99. Hopfl R, Petter A, Thaler P, Sarcletti M, Widschwendter A, Zangerle R.
High prevalence of high risk human papillomavirus-capsid antibodies in
180
human immunodeficiency virus-seropositive men: a serological study. BMC
Infect Dis. 2003 Apr 30;3:6.
100. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine
MD, et al. High prevalence of anal human papillomavirus infection and anal
cancer precursors among HIV-infected persons in the absence of anal
intercourse. Ann Intern Med. 2003 Mar 18;138(6):453-9.
101. Dolei A, Curreli S, Marongiu P, Pierangeli A, Gomes E, Bucci M, et al.
Human immunodeficiency virus infection in vitro activates naturally integrated
human papillomavirus type 18 and induces synthesis of the L1 capsid protein.
J Gen Virol. 1999 Nov;80 ( Pt 11 ):2937-44.
102. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors
for human papillomavirus infection of the anal canal in human
immunodeficiency virus (HlV)-positive and HIV-negative homosexual men. J
Infect Dis. 1998;177(2):361-7.
103. Zaki SR, Judd R, Coffield LM, Greer P, Rolston F, Evatt BL. Human
papillomavirus infection and anal carcinoma. Retrospective analysis by in situ
hybridization and the polymerase chain reaction. Am J Pathol. 1992
Jun;140(6):1345-55.
104. Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic
sequences of 95 papillomavirus types: uniting typing, phylogeny, and
taxonomy. J Virol. 1995 May;69(5):3074-83.
105. Palefsky JM. Human papillomavirus infection and anogenital neoplasia
in human immunodeficiency virus-positive men and women. J Natl Cancer
Inst Monogr. 1998(23):15-20.
106. Moscicki AB, Hills NK, Shiboski S, Darragh TM, Jay N, Powell K, et al.
Risk factors for abnormal anal cytology in young heterosexual women. Cancer
Epidemiol Biomarkers Prev. 1999;8(2): 173-8.
107. Kiviat N, Rompalo A, Bowden R, Galloway D, Holmes KK, Corey L, et
al. Anal human papillomavirus infection among human immunodeficiency
virus-seropositive and -seronegative men. J Infect Dis. 1990;162(2):358-61.
108. Law CL, Qassim M, Thompson CH, Rose BR, Grace J, Morris BJ, et al.
Factors associated with clinical and sub-clinical anal human papillomavirus
infection in homosexual men. Genitourin Med. 1991;67(2):92-8.
109. Palefsky JM, Shiboski S, Moss A. Risk factors for anal human
papillomavirus infection and anal cytologic abnormalities in HIV-positive and
HIV-negative homosexual men. J Acquir Immune Defic Syndr. 1994;7(6):599-
606.
110. Breese PL, Judson FN, Penley KA, Douglas JM, Jr. Anal human
papillomavirus infection among homosexual and bisexual men: prevalence of
type-specific infection and association with human immunodeficiency virus.
Sex Transm Dis. 1995 Jan-Feb;22(1):7-14.
111. Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D,
Colfax G, et al. Age-Specific prevalence of anal human papillomavirus
infection in HIV-negative sexually active men who have sex with men: the
EXPLORE study. J Infect Dis. 2004 Dec 15; 190(12):2070-6.
112. Arany I, Tyring SK. Systemic immunosuppression by HIV infection
influences HPV transcription and thus local immune responses in condyloma
acuminatum. Int J STD AIDS. 1998 May;9(5):268-71.
113. Kiviat NB, Critchlow CW, Hawes SE, Kuypers J, Surawicz C,
Goldbaum G, et al. Determinants of human immunodeficiency virus DNA and
181
RNA shedding in the anal-rectal canal of homosexual men. J Infect Dis.
1998;177(3):571-8.
114. Chin-Hong PV, Palefsky JM. Natural history and clinical management
of anal human papillomavirus disease in men and women infected with
human immunodeficiency virus. Clin Infect Dis. 2002 Nov 1 ;35(9):1127-34.
115. Palefsky JM. Anal squamous intraepithelial lesions in human
immunodeficiency virus-positive men and women. Semin Oncol.
2000;27(4):471-9.
116. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T,
Crowley-Nowick PA, et al. Prevalence of and risks for cervical human
papillomavirus infection and squamous intraepithelial lesions in adolescent
girls: impact of infection with human immunodeficiency virus. Arch Pediatr
Adolesc Med. 2000 Feb;154(2):127-34.
117. Yoon H, Chung MK, Min SS, Lee HG, Yoo WD, Chung KT, et al.
Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1
motif can induce peptide-specific cytotoxic T-cells from peripheral blood
mononuclear cells of healthy donors. Virus Res. 1998 Mar;54(1):23-9.
118. Lowy DR, Schiller JT. Papillomaviruses and cervical cancer:
pathogenesis and vaccine development. J Natl Cancer Inst Monogr.
1998(23):27-30.
119. Rose RC, White Wl, Li M, Suzich JA, Lane C, Garcea RL. Human
papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing
antibodies. J Virol. 1998 Jul;72(7):6151-4.
120. Hines JF, Ghim SJ, Jenson AB. Prospects for human papillomavirus
vaccine development: emerging HPV vaccines. Curr Opin Obstet Gynecol.
1998 Feb;10(1):15-9.
121. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW,
Westmoreland D, et al. A recombinant vaccinia virus encoding human
papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for
cervical cancer. Lancet. 1996 Jun 1 ;347(9014):1523-7.
122. Greene I. Therapy for genital warts. Dermatol Clin. 1992
Jan;10(1):253-67.
123. von Krogh G, Wikstrom A. Efficacy of chemical and/or surgical therapy
against condylomata acuminata: a retrospective evaluation. Int J STD AIDS.
1991 Sep-Oct;2(5):333-8.
124. von Krogh G. Genitoanal papillomavirus infection: diagnostic and
therapeutic objectives in the light of current epidemiological observations. Int J
STD AIDS. 1991 Nov-Dec;2(6):391-404.
125. Longstaff E, von Krogh G. Condyloma eradication: self-therapy with
0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations-an
integrated safety assessment. Regul Toxicol Pharmacol. 2001 Apr;33(2):117-
37.
126. Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% v
podophyllin 20% to treat penile warts. Genitourin Med. 1988 Aug;64(4):263-5.
127. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS.
An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion
and 25% podophyllotoxin solution in the treatment of condylomata acuminata
in males and females. Int J STD AIDS. 1993 Jul-Aug;4(4):194-9.
128. Maw RD. Treatment of anogenital warts. Dermatol Clin. 1998
Oct;16(4):829-34, xv.
182
129. Bellina JH. The use of the carbon dioxide laser in the management of
condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol. 1983
Oct 15; 147(4):375-8.
130. Kraus SJ, Stone KM. Management of genital infection caused by
human papillomavirus. Rev Infect Dis. 1990 Jul-Aug;12 Suppl 6:S620-32.
131. Hallmo P, Naess 0. Laryngeal papillomatosis with human
papillomavirus DNA contracted by a laser surgeon. Eur Arch Otorhinolaryngol.
1991 ;248(7):425-7.
132. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M,
et al. Phase II double-blind, placebo-controlled study of the safety and efficacy
of cidofovir topical gel for the treatment of patients with human papillomavirus
infection. Clin Infect Dis. 2001 Sep 1 ;33(5):597-602.
133. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Inhibiting
effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma
(SiHa) xenografts in athymic nude mice. Oncol Res. 1998;10(10):533-9.
134. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E.
Antiproliferative effects of acyclic nucleoside phosphonates on human
papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell
lines. Oncol Res. 1998; 10(10):523-31.
135. Bekassy Z, Westrom L. Infrared coagulation in the treatment of
condyloma acuminata in the female genital tract. Sex Transm Dis. 1987 Oct-
Dec;14(4):209-12.
136. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful
tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum.
2005 May;48(5):1042-54.
137. Halasz CL. Treatment of common warts using the infrared coagulator.
J Dermatol Surg Oncol. 1994 Apr;20(4):252-6.
138. Wang XL, Wang HW, Wang HS, Xu SZ, Liao KH, Hillemanns P.
Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of
urethral condylomata acuminata. Br J Dermatol. 2004 Oct;151(4):880-5.
139. Beutner KR. Patient-applied treatment for external genital warts: the
time has come. West J Med. 1998 Oct;169(4):227-8.
140. Hengge UR, Ruzicka T. Topical immunomodulation in dermatology:
potential of toll-like receptor agonists. Dermatol Surg. 2004 Aug;30(8):1101-
12.
141. Beutner KR, Tyring SK, Trofatter KF, Jr., Douglas JM, Jr., Spruance S,
Owens ML, et al. Imiquimod, a patient-applied immune-response modifier for
treatment of external genital warts. Antimicrob Agents Chemother. 1998
Apr;42(4):789-94.
142. Skinner RB, Jr. Imiquimod. Dermatol Clin. 2003 Apr;21(2):291-300.
143. Trofatter KF, Jr. Interferon treatment of anogenital human
papillomavirus-related diseases. Dermatol Clin. 1991 Apr;9(2):343-52.
144. Petersen CS, Bjerring P, Larsen J, Blaakaer J, Hagdrup H, From E, et
al. Systemic interferon alpha-2b increases the cure rate in laser treated
patients with multiple persistent genital warts: a placebo-controlled study.
Genitourin Med. 1991 Apr;67(2):99-102.
145. Gonzalez-Sanchez JL, Martinez-Chequer JC, Flernandez-Celaya ME,
Barahona-Bustillos E, Andrade-Manzano AF. Randomized placebo-controlled
evaluation of intramuscular interferon beta treatment of recurrent human
papillomavirus. Obstet Gynecol. 2001 Apr;97(4):621-4.
183
146. Shillitoe EJ. Papillomaviruses as targets for cancer gene therapy.
Cancer Gene Ther. 2005 Dec 9.
147. Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor
in the development of condyloma acuminatum and squamous neoplasia of the
cervix. Acta Cytol. 1983 May-Jun;27(3):220-4.
148. Johnstone FD, McGoogan E, Smart GE, Brettle RP, Prescott RJ. A
population-based, controlled study of the relation between HIV infection and
cervical neoplasia. Br J Obstet Gynaecol. 1994 Nov; 101(11):986-91.
149. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency
diseases. A literature review. Cancer. 1971 Jul;28(1):89-98.
150. Palefsky JM. Human papillomavirus-associated anogenital neoplasia
and other solid tumors in human immunodeficiency virus-infected individuals.
CurrOpin Oncol. 1991 ;3(5):881 -5.
151. van Driel WJ, Kenter GG, Fleuren GJ, Melief CJ, Trimbos BJ.
Immunotherapeutic strategies for cervical squamous carcinoma. Hematol
Oncol Clin North Am. 1999 Feb;13(1):259-73.
152. Pardoll DM. Cancer vaccines. Nat Med. 1998 May;4(5 Suppl):525-31.
153. Chu NR, Wu HB, Wu T, Boux LJ, Siegel Ml, Mizzen LA.
Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing
tumour by administration of fusion protein comprising Mycobacterium bovis
bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol.
2000 Aug;121(2):216-25.
154. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, et
al. Encapsulated plasmid DNA treatment for human papillomavirus 16-
associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res. 2002
May;8(5):1028-37.
155. Rowen D, Lacey C. Toward a human papillomavirus vaccine. Dermatol
Clin. 1998 Oct;16(4):835-8.
156. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et
al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med.
2002 Nov 21 ;347(21): 1645-51.
157. Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, et al.
Dose-ranging studies of the safety and immunogenicity of human
papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in
young healthy women. Vaccine. 2004 Jul 29;22(21-22):2943-52.
158. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A,
et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of
infection with human papillomavirus types 16 and 18 in young women: a
randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447): 1757-65.
159. Cubie HA, Plumstead M, Zhang W, de Jesus O, Duncan LA, Stanley
MA. Presence of antibodies to human papillomavirus virus-like particles
(VLPs) in 11-13-year-old schoolgirls. J Med Virol. 1998 Nov;56(3):210-6.
160. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM.
Colposcopic appearance of anal squamous intraepithelial lesions: relationship
to histopathology. Dis Colon Rectum. 1997;40(8):919-28.
161. O'Connor JJ. Colposcopy in anorectal disease. Surg Gynecol Obstet.
1978;147(6):924-5.
162. Rocha-Zavaleta L, Garcia-Carranca A, Lira de la Cruz A, Barrios T,
Valdespino V, Cruz-Talonia F. Molecular evaluation of the prevalence of
184
oncogenic human papillomavirus genotypes in cervical acetowhite lesions.
Intervirology. 2002;45(2):111-4.
163. Lauke H. Rapid method to detect CIS-cells. Adv Exp Med Biol.
1997;424:69-70.
164. Ayre JE. Cervical cytology as a practical screening procedure for
cancer. N Engl J Med. 1952 Sep 4;247(10):361 -3.
165. Galloway DA. Serological assays for the detection of HPV antibodies.
IARC Sci Publ. 1992(119):147-61.
166. Carter JJ, Hagensee M, Taflin MC, Lee SK, Koutsky LA, Galloway DA.
HPV-1 capsids expressed in vitro detect human serum antibodies associated
with foot warts. Virology. 1993;195(2):456-62.
167. Carter JJ, Hagensee MB, Lee SK, McKnight B, Koutsky LA, Galloway
DA. Use of HPV 1 capsids produced by recombinant vaccinia viruses in an
ELISA to detect serum antibodies in people with foot warts. Virology.
1994;199(2):284-91.
168. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller
JT. A virus-like particle enzyme-linked immunosorbent assay detects serum
antibodies in a majority of women infected with human papillomavirus type 16.
J Natl Cancer Inst. 1994 Apr 6;86(7):494-9.
169. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al.
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody
responses following incident infection. J Infect Dis. 2000; 181 (6): 1911-9.
170. Wideroff L, Schiffman MH, Hoover R, Tarone RE, Nonnenmacher B,
Hubbert N, et al. Epidemiologic determinants of seroreactivity to human
papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-
positive and-negative women. J Infect Dis. 1996 Nov;174(5):937-43.
171. Hagensee ME, Koutsky LA, Lee SK, Grubert T, Kuypers J, Kiviat NB,
et al. Detection of cervical antibodies to human papillomavirus type 16 (HPV-
16) capsid antigens in relation to detection of HPV-16 DNA and cervical
lesions. J Infect Dis. 2000; 181 (4): 1234-9.
172. Lorincz AT. Molecular methods for the detection of human
papillomavirus infection. Obstet Gynecol Clin North Am. 1996 Sep;23(3):707-
30.
173. Moberg M, Gustavsson I, Gyllensten U. Real-time PCR-based system
for simultaneous quantification of human papillomavirus types associated with
high risk of cervical cancer. J Clin Microbiol. 2003 Jul;41(7):3221-8.
174. Trofatter KF, Jr. Diagnosis of human papillomavirus genital tract
infection. Am J Med. 1997 May 5;102(5A):21-7.
175. Wright TC, Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001
Consensus Guidelines for the management of women with cervical cytological
abnormalities. Jama. 2002 Apr 24;287(16):2120-9.
176. Sarode VR, Werner C, Gander R, Foster B, Fulmer A, Saboorian MH,
et al. Reflex human papillomavirus DNA testing on residual liquid-based
(TPPT) cervical samples: focus on age-stratified clinical performance. Cancer.
2003 Jun 25;99(3):149-55.
177. Soderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L.
Comparison between the Hybrid Capture II test and a PCR-based human
papillomavirus detection method for diagnosis and posttreatment follow-up of
cervical intraepithelial neoplasia. J Clin Microbiol. 2005 Jul;43(7):3260-6.
185
178. Cubie HA, Seagar AL, McGoogan E, Whitehead J, Brass A, Arends
MJ, et al. Rapid real time PCR to distinguish between high risk human
papillomavirus types 16 and 18. Mol Pathol. 2001 Feb;54(1):24-9.
179. Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, et al.
Analysis of human papillomavirus type 16 variants indicates establishment of
persistent infection. J Infect Dis. 1995;172(3):747-55.
180. Sadler TW, editor. Langman's Embryology. 6th ed: Williams and
Wilkins.
181. Haga T, Kim SH, Jensen RH, Darragh T, Palefsky JM. Detection of
genetic changes in anal intraepithelial neoplasia (AIN) of HIV-positive and
HIV-negative men. J Acquir Immune Defic Syndr. 2001 ;26(3):256-62.
182. Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman
ME, et al. Human papillomavirus-the most significant risk determinant of
cervical intraepithelial neoplasia. Int J Cancer. 1996 Mar 1 ;65(5):601-6.
183. Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ,
Kenemans P, Helmerhorst TJ, et al. PCR-based high-risk HPV test in cervical
cancer screening gives objective risk assessment of women with
cytomorphologically normal cervical smears. Int J Cancer. 1996 Dec
11 ;68(6):766-9.
184. Palefsky JM, Gonzales J, Greenblatt RM, Ahn DK, Hollander H. Anal
intraepithelial neoplasia and anal papillomavirus infection among homosexual
males with group IV HIV disease. Jama. 1990;263(21):2911-6.
185. Palefsky JM, Holly EA, Gonzales J, Berline J, Ahn DK, Greenspan JS.
Detection of human papillomavirus DNA in anal intraepithelial neoplasia and
anal cancer. Cancer Res. 1991 ;51 (3):1014-9.
186. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N
Engl J Med. 2000 Mar 16;342(11):792-800.
187. The 1988 Bethesda System for reporting cervical/vaginal cytological
diagnoses. National Cancer Institute Workshop. Jama. 1989 Aug
18;262(7):931 -4.
188. Desanto D, Higgins LW, Martin PL, Slate TA. A five-year community
study of Papanicolaou screening for cervical cancer. Trans Pac Coast Obstet
Gynecol Soc. 1954;22:121-9.
189. Darragh TM, Jay N, Tupkelewicz BA, Hogeboom CJ, Holly EA,
Palefsky JM. Comparison of conventional cytologic smears and ThinPrep
preparations from the anal canal. Acta Cytol. 1997;41 (4): 1167-70.
190. Solomon D, Schiffman M, Tarone R. Comparison of three management
strategies for patients with atypical squamous cells of undetermined
significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001
Feb 21 ;93(4):293-9.
191. National Institutes of Health Consensus Development Conference
statement on cervical cancer. April 1-3, 1996. Gynecol Oncol. 1997
Sep;66(3):351-61.
192. Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and
human papillomavirus infection. J Acquir Immune Defic Syndr. 1999;21(Suppl
1):S42-8.
193. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen
JJ. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids,
and smoking. J Natl Cancer Inst. 1989;81 (22): 1726-31.
186
194. Beckmann AM, Daling JR, Sherman KJ, Maden C, Miller BA, Coates
RJ, et al. Human papillomavirus infection and anal cancer. Int J Cancer.
1989;43(6):1042-9.
195. zur Hausen H. Human papillomaviruses in the pathogenesis of
anogenital cancer. Virology. 1991 Sep;184(1):9-13.
196. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM.
Anal cytology as a screening tool for anal squamous intraepithelial lesions. J
Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(5):415-22.
197. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J,
Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial
neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med.
1992;327(18): 1272-8.
198. Melbye M, Smith E, Wohifahrt J, Osterlind A, Orholm M, Bergmann OJ,
et al. Anal and cervical abnormality in women-prediction by human
papillomavirus tests. Int J Cancer. 1996;68(5):559-64.
199. Owen WF, Jr. Sexually transmitted diseases and traumatic problems in
homosexual men. Ann Intern Med. 1980 Jun;92(6):805-8.
200. Frisch M, Fenger C, van den Brule AJ, Sorensen P, Meijer CJ,
Walboomers JM, et al. Variants of squamous cell carcinoma of the anal canal
and perianal skin and their relation to human papillomaviruses. Cancer Res.
1999 Feb 1 ;59(3):753-7.
201. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell
control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92(9):690-
8.
202. Fenger C, Frisch M, Jass JJ, Williams GT, Hilden J. Anal cancer
subtype reproducibility study. Virchows Arch. 2000 Mar;436(3):229-33.
203. Melbye M, Frisch M. The role of human papillomaviruses in anogenital
cancers. Semin Cancer Biol. 1998;8(4):307-13.
204. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts
R, et al. Virologic, immunologic, and clinical parameters in the incidence and
progression of anal squamous intraepithelial lesions in HIV-positive and HIV-
negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol.
1998;17(4):314-9.
205. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA,
Shah KV, et al. Human papillomavirus is a necessary cause of invasive
cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9.
206. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High
incidence of anal high-grade squamous intra-epithelial lesions among HIV-
positive and HIV-negative homosexual and bisexual men. Aids.
1998;12(5):495-503.
207. Frazer IH, Medley G, Crapper RM, Brown TC, Mackay IR. Association
between anorectal dysplasia, human papillomavirus, and human
immunodeficiency virus infection in homosexual men. Lancet.
1986;2(8508):657-60.
208. Devaraj B, Cosman BC. Expectant Management of Anal Squamous
Dysplasia in Patients With HIV. Dis Colon Rectum. 2006 Jan;49(1):36-40.
209. Scholefield JH, Castle MT, Watson NF. Malignant transformation of
high-grade anal intraepithelial neoplasia. Br J Surg. 2005 Sep;92(9):1133-6.
187
210. Jablonska S, Majewski S. Bowenoid papulosis transforming into
squamous cell carcinoma of the genitalia. Br J Dermatol. 1999
Sep;141(3):576-7.
211. Harlan LC, Bernstein AB, Kessler LG. Cervical cancer screening: who
is not screened and why? Am J Public Health. 1991 ;81 (7):885-90.
212. Hutchinson ML, Isenstein LM, Goodman A, Hurley AA, Douglass KL,
Mui KK, et al. Homogeneous sampling accounts for the increased diagnostic
accuracy using the ThinPrep Processor. Am J Clin Pathol. 1994
Feb;101(2):215-9.
213. Sherman ME, Friedman HB, Busseniers AE, Kelly WF, Carner TC,
Saah AJ. Cytologic diagnosis of anal intraepithelial neoplasia using smears
and cytyc thin-preps. Mod Pathol. 1995 Apr;8(3):270-4.
214. Hutchinson ML, Agarwal P, Denault T, Berger B, Cibas ES. A new look
at cervical cytology. ThinPrep multicenter trial results. Acta Cytol. 1992 Jul-
Aug;36(4):499-504.
215. Aponte-Cipriani SL, Teplitz C, Rorat E, Savino A, Jacobs AJ. Cervical
smears prepared by an automated device versus the conventional method. A
comparative analysis. Acta Cytol. 1995 Jul-Aug;39(4):623-30.
216. Wilbur DC, Cibas ES, Merritt S, James LP, Berger BM, Bonfiglio TA.
ThinPrep Processor. Clinical trials demonstrate an increased detection rate of
abnormal cervical cytologic specimens. Am J Clin Pathol. 1994
Feb;101(2):209-14.
217. Stoler MH, Schiffman M. Interobserver reproducibility of cervical
cytologic and histologic interpretations: realistic estimates from the ASCUS-
LSIL Triage Study. Jama. 2001 Mar21;285(11):1500-5.
218. Colquhoun P, Nogueras JJ, Dipasquale B, Petras R, Wexner SD,
Woodhouse S. Interobserver and intraobserver bias exists in the interpretation
of anal dysplasia. Dis Colon Rectum. 2003 Oct;46(10): 1332-6; discussion 6-8.
219. Northfelt DW, Swift PS, Palefsky JM. Anal neoplasia. Pathogenesis,
diagnosis, and management. Hematol Oncol Clin North Am. 1996; 10(5): 1177-
87.
220. Panther LA, Wagner K, Proper J, Fugelso DK, Chatis PA, Weeden W,
et al. High resolution anoscopy findings for men who have sex with men:
inaccuracy of anal cytology as a predictor of histologic high-grade anal
intraepithelial neoplasia and the impact of HIV serostatus. Clin Infect Dis.
2004 May 15;38(10): 1490-2.
221. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML,
Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for
anal squamous intraepithelial lesions in homosexual and bisexual HIV-
positive men. Jama. 1999;281(19):1822-9.
222. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM.
Cost-effectiveness of screening for anal squamous intraepithelial lesions and
anal cancer in human immunodeficiency virus-negative homosexual and
bisexual men. Am J Med. 2000;108(8):634-41.
223. Scholefield JH, Johnson J, Hitchcock A, Kocjan G, Smith JH, Smith
PA, et al. Guidelines for anal cytology-to make cytological diagnosis and
follow up much more reliable. Cytopathology. 1998 Feb;9(1):15-22.
224. Spires SE, Banks ER, Weeks JA, Banks HW, Davey DD. Assessment
of cervicovaginal smear adequacy. The Bethesda System guidelines and
reproducibility. Am J Clin Pathol. 1994 Sep;102(3):354-9.
188
225. Strander B, Ellstrom-Andersson A, Franzen S, Milsom I, Radberg T.
The performance of a new scoring system for colposcopy in detecting high-
grade dysplasia in the uterine cervix. Acta Obstet Gynecol Scand. 2005
Oct;84(10): 1013-7.
226. Mandard AM, Tourneux J, Gignoux M, Blanc L, Segol P, Mandard JC.
In situ carcinoma of the esophagus. Macroscopic study with particular
reference to the Lugol test. Endoscopy. 1980 Mar;12(2):51-7.
227. Freitag CP, Barros SG, Kruel CD, Putten AC, Dietz J, Gruber AC, et al.
Esophageal dysplasias are detected by endoscopy with Lugol in patients at
risk for squamous cell carcinoma in southern Brazil. Dis Esophagus.
1999;12(3):191-5.
228. Scholefield JH, Ogunbiyi OA, Smith JH, Rogers K, Sharp F. Anal
colposcopy and the diagnosis of anal intraepithelial neoplasia in high-risk
gynecologic patients. Int J Gynecol Cancer. 1994 Mar;4(2):119-26.
229. Mathews WC, Sitapati A, Caperna JC, Barber RE, Tugend A, Go U.
Measurement characteristics of anal cytology, histopathology, and high-
resolution anoscopic visual impression in an anal dysplasia screening
program. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5.
230. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Hogeboom CJ, Darragh
TM. Anal cytological abnormalities and anal HPV infection in men with
Centers for Disease Control group IV HIV disease. Genitourin Med.
1997;73(3):174-80.
231. Koblin BA, Hessol NA, Zauber AG, Taylor PE, Buchbinder SP, Katz
MH, et al. Increased incidence of cancer among homosexual men, New York
City and San Francisco, 1978-1990. Am J Epidemiol. 1996 Nov
15; 144(10):916-23.
232. Scholefield JH, Hickson WG, Smith JH, Rogers K, Sharp F. Anal
intraepithelial neoplasia: part of a multifocal disease process. Lancet. 1992
Nov 21 ;340(8830):1271-3.
233. Melbye M, Sprogel P. Aetiological parallel between anal cancer and
cervical cancer. Lancet. 1991 Sep 14;338(8768):657-9.
234. Quakers JR, Lee NC, Smith RA, Aubert RE. Breast and cervical cancer
surveillance, United States, 1973-1987. Mor Mortal Wkly Rep CDC Surveill
Summ. 1992 Apr 24;41 (2): 1-7.
235. Ogunbiyi OA, Scholefield JH, Raftery AT, Smith JH, Duffy S, Sharp F,
et al. Prevalence of anal human papillomavirus infection and intraepithelial
neoplasia in renal allograft recipients. Br J Surg. 1994 Mar;81(3):365-7.
236. Ogunbiyi OA, Scholefield JH, Rogers K, Sharp F, Smith JH, Polacarz
SV. C-myc oncogene expression in anal squamous neoplasia. J Clin Pathol.
1993 Jan;46(1):23-7.
237. Ogunbiyi OA, Scholefield JH, Sharp F, Ginsberg R, Rogers K.
Nucleolar organiser regions (AgNORS) in anal intraepithelial neoplasia and
invasive anal squamous cell carcinoma. J Clin Pathol. 1992 Oct;45(10):889-
93.
238. Xi LF, Critchlow CW, Wheeler CM, Koutsky LA, Galloway DA, Kuypers
J, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type
16 variants. Cancer Res. 1998;58(17):3839-44.
239. Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom AC, Shah
K, et al. Advanced-stage cervical carcinomas are defined by a recurrent
pattern of chromosomal aberrations revealing high genetic instability and a
189
consistent gain of chromosome arm 3q. Genes Chromosomes Cancer. 1997
Aug;19(4):233-40.
240. Sayers SJ, McMillan A, McGoogan E. Anal cytological abnormalities in
HIV-infected homosexual men. Int J STD AIDS. 1998 Jan;9(1):37-40.
241. Lacey HB, Wilson GE, Tilston P, Wilkins EG, Bailey AS, Corbitt G, et
al. A study of anal intraepithelial neoplasia in HIV positive homosexual men.
SexTransm Infect. 1999;75(3):172-7.
242. Palefsky JM, Holly EA, Gonzales J, Lamborn K, Hollander H. Natural
history of anal cytologic abnormalities and papillomavirus infection among
homosexual men with group IV HIV disease. J Acquir Immune Defic Syndr.
1992;5(12): 1258-65.
243. Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S,
Colfax G, et al. Age-related prevalence of anal cancer precursors in
homosexual men: the EXPLORE study. J Natl Cancer Inst. 2005 Jun
15;97(12):896-905.
244. Conti M, Agarossi A, Parazzini F, Muggiasca ML, Boschini A, Negri E,
et al. HPV, HIV infection, and risk of cervical intraepithelial neoplasia in former
intravenous drug abusers. Gynecol Oncol. 1993 Jun;49(3):344-8.
245. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW.
Antibodies to human papillomavirus 16 and subsequent in situ or invasive
cancer of the cervix. Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):233-7.
246. Bryan JT, Stoler MH, Tyring SK, McClowry T, Fife KH, Brown DR.
High-grade dysplasia in genital warts from two patients infected with the
human immunodeficiency virus. J Med Virol. 1998 Jan;54(1):69-73.
247. Metcalf AM, Dean T. Risk of dysplasia in anal condyloma. Surgery.
1995 Oct;118(4):724-6.
248. Surawicz CM, Kirby P, Critchlow C, Sayer J, Dunphy C, Kiviat N. Anal
dysplasia in homosexual men: role of anoscopy and biopsy.
Gastroenterology. 1993; 105(3):658-66.
249. Friedman HB, Saah AJ, Sherman ME, Busseniers AE, Blackwelder
WC, Kaslow RA, et al. Human papillomavirus, anal squamous intraepithelial
lesions, and human immunodeficiency virus in a cohort of gay men. J Infect
Dis. 1998 Jul;178(1):45-52.
250. Aynaud O, Piron D, Barrasso R, Poveda JD. Comparison of clinical,
histological, and virological symptoms of HPV in HIV-1 infected men and
immunocompetent subjects. SexTransm Infect. 1998 Feb;74(1):32-4.
251. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Bonner H, Jay N, et
al. Effect of highly active antiretroviral therapy on the natural history of anal
squamous intraepithelial lesions and anal human papillomavirus infection. J
Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8.
252. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, et al.
Anal intraepithelial neoplasia in the highly active antiretroviral therapy era
among HIV-positive men who have sex with men. Aids. 2005 Sep
2; 19(13): 1407-14.
253. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical
treatment of high-grade anal squamous intraepithelial lesions: a prospective
study. Dis Colon Rectum. 2002 Apr;45(4):453-8.
254. Hamdan KA, Tait IS, Nadeau V, Padgett M, Carey F, Steele RJ.
Treatment of grade III anal intraepithelial neoplasia with photodynamic
therapy: report of a case. Dis Colon Rectum. 2003 Nov;46(11):1555-9.
190
255. Park KC, Kim KH, Youn SW, Hwang JH, Park KH, Ahn JS, et al.
Heterogeneity of human papillomavirus DNA in a patient with Bowenoid
papulosis that progressed to squamous cell carcinoma. Br J Dermatol. 1998
Dec; 139(6): 1087-91.
256. Bowen JT. Centennial paper. May 1912 (J Cutan Dis Syph
1912;30:241-255). Precancerous dermatoses: a study of two cases of chronic
atypical epithelial proliferation. By John T. Bowen, M.D., Boston. Arch
Dermatol. 1983 Mar;119(3):243-60.
257. Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM.
Perianal Bowen's disease and anal intraepithelial neoplasia: review of the
literature. Dis Colon Rectum. 1999;42(7):945-51.
258. Fazio VW, Tjandra JJ. The management of perianal diseases. Adv
Surg. 1996;29:59-78.
259. Sober AJ, Burstein JM. Precursors to skin cancer. Cancer. 1995 Jan
15;75(2 Suppl):645-50.
260. Graham BD, Jetmore AB, Foote JE, Arnold LK. Topical 5-fluorouracil in
the management of extensive anal Bowen's disease: a preferred approach.
Dis Colon Rectum. 2005 Mar;48(3):444-50.
261. Mandekou-Lefaki I, Delli F, Koussidou-Eremondi T, Mourellou-Tsatsou
O, Dionyssopoulos A. Imiquimod 5% cream: a new treatment for bowen's
disease. Int J Tissue React. 2005;27(1):31-8.
262. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie
RM. Comparison of photodynamic therapy with cryotherapy in the treatment
of Bowen's disease. Br J Dermatol. 1996 Nov;135(5):766-71.
263. Dave R, Monk B, Mahaffey P. Treatment of Bowen's disease with
carbon dioxide laser. Lasers Surg Med. 2003;32(5):335.
264. Britton JE, Goulden V, Stables G, Stringer M, Sheehan-Dare R.
Investigation of the use of the pulsed dye laser in the treatment of Bowen's
disease using 5-aminolaevulinic acid phototherapy. Br J Dermatol. 2005
Oct;153(4):780-4.
265. Peters RK, Mack TM, Bernstein L. Parallels in the epidemiology of
selected anogenital carcinomas. J Natl Cancer Inst. 1984;72(3):609-15.
266. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR.
Anal cancer incidence and survival: the surveillance, epidemiology, and end
results experience, 1973-2000. Cancer. 2004 Jul 15; 101 (2):281 -8.
267. Rabkin CS, Yellin F. Cancer incidence in a population with a high
prevalence of infection with human immunodeficiency virus type 1. J Natl
Cancer Inst. 1994 Nov 16;86(22): 1711-6.
268. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal
cancer incidence in the United States, 1940-1989. Am J Epidemiol. 1994 Apr
15; 139(8):772-80.
269. Rabkin CS. Epidemiology of AIDS-related malignancies. Curr Opin
Oncol. 1994 Sep;6(5):492-6.
270. Frisch M, Melbye M, Moller H. Trends in incidence of anal cancer in
Denmark. Bmj. 1993 Feb 13;306(6875):419-22.
271. Scholefield JH, Thornton Jones H, Cuzick J, Northover JM. Anal
cancer and marital status. Br J Cancer. 1990 Aug;62(2):286-8.
272. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, et
al. Sexual practices, sexually transmitted diseases, and the incidence of anal
cancer. N Engl J Med. 1987;317(16):973-7.
191
273. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated
cancers in patients with human immunodeficiency virus infection and acquired
immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18): 1500-10.
274. Selik RM, Rabkin CS. Cancer death rates associated with human
immunodeficiency virus infection in the United States. J Natl Cancer Inst.
1998 Sep 2;90(17):1300-2.
275. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al.
Spectrum of AIDS-associated malignant disorders. Lancet.
1998;351 (9119): 1833-9.
276. Melbye M, Cote TR, Kessler L, Gail M, Biggar RJ. High incidence of
anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet.
1994 Mar 12;343(8898):636-9.
277. Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J,
Mandalia S, et al. HIV-Associated Anal Cancer: Has Highly Active
Antiretroviral Therapy Reduced the Incidence or Improved the Outcome? J
Acquir Immune Defic Syndr. 2004 Dec 15;37(5): 1563-5.
278. Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H.
Increased incidence of squamous cell anal cancer among men with AIDS in
the era of highly active antiretroviral therapy. Sex Transm Dis. 2005
May;32(5):314-20.
279. Cress RD, Holly EA. Incidence of anal cancer in California: increased
incidence among men in San Francisco, 1973-1999. Prev Med. 2003
May;36(5):555-60.
280. Ogunbiyi OA, Scholefield JH, Robertson G, Smith JH, Sharp F, Rogers
K. Anal human papillomavirus infection and squamous neoplasia in patients
with invasive vulvar cancer. Obstet Gynecol. 1994;83(2):212-6.
281. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F,
Salat A. Prevalence of anal HPV infection in solid-organ transplant patients
prior to immunosuppression. Transpl Int. 2004 Aug;17(7):366-9.
282. Dragieva G, Scharer L, Dummer R, Kempf W. Photodynamic therapy-
a new treatment option for epithelial malignancies of the skin. Onkologie.
2004 Aug;27(4):407-11.
283. Morson BC. Genesis of colorectal cancer. Clin Gastroenterol. 1976
Sep;5(3):505-25.
284. McConnell EM. Squamous carcinoma of the anus-a review of 96
cases. Br J Surg. 1970 Feb;57(2):89-92.
285. Beahrs OH, Wilson SM. Carcinoma of the anus. Ann Surg. 1976
Oct;184(4):422-8.
286. Boman BM, Moertel CG, O'Connell MJ, Scott M, Weiland LH, Beart
RW, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188
cases. Cancer. 1984 Jul 1 ;54(1):114-25.
287. Basik M, Rodriguez-Bigas MA, Penetrante R, Petrelli NJ. Prognosis
and recurrence patterns of anal adenocarcinoma. Am J Surg. 1995
Feb;169(2):233-7.
288. Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of
the anal canal: the spectrum of disease, treatment, and outcomes. Cancer.
1999;85(8): 1686-93.
289. Greenall MJ, Quan SH, Stearns MW, Urmacher C, DeCosse JJ.
Epidermoid cancer of the anal margin. Pathologic features, treatment, and
clinical results. Am J Surg. 1985 Jan;149(1):95-101.
192
290. Dougherty BG, Evans HL. Carcinoma of the anal canal: a study of 79
cases. Am J Clin Pathol. 1985 Feb;83(2):159-64.
291. Frost DB, Richards PC, Montague ED, Giacco GG, Martin RG.
Epidermoid cancer of the anorectum. Cancer. 1984 Mar 15;53(6): 1285-93.
292. O'Brien PFH, Jenrette JM, Wallace KM, Metcalf JS. Epidermoid
carcinoma of the anus. Surg Gynecol Obstet. 1982 Nov;155(5):745-51.
293. Jensen SL, Hagen K, Shokouh-Amiri MFI, Nielsen OV. Does an
erroneous diagnosis of squamous-cell carcinoma of the anal canal and anal
margin at first physician visit influence prognosis? Dis Colon Rectum. 1987
May;30(5):345-51.
294. Golden GT, Florsley JS, III. Surgical management of epidermoid
carcinoma of the anus. Am J Surg. 1976 Mar;131(3):275-80.
295. Paradis P, Douglass HO, Jr., Holyoke ED. The clinical implications of a
staging system for carcinoma of the anus. Surg Gynecol Obstet. 1975
Sep;141(3):411-6.
296. Tanum G, Tveit K, Karlsen KO, Flauer-Jensen M. Chemotherapy and
radiation therapy for anal carcinoma. Survival and late morbidity. Cancer.
1991 May 15;67(10):2462-6.
297. Sawyers JL. Squamous cell cancer of the perianus and anus. Surg Clin
North Am. 1972 Aug;52(4):935-41.
298. Mendenhall WM, Zlotecki RA, Vauthey JN, Copeland EM, 3rd.
Squamous cell carcinoma of the anal margin. Oncology (Williston Park). 1996
Dec;10(12):1843-8; discussion 8, 53-4.
299. Cummings BJ. Concomitant radiotherapy and chemotherapy for anal
cancer. Semin Oncol. 1992 Aug;19(4 Suppl 11): 102-8.
300. Quan SH. Anal cancers. Squamous and melanoma. Cancer. 1992 Sep
1;70(5 Suppl): 1384-9.
301. Nigro ND, Vaitkevicius VK, Considine B, Jr. Combined therapy for
cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974 May-
Jun;17(3):354-6.
302. Nigro ND. An evaluation of combined therapy for squamous cell cancer
of the anal canal. Dis Colon Rectum. 1984 Dec;27(12):763-6.
303. BurokerTR, Nigro N, Bradley G, Pelok L, Chomchai C, Considine B, et
al. Combined therapy for cancer of the anal canal: a follow-up report. Dis
Colon Rectum. 1977 Nov-Dec;20(8):677-8.
304. Sato H, Koh PK, Bartolo DC. Management of anal canal cancer. Dis
Colon Rectum. 2005 Jun;48(6):1301-15.
305. Flung A, Crane C, Delclos M, Ballo M, Ajani J, Lin E, et al. Cisplatin-
based combined modality therapy for anal carcinoma: a wider therapeutic
index. Cancer. 2003 Mar 1 ;97(5):1195-202.
306. Singh R, Nime F, Mittelman A. Malignant epithelial tumors of the anal
canal. Cancer. 1981 Jul 15;48(2):411-5.
307. Goldman S, Auer G, Erhardt K, Seligson U. Prognostic significance of
clinical stage, histologic grade, and nuclear DNA content in squamous-cell
carcinoma of the anus. Dis Colon Rectum. 1987 Jun;30(6):444-8.
308. Goldman S, Glimelius B, Pahlman L, Stahle E, Wilander E. Anal
epidermoid carcinoma: a population-based clinico-pathological study of 164
patients. Int J Colorectal Dis. 1988 Jun;3(2):109-18.
193
309. Salmon RJ, Zafrani B, Labib A, Asselain B, Girodet J. Prognosis of
cloacogenic and squamous cancers of the anal canal. Dis Colon Rectum.
1986 May;29(5):336-40.
310. Shepherd NA, Scholefield JH, Love SB, England J, Northover JM.
Prognostic factors in anal squamous carcinoma: a multivariate analysis of
clinical, pathological and flow cytometric parameters in 235 cases.
Histopathology. 1990 Jun;16(6):545-55.
311. Williams GR, Talbot IC. Anal carcinoma-a histological review.
Histopathology. 1994 Dec;25(6):507-16.
312. Tanum G, Stenwig AE, Bormer OP, Tveit KM. Carcinoembryonic
antigen in anal carcinoma. Acta Oncol. 1992;31(3):333-5.
313. Klencke BJ, Palefsky JM. Anal cancer: an HIV-associated cancer.
Hematol Oncol Clin North Am. 2003 Jun;17(3):859-72.
314. Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC. Perianal
Bowen's disease: a clinicopathologic study of 47 patients. Dis Colon Rectum.
1997;40(11):1286-93.
315. Herbert A, Smith JA. Cervical intraepithelial neoplasia grade III (CIN 111)
and invasive cervical carcinoma: the yawning gap revisited and the treatment
of risk. Cytopathology. 1999 Jun;10(3):161-70.
316. Holmes F, Borek D, Owen-Kummer M, Hassanein R, Fishback J,
Behbehani A, et al. Anal cancer in women. Gastroenterology. 1988;95(1):107-
11.
317. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et
al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1
infection. Ann Intern Med. 1997 Jun 15;126(12):946-54.
318. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et
al. Comparison of self-collected vaginal, vulvar and urine samples with
physician-collected cervical samples for human papillomavirus testing to
detect high-grade squamous intraepithelial lesions. Cmaj. 2000 Sep
5;163(5):513-8.
319. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two
types of murine helper T cell clone. I. Definition according to profiles of
lymphokine activities and secreted proteins. J Immunol. 1986 Apr
1;136(7):2348-57.
320. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine
dysregulation in human infectious, neoplastic, and inflammatory diseases.
Clin Microbiol Rev. 1996 Oct;9(4):532-62.
321. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, et
al. Cytokine production patterns in cervical intraepithelial neoplasia:
association with human papillomavirus infection. J Natl Cancer Inst. 1997 Feb
5;89(3):245-50.
322. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol
Today. 1991 Aug;12(8):256-7.
323. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom
BR, et al. Defining protective responses to pathogens: cytokine profiles in
leprosy lesions. Science. 1991 Oct 11 ;254(5029):277-9.
324. Clerici M, Shearer GM. A TH1->TH2 switch is a critical step in the
etiology of HIV infection. Immunol Today. 1993 Mar;14(3):107-11.
194
325. Thiounn N, Pages F, Flam T, Tartour E, Mosseri V, Zerbib M, et al. IL-6
is a survival prognostic factor in renal cell carcinoma. Immunol Lett. 1997
Jul;58(2):121-4.
326. Ho LJ, Shaio MF, Chang DM, Liao CL, Lai JH. Infection of human
dendritic cells by dengue virus activates and primes T cells towards ThO-like
phenotype producing both Th1 and Th2 cytokines. Immunol Invest.
2004;33(4):423-37.
327. Howe RC, Ovsyannikova IG, Pinsky NA, Poland GA. Identification of
ThO cells responding to measles virus. Hum Immunol. 2005 Feb;66(2):104-15.
328. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than
answers. Nat Rev Immunol. 2002 Jun;2(6):389-400.
329. McHugh RS, Shevach EM. The role of suppressor T cells in regulation
of immune responses. J Allergy Clin Immunol. 2002 Nov; 110(5):693-702.
330. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1,
Th2 and more. Immunol Today. 1996 Mar;17(3):138-46.
331. Ljunggren G, Anderson DJ. Cytokine induced modulation of MHC class
I and class II molecules on human cervical epithelial cells. J Reprod Immunol.
1998 Jul;38(2): 123-38.
332. Liles WC, Van Voorhis WC. Review: nomenclature and biologic
significance of cytokines involved in inflammation and the host immune
response. J Infect Dis. 1995 Dec;172(6):1573-80.
333. El-Sherif AM, Seth R, Tighe PJ, Jenkins D. Quantitative analysis of IL-
10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus
type 16 associated cervical precancer. J Pathol. 2001 Sep; 195(2): 179-85.
334. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their
actions. Annu Rev Biochem. 1987;56:727-77.
335. Baron S, Tyring SK, Fleischmann WR, Jr., Coppenhaver DH, Niesel
DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical
applications. Jama. 1991 Sep 11 ;266(10):1375-83.
336. Farrar MA, Schreiber RD. The molecular cell biology of interferon-
gamma and its receptor. Annu Rev Immunol. 1993;11:571-611.
337. Kasahara T, Hooks JJ, Dougherty SF, Oppenheim JJ. Interleukin 2-
mediated immune interferon (IFN-gamma) production by human T cells and T
cell subsets. J Immunol. 1983 Apr;130(4):1784-9.
338. Robb RJ, Smith KA. Heterogeneity of human T-cell growth factor(s)
due to variable glycosylation. Mol Immunol. 1981 Dec;18(12):1087-94.
339. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T
lymphocytes from normal human bone marrows. Science. 1976 Sep
10; 193(4257): 1007-8.
340. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex:
its structure, function, and target genes. Annu Rev Immunol. 1993; 11:245-68.
341. Arai Kl, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines:
coordinators of immune and inflammatory responses. Annu Rev Biochem.
1990;59:783-836.
342. Paul WE. lnterleukin-4: a prototypic immunoregulatory lymphokine.
Blood. 1991 May 1;77(9):1859-70.
343. Hazelbag S, Fleuren GJ, Baelde JJ, Schuuring E, KenterGG, Gorter A.
Cytokine profile of cervical cancer cells. Gynecol Oncol. 2001 Nov;83(2):235-
43.
195
344. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR.
lnterleukin-10. Annu Rev Immunol. 1993;11:165-90.
345. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, et al.
High level IL-12 production by murine dendritic cells: upregulation via MHC
class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp
Med. 1996 Aug 1 ;184(2):741-6.
346. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al.
Human non-small cell lung cancer cells express a type 2 cytokine pattern.
Cancer Res. 1995 Sep 1 ;55(17):3847-53.
347. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, et al.
IL-10 production in cutaneous basal and squamous cell carcinomas. A
mechanism for evading the local T cell immune response. J Immunol. 1995
Aug 15;155(4):2240-7.
348. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of
the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol. 1995
Feb;146(2):317-22.
349. Huang M, Sharma S, Mao JT, Dubinett SM. Non-small cell lung
cancer-derived soluble mediators and prostaglandin E2 enhance peripheral
blood lymphocyte IL-10 transcription and protein production. J Immunol. 1996
Dec 15; 157(12):5512-20.
350. Caruso C, Candore G, Modica MA, Bonanno CT, Sireci G, Dieli F, et
al. Major histocompatibility complex regulation of cytokine production. J
Interferon Cytokine Res. 1996 Dec;16(12):983-8.
351. Torres LM, Cabrera T, Concha A, Oliva MR, Ruiz-Cabello F, Garrido F.
HLA class I expression and HPV-16 sequences in premalignant and
malignant lesions of the cervix. Tissue Antigens. 1993 Feb;41(2):65-71.
352. Cromme FV, Snijders PJ, van den Brule AJ, Kenemans P, Meijer CJ,
Walboomers JM. MHC class I expression in HPV 16 positive cervical
carcinomas is post-transcriptionally controlled and independent from c-myc
overexpression. Oncogene. 1993 Nov;8(11):2969-75.
353. Rosini S, Caltagirone S, Tallini G, Lattanzio G, Demopoulos R, Piantelli
M, et al. Depletion of stromal and intraepithelial antigen-presenting cells in
cervical neoplasia in human immunodeficiency virus infection. Hum Pathol.
1996 Aug;27(8):834-8.
354. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient
expression of components of the MHC class I antigen processing machinery
in human cervical carcinoma. Int J Oncol. 2001 Dec;19(6):1211-20.
355. Belec L, Gherardi R, Payan C, Prazuck T, Malkin JE, Tevi-Benissan C,
et al. Proinflammatory cytokine expression in cervicovaginal secretions of
normal and HIV-infected women. Cytokine. 1995 Aug;7(6):568-74.
356. Olaitan A, Johnson MA, Reid WM, Poulter LW. Changes to the
cytokine microenvironment in the genital tract mucosa of HIV+ women. Clin
Exp Immunol. 1998 Apr;112(1): 100-4.
357. Stellato G, Nieminen P, Aho M, Lehtinen T, Lehtinen M, Paavonen J.
Type 1 cytokine response and treatment outcome of genital HPV lesions.
Genitourin Med. 1997 Oct;73(5):387-90.
358. Arany I, Grattendick KG, Tyring SK. lnterleukin-10 induces transcription
of the early promoter of human papillomavirus type 16 (HPV16) through the
5'-segment of the upstream regulatory region (URR). Antiviral Res. 2002
Aug;55(2):331-9.
196
359. Scott M, Stites DP, Moscicki AB. Th1 cytokine patterns in cervical
human papillomavirus infection. Clin Diagn Lab Immunol. 1999 Sep;6(5):751-
5.
360. Jacobs N, Giannini SL, Doyen J, Baptista A, Moutschen M, Boniver J,
et al. Inverse modulation of IL-10 and IL-12 in the blood of women with
preneoplastic lesions of the uterine cervix. Clin Exp Immunol. 1998
Jan;111(1):219-24.
361. al-Saleh W, Giannini SL, Jacobs N, Moutschen M, Doyen J, Boniver J,
et al. Correlation of T-helper secretory differentiation and types of antigen-
presenting cells in squamous intraepithelial lesions of the uterine cervix. J
Pathol. 1998 Mar;184(3):283-90.
362. Rothwell NJ. The endocrine significance of cytokines. J Endocrinol.
1991 Feb;128(2):171-3.
363. Rani S, Vaidya MC, Rani K. Role of cell growth factor (interleukin-2)
and its receptors in carcinoma cervix patients. J Steroid Biochem Mol Biol.
1992 Mar;41(3-8):837-9.
364. Tartour E, Gey A, Sastre-Garau X, Lombard Surin I, Mosseri V,
Fridman WH. Prognostic value of intratumoral interferon gamma messenger
RNA expression in invasive cervical carcinomas. J Natl Cancer Inst. 1998 Feb
18;90(4):287-94.
365. Mori H, Hanabayashi T, Yamada Y, Tamaya T. Decrease in interferon-
gamma production by peripheral blood mononuclear cells in patients with
uterine cervical cancer. J Clin Immunol. 1990 Jan;10(1):45-51.
366. York IA, Rock KL. Antigen processing and presentation by the class I
major histocompatibility complex. Annu Rev Immunol. 1996;14:369-96.
367. Woodworth CD, Lichti U, Simpson S, Evans CH, DiPaolo JA.
Leukoregulin and gamma-interferon inhibit human papillomavirus type 16
gene transcription in human papillomavirus-immortalized human cervical cells.
Cancer Res. 1992 Jan 15;52(2):456-63.
368. Gey A, Kumari P, Sambandam A, Lecuru F, Cassard L, Badoual C, et
al. Identification and characterisation of a group of cervical carcinoma patients
with profound downregulation of intratumoral Type 1 (IFNgamma) and Type 2
(IL-4) cytokine mRNA expression. Eur J Cancer. 2003 Mar;39(5):595-603.
369. Hedges SR, Sibley DA, Mayo MS, Hook EW, 3rd, Russell MW.
Cytokine and antibody responses in women infected with Neisseria
gonorrhoeae: effects of concomitant infections. J Infect Dis. 1998
Sep;178(3):742-51.
370. Cohen CR, Plummer FA, Mugo N, Maclean I, Shen C, Bukusi EA, et al.
Increased interleukin-10 in the the endocervical secretions of women with
non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-
1 transmission? Aids. 1999 Feb 25;13(3):327-32.
371. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, et al.
Changes in interleukin-2 and interleukin-4 production in asymptomatic, human
immunodeficiency virus-seropositive individuals. J Clin Invest. 1993
Mar;91(3):759-65.
372. Markowitz N, Hansen Nl, Wilcosky TC, Hopewell PC, Glassroth J,
Kvale PA, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-
seronegative persons. Pulmonary Complications of HIV Infection Study
Group. Ann Intern Med. 1993 Aug 1; 119(3): 185-93.
197
373. Ramalingam S, Kannangai R, Vijayakumar TS, Mathai D, Abraham
OC, Subramanian S, et al. Subtype & cytokine profiles of HIV infected
individuals from south India. Indian J Med Res. 2005 Apr;121(4):226-34.
374. Berger S, Ballo H, Stutte HJ. Distinct antigen-induced cytokine pattern
upon stimulation with antibody-complexed antigen consistent with a Th1~
>Th2-shift. Res Virol. 1996 Mar-Jun;147(2-3):103-8.
375. Trabattoni D, Lo Caputo S, Biasin M, Seminari E, Di Pietro M, Ravasi
G, et al. Modulation of Human Immunodeficiency Virus (HlV)-Specific Immune
Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy
Regimen for HIV-infected, Drug-Experienced Patients. Clin Diagn Lab
Immunol. 2002 Sep;9(5):1114-8.
376. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced
type 1 /type 2 response is associated with long-term nonprogressive human
immunodeficiency virus type 1 infection. J Virol. 2002 Sep;76(18):9011-23.
377. Vigano A, Balotta C, Trabattoni D, Bricalli D, Crupi L, Palomba E, et al.
Long-term resistance to HIV infection in vertical HIV infection: cytokine
production, HIV isolation, and HIV phenotype define long-term resistant hosts.
Pathobiology. 1997;65(4): 169-76.
378. Wu TC. Immunology of the human papilloma virus in relation to cancer.
Curr Opin Immunol. 1994 Oct;6(5):746-54.
379. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, et
al. Immunological events in regressing genital warts. Am J Clin Pathol. 1994
Dec;102(6):768-74.
380. Chirgwin JM, Przybyla AE, 'MacDonald RJ, Rutter WJ. Isolation of
biologically active ribonucleic acid from sources enriched in ribonuclease.
Biochemistry. 1979 Nov 27;18(24):5294-9.
381. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987
Apr; 162(1): 156-9.
382. Struhl K. Current Protocols in Molecular Biology. Struhl K, editor. New
York, N.Y.: John Wiley & Sons, Inc.; 1992.
383. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al.
Primer-directed enzymatic amplification of DNA with a thermostable DNA
polymerase. Science. 1988 Jan 29;239(4839):487-91.
384. Li HH, Gyllensten UB, Cui XF, Saiki RK, Erlich HA, Arnheim N.
Amplification and analysis of DNA sequences in single human sperm and
diploid cells. Nature. 1988 Sep 29;335(6189):414-7.
385. Tindall KR, Kunkel TA. Fidelity of DNA synthesis by the Thermus
aquaticus DNA polymerase. Biochemistry. 1988 Aug 9;27(16):6008-13.
386. Lau AS, Sigaroudinia M, Yeung MC, Kohl S. lnterleukin-12 induces
interferon-gamma expression and natural killer cytotoxicity in cord blood
mononuclear cells. Pediatr Res. 1996 Jan;39(1): 150-5.
387. Sorg RV, Enczmann J, Sorg UR, Schneider EM, Wernet P.
Identification of an alternatively spliced transcript of human interleukin-4
lacking the sequence encoded by exon 2. Exp Hematol. 1993 Apr;21(4):560-
3.
388. Southern EM, Mitchell AR. Chromatography of nucleic acid digests on
thin layers of cellulose impregnated with polyethyleneimine. Biochem J. 1971
Jul;123(4):613-7.
198
389. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a
mucosal catastrophe? Nat Immunol. 2006 Mar;7(3):235-9.
390. Bardeguez AD, Skurnick JH, Perez G, Colon JM, Kloser P, Denny TN.
Lymphocyte shedding from genital tract of human immunodeficiency virus-
infected women: immunophenotypic and clinical correlates. Am J Obstet
Gynecol. 1997 Jan;176(1 Pt 1):158-65.
391. Fernandes AP, Goncalves MA, Duarte G, Cunha FQ, Simoes RT,
Donadi EA. HPV16, HPV18, and HIV infection may influence cervical cytokine
intralesional levels. Virology. 2005 Apr 10;334(2):294-8.
392. McGowan I, Elliott J, Fuerst M, Taing P, Boscardin J, Poles M, et al.
Increased HIV-1 mucosal replication is associated with generalized mucosal
cytokine activation. J Acquir Immune Defic Syndr. 2004 Oct 1 ;37(2):1228-36.
393. Azar KK, Tani M, Yasuda H, Sakai A, Inoue M, Sasagawa T. Increased
secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical
squamous intraepithelial lesions. Hum Pathol. 2004 Nov;35(11):1376-84.
394. Lettesjo H, Hansson T, Peterson C, Ung KA, Ringstrom G,
Abrahamsson H, et al. Detection of inflammatory markers in stools from
patients with irritable bowel syndrome and collagenous colitis. Scand J
Gastroenterol. 2006 Jan;41(1):54-9.
395. Berrebi D, Languepin J, Ferkdadji L, Foussat A, De Lagausie P, Paris
R, et al. Cytokines, chemokine receptors, and homing molecule distribution in
the rectum and stomach of pediatric patients with ulcerative colitis. J Pediatr
Gastroenterol Nutr. 2003 Sep;37(3):300-8.
396. Zheng Z, Luo Y, McMaster GK. Sensitive and quantitative
measurement of gene expression directly from a small amount of whole
blood. Clin Chem. 2006 Jul;52(7):1294-302.
397. Scott ME, Ma Y, Farhat S, Shiboski S, Moscicki AB. Covariates of
cervical cytokine mRNA expression by real-time PCR in adolescents and
young women: effects of Chlamydia trachomatis infection, hormonal
contraception, and smoking. J Clin Immunol. 2006 May;26(3):222-32.
398. Williams Dl, Stephenson JM, Hart GJ, Copas A, Johnson AM, Williams
IG. A case control study of HIV seroconversion in gay men, 1988-1993: what
are the current risk factors? Genitourin Med. 1996 Jun;72(3):193-6.
399. Buchbinder SP, Douglas JM, Jr., McKirnan DJ, Judson FN, Katz MH,
MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in
homosexual men in the United States: risk behavior, seroincidence, and
willingness to participate. J Infect Dis. 1996 Nov;174(5):954-61.
400. Craib KJ, Meddings DR, Strathdee SA, Hogg RS, Montaner JS,
O'Shaughnessy MV, et al. Rectal gonorrhoea as an independent risk factor for
HIV infection in a cohort of homosexual men. Genitourin Med. 1995
Jun;71(3):150-4.
401. Holmberg SD, Stewart JA, Gerber AR, Byers RH, Lee FK, O'Malley
PM, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV
infection. Jama. 1988 Feb 19;259(7): 1048-50.
402. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M,
Morales J, et al. Population-based study of human papillomavirus infection
and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000 Mar
15;92(6):464-74.
403. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et
al. Epidemiology of acquisition and clearance of cervical human
199
papillomavirus infection in women from a high-risk area for cervical cancer. J
Infect Dis. 1999 Nov;180(5):1415-23.
404. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of
cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998
Feb 12;338(7):423-8.
405. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al.
Persistent genital human papillomavirus infection as a risk factor for persistent
cervical dysplasia. J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71.
406. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang
T, et al. Persistence of type-specific human papillomavirus infection among
cytologically normal women. J Infect Dis. 1994 Feb;169(2):235-40.
407. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA,
et al. Declining prevalence of cervicovaginal human papillomavirus infection






Self-Collected Versus Clinician-Collected Anal Cytology
Specimens to Diagnose Anal Intraepithelial Neoplasia in
HIV-Positive Men
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Background: Anal intraepithelial neoplasia (AIN) is common in
men who have sex with men (MSM) and may be diagnosed by anal
cytology screening.
Methods: One hundred two MSM with clinician-collected anal cy¬
tology and histopathology specimens were assessed from a cohort
study of AIN at the University of California at San Francisco. The
men were given a cytology self-collection kit with written instruc¬
tions for use and requested to collect the sample 1 month after the
clinic visit.
Results: Ninety-one percent of self-collected and 99% of clinician-
collected anal cytology samples were adequate for interpretation. The
sensitivity of abnormal anal cytology to detect AIN by histology was
68% in self-collected samples and 70% in clinician-collected
samples, and the sensitivity to detect AIN 2 or AIN 3 was 71% and
74%, respectively. Cytologic results did not differ by grade between
self-collected and clinician-collected samples. Among MSM diag¬
nosed with AIN 2 or 3 by biopsy, 33% of self-collected and 39% of
clinician-collected cytology samples were high-grade. The sensitivity
of both self-collected and clinician-collected samples to detect AIN 2
or 3 was higher among HIV-positive MSM than among HIV-negative
MSM.
Conclusions: MSM with biopsy-proven AIN can self-collect anal
cytology samples with sensitivity comparable with that of experi¬
enced clinicians. This may facilitate screening for AIN.
(JAcquir Immune Defic Syndr 2004;36:915-920)
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The incidence of anal cancer in the United States is increas¬ing and is 0.8-0.9 case per 100,000 persons among the
general population.1'2 Before the HIV epidemic, the incidence
of anal cancer was estimated to be as high as 35 cases per
100,000 persons among men who have sex with men (MSM),3
with recent data indicating that the incidence among HIV-
positive MSM is approximately twice that among HIV-
negative MSM.4'5 Thus, the incidence of anal cancer among
both HIV-negative and HIV-positive MSM is higher than the
current incidence ofcervical cancer among women and is simi¬
lar to the incidence of cervical cancer before the introduction
ofcervical cytology screening.6 Although the magnitude of the
increase in anal cancer compared with the general population
is greater among HIV-positive MSM than among HIV-
positive women, the latter are also at increased risk of anal
cancer.7
Anal cancer and cervical cancer are similar histologi¬
cally, and like cervical intraepithelial neoplasia and cervical
cancer, anal intraepithelial neoplasia (AIN) and anal cancer are
associated with oncogenic human papillomaviruses.8-12 It is
believed that AIN 2 or 3 precedes the development of anal
cancer in the same way that cervical intraepithelial neoplasia 2
or 3 precedes cervical cancer (J.M. Palefsky, unpublished ob¬
servations). Similarly, Bowen disease (perianal AIN 3) may
progress to invasive anal cancer.13'14 Analogous to the treat¬
ment of cervical intraepithelial neoplasia 2 or 3 to prevent the
development of cervical cancer, treatment of AIN 2 or 3 may
prevent progression to anal cancer.
Anal and cervical cytology findings are both described
using the Bethesda classification system15 and are reported, in
increasing severity, as atypical squamous cells of undeter¬
mined significance, atypical squamous cells suggestive of
high-grade change, low-grade squamous intraepithelial le¬
sions, and high-grade squamous intraepithelial lesions
(HSIL).16
Anal cytology has been studied as a screening test for
AIN in MSM.17-19 In the largest study, using anal histopathol¬
ogy as a gold standard, sensitivity of 69% for HIV-positive
individuals and sensitivity of47% for HIV-negative individu-
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als were found using high-resolution anoscopy (HRA) and bi¬
opsy to detect AIN.19 HRA is colposcopy of the anus and peri¬
anal region using 3% acetic acid. The sensitivity is comparable
with that of cervical cytology screening for the detection of
cervical intraepithelial neoplasia in the general female popu¬
lation.19 The method by which anal cytology samples are pro¬
cessed has also been investigated. In addition to conventional
cell fixation and staining by the Papanicolaou method, cytol¬
ogy samples may be prepared using the ThinPrep technique
before staining with the Papanicolaou method.20 Both sam¬
pling methods have been validated for the anal canal and found
to be comparable in the assessment of anal cytology.20
Although somewhat theoretical and not universally ac¬
cepted, using a state-transition Markov model, we projected
that anal cytology screening to identify individuals with HSIL
with subsequent treatment of the lesion should be cost-
effective to prevent anal cancer when performed annually for
HIV-positive MSM and every 2-3 years for HIV-negative
MSM.21'22
Several barriers currently exist to the implementation of
an anal cytology screening program for at-risk individuals.
One obstacle is the lack of studies to document that treatment
of AIN reduces the incidence of anal cancer. Performance of
such studies is hampered by the large numbers of subjects
needed, difficulties in assembling an appropriate control
group, and the long follow-up needed to assess the impact on
cancer incidence. Other obstacles include a paucity of clini¬
cians trained in collecting anal cytology samples, reluctance of
some clinicians to address the issue ofAIN with their patients,
and patients' feelings of embarrassment and fear of potential
discomfort associated with the collection of anal specimens.
Collection of anal cytology samples by subjects themselves
has the potential to obviate some of these concerns.
The purpose of this study was to assess the performance
of results from anal cytology samples collected by study par¬
ticipants at home compared with samples collected by experi¬
enced research clinicians in a clinic ofMSM with a high preva¬
lence of AIN. Anal histopathology was used as the gold stan¬
dard for this research comparison.
METHODS
Subjects
This study was performed with the approval of the Uni¬
versity of California at San Francisco Committee on Human
Research. Informed consent was obtained from all subjects.
Participants were 505 HIV-positive MSM and 364 HIV-
negative MSM enrolled the University of California at San
Francisco Anal Neoplasia Study. Of these men, 469 HIV-
positive subjects and 256 HIV-negative subjects underwent bi¬
opsy at least once during the study. Study participants were
examined every 3-6 months with anal cytology and HRA with
biopsy of any suspicious lesions. Demographic information
was collected and blood samples were obtained for HIV anti¬
body testing.
One hundred twenty-five study participants from our on¬
going cohort study of anal neoplasia were invited to partici¬
pate. Criteria for study eligibility included having had an anal
cytology sample taken using glass-slide smears and ethanol
fixation and a simultaneous biopsy of any visible anal lesion
that appeared dysplastic using HRA. The study participants
had previously had anal cytology samples collected in the
clinic by their practitioner. The men were consecutively cho¬
sen for participation during the study period, and neither cy¬
tology nor anal biopsy results were known at the time of en¬
rollment. A clinician provided an explanation of the study, and
informed consent was obtained from study subjects. Cytology
specimen collection and HRA were performed as described
previously with standard glass slides and ethanol fixation used
to process the cytology specimens for clinician-collected
samples.19
Self-Collection of Samples
We previously showed that glass-slide cytology and liq¬
uid cytology have similar performance characteristics.20 The
study participants used liquid cytology methods to collect their
specimens at home because it was a substantially easier pro¬
cess. The men were given written instructions on how to self-
collect an anal cytology sample. The collection kit consisted of
1 bottle of Cytyc ThinPrep sample collection medium (Cytyc
Corp., Boxborough, MA), 1 Dacron swab, 2 sealable plastic
bags for disposal of sampling materials, and 1 pair of latex
gloves. To allow for healing of the initial anal biopsy site, par¬
ticipants were requested to wait 1 month from the time of the
original anal cytology and biopsy before collecting their cytol¬
ogy sample.
While wearing latex gloves, the men were instructed to
remove the Dacron swab from its sterile package and moisten
it with tap water before inserting it 2 inches into the anal canal.
Applying gentle pressure to the walls of the anal canal, partici¬
pants were instructed to remove the swab with a spiral motion
over a 10-second period. The swab was to be immediately
placed into an open Cytyc bottle containing Cytyc ThinPrep
medium and agitated vigorously to disgorge the cells from the
swab before it was removed from the bottle. The men were
instructed to close the Cytyc bottle tightly, store it at room
temperature, and return it to the clinic in a sealed plastic bag
within 1 week of specimen collection.
Evaluation of Samples
The same pathologist (T.M.D.) analyzed all clinician-
collected cytology and biopsy samples. Because of the differ¬
ent sampling method used, the pathologist knew whether the
specimen was clinician collected or self-collected. However,
all specimen findings were interpreted without reference to the
paired specimen. Cytology findings were classified according
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to the Bethesda classification system as inadequate for inter¬
pretation (sample contained less than -2000 to 3000 nucleated
squamous cells), negative for squamous intraepithelial lesions,
atypical squamous cells of undetermined significance, low-
grade squamous intraepithelial lesions, or HSIL.
Statistical Analysis
Statistical analysis was performed using version 8 of the
Statistical Analysis System (SAS, Inc., Cary, NC). The sensi¬
tivity of anal cytology to detect low-grade squamous intraepi¬
thelial lesions and HSIL was defined as the number of speci¬
mens with abnormal cytology divided by the number of indi¬
viduals with AIN. The Fisher exact text was used to assess the
level of statistical difference between sample specimens.
RESULTS
MSM who had had a prior clinician-collected anal cy¬
tology and HRA examination with anal biopsy were consecu¬
tively enrolled from the University of California at San Fran¬
cisco Anal Neoplasia Study. Approximately 10% of the men
invited to participate declined to do so. Of the men who agreed
to participate, -20% did not return the required materials in a
timely fashion. Of the 106 remaining participants, 4 were ex¬
cluded because they had incomplete clinician-collected cytol¬
ogy and clinic biopsy data. One hundred two subjects were
therefore included in the analysis, and of these subjects, 82
were HIV positive and 20 were HIV negative. The mean age at
the time of sampling was 45 years (range, 29-72 years). Most
of the study participants were white non-Hispanic, (n = 89
[87%]); the rest were white Hispanic (n = 2 [2%]), black (n = 3
[3%]), Amerindian (n = 1 [1%]), Asian (n = 3 [3%]), and other
(n = 4 [4%]).
Results of the clinician-collected cytology and the cor¬
responding histology are shown in Table 1. Results of the self-
collected cytology and the corresponding histology are shown
in Table 2. Specimen adequacy was high in both clinician-
collected (101/102, 99%) and self-collected (93/102,91%) cy¬
tology specimens, with a significantly higher rate of adequacy
seen in the clinician-collected samples (P = 0.02). The ad¬
equacy rate of self-collected samples was similar for HIV-
positive (93%) and HIV-negative (85%) men (P = 0.37).
The sensitivity of any grade of anal cytology abnormal¬
ity for detection of AIN 1, AIN 2, or AIN 3 was comparable
between clinician-collected (70%) and self-collected (68%)
samples. The sensitivity of any grade of anal cytology abnor¬
mality for detection ofa high-grade lesion (ie, AIN 2 or 3) was
also comparable between clinician-collected (74%) and self-
collected (71%) samples. However, the sensitivity of anal cy¬
tology to detect AIN in self-collected samples was higher
among HIV-positive men than among HIV-negative men.
Three (20%) of 15 HIV-negative men with AIN had abnormal
cytology compared with 56 (77%) of 73 HIV-positive men
(P < 0.01). The sensitivity for detection ofAIN 2 or 3 specifi¬
cally in self-collected specimens was also higher among HIV-
positive men than among HIV-negative men. Among the 57
HIV-positive men with biopsy-proven AIN 2 or 3, anal cytol¬
ogy was abnormal in 43 (75%), compared with 4 (40%) of 10
HIV-negative men (P = 0.05). The sensitivity of anal cytology
to detect either AIN overall or AIN 2 or 3 specifically was also
higher for HIV-positive men in the clinician-collected
samples, and the magnitude of these differences in sensitivity
was similar to those seen in self-collected samples (P = 0.15
for AIN overall; P = 1.0 for AIN 2 or 3). Overall cytologic
results did not differ by grade between clinician-collected and
self-collected samples. Among men diagnosed with AIN 2 or 3
by biopsy, 39% with AIN 2 and 33% with AIN 3 had HSIL by
cytology.
DISCUSSION
Recent guidelines from the US Public Health Service for
the treatment of opportunistic infections in HIV-positive indi¬
viduals indicate that although anal cytology screening has not
TABLE 1. Comparison of Findings for Clinician-Collected Anal Cytology Specimens With Those for Clinic Biopsy
Anal Histopathology
Clinician-Collected
Cytology Normal Atypical AIN 1 AIN 2 or 3 Insufficient Total (%)
Normal 4 1 10 18 0 33 (32)
ASCUS 1 0 0 2 0 3(3)
LSIL 0 1 13 22 0 36(35)
HSIL 0 0 2 27 0 29(28)
Insufficient 0 0 1 0 0 1 (1)
Total (%) 5(5) 2(2) 26 (26) 69 (68) 0 102
AIN 1 indicates low-grade AIN; AIN 2 or 3, high-grade AIN; ASCUS, atypical squamous cells ofundetermined significance; insufficient, insufficient cellular
material for interpretation; LSIL, low-grade squamous intraepithelial lesions.
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TABLE 2. Comparison of Findings for Self-Collected Anal Cytology With Those for Clinic Biopsy
Anal Histopathologv
Self-Collected
Cytology Normal Atypical AIN 1 AIN 2 or 3 Insufficient Total (%)
Normal 3 1 8 20 0 32(31)
ASCUS 0 0 1 3 0 4(4)
LSIL 0 1 10 22 0 33 (32)
HSIL 0 0 1 23 0 24 (24)
Insufficient 2 0 6 1 0 9(9)
Total (%) 5(5) 2(2) 26 (26) 69 (68) 0 102
AIN 1 indicates low-grade AIN; AIN 2 or 3, high-grade AIN; ASCUS, atypical squamous cells ofundetermined significance; insufficient, insufficient cellular
material for interpretation; LSIL, low-grade squamous intraepithelial lesions.
yet been formally recommended, anal cytology screening
should be considered for HIV-positive men and women.23
Anal cytology should be used as a screening tool to identify
individuals who would benefit from HRA to detect and treat
AIN.19 The current recommendation is to refer patients with
any grade of anal cytologic abnormality for HRA.23-24 More¬
over, our group previously showed that detection of HSIL by
anal cytology has a high positive predictive value for detection
ofbiopsy-proven high-grade AIN.19 Thus, inability to confirm
high-grade AIN by HRA-directed biopsy in a patient with
HSIL by cytology should prompt a repeated examination.
In this study, we compared overall rates of abnormality
between samples collected by clinicians and study partici¬
pants. The results of this study strongly suggest that this popu¬
lation of MSM with previous experience of having had anal
swabs used to collect cytology specimens and anal biopsy
specimens of lesions clinically suspicious for anal dysplasia
obtained by a clinician are capable of self-collecting samples
with sensitivity comparable with that of experienced clini¬
cians. This was accomplished with only written instructions on
how to self-collect an anal cytology specimen in this experi¬
enced population.
The primary goal of anal cancer prevention is to detect
and treat high-grade AIN before it progresses to cancer. To this
end, we also compared the sensitivity of cytology specimens
collected by clinicians and subjects to detect AIN 2 or 3 by
biopsy and found that the sensitivity for the 2 groups was com¬
parable. This ability to self-collect anal cytology specimens
may allow high-risk populations to be screened outside of a
medical setting and allow for subsequent evaluation with HRA
and treatment of lesions in individuals with abnormal cytology
findings. It could also provide a useful tool for epidemiologic
studies of anal cytology and possibly anal human papilloma¬
viruses in large population-based cohorts.
The rates of clinician-collected and self-collected anal
cytology specimen adequacy were similar to those seen in a
previous study that validated anal cytology as a screening test
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for AIN.19 In the present study, specimens collected by clini¬
cians had a slightly lower inadequacy rate than those collected
by study subjects. However, this should not affect the role of
self-screening because patients with inadequate specimens
could be informed of the need to repeat the test. Notably, the
sensitivity of anal cytology to detect AIN overall and AIN 2 or
3 specifically was significantly higher among HIV-positive
men than among HIV-negative men, a finding consistent with
our earlier study.19 We speculate that this reflects the larger
size of lesions typically found in HIV-positive men, leading to
a higher likelihood of detection. Another explanation is that
HIV-negative men were not as vigorous in obtaining speci¬
mens as the HIV-positive men. This is less likely because rates
of specimen sufficiency were similar between HIV-positive
and HIV-negative men. Further, the clinician-collected speci¬
mens were less sensitive for HIV-negative men than for HIV-
positive men, similar to our findings for the self-collected
specimens. Because participants were enrolled in the study
only if they had undergone anal biopsy, the prevalence ofAIN
in the study was very high, and there were too few participants
with normal anoscopic examination findings to assess differ¬
ences in other measures of screening validity (eg, specificity
and positive and negative predictive values) between sample
specimens.
We do not yet have any data on the performance of self-
collected anal cytology specimens for a population with a
lower prevalence ofdisease. If a population has a lower preva¬
lence of disease than the population in the present study be¬
cause it has a higher proportion ofHIV-negative men, then this
might lead to lower sensitivity of the test for this population. In
addition, it is likely that the positive predictive value for such a
population would be lower than for our study population and
the negative predictive value would be higher.
As with previous studies of anal and cervical cytology, a
substantial proportion of normal cytology specimens was
falsely negative. In this study, -30% of subjects with biopsy-
proven AIN had normal cytology findings, suggesting that,
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similar to cervical screening, sequential anal cytology screen¬
ing may be necessary to detect AIN in this population. In this
context, the role of testing for high-risk human papillomavi¬
ruses as an adjunct to anal cytology has not been characterized.
Previous studies have shown that detection ofmultiple human
papillomavirus types is a risk factor for progression of low-
grade squamous intraepithelial lesions to HSIL, although the
risk ofprogression associated with individual high-risk human
papillomavirus types has not been fully addressed.25
The findings for self-collected anal cytology specimens
were encouraging in this study, although the results should be
interpreted with caution. The study participants had experi¬
enced the collection ofmultiple anal cytology samples by cli¬
nicians in the past and were aware of how an adequately col¬
lected sample felt while being taken. This experience may
have enhanced their ability to take an adequate specimen. Self-
collected samples were taken 1 month after clinic anal cytol¬
ogy and anal biopsy. It is possible, although unlikely given the
slow progression of dysplastic lesions in the cervical and anal
canal, that the degree of dysplasia may have changed during
this time. It is possible, although unlikely, that taking an anal
biopsy specimen could completely have removed the dysplas¬
tic lesion or changed the natural history of the lesion. Clini¬
cian-collected cytology specimens were obtained using a glass
slide and were preserved in ethanol, whereas self-collected
specimens were processed using liquid cytology methods. The
liquid method may have facilitated improved specimen ad¬
equacy by reducing processing problems associated with fecal
contamination and low cell count. However, when previously
assessed using a split-sample technique, both methods were
shown to be comparable, although this may not have been the
case in this study.20
One of the strengths of this study was that the same pa¬
thologist analyzed all of the cytology and biopsy specimens,
facilitating comparison of the results. The pathologist was also
aware if the cytology specimen was clinician or subject col¬
lected because of the different sampling methods used. There¬
fore, a potential bias may have been introduced into the inter¬
pretation of cytology results. However, we do not believe that
this affected the results in a substantive way because the pa¬
thologist interpreted the samples at least 1 month apart and
would not have known the findings for the other samples col¬
lected from the same participant.
In summary, these data indicate that self-collected anal
cytology specimens, when adequate for interpretation, had
sensitivity similar to that of specimens collected by experi¬
enced clinicians. The sensitivity of anal cytology sampling to
detect AIN 2 and 3 is good among HIV-positive men, but fur¬
ther effort is needed to improve sampling among HIV-negative
men. If successful, this technique could greatly facilitate insti¬
tution ofanal cytology screening to prevent anal cancer among
at-risk individuals and would be a useful tool to define the
prevalence of abnormal anal cytology findings among large
populations. Further research is needed to determine whether
this technique works as well when performed by individuals
with no prior experience with anal cytology and among a popu¬
lation with a lower prevalence of AIN. In addition, the sensi¬
tivity, specificity, and positive and negative predictive values
should be studied for populations with a lower prevalence of
AIN and with a larger number of HIV-negative men.
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Effects of a behavioural intervention to reduce acquisition of
HIV infection among men who have sexwith men: the
EXPLORE randomised controlled study
The EXPLORE Study Team *
Summary
Background Effective interventions are needed to prevent acquisition of HIV infection in men who have sex with
men. To date, no behavioural interventions specifically for this risk group have been tested with HIV infection as the
primary outcome.
Methods This multisite two-group randomised controlled phase lib trial tested the efficacy of a behavioural
intervention in preventing HIV infection among 4295 men who have sex with men. The experimental intervention
consisted of ten one-on-one counselling sessions followed by maintenance sessions every 3 months. The standard
condition was twice-yearly Project RESPECT individual counselling. Twice-yearly follow-up visits included testing
for HIV antibody and assessment of behavioural outcomes.
Findings The rate of acquisition ofHIV infection was 18 -2% (95% CI -4-7 to 36 -0) lower in the intervention group
than the standard group. Adjustment for baseline covariates attenuated the intervention effect to 15 -7% (—8 • 4 to
34-4). The effect was more favourable in the first 12-18 months of follow-up. The occurrence of unprotected
receptive anal intercourse with HIV-positive and unknown-status partners was 20-5% (10-9 to 29 0) lower in the
intervention than in the standard group.
Interpretation The results from the primary analyses allow us to rule out that the experimental intervention is
associated with a 35% lower rate ofHIV acquisition than in the standard group. The overall estimate of a difference
of 18 -2%, more favourable estimates of effect in the first 12-18 months, and similar effects on risk behaviours
suggest that prevention of HIV infection among men who have sex with men by a behavioural intervention is
feasible. Further work should be done to develop more effective interventions.
Introduction
In 2002, men who have sex with men accounted for 44%
of all new diagnoses of HIV infection and AIDS in the
USA.1 The need for interventions to prevent HIV
infection with proven efficacy in this risk group is
reinforced by the increase in HIV infection among this
group during the past 7 years, in contrast to declining
rates of risk behaviours and seroincidence observed in
the 1980s and early 1990s.2"10 A recent meta-analysis of
behavioural interventions for men who have sex with
men showed that interventions focused on interpersonal
skills related to risk reduction can reduce self-reported
episodes of unprotected anal intercourse.11 Previous
publications also show that interventions should target
use of alcohol and recreational drugs, social norms
encouraging risk taking, enjoyment of risk-related
sexual behaviour, and life events and environments that
trigger risk taking.12" These components built into
interventions individually tailored to assist a man to
move toward risk reduction based on his own and his
partners' serostatus, could have the greatest success in
reducing risk of infection among men who have sex
with men.14
The EXPLORE study was designed as a multisite two-
group randomised controlled phase lib or screening
trial" to test the effect of a behavioural intervention in
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preventing acquisition of HIV infection among men
who have sex with men in the USA. Until this trial, no
behavioural interventions specifically for this risk group
have been tested in a randomised controlled design with
this outcome measure. We aimed to develop and test an
intervention that incorporated the best information
about effective strategies to address the many factors
associated with acquisition of HIV infection among
men who have sex with men. Furthermore, we assessed
and documented the quality of the intervention delivery
to ensure it was delivered according to protocol.
We report the primary study outcomes of the
EXPLORE study.
Methods
This study was carried out in six US cities: Boston, MA;
Chicago, IL; Denver, CO; New York, NY; San Francisco,
CA; and Seattle, WA. Details of the baseline
methods and intervention have been published
elsewhere.'4-" Intervention and training manuals,
the protocol, outcome measures, and interview
details are available from the EXPLORE website
(http://www.explorestudy.org). The study was approved
by the institutional review boards at each of the
participating institutions, and participants provided
written informed consent.
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Figure 1: Trial profile
*Owing to the common close-out date, percentage is calculated on the basis of participants due at that visit.
Study population
Study participants were recruited at each site between
January, 1999, and February, 2001. Recruitment strategies
included outreach in streets, at dance clubs, bars,
bathhouses, sex clubs, health clubs, and video arcades.
Staff within each city also mounted public relations and
advertising campaigns, with emphasis on the gay media.
Participants also came to the study through internet sites,
community forums, community agencies, and referrals
from other study participants and clinics. Men were
eligible if they were negative for HIV antibodies, were
aged 16 years or older, and reported having engaged in
anal intercourse with one or more men in the previous
year. Men were excluded if they reported a mutually
monogamous relationship lasting 2 years or longer with a
male partner known to be HIV seronegative.
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Design and procedures
Baseline procedures have been described elsewhere."
After informed consent had been given, trained
interviewers collected information on respondents'
demographic characteristics, reasons for participating in
the study, history of sexually transmitted diseases, use of
postexposure prophylaxis, and history of counselling
and psychotherapy. Audio-computer-assisted self-
interviewing (ACASI) technology was used to collect
information on attitudes towards safer sex, social
activities within the gay community, depression, alcohol
and drug use, and sexual behaviours. Participants were
asked about sexual behaviours in the previous 6 months
with partners of each HIV-serostatus type (negative,
positive, and unknown). After completing the
interviews, participants received HIV pretest
counselling, and blood samples were collected for HIV-
antibody testing.
About 2 weeks after being screened, participants
underwent post-test counselling after receiving the HIV
test result. Those with a positive test result at baseline
were referred to medical and social services. Men who
had no detectable HIV antibodies at the baseline
interview were asked to enrol in the trial. The EXPLORE
statistical centre generated the allocation sequence to
randomise participants to intervention or control
conditions in a ratio of one to one (figure 1).
Randomisation was stratified by study site and was
blocked with random sequences of block sizes.
Randomisation was obtained by a telephone call to a
voice-prompted, interactive computer program at the
statistical centre. Study staff answered questions about
the participant's eligibility for randomisation, and the
computer verified eligibility, then randomly assigned
the participant to one of the two counselling groups.
The experimental intervention, described in detail
elsewhere,14 consisted of ten core counselling modules
delivered at one-on-one counselling sessions, typically
with one module being delivered per session within
4—6 months of randomisation. For purposes of analysis,
the variable "session modules" was defined as the
maximum number of modules or sessions completed
within 6 months of randomisation. After the initial ten
modules, maintenance sessions were delivered every
3 months until the end of the study.
The intervention was designed to address individual,
interpersonal, and situation-related factors associated
with risk taking among men who have sex with men,
>uch as greater pleasure in or enjoyment of risk-related
sexual behaviour, negative mood states, communication
iifficulties, social norms encouraging misperceptions of
"isk and risk taking, use of alcohol or recreational drugs,
rnd life events and environments that are catalysts for
risk taking. An intervention manual detailed the
materials to be covered at each of the ten core
rehavioural intervention modules. The first three
modules established rapport between the counsellor and
participant and provided detailed personalised risk
assessments to guide the future focus of the
intervention sessions. The remaining sessions covered
sexual communication, knowledge of personal and
others' HIV serostatus in making sexual decisions, and
alcohol and drug use in conjunction with risk
behaviours. Modules were also offered on how unsafe
sex could be triggered by meeting certain types of
partners, by places or events related to selection of
partners, and by cognitive or emotional cues associated
with risk taking. Motivational interviewing was used to
help participants make and sustain changes in
knowledge, attitudes, beliefs, and behaviours.17
The standard condition was twice-yearly counselling
on risk reduction based on the Centers for Disease
Control and Prevention Project RESPECT model.18
Intervention and standard counselling sessions were
carried out at the study sites by counsellors who had
completed the required 40 h of training. Counsellors
were trained to deliver both the standard and the
interventional material. Several approaches were used
to assess and ensure adherence to the intervention and
standard protocols and to keep cross-contamination to
a minimum. First, sessions were audio-taped and a
planned 10% random sample of tapes (11-5%) were
selected for review by raters at the intervention
coordinating centre. The sessions were scored on many
items specific to the session. The quality-assurance
scores were percentages of the total possible score;
sessions with scores above 80% were deemed to have
followed the protocol and, therefore, to be acceptable.
Another approach was to assess the duration of
sessions; the intervention sessions were designed to be
longer than the standard sessions. Finally, data on
quality-assurance scores and duration of sessions were
shared with study sites regularly, for monitoring and
continuing training purposes, by the clinical
coordinator at each site and the intervention
coordinating centre.
Follow-up visits were scheduled every 6 months for
participants assigned to both study groups. These visits
consisted of behavioural surveys with both face-to-face
interviews and the ACASI technology. All sexual-
behaviour outcomes were collected by ACASI. To
mitigate further against participants' under-reporting
of risk behaviours owing to social desirability, no
study staff had access to any ACASI risk-behaviour
information for any participant, including during
counselling sessions. Blood samples were collected for
testing for HIV antibodies.
Antibodies to HIV were detected by ELISA. Serum
samples shown to be reactive after a first test were
retested in duplicate. Repeatedly reactive samples were
confirmed by western-blot assay or immunofluo¬
rescence assay. Participants with a positive test result at
any follow-up visit were referred to medical and social
services.
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Characteristic Number of participants
Intervention (n=2144) Standard (n=2151)
Age, years
16-19 43(2-0%) 50(2-3%)
20-25 359(16-7%) 362 (16-8%)
26-30 450 (21-0%) 463 (21 5%)
31-35 458(21-4%) 452 (21-0%)
36-40 376(17 5%) 379 (17-6%)
>40 458(214%) 445 (20 7%)
Race/ethnicity
White 1559 (72 8%) 1553 (72-2%)
Hispanic 322 (15 0%) 330(15-3%)
African-American 131 (6-1%) 150 (7-0%)
Other 131 (6-1%) 118(5-5%)
Education
High school or less 198 (9-2%) 209(9-7%)
Some college 557 (26-0%) 572 (26-6%)
College 761 (35 5%) 773 (36-0%)
After college 628 (29 3%) 595 (27 7%)
Household annual income, US$
<12 000 280(13 1%) 282 (13-1%)
12 000-29999 579 (27 0%) 587(27-4%)
30 000-59 999 839 (39 2%) 817 (38-1%)
»60 000 444(20-7%) 460 (21-4%)
Currently a student 338 (15 8%) 362 (16-8%)
Employment status
Fulltime 1623 (75 7%) 1624(75 5%)
Part time 208 (9 7%) 218(10-1%)
Unemployed 219(10-2%) 208(9-7%)
Other 94(4-4%) 101(4-7%)
Number of male partners in previous 6 months
0 25(12%) 17 (0 8%)
1 142 (6 6%) 164 (7-6%)
2-5 678 (31-7%) 704(32-7%)
6-9 393 (18 4%) 357(16-6%)
S10 904(42-2%) 908(42-2%)
Female sex partner in previous 6 months 86 (4-0%) 92(4-3%)
HIV-positive male partner in previous 6 months 595 (27 8%) 620 (28-9%)
Anal sex in previous 6 months
Any unprotected anal sex 1442 (67-7%) 1501 (70-4%)
Unprotected anal sex with positive or unknown-status partner 999(46-9%) 1049(49 0%)
Unprotected receptive anal sexwith positive or unknown-status partner 598 (28-0%) 608 (28-5%)
Receptive anal sex 1587 (74 2%) 1597 (74 7%)
Unprotected receptive anal sex 1011 (47-4%) 1031 (48 5%)
Insertive anal sex 1731 (80 9%) 1760(82 1%)
Unprotected insertive anal sex 1135(53 3%) 1206(56 5%)
Alcohol and drug use in previous 6 months
Heavy alcohol use* 234(110%) 219(10-2%)
Non-injection-drug use 1392 (65-0%) 1382 (644%)
Injection-drug use 222 (10 4%) 217(10-1%)
Depression* 1024(47-8%) 1006 (46-8%)
Where totals do not reach 2144/2151, data were missing. *Four or more drinks every day or six or more drinks on a typical daywhen drinking in the last 6 months. tBasedon a shortened
version of the Center for Epidemiologic Studies depression scale.
Table: Baseline characteristics by study group
Statistical analysis
This screening or phase lib trial was designed to have a
high probability of establishing benefit for a highly
effective intervention or of ruling out benefit for a
totally ineffective intervention. Furthermore, for
interventions with lower yet worthwhile efficacy (eg,
35% efficacy), the trial would have high probability of
either establishing benefit or indicating plausible
efficacy deserving of further study; in that instance, the
trial would inform the development of future efficacy
trials.
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The EXPLORE study was designed so that the
intervention strategy would be declared beneficial if the
difference in the rate of acquisition of HIV infection
between intervention and standard groups was
significantly above 10% in favour of the intervention
group (that is, that the lower limit of the 95% CI was
above 10%). If not, and the difference was significantly
below 35% (that is, the upper limit of the 95% CI was
below 35%), the benefit of the intervention strategy would
be ruled out. In case neither was true, the intervention
would be judged plausibly effective with merit for
Articles
further evaluation, possibly with refinements. With the
target sample size of 4350 and an expected rate of
acquisition of HIV infection of 1-55 per 100 person-
years in the standard group, if the true difference in the
rate of HIV infection was 35% in favour of the
intervention group, there would be a 3 • 0% chance of
ruling out benefit, a 50-0% chance of declaring benefit,
and a 46 ■ 9% chance of stating that the intervention had
plausible efficacy. Furthermore, if the true difference in
the rate of HIV infection was 0%, there would be a
75 ■ 0% chance of ruling out benefit.
By intention to treat, comparisons were made
between the participants assigned to the intervention
group and those assigned to the standard group,
irrespective of the amount of counselling received. The
primary analysis was to assess the intervention effect on
rate of acquisition of HIV infection. A proportional-
hazards model was adopted on the discrete timescale of
twice-yearly visits, with the intervention-group indicator
as the only covariate. The odds ratio of HIV infection
was estimated and the intervention effect was defined
as one minus the odds ratio (ie, the percentage of
reduction in HIV infection). We assumed in the
analysis that HIV serostatus was negative at a missing
visit if there were no positive results at earlier visits and
an assessment was made at a subsequent visit.
As secondary endpoints, serodiscordant (ie, with
HIV-positive or status-unknown partner) unprotected
receptive anal intercourse, serodiscordant unprotected
anal intercourse, and unprotected anal intercourse were
assessed at twice-yearly visits. For each endpoint, its
occurrence during the 6 months before a visit was used
and a logistic regression model was adopted with visit-
independent intervention effect and visit-specific
intercepts. The generalised estimating equations
approach was used to account for within-participant
correlation of repeated outcome measures, with an
independent working correlation.
For both primary endpoint and secondary endpoints,
additional analyses were done to adjust for baseline
characteristics. Specifically, for rate of acquisition of
HIV infection, in the proportional-hazards model, we
added the following baseline variables as additional
covariates: age, injection-drug use, sex with HIV-positive
male partner, sex with HIV-positive female partner,
unprotected receptive anal sex, and unprotected
insertive anal sex, as well as site and race/ethnicity as
stratification variables. This step was an attempt to
account for imbalances in randomisation and loss to
follow-up with respect to baseline characteristics. For
serodiscordant unprotected receptive anal intercourse,
its baseline measure was added to the logistic regression
model as a visit-independent effect. The same approach
was used in the adjusted analyses of serodiscordant
unprotected anal intercourse and unprotected anal
intercourse by adding their respective baseline
measures to the regression models.
Before the final analyses, we identified three potential
effect modifiers: alcohol use, non-injection-drug use,
and depression. Alcohol use was classified as none,
light, moderate, or heavy, and non-injection-drug use
and depression as yes or no. Subgroup analyses
were done for rate of acquisition of HIV infection and
occurrence of unprotected anal intercourse, serodis¬
cordant unprotected anal intercourse, and serodiscordant
unprotected receptive anal intercourse for each potential
effect modifier.
Role of funding sources
The study sponsors participated on the EXPLORE
protocol team and provided review of the study design
and implementation, including assurance of adherence
to good clinical practice in data collection. The sponsors
had no role in analysis or interpretation of data or in the
writing of the report.
Results
Of the 4862 men screened for the study, 4296 enrolled
and were randomly assigned to the two study
groups (figure 1). The final analysis was based on
4295 participants; one participant was randomised in
the absence of informed consent.
The mean age of the participants was 34-0 years
(SD 9-4) and 19-0% were 25 years of age or younger.
72-5% of the participants were white, 15-2% were
hispanic, and 6-5% were African-American. 35-8%
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Figure 2: Kaplan-Meier curve of proportion of participants infected with HIV
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had an annual household income of less than
US$30 000. The enrolled men reported a median of
seven male sex partners in the 6 months before
screening (IQR three to 18); however, 42-2% reported
having ten or more male partners and 28-4% having
an HIV-infected partner. 69-1% reported any
unprotected anal intercourse, 48-0% reported
unprotected receptive anal intercourse, and 54-9%
reported unprotected insertive anal intercourse. 47 • 9%
reported unprotected anal intercourse with an HIV-
positive or unknown-status partner, and 28-2%
reported unprotected receptive anal intercourse with
an HIV-positive or unknown-status partner. Heavy
alcohol use was reported by 11 -0% of participants and
any non-injection-drug use by 64-7%. At baseline,
47 ■ 3% of men had symptoms of depression as found
by a shortened version of the Center for Epidemiologic
Studies depression scale. Baseline characteristics were
well balanced between the intervention and standard
groups, with the exception of unprotected insertive anal
intercourse (table).
Of the 2144 men assigned the intervention, 1598
(74-5%) completed all ten initial session-modules,
154 (7-2%) completed seven to nine, 105 (4-9%)
completed four to six, 258 (12-0%) completed one to
three, and 29 (1-4%) did not complete any. More than
70% of the men in the intervention group received
maintenance sessions except at the 33-month, 39-month,
and 45-month visits (figure 1).
Of the initial ten sessions, 1691 were reviewed and
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80% or higher. 651 maintenance visits for the
intervention group were also reviewed and 77 • 1% met
this criterion. The proportion of the 6-monthly visits that
met the quality-assurance criterion did not differ
significantly between the intervention and standard
groups (76-9% of 657 reviewed vs 80-7% of 841
reviewed, p=0-0677). The mean duration of the sessions
at the 6-monthly visits was 16-1 min longer for
intervention sessions than for standard sessions (37-9
[SD 20-4] vs 21 -8 [11-1] min; p<0-0001).
Visit retention rates were above 83% in the
intervention group and above 87% in the standard group
during the follow-up period (figure 1). Retention was
consistently higher in the standard group than in the
intervention group. Lower retention, as defined by final-
visit retention status, was significantly associated with
minority-group status (89 • 5% white men retained vs
83-9% others), younger age (89 -8% >25 years vs 80-0%
<25 years), reporting of female sex partners at baseline
(88 ■ 5% no female partners vs 74 • 2% one or more
female partners), and reporting of unprotected receptive
anal intercourse at baseline (89-0% no unprotected
receptive anal intercourse vs 86-7% reporting
unprotected receptive anal intercourse). In the
intervention group, retention also was significantly
associated with completion of the initial ten session-
modules (92-2% for nine or ten session-modules vs
63 • 6% for less than nine session-modules).
The overall rate of acquisition of HIV infection in the
study cohort was 21 per 100 person-years (95% CI 1-9
to 2-4). There were 6037 person-years of follow-up in
the intervention group and 6203 in the standard group.
115 intervention-group participants and 144 standard-
group participants became infected with HIV during the
study. By intention-to-treat analysis, the odds ratio was
0-82 (95% CI 0-64 to 1-05) for the intervention group
relative to the standard group (figure 2). Thus, the
difference in the rate ofacquisition ofHIV infection was
18-2% (95% CI -4-7 to 36-0) in favour of the
intervention group. The data suggest that the difference
in acquisition of HIV infection was greatest in the first
12-18 months of the study (figure 2).
After adjustment for study site and baseline
characteristics associated with retention and distributed
differently in the two study groups, the estimated odds
ratio for the intervention was 0-84 (0-66 to 108),
translating to a 15-7% (-8-4 to 34-4) difference in HIV
acquisition in favour of the intervention group.
Subgroup analyses by baseline alcohol use, non-
injection-drug use, and depression score were
consistent with the overall results (data not shown).
The estimated odds ratios of reporting unprotected
anal intercourse and serodiscordant unprotected anal
intercourse in the intervention group relative to the
standard group (figure 3) were 0-86 (0 -79 to 0-94) and
0-85 (0-78 to 0-94). These odds ratios translate to
differences in favour of the intervention group of 13 • 9%
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(5 ■ 6 to 21 • 5) in unprotected anal intercourse and 14 • 8%
(6-3 to 22-5) in serodiscordant unprotected anal
intercourse. We also examined the highest risk
behaviour, unprotected receptive anal sex with a partner
positive for HIV or of unknown status; the estimated
odds ratio was 0-80 (0-71 to 0-89), translating to a
difference of 20 ■ 5% (10 • 9 to 29 ■ 0).
After adjustment for study site and baseline
characteristics associated with retention and distributed
differently in the two groups, the efficacy estimates for
unprotected anal intercourse, serodiscordant unpro¬
tected anal intercourse, and serodiscordant unprotected
receptive anal intercourse were 13-2% (4-8 to 20-9),
14-8% (6-5 to 22-4), and 22-5% (13-3 to 30-7).
Subgroup analysis of the sexual behavioural outcomes
showed similar results to overall results (data not
shown),
Discussion
Challenges for trials of behavioural interventions have
been completion of the intervention and retention of
study participants over time." Most participants in the
EXPLORE intervention group received all ten initial
session-modules and maintenance sessions, and the
sessions were delivered with high conformity with the
protocol. Visit retention was above 87% in the standard
group and above 83% in the intervention group over the
4-year study.
The primary analysis found that the intervention was
associated with an 18-2% lower rate of acquisition of
HIV infection; an analysis adjusted for baseline
covariates attenuated the intervention effect to 15-7%.
Analysis of the behavioural outcomes found that the
intervention significantly affected the occurrence of the
highest risk behaviour,20 unprotected receptive anal
intercourse with HIV-positive and unknown-status
partners, as well as unprotected anal intercourse with
HIV-positive and unknown-status partners, and
unprotected anal intercourse.
The results from the primary analyses allow us to rule
out that the experimental intervention lowers the rate of
HIV acquisition relative to the standard group by 35%.
The overall estimate of an 18 • 2% difference between the
groups, together with more favourable estimates of
effect in the first 12-18 months and similar changes in
risk behaviours, suggests that a behavioural intervention
can prevent HIV infection, not just reduce the frequency
of self-reported risk behaviours. Further analyses of
our data are under way with the aim of generating
hypotheses to help develop more effective behavioural
interventions. For example, are there subpopulations of
men who have sex with men with demographic
characteristics, baseline risk behaviours, or psychosocial
measures for whom the behavioural intervention was
more beneficial? With such evidence, more targeted
behavioural interventions could be developed and tested.
Furthermore, although over 70% ofmen completed the
ten-session intervention in this study, other designs of
such interventions should be explored to improve the
acceptability to different groups and facilitate
implementation in community settings.
We are aware ofonly one other trial of an intervention
to reduce HIV risk for men who have sex with men that
involved a biological endpoint.2' In that study, the
intervention was a 1-day workshop combining several
models of behaviour change with motivational
interviewing strategy. The primary infection outcome
was a new sexually transmitted disease, as assessed
from clinical and laboratory databases, and behavioural
outcomes were collected by mailed questionnaire.
Contrary to expectations, over 12 months of follow-up, a
larger proportion ofmen in the intervention group than
in the control group receiving standard care had a new
sexually transmitted disease. Behavioural outcomes did
not significantly differ between the groups.21
Two other large-scale trials of behavioural interven¬
tions with biological outcomes have been carried out in
the USA among predominantly heterosexual popula¬
tions. The Project RESPECT trial tested individually
delivered interactive risk-reduction interventions
delivered in either two or four sessions and found, over
12 months, a 20% lower rate ofnew sexually transmitted
diseases than with people receiving didactic messages.
The effect of the intervention was strongest early in
follow-up.18 The National Institute of Mental Health
Multisite HIV Prevention Trial of a seven-session small
group intervention found no difference between study
groups in overall rate of reinfection with sexually
transmitted diseases over 12 months.22 Other smaller
randomised trials of behavioural interventions have
been done with sexually transmitted disease outcomes
among women, patients with sexually transmitted
diseases, and adolescents, with only one demonstrating
a significant effect on rates of sexually transmitted
disease."-21 The lower rate of HIV acquisition with the
intervention in the first 18 months of follow-up in
EXPLORE was similar to that found with sexually
transmitted diseases in Project RESPECT. Furthermore,
the EXPLORE study found similar effects on risk
behaviours over 12-18 months of follow-up to Project
RESPECT and the meta-analysis of HIV intervention
studies among men who have sex with men.11
The EXPLORE trial had several limitations. First, the
study sample recruited is not necessarily representative of
men who have sex with men in the participating cities.
Eligibility criteria were established to enrol a high-risk
HIV-antibody-negative population for a trial with an HIV-
infection endpoint. Furthermore, generalisability is
limited since black and hispanic men, younger men, and
those of lower socioeconomic status were less likely to
enrol in the study, were more likely not to be eligible for
the study owing to behavioural characteristics, and were
more likely to be HIV infected" and not retained in
follow-up than white men in the study. However, the
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population recruited was clearly at high risk as shown by
the rate of acquisition of HIV infection and self-reported
behaviours, which emphasises the need for prevention
efforts to continue for many subpopulations ofmen who
have sex with men. Second, the full effect of the
intervention may have been muted for several reasons.
The standard condition was based on the best available
model, the Project RESPECT two-session behavioural
intervention model, and decreases in sexual risk
behaviours were observed in both study groups in the
EXPLORE study. The amount of counselling in the
standard group was probably more than that given in
most public health settings and not equivalent to usual
care, in which individuals would voluntarily seek
anonymous counselling and testing in many cases, or to
typical HIV counselling delivered in the community. In
addition to the counselling, participants in both groups
received much attention during the study, including
repeat HIV-antibody testing, scheduling, and reminder
letters or calls for all visits, newsletters, and other activities
to maintain involvement and retention. Another possible
reason for a muted intervention effect is cross-
contamination if participants in the control group were in
contact with others who were part of the intervention
group. This effect, however, was likely to
be negligible because only 13% of the men were enrolled
as referrals from friends. Other community HIV-
prevention efforts available to participants in both groups
could also affect the results. Finally, the full effect of
the intervention could have been dampened because not
all intervention-group participants received the full
initial ten session-modules or attended all maintenance
visits. However, only 13% of the intervention-group
participants received three or fewer of the initial session-
modules.
A third limitation was a differential in retention
between the study groups, with 90% and 86% retained at
their final visit in the standard and intervention groups,
respectively; those not retained tended to be from
higher-risk subgroups. This higher rate ofnon-retention
in the intervention group can be explained by the low
retention rate in the participants who had lower
adherence to the initial ten session-modules. Although
the men in the intervention group who completed at
least nine of the initial ten session-modules had a
retention rate of 92%, close to that achieved in the
control group, the remainder of the intervention group
had only 64% retention. These data suggest that
approaches are needed to improve the capture of longer-
term outcome results, particularly among participants
who have lower adherence to behavioural interventions.
Other research has shown that self-reported
behavioural outcomes can overestimate the benefit of
behavioural interventions and that the relation between
the frequency of reported sexual behaviours and rate of
HIV infection is probably complex and dependent on
factors related to selection of partners and background
prevalence of HIV infection.19'21 The use of ACASI
technology in our study might have helped to limit
potential problems with the validity of self-reported
behaviours.24-25
The challenge for behavioural interventions has been
maintenance ofbehaviour change over extended periods.
The EXPLORE study was done during a period of
substantial changes in the prevalence of risk behaviours
and HIV incidence in communities ofmen who have sex
with men, probably related to widespread use of highly
active antiretroviral treatments and shifts in social
norms.92''27 This trial provides encouragement that
behavioural interventions can achieve reductions in risk
in the short term. However, achievement of long-term
effects is one of the most challenging features to face in
design of effective behavioural interventions. In the long
run, engagement of individuals at high risk in intensive
interventions over a short period and delivery of periodic
"boosters" may not be effective. A different model should
be considered for long-term behavioural change, possibly
combining improved, individualised interventions with
community and structural changes to encourage and
support behavioural change, particularly in relation to
unprotected anal sex and disclosure ofHIV serostatus.
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1.0 INTRODUCTION
1.1 Background
Human papillomavirus (HPV) infection is one of the most common sexually
transmitted agents among both men and women, and HPV-associated anal condyloma
is one of the most common sexually transmitted diseases among MSM practicing
receptive anal intercourse. HPV has received much attention in the last decade due to
its causal association with anogenital squamous cell cancer, including cancer of the
cervix, vulva, vagina, penis and anus.
There are two important reasons to study anal HPV infection and HPV-related lesions
in the anal canal ofMSM. The first is that anal HPV infection may lead to
development of anal cancer and its putative precursors, anal squamous intraepithelial
lesions (ASIL). An understanding of the biology ofHPV infection and ASIL is
critical to the development of an effective strategy for prevention of anal cancer in
MSM, which as described below, is relatively common and potentially preventable.
The second reason is perhaps even more important, which is that anal HPV infection
and ASIL may represent important risk factors for the acquisition ofHIV infection
among HIV- men, as well as new strains ofHIV among men who are already HIV+.
A) Anal HPV infection and ASIL as risk factors for anal cancer
The primary reason to expand our knowledge about anal HPV infection and ASIL is
their putative relationship with invasive anal cancer. Anal cancer and its precursors
among MSM have been the focus of study for a number of years. The reason for this
focus is that the incidence of anal cancer among MSM was approximately 35/100,000
prior to the HIV epidemic (1, 2). Therefore the incidence of anal cancer in this group
prior to the HIV epidemic was similar to that of cervical cancer in women prior to the
introduction of cervical cytology screening and several-fold higher than current rates
of cervical cancer in women (3). Historically, most anal cancers in men and women
occur after the age of 50 but anal cancer has recently been increasing among younger
men. The relationship between anal cancer incidence and the HIV epidemic is not yet
clear. One study suggested that the increase in anal cancer among single, never-
married men in San Francisco between the ages of 25 and 44 years predated the HIV
epidemic (4). In contrast, others have shown that the rate of invasive anal cancer
increased with increasing proximity to an AIDS diagnosis, suggesting an association
between anal cancer and HIV-related immunosuppression (5).
The term "ASIL" encompasses a wide range of HPV-related changes in epithelial
cells. At one end of the ASIL spectrum are "condyloma" and "mild dysplasia" or
"anal intraepithelial neoplasia 1" (AIN 1). Analogous to the Bethesda system of
grading cervical cytology (6), we, as well as others, have consolidated these into low-
grade squamous intraepithelial lesions (LSIL). At the other end of the ASIL
spectrum, the terms "AIN 2" (moderate dysplasia) and "AIN 3" (severe dysplasia)
have been consolidated into high-grade squamous intraepithelial lesions (HSIL).
Each of these categories is diagnosed using the same criteria as those used for cervical
disease (7). HSIL is considered to be the true cancer precursor lesion and is always
treated to prevent cancer when possible. While LSIL is not considered pre-cancerous
per se, and is usually not treated, it may progress to HSIL. Another grade of
cytologic abnormality known as "atypical squamous cells of undetermined
significance" (ASCUS) may also be found. ASCUS is between normal and LSIL in its
8 February 2001 HPVSSP Manual Version 1.0 2
HPV Protocol Version 3.0
association with HPV infection and concurrent presence of ASIL on anoscopy and we
customarily include ASCUS in the "abnormal" cytology category.
The paradigm for the clinical significance ofASIL and its relationship to invasive
anal cancer is cervical SIL (CSIL) and invasive cervical cancer. The basis for this
parallel is four-fold: 1) the presence of a transformation zone in the anal canal similar
to that of the cervix. Many HPV-related lesions of the cervix arise in the cervical
transformation zone, the site where the columnar epithelium of the endocervix meets
the squamous epithelium of the exocervix. A similar area is present in the anal canal
at the anorectal junction, where the columnar epithelium of the rectum meets the
squamous epithelium of the anal canal; 2) ASIL is histologically quite similar to
CSIL. Invasive anal cancer likewise is histologically similar to invasive cervical
cancer. As with invasive cervical cancer, many cases of invasive anal cancer have
overlying HSIL suggesting that HSIL is the lesion from which the cancer arose; 3) the
relationship between HPV and anal disease has been documented in a number of
publications (7-9) and is similar to the relationship between HPV and cervical disease.
As in the cervix, HPV 16 is the most common HPV type found in association with
anal cancer and there are few anal cancer cases with only the "benign" HPV types
such as 6 or 11 (7, 8) and 4) the range ofHPV types found in the anal canal is similar
to that of the cervix (10). Since development of cervical cancer is preventable
through detection and treatment ofCSIL before it progresses to cancer, it is highly
likely that treatment ofASIL will prevent development of anal cancer. Anal cancer is
thus one of the few preventable malignancies in either HIV+ or HIV- men, and an
understanding of the natural history ofASIL and associated risk factors is clearly
needed to develop appropriate prevention strategies.
For the last five years, we have performed studies of the prevalence of anal HPV
infection and ASIL in a cohort of 346 HIV+ and 242 HIV- men, as well as changes in
infection and disease over a 4-year follow-up period. The results of these studies are
summarized in the Preliminary Data section and in manuscripts in the appendices.
Because the subjects were enrolled primarily from the San Francisco Men's Health
Study, the mean age at enrollment of the HIV+ men was 42 years (range, 24-64) and
the mean age of the HIV- men was 45 years (range, 26-73). A high proportion of
HIV+ and HIV- men had anal HPV infection and ASIL at baseline and after 4 years
of follow-up; the projected incidence ofHSIL was 49% among HIV+ men and 17%
among HIV- men. These data indicate that a large proportion of both HIV+ and HIV-
men are at risk of developing anal cancer.
This study will be performed in HIV- men, but will also have important implications
for HIV+ men. Since a high proportion ofHIV- men had anal HPV infection at
baseline, we believe that many HIV+ men will have acquired HPV infection and
possibly ASIL prior to acquisition ofHIV infection. An understanding of anal HPV
infection and ASIL among HIV+ men is therefore dependent on understanding the
dynamics of infection and disease prior to seroconversion.
Risk factors for acquisition ofHPV infection and development ofASIL also remain
poorly understood. In our cohort study described above, we did not have a sufficient
number ofHIV- men to perform multivariate analyses of risk factors. Even more
importantly, since most of the men were in their forties, we believe that they may
have acquired HPV infection too long ago to provide meaningful data. For this
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reason, studies ofHIV- men younger than age 26 provides an ideal opportunity to
better understand risk factors for HPV infection and ASIL. To illustrate this point, we
have been studying anal HPV infection in high-risk HIV+ and HIV- women, mostly
age 35 or older. When queried about receptive anal intercourse as a risk factor for
HPV infection and ASIL, there was no clear association. However, when we repeated
this study among adolescent women who had recently initiated sexual activity, we
found anal HPV infection in nearly 30%, and there was a clear correlation with
receptive anal intercourse in this group.
B) Anal HPV infection and ASIL as risk factors for HIV seroconversion
Several studies have documented the role of sexually transmitted diseases (STDs) as
cofactors for HIV acquisition (11-14). To date there have not been any rigorous
studies of the role ofHPV infection or ASIL in potentiating HIV acquisition. The
role that STDs play in HIV acquisition may be twofold. First, these STDs are often
associated with mucosal friability and the increased possibility of body fluid
exchange, including blood, may enhance HIV transmission. Second, these STDs lead
to inflammatory responses, and the increased presence of lymphocytes prone to HIV
infection may also potentiate HIV acquisition. HPV-related diseases may lead to HIV
acquisition for both of these reasons. In our experience, men who have internal anal
lesions, whether low-grade or high-grade, bleed very easily when a swab is passed
into the anal canal to obtain specimens for HPV testing or cytology. Insertion of
objects into the anal canal, as in receptive anal intercourse, may similarly lead to more
frequent and larger volumes of bleeding if ASIL is present. Biopsies ofASIL
frequently show a lymphocytic infdtration, similar to cervical SIL lesions in which
the majority of the lymphocytes in cervical lesions are CD4 cells. Therefore it is
likely that cells susceptible to HIV infection are present in larger quantities in ASIL
lesions, at sites that are also likelier to bleed. For both these reasons, we believe that
HPV infection and ASIL increase the risk ofHIV acquisition among HIV- men.
Additionally, HIV+ men who have ASIL at the time of engaging in receptive anal
intercourse may be at risk of exposure to new HIV strains and may also be likelier to
transmit HIV to active partners. Since women have been shown to acquire cervical
HPV infection soon after initiation of sexual activity, we hypothesize that MSM also
acquire HPV infection soon after initiating receptive anal intercourse. If so, then they
may have HPV infection and possibly ASIL at a time of their lives when they may be
most likely to practice unsafe sex with a large number of partners. If our data do
show that ASIL is a risk factor for HIV acquisition, this may have important
implications for development of new strategies to prevent HIV transmission.
Specifically, detection and treatment ofASIL in high-risk HIV- MSM may be useful
to lower the risk ofHIV acquisition.
In summary, more information is needed on the biology of anal HPV infection and
ASIL among MSM. These data are needed to better understand HPV infection and
ASIL as risk factors for anal cancer in both HIV- and HIV+ men. They are also
needed to determine ifHPV infection and ASIL are risk factors for HIV acquisition.
1.2 Rationale
Anal cancer is a relatively common malignancy among men who have sex with men
(MSM) and may be even more common among HIV+ MSM. In the past few years,
we have collected much data on anal HPV infection and anal squamous intraepithelial
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lesions (ASIL) from a cohort of 346 HIV+ and 262 HIV- MSM. These data show that
anal HPV infection and ASIL are very common among men in the 35-45 year age
range. Our follow up of the cohort showed that the 4-year projected incidence of the
putative anal cancer precursor lesion high-grade squamous intraepithelial lesion
(HSIL) was 49% among HIV+ men and 17% among HIV- men. While men with anal
HPV infection and ASIL are probably at increased risk of anal cancer, little is known
about the prevalence or incidence ofHPV infection and ASIL in men at either end of
the age spectrum, i.e., men over the age of 50 years and men aged 25 years or less.
Although these studies will be performed in HIV- men, but will also have important
implications for HIV+ men, since we believe that many HIV+ men will have acquired
HPV infection and possibly ASIL prior to acquisition ofHIV infection. An
understanding of anal HPV infection and ASIL among HIV+ men is therefore
dependent on understanding the dynamics of infection and disease prior to
seroconversion. Knowledge of the natural history of anal HPV infection and ASIL in
the early years after sexual activity begins will therefore be very important. Like
cervical cancer, anal cancer may be preventable through screening for and treatment
ofASIL, and data collected in this study could have important implications for
development of anal cancer screening programs for both HIV+ and HIV- men.
1.3 Study design overview
Our proposed study will characterize HPV infection and anal cytologic abnormalities
in 1400 to 2000 MSM chosen from among 2900 men recruited into four of six
HIVNET 015 (Explore) study sites. Enrollment into HPV ancillary study ends July
31,2002.
At 12, 18, 24 and 30 months after enrollment to HIVNET 015 (Explore), and at 6-
month intervals for the duration of this study, we will obtain a minimum one anal
swab from each participant. The swab will be for anal cytology [per our standard
protocol] using the Thinprep method as well as for HPV testing.
In designing the behavioral intervention study, the investigators assumed that the HIV
seroincidence during the planned follow-up period would be approximately equal to
that observed in VPS (1,55/100-person years). These seroconversion rates were used
in determining sample size calculations for our proposed study examining the
association between HPV infection, ASIL and HIV seroconversion. Since one half of
our study subjects will be in the intervention group, for the purposes of sample size
determination, we have assumed that the intervention will be successful in reducing
HIV seroconversion by 30%.
2. STUDY OBJECTIVES
The following objectives will be addressed:
2.1 To study the prevalence, incidence and risk factors for anal human papillomavirus
infection in a cohort of sexually active HIV- MSM.
2.2 To study the prevalence, incidence and risk factors for anal cytologic
abnormalities in a cohort of sexually active HIV- MSM.
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2.3 To study the association between HIV seroconversion and detection of anal
cytologic abnormalities or anal HPV infection in a cohort of sexually active HIV-
MSM.
3. STUDY DESIGN
Our proposed study will characterize HPV infection and anal cytologic abnormalities
in 1400 - 2000 MSM chosen from among 2900 (four out of six sites) men recruited
into HIVNET 015. All eligible participants will be offered enrollment over a
maximum of a two-year accrual period until a total of 1400 - 2000 men are enrolled.
Study enrollment ends July 31, 2002.
HIVNET 015 participants will be offered enrollment in the HPV study at the Month
12 study visit, unless the participant has been on study more than 486 days (closing
date of the Month 12-visit window) when the study is implemented. Thus some
participants will be offered enrollment at the Month 18 study visit, and a few will be
offered enrollment at the Month 24 study visit and Month 30 study visit.
At HPV study enrollment and at three 6-month interval visits (or two 6-month interval
visits for Month 30 enrollees) and for the duration of this HPV study, we will obtain a
minimum of one anal swab from each participant. The swab will be used for anal
cytology [per our standard protocol] using the Thinprep method as well as for HPV
testing.
4. PARTICIPANT ELIGIBILITY
This study will include up to 2000 men at high risk for HIV infection enrolled in the
HIVNET 015: A Randomized Clinical Trial of the Efficacy of a Behavioral
Intervention to Prevent Acquisition ofHIV Among Men who have Sex with Men.
4.1 Inclusion criteria
Persons may be included in the study if they meet the following criteria
• Enrolled in the HIVNET 015 (Explore)
• Willing and able to provide written informed consent.
4.2 Exclusion Criteria
Persons will be excluded from the study if they:
• Have an obvious psychological/psychiatric disorder that would
invalidate the informed consent process, or otherwise contraindicate
participation in the study.
• Having any other condition that in the opinion of the study site
Principal Investigator will interfere with achieving the study
objectives.
4.3 Conditions for withdrawal
Participants may withdraw from study participation at any time, for any reason,
without loss of other benefits or services to which they are entitled. Withdrawal from
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the HPV ancillary study does not affect participation in the HIVNET 015 (Explore)
trial.
Participants may be withdrawn from the study due to inability to comply with study
procedures. Participants also may be withdrawn at the request of the study site
investigator, following review with the co-chairs, protocol bio-statistician, and the
Protocol Coordination Team (PCT) Project Officer.
5. STUDY PROCEDURES
An overview of the study visit and procedure schedule is presented in Table 1.
Table 1. Schedule for visits and procedures during the study.
D = HPV study visits for all enrolled participants
Di= HPV study visits for those who enroll at the Month 12 HIVNET 015 visit only
D2= HPV study visits for those who enroll at the Month 18 HIVNET 015 visit only
D3= HPV study visits for those who enroll at the Month 24 HIVNET 015 visit only
D4— HPV study visits for those who enroll at the Month 30 HIVNET 015 visit only
Study Month - HIVNET 015 12 15 18 21 24 27 30 33 36 39 42
Enrollment in HPV Study d, d2 d3 d4
Laboratory tests
















Remote Participation: Remote participation is not offered in the HPV ancillary
study. If a participant moves to a non-HPV HIVNET 015 (Explore) study site city, we
will not ask them to continue in the HPV study. An HPV ancillary study termination
form will filled out for participants who move and are unable to complete visits at an
HIVNET 015 (Explore) HPV ancillary study site.
5.1 Consent
The template for the consent form for the HPV ancillary study is in the HPV SSP
Section 10, Appendix. Each participant must sign the consent form prior to
participating in the HPV study.
5.2 Specimen collection
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Once the study is discussed with the subject and the consent form is signed.
1) Moisten Dacron™ swab (Dacron swab to be provided by J. Palefsky) in tap
water and insert swab into the anus as far as it will go
2) Remove swab slowly with gentle pressure on the walls, rotating the Q-tip as
you withdraw.
3) Insert swab into the Cytyc bottle, vigorously swirling the swab in the buffer
and squeezing the swab against the sides of the bottle.
4) Discard the swab.
5) Cap the bottle very tightly to prevent leakage. Label the bottle with the labels
provided and the date the specimen was collected.
6) Store Cytyc cytology bottles at room temperature until shipment. Specimens
may be stored for up to one week and shipped Monday to Thursday.




University of California San Francisco
San Francisco, CA 94143
5.3 Follow-up of anal cytology results
The study protocol calls for anal cytology results to usually be made available to
subjects within 2 months (and no longer than 4 months after collection) of their visit.
If the cytology shows FISIL or cancer (we expect this to happen very rarely if at all),
then the subject must be notified as soon as those results are available. Questions
about the results may be addressed to Dr. Joel Palefsky or Dr. Peter Chin-Hong
through a toll free 800 number. That number is 1-888-345-1588.






Specimens will be collected for testing at the Department ofPathology, UCSF
(cytology samples) and the Department of Laboratory Medicine, UCSF (HPV
samples).
6.1 Anal Cytology Testing
In this study, Thinprep anal cytologic smears will be prepared according to the
manufacturer's instructions. Our pathologist. Dr. Teresa Darragh, who is an expert in
gynecologic pathology and is one the most experienced pathologists in the world in
interpreting anal cytology and histopathology, will read each slide. She will interpret
the slides independently and without knowledge of the results of anal HPV DNA
testing. The criteria for grading anal cytologic smears will be identical to those for
cervical cytology (15).
6.2 HPV testing protocols
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The approach that we use for HPV testing uses PCR because it is an extremely
sensitive test that provides information on the presence of 39 different HPV types.
This test detects both high and low level infections. By determining the presence of
each type individually, we can also analyze other combinations such as HPV 16 and
18 together. We will determine how often these individual types persist and whether
we can detect new types over time.
To perform PCR. an aliquot of the Cytyc specimen is removed from each specimen
when the bottle is opened for the first time. The specimens are heated at 56°C for one
hour to inactivate HIV and digested with 10 mg/ml proteinase K. The PCR protocol
that we use was adapted from a method by Ting et al and is being used by others and
us for many different studies (16). The sample for PCR is added to a tube containing
one ml ammonium acetate/EtOH solution, and the DNA is allowed to precipitate at -
20°C overnight or at -70°C for one hour. Thirty five cycles of amplification are
performed. Detection of the PCR products is performed using a non-radioactive
enhanced chemiluminescence (ECL) dot blot technique. Each membrane contains a
set of negative LI hybridization controls that include human HPV-negative cells and
specimens containing all the components of the reaction except target DNA. Positive
controls consist of plasmid amplifications of the different HPV types. Each
membrane also contains five specimens chosen at random to be amplified and probed
in duplicate, and therefore 5% of our specimens are tested twice as a check for assay
reliability. The PCR product is fixed to the membrane in a UV-crosslinker. ECL
detection is performed according to the manufacturer's (Amersham) instructions, and
the blots are exposed to X-ray film at room temperature for 15 minutes and two hours.
The blots are probed with a generic probe mix consisting of biotinylated HPV LI
PCR products from HPV 11, 16, 18, and 51. A second membrane is probed with 13-
globin oligonucleotide probe to detect the presence of human DNA and the integrity
of the amplification reaction. Ten more membranes containing specimens positive
with the generic probe are made and probed with each of the following types
individually: 6, 11, 16, 18, 26, 31, 32, 33, 35, 39, 40, 45, 51, 52, 53, 54, 55, 56, 58, 59,
61, 66, 68, 69, 70, 73, AE2, Pap 155, Pap 291, and the following types together in a
probe mixture: HPV 2, 13, 34, 42, 57, 62, 64, 67, 72, W13B. The presence of a dot
on the membrane with a probe for a given HPV type indicates positivity for that type.
If a specimen is negative for 13-globin, this implies that the specimen contains an
inadequate number of cells or an inhibitor of the amplification reaction. HPV results
from these specimens are excluded from analysis.
Specimens that are positive with the generic probe, but negative for the 39 specific
types are considered to have an "unknown" HPV type. Because of its high sensitivity,
PCR by definition must be performed with great care to avoid the possibility of
contamination. We take all possible precautions in handling our samples, including
separation of pre- and post-amplification products in different parts of our research
building. If any of the above negative and positive controls do not work, the reaction
is repeated. We perform a large volume ofHPV testing for this study and other
studies and to date we have not have problems with contamination.
7. EVALUATION OF OUTCOMES
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The outcomes to be measured are incidence of anal HPV infection, incidence of anal
cytological abnormality, prevalence of anal HPV infection, prevalence of anal
cytological abnormality, incidence ofHIV infection, demographics of anal HPV
infection/HIV infection/anal cytological abnormality, and retention in the study.
8. DATA COLLECTION
8.1 Participant charts
Each site will establish a chart for each participant enrolled in the study. Included in
this chart will be a progress notes documenting each participant, checklists indicating
completion of study procedures, and clinical study data. Additional detailed
documentation requirements are contained in the HIVNET 015 (Explore) SSP
manual.
8.2 Record Storage and Archive
All participant charts and DataFax forms must be stored in locked files in a secure
area at the study site. Provided they contain no participant identifying information, the
charts may be stored together with the DataFax forms. Otherwise, the charts and
forms should be stored separately. Informed consent forms, release of information
forms, and locator information must be kept in locked files in a secure area apart from
DataFax forms and any other documents bearing Participant ID number (see also
section 10.5.1).
Study sites will maintain all study documentation for at least five years after the
completion of the study, unless otherwise specified by the PCT (see also Section
11.6).
8 February 2001 HPV SSP Manual Version 1.0 10
HPV Protocol Version 3.0
9. STATISTICAL CONSIDERATIONS
9.1 Justification of sample size 1400 and 2000:
Primary Objectives 2.1.1 and 2.1.2: Age-related prevalence, incidence, and risk
factors for anal human papillomavirus infection and anal cytologic abnormalities.
Table 1 shows margins of sampling error (i.e., the half-width of 95% confidence
intervals) for baseline prevalence ofHPV infection, expected to be in the range of 30-
60%, and anal cytologic abnormalities, in the range of 5-20%, according to the age
stratum of the sample and the prevalence.
Table 1 (a and b): Margins of sampling error in percentage points for
baseline HPV and cytologic abnormalities prevalence, according to age
stratum (rows) and the percent prevalence of the outcome (columns).
la. Total sample size 2000
5 10 20 30 40 50 60
<= 25 1.6 2.2 3.0 3.4 3.6 3.7 3.6
26-45 1.3 1.8 2.4 2.7 2.9 3.0 2.9
>45 3.5 4.8 6.4 7.3 7.8 8.0 7.8
Overall 1.0 1.3 1.8 2.0 2.1 2.2 2.1
lb. Total sample size 1400
5 10 20 30 40 50 60
<= 25 1.9 2.7 3.5 4.1 4.3 4.4 4.3
26-45 1.5 2.1 2.8 3.2 3.5 3.5 3.5
>45 4.2 5.7 7.7 8.8 9.4 9.6 9.4
Overall 1.1 1.6 2.1 2.4 2.6 2.6 2.6
In the original overall sample, the margin of sampling error for HPV prevalence
would have been approximately plus or minus 2.0-2.2 percentage points, depending
on the actual prevalence; for men 25 or younger, the comparable margin would be
3.4-3.7 percentage points. Margins for the prevalence of cytologic abnormalities
would be somewhat narrower, except in the small stratum ofmen over 45. In this
table things don't look qualitatively worse.
In Table 2 a minimum odds-ratio with detectable 80% power is shown for the
association of dichotomous risk factors with prevalence of these outcomes. In these
computations the sample size is penalized by 10% to account for covariate
adjustment.
Table 2 (a and b): Minimum detectable odds-ratios for the association of
dichotomous exposures with prevalent HPV or cytologic abnormalities at
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baseline according to the percent prevalence of exposure (rows), and the
percent prevalence of the outcome (columns).
la. Total sample size 2000
5 10 20 30 40 50 60
10 2.4 1.9 1.7 1.6 1.6 1.6 1.6
30 1.9 1.6 1.4 1.4 1.3 1.3 1.4
50 1.8 1.6 1.4 1.3 1.3 1.3 1.3
70 2.1 1.7 1.5 1.4 1.3 1.3 1.3
90 3.1 2.5 1.8 1.7 1.5 1.6 1.6
lb. Total sample size 1400
5 10 20 30 40 50 60
10 2.8 2.2 1.9 1.8 1.7 1.7 1.8
30 2.2 1.8 1.5 1.5 1.4 1.4 1.4
50 2.1 1.7 1.5 1.4 1.4 1.4 1.4
70 2.6 1.9 1.6 1.5 1.4 1.4 1.4
90 6.4 3.1 2.2 1.9 1.8 1.7 1.7
In most cases, minimum detectable odds-ratios with the sample of 2000 were
considerably less than 2, and this remains the case. Minimum detectable associations
with continuous predictors would be smaller.
Incidence of both cytologic abnormalities and HPV over the course of the 2 years is
expected to be in the range of 5-20% of those at risk. Of the overall sample, 40-70%
are expected to be at risk for incident HPV infection, while 10-50% — those with
prevalent or incident HPV infection — may be at risk for progression to cytologic
abnormalities. Table 3 shows margins of sampling error for cumulative incidence,
given this range of subsample sizes.
Table 3 (a and b): Margins of sampling error for incident HPV and
cytologic abnormalities, according to sample size of subset (rows) and
percent incidence of outcome (columns).
3a. Total sample size 2000
5 10 15 20
200 3.0 4.2 4.9 5.5
800 1.5 2.1 2.5 2.8
1000 1.4 1.9 2.2 2.5
1400 1.1 1.6 1.9 2.1
3b. Total sample size 1400
5 10 15 20
140 3.6 5.0 5.9 6.6
560 1.8 2.5 3.0 3.3
700 1.6 2.2 2.6 3.0
980 1.4 1.9 2.2 2.5
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Table 4 shows minimum detectable odds-ratios for the association of dichotomous
predictors with incident HPV infection, under the original assumptions that 1000
study participants are at risk and that the HPV endpoint is ascertained for 85% of
them. In the new version, 700 would be at risk instead of 1000.
Table 4 (a and b): Minimum detectable odds ratios for dichotomous
predictors of inicident HPV, according to percent exposure prevalence
(rows) and percent cumulative incidence (columns)
4a. Total 1000 at risk
5 10 15 20
20 3.0 2.3 2.0 1.9
40 2.8 2.1 1.8 1.7
60 3.4 2.2 1.9 1.8
80 8.0 3.1 2.4 2.1
4b. Total 700 at risk
5 10 15 20
20 3.7 2.7 2.3 2.1
40 3.5 2.4 2.1 1.9
60 5.0 2.7 2.2 2.0
80 NA 4.6 3.1 2.5
Minimum detectable odds-ratios would have been 2 or smaller in many situations,
provided incidence is at least 10%. This is no longer the case, but things are not
qualitatively worse. Again, minimum detectable associations with continuous
predictors will be smaller.
The incidence ofHIV infection was expected to be 1.55 per 100 person-years in the
usual care arm of the trial, approximately 30% lower in the behavioral intervention
arm, and, with remote follow-up, ascertained for 95% of the total cohort. Cumulative
incidence in the two years of the trial was to have been about 2.6%. New estimates
suggest that cumulative incidence may be higher, but since the HPV sample will have
been recruited later than originally expected, this may be outweighed by shorter
follow-up in for HPV ppts. Table 5 shows minimum detectable odds-ratios in the
sample of 2000, for the association of prevalent HPV infection or anal cytologic
abnormalities with incidence ofHIV, according to the percent prevalence of the
exposure (rows), and the percent cumulative incidence ofHIV (columns). The second
version of the table shows the same results for sample size 1400.
Table 5 (a and b): Minimum detectable odds-ratios for prevalent HPV or
cytologic abnormalities as predictors of cumulative incidence of HIV,
according to percent exposure prevalence (rows) and percent cumulative
HIV incidence (columns).
5a. Total sample size 2000
2 2.5 3
5 5.5 4.8 4.4
10 4.1 3.6 3.3
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20 3.4 3.0 2.7
40 3.3 2.8 2.5
60 4.3 3.5 3.0
5b. Total sample size 1400
2 2.5 3
5 7.2 6.2 5.5
10 5.2 4.5 4.0
20 4.3 3.7 3.3
40 4.4 3.6 3.2
60 7.7 5.1 4.1
9.2 Analysis Plan
Baseline and follow-up data will be entered on DataFax forms and faxed to the
FIIVNET Statistical Center (SC). The accuracy and internal consistency of the data
will be assured by well-established HIVNET procedures. In preliminary analysis,
bivariate relationships will be assessed using cross-tabulation, comparison ofmeans
and percentiles, and graphical tools. We will use pooled logistic regression (17,18) to
examine predictors of loss-to-follow-up in the intervals between visits. In addition, if
loss-to-follow-up exceeds 10%, we will use multiple imputation (19) to assess the
potential for attrition bias.
Specific aims 1 and 2: The pooled adjacent violators algorithm will be used to analyze
baseline current status data on HPV infection, both type-specific and overall, as well
as cytologic abnormalities, giving a nonparametric estimate of age-specific
prevalence. In the cross-sectional analysis of risk factors for prevalent HPV and
cytologic abnormalities, independent risk factors including age, sexual practices, and
substance use will be assessed using logistic regression.
Age-specific person-time incidence rates together with Poisson confidence intervals
will be computed using the prospective data. If reversion to negative PCR results is
observed, we will use the EM algorithm to take account of possible misclassification
of baseline negatives as uninfected, given the number of negative assays before their
first positive result, if any.
Since the time of incident HPV infections will be interval-censored between study
visits, pooled logistic regression will be used to identify independent risk factors for
acquisition ofHPV infection among study participants who are uninfected at baseline.
We will check for effects of treatment on incidence, mediation of any treatment effect
by follow-up risk behaviors, modeled by time-dependent covariates, and interaction of
treatment with other risk factors. To increase power, these models will include all at-
risk study participants; however, interactions of age with other risk factors will be
examined.
Analogous pooled logistic regression models will be used to identify risk factors for
development of cytologic abnormalities. In the statistical justification we take
account of expected false negative results in computing minimum detectable odds-
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ratios. Predictors of interest for both incident HPV and development of cytologic
abnormalities will include concurrent HSV-2 seroincidence and rectal gonorrhea, both
as time-dependent covariates.
Specific aim 3: New HIV infections will be interval censored so that pooled logistic
regression will again be used to assess the effect ofHPV infection on risk of acquiring
HIV. It will be important to distinguish between direct effects of anal HPV infection,
which should only increase risk of acquiring HIV among men who continue to
practice unprotected receptive anal intercourse, and indirect effects, in which HPV
infection serves as a marker for past (and thus also current) HIV risk behaviors. Thus
we will control for such risk behaviors, and test for interaction between HPV and
report of unprotected receptive anal intercourse in the preceding 6-12 months. We
will also examine the interaction of treatment with HPV infection, since treatment is
designed to reduce unprotected anal intercourse.
For all regression analyses, model selection will be guided by a preliminary
examination of bivariate relationships, by tests for goodness of fit, by biological and
psychological plausibility, and by previously reported associations and interactions.
10. HUMAN SUBJECTS
10.1 Institutional Review
Prior to study implementation, the protocol, informed consent forms, participant
education materials, data collection instruments, and other requested documents shall
be approved by local Institutional Review Board (IRB) that complies with 45 CRF 46.
Subsequently, all protocols must be re-reviewed at least annually. All protocol
amendments must be approved by the IRB prior to implementation. The study site is
responsible for preparation and submission of all documents and periodic reports
required by the IRB.
As described in section 11.2, PCT approval will follow local IRB approval.
10.2 Informed consent
Written informed consent will be obtained from each participant prior to enrollment,
and participants will be provided with a copy of the form. Each study site is
responsible for developing an informed consent form for local use based on the
template in Appendix 1 as well as obtaining PCT and IRB approval of the local form.
As described in Section 11.2, the PCT will review all locally developed informed
consent forms prior to and following local IRB approval of the forms, to ensure
adherence to template and 45 CRF 46. The PCT then will issue a formal approval to
the study site to initiate study operations. Documentation of any subsequent changes
in the consent forms must also be provided to the local IRB and the PCT prior to use
at the study site.
10.3 Study Risks
10.3.1 Health Risks
There are no risks involved in obtaining one additional anal swab, but this may
cause some discomfort.
10.3.2 Psychosocial Risks
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Subjects may become anxious if they learn that they have abnormal anal
cytology as a result of participating in this study. Participation in research may
involve loss of privacy. Research records will be handled as confidentially as
possible within the law. All records will be coded and kept in locked files, so
that only the study investigators have access to them. No individual identities
will be used in any reports or publications resulting from this study.
10.3.3 Procedures for minimizing risks
To minimize the above risks that involve discomfort, we try to be as gentle as
possible. We will make it clear to the subjects who have abnormal anal
cytology results that we do not yet understand the clinical significance of these
findings and that they should continue safe sex practices.
To minimize the risk of loss of confidentiality, all records will be coded and
kept in locked files, so that only the study investigators have access to them.
No individual identities will be used in any reports or publications resulting
from this study.
10.3.4 Discussion of risk to benefit ratio in this study
There are no serious risks of participating in this study. The benefits of
participating include being made aware of the presence of abnormal anal
cytology. As above, we will make it clear to the subjects that we do not yet
understand the clinical significance of these findings and that they should
continue safe sex practices. Men with HSIL will be referred for anoscopy and
therapy. Subjects will be contributing to our understanding of the risk factors
for anal HPV infection and ASIL. We already know that this contribution will
be beneficial because of the potential for progression to anal cancer. It may
also be beneficial if our study shows that anal HPV infection and/or ASIL are
also risk factors for HIV acquisition, since this might lead to new approaches
to reducing new HIV infection.
10.4 Study Benefits
10.4.1 Information
During the study, participants will receive the most current information and
counseling about HPV infection and anal cytology. There is no current
treatment for HPV infection, however participants may elect to seek ablative
therapy for condylomata. Although the subjects receive no direct benefits
other than knowledge of the results of their anal cytology, the information may
be of great value in assessing the role of anal HPV infection and associated
disease for others in the future. If an association is found then the results may
be of great importance to future efforts to prevent HIV infection.
10.4.2 Access to Care
Identification of undiagnosed HPV infection or anal cytologic abnormalities is
unlikely to have important benefits for the health of the study participants.
10.4.3 Benefit to Humanity
This study will provide information about age-related prevalence and
incidence ofHPV infection and abnormal anal cytology in men at high risk of
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HIV infection. It will also provide information on the seroconversion rate in
this population and any correlation with HPV infection and/or anal dysplasia.
This information may be useful when planning screening programs for intra
anal dysplasia and may contribute to the development of behavioral and
medical interventions for HPV infection. Determining ifHPV infection
and/or anal dysplasia place men at higher risk ofHIV infection may provide
useful knowledge for planning alternative HIV prevention strategies.
10.5 Confidentiality
10.5.1 Local Protections
All local study records will be kept in locked file cabinets in areas with limited
access. All local databases will be secured with password protected access
systems. All study data and specimens will be identified by a coded ID
number only, and records containing participant name or other personal
identifiers will be stored apart from coded ID records.
Locator information and any list linking Participant ID numbers to file names
or other identifying information will be stored in a separate, locked file in an
area with limited access. If participant ID's are entered into a computer
database, this database must be password-protected and maintained in a
directory separate from any study-specific data. File encryption is
encouraged, but not required.
Study information will not be released without the written permission of the
participant, except as necessary for monitoring by the NIAID, the PCT, the SC
or CL.
10.5.2 Statistical and Coordinating Center (SC) Protections
The SC provides several layers of participant data security including physical,
network and computer access security. Physical security ofall SC computers
and data is obtained through controlled and limited access to areas containing
the SC network. Access to the building and floor requires a personal keycard.
All computer servers are kept in locked offices. All network-wiring closets are
locked and only accessible to designated personnel.
Network security is established using a "firewall" computer to protect
participant data and other SC files from attack via the Internet connection.
This computer restricts and tightly regulates all network traffic between our
internal (secure) SC network and the rest of the Internet Access security is
obtained through the use of network login ID's, passwords and files
protections. Every user is required to have an individual login name and
password. A user connects to any SC computer from a network outside the
HIVNET SC (e.g., through a dial-up connection or the Internet) will be
required to use a SecurelD card. The SecurelD card generates a new, six-digit
number every sixty seconds. This, along with a Personal Identification
Number (PIN) known only to the registered owner of the SecurelD card,
forms the user's password. This system provides for an extremely secure
remote access to SC computing resources. In addition, the DataFax data
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management system provides additional levels of security that go beyond the
normal system security. Users are limited by login name and password to the
level of access that they have to any part of the DataFax server computer they
immediately fall under the DataFax security umbrella. Users must both be
registered to their DataFax security level as well as their system security level.
10.5.3 Federal Protections
The PCT will apply for a federal Certificate of Confidentiality for this study
upon receipt from all study sites documentation of local IRB approval. The
Certificate will apply to all study sites. Once secured, the Certificate of
Confidentiality provides that study staffmay not be compelled to disclose
study-related information by any Federal, State or local, civil, administrative,
or other proceedings.
10.6 Remuneration
Study participants will not be compensated for their time and effort in this HPV study.
11. ADMINISTRATIVE PROCEEDURES
11.1 Study Coordination
The study site investigators (or designees) and other key staff will participate in
training sessions prior to study start-up. Therefore, the protocol chairs, biostatistician,
and PCT protocol specialist will participate in conference calls, as required, to discuss
site operations, progress, and difficulties, and coordination.
11.2 Study Activation
Study sites will be approved to initiate implementation of this study according to PCT
Standard Operating Procedures. Briefly, the following steps will be completed:
• PCT review/approval of site-specific informed consent form
• Local IRB review/approval of protocol, site-specific informed consent form,
participant education materials, advertising and other recruitment materials,
data collection instruments, and any other documents requested by the IRB
• PCT review/approval of site activation documents: Investigator Agreement,
curriculum vitae of the Principal Investigator, documentation of IRB approval,
IRB-approved site-specific informed consent form, and protocol signature
page.
11.3 Study Monitoring
NIAID, the PCT, SC and CL will conduct a site visit to monitor adherence to human
subjects and other regulations, adherence to the study protocol and procedure
manuals, the quality of data collection at the study sites, and the accuracy of data
submitted to the SC. A minimum of two sites will be completed per year. Study sites
will allow HIVNET site visitors to inspect study facilities and documents, as well as
observe the performance of study procedures.
11.4 Protocol Compliance
This study will be conducted in full compliance with the protocol. The protocol will
not be amended without prior written approval by the Protocol Team and the PCT
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Project Officer. Protocol amendments must be submitted to the local IRB and PCT for
approval prior to implementing any amended procedures.
Study sites will be approved to initiate implementation of study amendments
according to PCT standard operating procedures, similar to those outlined for study




The study site will maintain all study records for at least five years after the
completion of the study, unless otherwise specified by the PCT. Study records include
all of the following: Administrative documentation including study approval and
initiation documents, site specific standard operating procedures, all reports and
correspondence relating to the study. Participant case histories including consent
forms, locator forms, DataFax forms and all other documents containing information
pertinent to the study participant. Additional detailed information on study
documentation requirements is contained in the HIVNET 015 (Explore) SSP manual.
11.7 Use of Information and Publications
All information collected for this study will be assembled, reviewed, and presented
and/or published with the policies contained in section 4 of the HIVMOP.








The following documents must be submitted to the PCT Protocol Specialist prior to
the initiation of any study operations.
• HIVNET Investigator's Agreement
• Curriculum Vitae for Principal Investigators
s Documentation of IRB approval
• IRB-approved consent form
• Completed protocol signature page
8 February 2001 HPV SSP Manual Version 1.0 19
HPV Protocol Version 3.0
I have read the protocol entitled "Anal HPV infection and neoplasia as risk factors for
HIV seroconversion" and agree to conduct the study in accordance with its provisions.
Principal Investigator Date
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How To Take An Anal Cytology Swab
The following video demonstrates the method used at the University of California,
San Francisco Anal Neoplasia Study to take an anal cytology swab.
When arranging the appointment it is usual to ask the subject to refrain from using an
enema or douche, or from having anything inserted into the anal canal in the 24 hours
prior to having the cytology swab. The reason for this is to increase the cellular yield
when the cytology swab is taken.
The subject has the procedure explained and questions are answered.
A tray is set up next to the examination table, upon which is placed a Dacron™ swab
moistened in tap water. Dacron™ must be used and not cotton because cotton swabs
do not release their cells into ThinPrep™ as efficiently as Dacron™. A jar of
ThinPrep™ fixative solution is also opened in preparation for the swab.
The subject is then placed in the left lateral position with their buttocks at the edge of
the examination table. The subject is then made as comfortable as possible. The
examiners' non-dominant hand is used to part the buttocks, allowing an unrestricted
view of the anal margin.
Holding the Dacron™ swab in the other hand, the swab is gently inserted with a
twisting motion to ten centimeters or until the examiners fingers touch the anal
margin. The swab is then slowly removed with lateral pressure (enough to bend the
swab) and a spiral motion to most efficiently sample the entire anal circumference
over the next ten seconds.
After removal the swab must be immediately submerged in ThinPrep™ solution to
prevent cellular air-drying artifact. The swab is then agitated and pressed against the
container walls to remove as much cellular material as possible. There is no need for
concern if fecal contamination is present. The ThinPrep™ bottle should be tightly
closed.
The procedure is now complete.
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Anal HPV And Anal Cytology Questions And Answers
Q What is this study all about?
A This study is about human papillomavirus, also known as HPV, or the wart virus,
and infections with HPV in the anus. The investigators in this study and others have done
many earlier studies to show that HPV infection is very common in gay and bisexual
men. There are two reasons anal HPV is important: first, HPV can cause anal cancer,
which in HIV-negative gay men is about 4 times more common than cervical cancer in
women. HPV can also cause anal warts. Anal cancer is often preceded by precursors,
known as squamous intraepithelial lesions or SIL. We believe that detection and
treatment of SIL may prevent development of anal cancer.
Second, we are concerned that anal HPV infection may increase the risk of acquiring
HIV infection. Since HPV causes warts, and warts bleed easily, it is conceivable that
having an anal wart and having receptive anal intercourse may lead to a higher risk of
getting HIV infection. So this study is trying to answer three important questions:
1) How common is anal HPV infection in HIV-negative men at different ages and in
different ethnic groups?
2) How common is anal SIL in HIV-negative men at different ages and in different ethnic
groups
3) Is there an association between having anal HPV infection or SIL and an increased risk
of getting HIV infection?
In this study, we will look for anal HPV using a technique called Hybrid Capture. We
look for anal SIL using a technique called anal cytology. To participate in this study you
will have one anal swab every 6 months that will be used to detect both anal HPV and
cytology. You will be given the results of your cytology within 2 months of your visit.
You will not be given the HPV results since we will not be performing the test until the
end of the study. If your anal cytology is abnormal, you may be referred for another test
call anoscopy but this is not part of the study.
Q. Can you explain exactly what is meant by anal cytology?
A. Anal cytology is a test that samples cells from the anal canal. The cells are then
examined by a pathologist who can grade the cells according to certain characteristics
and report them as normal, abnormal cells of undetermined significance (ASCUS), low
grade squamous intraepithelial lesions (LSIL) which includes wart virus change, high
grade squamous intraepithelial lesions (HSIL), and cancer. It is important to understand
that the cytology report is an indication of the actual grade of anal disease but that the
cytology may sometimes be negative even when a lesion is present. The cytology may
also not correlate with the actual grade of disease, which is usually determined by
performing a biopsy.
Q. What is ASCUS?
A. This is a diagnosis which is between normal and LSIL. It may have nothing to do
with anal HPV infection or it may reflect the presence of LSIL or HSIL.
Q. My anal cytology came back as LSIL. What does that mean?
A. LSIL consists of mild cellular changes including warty change. It is not thought to
be a pre-cancerous lesion or even to represent an increased risk of developing anal
cancer. However, in some people LSIL can progress into HSIL, which, in a very small
number of cases may develop into cancer.
Q. So what should I do?
A. There are currently no guidelines for the management of LSIL. However, we
currently recommend that if the LSIL persists for more than one year, then an anoscopy
and biopsy should be performed. This is not part of our study. The anoscopy involves a
clinician inserting an anoscope into the anal canal so that a biopsy can be taken of the
lesion under direct vision. As a biopsy is the most definitive method used to diagnose
abnormal tissue, unlike cytology, this will make sure that there is no HSIL present. If the
biopsy confirms HSIL then we usually recommend treating it.
Q. What happens ifmy next anal cytology is normal?
A. This means that the pathologist did not see any abnormal cells. However, as I
have mentioned, the sampling technique is not 100 per cent accurate so follow-up
cytologies are necessary to make sure that any abnormal areas were not missed. You will
be having 4 cytology tests every 6 months as part of this study.
Q. What happens ifmy cytology shows HSIL?
A. HSIL on cytology means that a potentially pre-cancerous area may be present in
your anal canal. Although not proven, it is thought that HSIL may progress to cancer so
we would normally want to confirm this diagnosis with an anoscopy and biopsy. If the
biopsy confirms HSIL, you have the options of treating the lesion or observing it with
regular cytologies over time. Observation may mean having an anal swab taken every 6
months to a year, although again, the optimal time spacing has not yet been
demonstrated. If you choose treatment, you should be aware that none of the available
treatment options have been fully validated with regard to outcome and recurrence of
HSIL.
The treatment options currently available include applying acid directly onto the lesion in
a doctor's office. This method works best for small discrete lesions that are not
circumferential. When the lesion is too large, surgery is usually performed. The surgery is
similar to having an operation on a hemorrhoid. It is performed as an outpatient in the
operating room and includes removal of the lesion with a scalpel or laser, destruction
with an electric needle. All of these procedures have potential complications and
significant post-operative pain which has proven difficult to control. New medical
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Background. In the United States, anal cancer in men who have sex with men (MSM) is more common than
cervical cancer in women. Human papillomavirus (HPV) is causally linked to the development of anal and cervical
cancer. In women, cervical HPV infection peaks early and decreases after the age of 30. Little is known about the
age-specific prevalence of anal HPV infection in human immunodeficiency virus (HlV)-negative MSM.
Methods. We studied the prevalence and determinants of anal HPV infection in 1218 HIV-negative MSM, 18-89
years old, who were recruited from 4 US cities. We assessed anal HPV infection status by polymerase chain reaction.
Results. HPV DNA was found in the anal canal of 57% of study participants. The prevalence of anal HPV
infection did not change with age or geographic location. Anal HPV infection was independently associated with
receptive anal intercourse (odds ratio [OR], 2.0; P< .0001) during the preceding 6 months and with >5 sex partners
during the preceding 6 months (OR, 1.5; Pc.0001).
Conclusions. Urban, HIV-negative MSM have a stable, high prevalence of anal HPV infection across all age
groups. These results differ substantially from the epidemiologic profile of cervical HPV infection in women. This
may reflect differences between these populations with respect to the number of new sex partners after the age
of 30 and may explain the high incidence of anal cancer in MSM.
Anal cancer is increasing in incidence in women and
men in the general population [1, 2], Such subpopu-
lations as men who have sex with men (MSM), HIV-
positive women and men, transplant recipients, and
women with cervical squamous intraepithelial lesions
are at an even higher risk than the general population
[3, 4], Before the HIV epidemic, US MSM were esti¬
mated to have an incidence of anal cancer of up to 35
cases/100,000 person-years (py)—similar to the inci¬
dence of cervical cancer in US women before the in¬
troduction of cervical cytology testing [5],
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necessary for the development of anal cancer [4, 7] and its
putative precursor lesion, anal intraepithelial neoplasia (also
known as "anal squamous intraepithelial lesions" [ASILs]).
Although the age-specific prevalence of cervical HPV infec¬
tion has been well described for women [8, 9], no studies have
examined the age-specific prevalence of anal HPV infection in
HIV-negative MSM. In women, the youngest sexually active
age groups have a disproportionately high prevalence of HPV
infection. The prevalence of cervical HPV infection decreases
sharply in women after the age of 30, leaving only a fraction
of women with persistent HPV infection; these women are
thought to have the highest risk for the development of invasive
cervical cancer [10]. To date, most of the published data on
anal HPV infection were obtained from studies that were con¬
ducted in either San Francisco, CA, or Seattle, WA, and that
were of HIV-positive MSM who spanned a narrow age range.
However, the majority of MSM are HIV negative. To better
understand the natural history of HPV infection and the po¬
tential effect of anal HPV infection on HIV-negative MSM, we
here report the results of the first study investigating anal HPV
infection in a geographically diverse population of HIV-nega¬
tive MSM who span a wide age range.
PARTICIPANTS, MATERIALS, AND METHODS
Study population. Study participants were recruited from
sites in 4 cities (Boston, MA; Denver, CO; New York, NY; and
San Francisco, CA). All were participants of the HIV Prevention
Trials Network EXPLORE study, a randomized clinical trial of
the efficacy of a behavioral intervention to reduce the risk of
HIV acquisition in sexually active HIV-negative MSM [11].
Males were eligible for the EXPLORE study if they were HIV
negative at baseline, were 3=16 years old, and reported having
receptive or insertive anal intercourse with 2*1 man during the
preceding year. Recruitment strategies varied by city but in¬
cluded advertising and outreach at bars, bathhouses, clubs (in¬
cluding sex and health clubs), and video arcades. Referrals were
also obtained via other cohort studies, current study partici¬
pants, community agencies and clinics, the Internet, mailings,
and a recruitment video. Baseline (study entry) visits for the
EXPLORE study occurred from January 1999 to February 2001,
with follow-up evaluations at 6-month intervals. Participants
at the 4 sites were offered enrollment into the HPV substudy
after the month-12 EXPLORE study visit. Between January
2001 and October 2002, 1409 men were enrolled into the HPV
substudy. Of these, 1218 men contributed interpretable HPV
data ((3-globin positive). At enrollment, each participant pro¬
vided written, informed consent. The present study was con¬
ducted with the approval of the institutional review boards of
each participating institution. The human-experimentation
guidelines of the US Department ofHealth and Human Services
and those of the participating institutions were followed in the
conduct of this clinical research.
Data collection. As part of the EXPLORE study, each par¬
ticipant reported drug use and sexual behavior using audio
computer-assisted self-interview (ACASI) technology. Recorded
questions were administered by audio or computer screen, and
answers were inputted by keyboard. ACASI has been shown to
increase the likelihood that such sensitive behaviors as having
unprotected anal intercourse are reported, compared with the
likelihood when interviewer-administered questionnaires are
used [12].
Anal sample collection and HPV testing. Trained person¬
nel at each site collected anal samples by rotating a water-
moistened Dacron swab in the anal canal, without direct vi¬
sualization. The swab was then agitated vigorously in 20 mL
of a methanol-based fixative (PreservCyt; Cytyc) for HPV DNA
testing by polymerase chain reaction (PCR).
To prepare samples, the PreservCyt solution was gently
swirled to suspend cells. For each sample, 1.5 mL of the solution
was transferred to a labeled microfuge tube by use of a transfer
pipette. The tubes were spun at 16 g for 15 min, were decanted,
and were dried either overnight or in a 65°C hot block for 1
h. The pellets were suspended in 100 yL of sample transport
medium (Digene) and 2 yL of 10 mg/mL proteinase K (PK;
Boehringer Mannheim). The samples were vortexed and di¬
gested in a water bath for 1 h at 56°C; were heated for 10 min
at 95°C, to inactivate PK; and were frozen until use. For am¬
plification, 5 /rL of each sample was used, and PCR was per¬
formed according to a standard 40-cycle protocol [13]. PCR
products from positive samples were typed by dot-blot hy¬
bridization, with 39 type-specific probes.
Statistical analyses. Age-specific prevalence of HPV was
estimated by use of sample proportions. Independent predictors
of anal HPV infection were identified by use of logistic re¬
gression. Predictors that were significant at P< .15 in both the
univariate and multivariate analysis were retained in the final
multivariate models. Analyses were conducted by use of Stata
software (version 8.0; Stata Corporation).
RESULTS
The median age of participants in the present study was 37
years (table 1). Sixty-seven percent had an annual income of
>$30,000, and 72% had at least an undergraduate degree. Sev¬
enty-eight percent were white, 14% were Latino, 6% were Af¬
rican American, and 3% were Asian. The median age at first
receptive anal intercourse was 20 years. Forty-nine percent were
current smokers or had smoked >100 cigarettes in the past.
Participants reported a median of 8 sex partners during the
preceding 6 months, and 77% reported having receptive anal
intercourse during the preceding 6 months. Eight percent re¬
ported a history of injection drug use. There was no statistical
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Table 1. Selected demographic and behavioral characteristics of 1409 participants at
enrollment.
Characteristic Value
Age, median (IQR), years 37 (31--43)
Education, undergraduate degree or more 72









Age at first anal receptive intercourse, median (IQR), years 20 (17--24)
No. of male sex partners during the preceding 6 months, median (IQR) 8 (4-20)
Receptive anal intercourse during the preceding 6 months 77
Condom use during the preceding 6 months, always 38
Current smoker 22
Injection drug use during the preceding 6 months 8
NOTE. Data are percentage of participants, unless otherwise noted. IQR, interquartile range.
difference between the HPV substudy participants and the en¬
tire EXPLORE cohort with respect to age, ethnicity or race,
income, sexual behavior, and illicit drug use.
Age-specific prevalence ofanal HPV infection. The overall
prevalence of anal HPV infection was 57%. Figure 1 and table
2 show the age-specific prevalence of HPV infection in partic¬
ipants. The prevalence of HPV infection was similar across all
age groups. The most common HPV type detected in this study
population was HPV-16, identified in 12% of participants. The
prevalence of all high-risk HPV types (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68, and 73) was 26% and was similar
across all age groups. The prevalence of all low-risk HPV types
(6, 11, 53-55, 66, Pap 155, and Pap 291) was also 26%. HPV-
positive participants were infected with a mean of 1.8 HPV
types (range, 1-10 HPV types); this value, too, was similar
across all age groups. Forty-five percent of HPV-positive par¬
ticipants were infected with >1 HPV type. Figure 2 shows the
distribution of the number of HPV types infecting each par¬
ticipant, by age group. Figure 3 shows the age-specific distri¬
bution of the 5 most common HPV types detected in the anal
canals of participants (16, 6, 11, 53, and 18). In logistic models
that adjusted for variables that potentially confound the as¬
sociation between age and type, the prevalence of these HPV
types and the next 5 most common HPV types (31, Pap 155,
33, 61, and 66) was similar across all age groups.
The prevalence of anal HPV infection was similar across
study sites. Sixty-one percent of participants in San Francisco,
57% of participants in Boston, 60% of participants in New
York, and 49% of participants in Denver were found to have
anal HPV infection.
Risk factors for anal HPV infection. In a multivariate lo¬
gistic model of predictors of having any anal HPV infection,
there was strong evidence for an effect of a history of receptive
anal intercourse and of the number of male sex partners during
the preceding 6 months (table 3). The following variables were
not significant in univariate analysis (P>.20): age; smoking;
age at first receptive anal intercourse; ethnicity or race; edu¬
cation; employment status; condom use; use of alcohol, ma¬
rijuana, crack, ecstasy, or injection drugs; and recent history or















Figure 1. Prevalence of human papillomavirus (HPV) DNA in the anal
canals of HIV-negative men who have sex with men, by age group and by
cancer-associated risk type. High-risk (HR) types include 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68, and 73; low-risk (LR) types include 6,11, 53-




<25 25-29 30-34 35-39 40-44 45-49 50-54 S55
Age, years
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Table 2. Prevalence of human papillomavirus (HPV) DNA in the anal canals of HIV-negative men who have sex with men, by age
and cancer-associated risk type.
Category <25 years 25-29 years 30-34 years 35-39 years 40-44 years 45-49 years 50-54 years &50 years Total8
Any HPV type 50/98(51) 91/167(55) 165/271(61) 160/273(59) 97/180(54) 72/125(58) 30/53(57) 27/51(53) 692/1218(57)
HPV HR type 16/98(16) 41/167(25) 82/271(30) 72/273(26) 47/180(26) 29/125(23) 14/53(26) 11/51(22) 312/1218(22)
HPV LR type 27/98(28) 48/167(29) 77/271(28) 84/273(31) 40/180(22) 28/125(22) 7/53(13) 11/51(22) 322/1218(22)
NOTE. Data are proportion (%) of study population. High-risk (HR) types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73; low-risk (LR) types
include 6, 11, 53-55, 66, Pap 155, and Pap 291.
a Of 1409 baseline samples, 191 were uninterpretable by polymerase chain reaction {/3-globin negative).
The following variables were included but were not significant
in multivariate proportional-hazards analysis: age, smoking, age
at first receptive anal intercourse, and income. In a multivariate
logistic model of predictors of infection with any high-risk HPV
type, there also was strong evidence for an effect of a history
of receptive anal intercourse during the preceding 6 months
(odds ratio [OR], 2.1 [95% confidence interval {CI}, 1.4-3.2];
P<.0001) and moderate evidence for an effect of number of
male sex partners >5 during the preceding 6 months (OR, 1.2
[95% CI, 1.0—1.5]; P = .06), with age, smoking, and age at first
receptive anal intercourse controlled for.
DISCUSSION
This is the first study to investigate the age-specific prevalence
of anal HPV infection in HIV-negative MSM. The striking find¬
ing of the present study is that urban HIV-negative MSM have
high rates of anal HPV infection across all age groups. Using
PCR testing, we found that 57% of the HIV-negative MSM in
the present studywere HPV positive and that 26% were infected
with a high-risk HPV type. Therefore, a high proportion of
HIV-negative MSM may be at risk for developing anal cancer.
Multiple studies have shown that, in women, cervical HPV
infection is strongly related to age [8, 9]. Most cervical HPV
infections are believed to be self-limited. A small proportion
of women have persistent HPV infections, leading to a peak in
precancerous cervical cytologic abnormalities during the age
range of the late 20s [8], In addition, there is a second, smaller
peak in the prevalence of HPV infection in women after the
age of 55 [5]. It is speculated that this second peak is due to
new exposures in older women or to age-related attenuation
of immune responses. In contrast, the age-specific prevalence
of anal HPV infection in the HIV-negative MSM in the present
study was similar across all age groups.
The difference between the age-related prevalence of HPV
infection of the cervix in women and of the anus in men may
be explained by several factors. Despite a common embryologic
origin and transformation zone histology [14], there may be
organ-specific differences and unique hormonal environments
that account for this disparity. HPV may persist longer in the
anus, for example, or hormone-related changes in the trans¬
formation zone in women may make them more susceptible
to HPV infection at particular times. Another explanation for
the disparity may be differences in sexual behavior between the
HIV-negative MSM in the present study and women in the
general population. Our study participants had more new sex
partners than has been reported by most women >30 years old
<25 25-29 30-34 35-39 40-44 45-49 50-54 £55
Age, years
Figure 2. Distribution of the number of human papillomavirus (HPV) types infecting each participant in the study population of HIV-negative men who have
sex with men, by age group.




























Figure 3. Distribution of human papillomavirus (HPV) types in HIV-negative men who have sex with men. The 5 most common HPV types (16, 6, 11, 53,
and 18) detected in the anal canals of the study population are shown.
[ 15]. New exposures best explains the high prevalence after the
age of 30 years, because the main risk factor for anal HPV
infection was the number of male sex partners during the pre¬
ceding 6 months. However, because the overall prevalence of
HPV and the mean number of HPV types did not increase
with age, our data also suggest that most newly acquired HPV
infections are transient—or that, if they are persistent, they are
suppressed to levels that are too low to be detectable by PCR.
If lifelong type-specific immunity is gained when an HPV
type is cleared, then we would expect that the spectrum ofHPV
types detected in the present study population would have var¬
ied among the different age groups. However, this was not ob¬
served (figure 3). We propose that lifelong immunity does not
persist and that individuals exposed to a given HPV type might
be susceptible to infection, at least transiently, even if previous¬
ly infected with that type. Prospective studies of MSM will be
needed to definitively answer this question.
The prevalence ofHPV infection was high in our study pop¬
ulation, a finding similar to those of previous studies [16], A
wide array of HPV types was identified, and multiple infections
were common. HPV-16, a high-risk HPV type strongly finked
to invasive cervical and anal cancer, was the most frequent type
identified, another finding similar to those of previous studies
[17], Risk factors for any anal HPV infection and high-risk
HPV infection that were identified in our multivariate analysis
included receptive anal intercourse and the number of male
Table 3. Risk of infection with any human papillomavirus (HPV) type.






OR (95% CI) OR (95% CI)
Overall 692/1218 (56.8)
Receptive anal intercourse during the preceding 6 months <.0001 <.0001
No 114/274 (41.2) 1.0 1.0
Yes 579/944 (61.3) 2.3 (1.7-3.0) 2.0 (1.5-2.8)
Use of cocaine during the preceding 6 months .01 .42
No 555/1006 (55.1) 1.0 1.0
Yes 137/211 (64.9) 1.5 (1.1-2.0) 1.2 (0.8-1.7)
Use of "poppers" during the preceding 6 months .02 .78
No 416/767 (54.2) 1.0 1.0
Yes 276/448 (61.6) 1.3 (1.0-1.7) 1.0 (0.7-1.3)
No. of male sex partners during the preceding 6 months <.0001a <.00013
=S5 partners 232/464 (50.0) 1.0 1.0
6-30 partners 360/606 (59.4) 1.5 (1.1-1.8) 1.4 (1.1-1.9)
>30 partners 99/147 (67.4) 2.1 (1.4-3.2) 2.3 (1.5-3.6)
NOTE. CI, confidence interval; MSM, men who have sex with men; OR, odds ratio.
a For linear trend.
2074 • JID 2004:190 (15 December) • Chin-Hong et al.
sex partners during the preceding 6 months. These findings are
also consistent with those of previous studies [13].
Two of the strengths of the present study are its size and
that it is the first multicity study of anal HPV infection. One
potential limitation of the present study is that it is not clear
whether our results can be generalized to some groups ofMSM.
EXPLORE participants were HIV-negative MSM who had had
anal intercourse during the year preceding study entry. Al¬
though we do not know whether these results can be generalized
to MSM in rural areas, we do believe that these results can be
generalized to MSM in urban areas, where a high proportion
of MSM live. Data from the population-based Urban Men's
Health Study (UMHS) [18], conducted in 4 cities, suggest that
our cohort is highly representative of urban MSM with respect
to age at first anal intercourse, history of any anal sex, and anal
sex during the preceding year. The UMHS has shown that 91%
of all MSM in San Francisco, Chicago, New York, and Los
Angeles had at least 1 sex partner during the preceding year.
We considered MSM >45 years old to compose the group that
was most likely to be the least comparable to the EXPLORE
cohort; however, even this group in the UMHS was similar to
the EXPLORE cohort. Among MSM >45 years old in the
UMHS, 48% had >1 sex partner during the preceding year,
and 74% had at least 1 sex partner during the preceding year.
At a minimum, the findings of the present study can be gen¬
eralized to 50%-75% of urban MSM. Therefore, we strongly
believe that the present study has broad public-health impli¬
cations. Other recent cross-sectional surveys of MSM in San
Francisco [19], London [20], and other cities report comparable
sexual behaviors in respondents.
In the present study, the proportion of /3-globin-negative
samples was moderately high (>10%). This may reflect the in¬
experience of the study personnel who collected the samples
using Dacron swabs, rather than any inherent defect in the
Dacron material. In future prospective analyses, analysis of the
proportion of insufficient anal HPV samples stratified by pro¬
vider experience will help answer this question. Finally, al¬
though the MSM in the present study were HIV negative at
baseline, there is a chance that a small proportion of them had
seroconverted to HIV positive by the time of enrollment into
the HPV substudy. The Vaccine Preparedness Study, which had
a population similar to ours, reported an HIV-seroconversion
rate of 1.5 seroconversions/100 py [21]. This rate would affect
our anal HPV and ASIL prevalence estimates only slightly, be¬
cause of the relatively small numbers involved.
Given the results of the present study, assumptions about
extrapolating data from cervical disease in women to anal HPV
infection in HIV-negative MSM must be questioned. Our data
suggest that anal HPV infection in HIV-negative MSM has a
unique epidemiologic profile that must be carefully explored
in future studies, particularly in light of promising new HPV
therapeutic and prophylactic vaccines [22].
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APPENDIX 7
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Age-Related Prevalence of Anal Cancer Precursors in
Homosexual Men: The EXPLORE Study
Peter V. Chin-Hong, Eric Vittinghoff, Ross D. Cranston, Lynette Browne,
Susan Buchbinder, Grant Colfax, Maria Da Costa, Teresa Darragh, Dana Jones Benet,
Franklyn Judson, Beryl Koblin, Kenneth H. Mayer, Joel M. Palefsky
Background: Infection with human papillomavirus (HPV) is
causally linked to the development of anal and cervical
cancer. In the United States, the incidence of anal cancer
among men who have sex with men (MSIM) is higher than
the incidence of cervical cancer among women. Anal squa¬
mous intraepithelial lesions (ASILs) are anal cancer precur¬
sors comprising low-grade squamous intraepithelial lesions
(LSILs) and high-grade squamous intraepithelial lesions
(HSILs). The prevalence of cervical cancer precursor
lesions peaks at around 30 years of age. The age-related prev¬
alence ofASILs in HIV-negative MSM is unknown. Methods:
We conducted a cross-sectional analysis of the prevalence
and determinants of ASILs in 1262 HIV-negative MSM aged
18-89 years recruited from four U.S. cities. Anal cytology and
behavioral data were obtained. Anal HPV infection status
was assessed by polymerase chain reaction. Independent
predictors of ASILs were identified using logistic regression.
All statistical tests were two-sided. Results: The prevalences
of LSILs and HSILs were 15% and 5%, respectively, and did
not change with age. In a multivariable analysis, the risk of
LSILs was associated with having more than five male recep¬
tive anal sex partners (P=.03), any use ofpoppers (alkyl nitrites)
in the previous 6 months |odds ratio (OR) = 1.6, 95% confi¬
dence interval (CI)= 1.1 to 2.5; /> = .03| or use of injection drugs
two or more times per month during the previous 6 months
[OR = 19,95% CI = 1.3 to 277; P= .03], older age at first recep¬
tive anal intercourse (P = .004), and infection with a greater
number of HPV types (P<.001 for linear trend). The risk of
HSILs was associated with any anal HPV infection (OR = 3.2,
95% CI = 1.1 to 9.4; P= .039) and infection with an increasing
number of HPV types (/'<.001 for linear trend). Conclusions:
Sexually active HIV-negative MSM in all age groups have a
high prevalence of ASILs, possibly reflecting their ongoing
sexual exposure to HPV. |J Natl Cancer Inst 2005;97:896-905]
Before the human immunodeficiency virus/acquired immuno¬
deficiency syndrome (HIV/AIDS) epidemic, it was estimated
that, in the United States, the incidence of anal cancer in men
who have sex with men (MSM) is higher than the incidence
of cervical cancer in women (1,2). Current data indicate that
the incidence of anal cancer in men has continued to increase (3).
Infection with human papillomavirus (HPV) is causally linked
to the development of anal and cervical cancers and their
associated precancerous lesions. Anal squamous intraepithelial
lesions (ASILs) are the putative precursors of anal cancer, just as
cervical squamous intraepithelial lesions (CSILs) are the precur¬
sors of cervical cancer (4-8). ASILs range from low-grade squa¬
mous intraepithelial lesions (LSILs) to high-grade squamous
intraepithelial lesions (HSILs). We believe that HSILs are the
true invasive anal cancer precursors. LSILs are not believed to be
a direct precursor to anal cancer but may precede the later devel¬
opment of HSILs (7).
Several studies have shown that the detection of cervical cyto¬
logic abnormalities (i.e., LSILs and HSILs) is strongly associated
with age. Using population-based sampling, Herrero et al. (9,10)
demonstrated that the prevalence of LSILs in the cervix peaked
at 5.2% among women younger than 25 years, decreased sharply
to 2.7% by ages 25-34 years, and then continued to decrease to
0.4% among women older than 65 years. The prevalence of
HSILs in the cervix peaked later, at ages 25-34 years, and was
followed by a less pronounced decline at ages 35—44 years and a
smaller increase in prevalence among women older than 65 years
old compared with the increase that was observed at ages 25-34
years. It has been estimated that cervical HSILs, if undetected,
can progress to invasive cervical cancer in 9-10 years (11).
Knowledge of the age-related prevalence and natural history
of CSILs has guided the development of screening strategies for
cervical cancer, in which women older than 30 years who have
had no previously detected lesion may undergo cytology screen¬
ing at longer than annual intervals because they have a relatively
low likelihood of developing a cervical lesion de novo (12,13).
Although several studies have examined the age-associated
distribution ofCSILs in women (9,14), and one study has inves¬
tigated the age-associated prevalence of anal HPV infection in
MSM (15), no studies have reported the age-associated prevalence
of ASILs in MSM or in other populations at high risk for anal
cancer. Two studies of ASILs in MSM reported the prevalence,
incidence, and risk factors for ASILs for a narrow age spectrum
ofmen living in Seattle (16) or San Francisco (17) only. As is the
case for CSILs, understanding how age affects the prevalence
of ASILs may have implications for anal cytology screening
recommendations.
The objectives of this study were to describe the age-related
prevalence and risk factors for ASILs in MSM. We also com¬
pared the prevalence ofASILs among MSM in four U.S. cities.
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We report results of the first study to describe ASILs in a geo¬




We enrolled men who were concurrently enrolled in four of
six EXPLORE trial study cities (Boston, Denver, New York, and
San Francisco). The EXPLORE trial is a randomized clinical
trial of the efficacy of a behavioral intervention to reduce the
risk of HIV acquisition among sexually active HIV-negative
MSM (18-20). Men were eligible for the EXPLORE trial if, at
baseline, they were HIV-negative, were 16 years of age or older,
and reported having had receptive or insertive anal sex with one
or more men during the previous year. Men who had been
involved in seroconcordant, monogamous relationships with a
male partner for 2 or more years were excluded from the
EXPLORE trial. Recruitment strategies for the EXPLORE
trial varied slightly among study sites and included advertising
and outreach at clubs, bars, bathhouses, sex clubs, health clubs,
and video arcades. EXPLORE baseline visits occurred from
January 28, 1999, to February 7, 2001, and subsequent visits
were made at 6-month intervals. Enrollment in the HPV
substudy was offered to EXPLORE participants in four of six
cities after the month 12 EXPLORE study visit. From January 2,
2001 to October 23, 2002, 1409 men were enrolled in the HPV
substudy. At enrollment, each participant provided written
informed consent. This study was conducted with the approval
of the institutional review boards of each participating center
(the University of California at San Francisco; the Department
of Public Health at San Francisco, CA and Denver, CO; the
New York Blood Center; and the Fenway Community Health
Center).
Data Collection
The EXPLORE trial collected information on participants'
reported drug use and sexual behaviors with the use of Audio
Computer-Assisted Self-Interview (ACASI) technology (21) that
enabled study participants to either hear or read the questions and
enter their answers on a keyboard. Both English and Spanish ver¬
sions of the study questionnaire were available. Compared with
interviewer-administered questionnaires, ACASI has been shown
to increase the likelihood that sensitive behaviors, such as unpro¬
tected anal intercourse, are accurately reported (21). We obtained
additional data on sexual history and smoking for the HPV sub-
study by having each participant complete a questionnaire which
they then sealed in an envelope after completion for collec¬
tion. Questionnaires were batched and returned to us by study
coordinators.
Anal sample collection and cytology. Trained personnel at
each study site collected anal specimens from each study
participant by rotating a water-moistened Dacron swab in the anal
canal without direct visualization. The swab was then agitated
vigorously in a methanol-based fixative (PreservCyt solution;
Cytyc Corporation, Boxborough, MA). The resulting solution
was then stored at room temperature and later used for the
preparation of thin-layer slides for cytology as well as for the
detection of HPV DNA by the polymerase chain reaction (PCR).
Anal cytology was evaluated by a single pathologist (T. Darragh)
who had no knowledge of the clinical status of the participants,
their questionnaire or ACASI responses, or other test results.
Anal cytology specimens were classified as normal, atypical
squamous cells (ASCs) comprising ASCs of undetermined
significance and ASCs that cannot exclude HSILs), LSILs, or
HSIL, using the 2001 Bethesda System criteria that are used to
evaluate cervical cytology (22).
HPV DNA testing. To prepare DNA from the anal specimens,
we gently swirled the PreservCyt solutions containing the anal
sample to suspend the cells, removed 1.5 mL of the solution to
labeled microfuge tubes, and centrifuged the tubes at 16g for 15
minutes. The supernatants were decanted, and pelleted material
was dried overnight at room temperature or for 1 hour at 65 °C.
The pellets were resuspended in 100 pL Sample Transport
Medium (Digene, Silver Spring, MD) and 200 pg/mL proteinase K
(Boehringer Mannheim, Indianapolis, IN), mixed by vortexing,
incubated for 1 hour at 56 °C in a water bath, heated for
10 minutes at 95 °C for to inactivate the proteinase K, and frozen
at -20 °C.
We used 5 pL of each sample to detect the presence of one or
more HPV types by PCR amplification using a standard 40-cycle
protocol, as previously described (23). PCR products from posi¬
tive samples were typed by dot-blot hybridization with 39 type-
specific probes. We classified HPV types as high risk (HPV types
16, 18,31, 33, 35, 39,45, 51, 52, 56, 58, 59, 68, or 73) or low risk
(HPV types 6, 11, 53, 54, 55, 66, Pap 155, or Pap 291) based on
the strength of the association of specific HPV types to invasive
anogenital cancer (24,25).
Statistical Analysis
We used sample proportions to estimate the age-specific
prevalence of LSILs and HSILs. Independent determinants of
ASILs were identified using logistic regression methods. Fac¬
tors that were statistically significantly associated with ASILs at
P<.\5 in univariate analyses, as well as those that were identi¬
fied as being important in previous studies, were retained in the
final multivariable models. We used a polytomous logistic re¬
gression model to estimate and compare associations with risk
factors that distinguished between participants with normal
cytology (the referent group) and participants with LSILs and
HSILs. The analysis was carried out using Stata software (ver¬
sion 8.0; Stata Corporation, College Station, TX). All statistical
tests were two-sided.
Results
Characteristics of Study Participants at Baseline
Of 1409 participants recruited for this study, samples from
1262 men were sufficient for cytologic analysis at baseline.
Participants had a median age of 37 years (interquartile range
[IQR] = 31^13 years) (Table 1). The median age of participants at
first receptive anal intercourse was 20 years (IQR = 17-24 years).
Study participants reported having a median of eight sex partners
(IQR = 4-20) and three receptive anal sex partners (IQR = 0-11)
during the previous 6 months. Men younger than 35 years reported
a median of eight sex partners (IQR = 4-16 partners), men at least
35 years old but younger than 50 years also reported a median of
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Any female sexual partners, %+












Current smoker, <1 pack/day
Current smoker, >1 pack/day
Injection drug use, %+
Diagnosed with genital warts, %t
*IQR = interquartile range.
tDuring the previous 6 months.
eight sex partners (IQR = 4-20 partners), and men 50 years of age
or older reported a median of 10 partners (IQR = 3-24 partners)
during the previous 6 months. Condoms were always used by 38%
of the study participants during the previous 6 months. Partici¬
pants in San Francisco, New York, Boston, and Denver were simi¬
lar with respect to median age, other sociodemographic factors,
and the median number of receptive anal sex partners they reported
having in the previous 6 months (data not shown). There was no
statistically significant difference between HPV substudy partici¬
pants and all enrollees in the EXPLORE trial or between HPV
substudy participants with sufficient cytologic samples and those
with insufficient samples with respect to age, race, income, sexual
behavior, or illicit drug use (data not shown).
Prevalence of ASILs by Age and Geographic Location
The overall prevalence of any abnormal cytology (ASCs,
LSILs, or HSILs) in this population was 32% and was similar for
all age groups (i.e., a test of trend was not statistically signifi¬
cant). The overall prevalence of ASILs (either LSILs or HSILs)
was 20%, and the prevalences of LSILs and HSILs were 15%
and 5%, respectively. The prevalences of LSILs and HSILs were
similar for all age groups (Figure 1).
The prevalence of ASILs was also similar for all study sites
(Figure 2). Cytologic examination revealed that 23% ofparticipants
in San Francisco, 19% of participants in New York, 21% of par¬
ticipants in Boston, and 17% of participants in Denver had ASILs
(P = .23 for any differences between cities). Study participants in
San Francisco had the highest prevalence ofHSILs (8%), followed
by those in New York (5%), Boston (4%), and Denver (4%)
(P = .051 for any differences between cities). The prevalences of
LSILs and ASCs were similar when stratified by city.
<25 25-29 30-34 35-39 40-44 45-49 50-54 >54
Age group (years)
Fig. I. Prevalence of anal squamous intraepithelial lesions (ASIL) by age group.
LSIL = low-grade squamous intraepithelial lesion; HSIL = high-grade squamous
intraepithelial lesion.
Risk Factors for ASILs
Variables that were statistically significantly associated with
the risk ofASILs in unadjusted analyses included higher number
of male receptive anal sex partners in the previous 6 months
(/,<.001 for linear trend), any use of poppers (alkyl nitrites)
compared with no use in the previous 6 months (OR = 1.6, 95%
CI = 1.2 to 2.1, P = .002), use of injection drugs two or more
times per month compared with no use in the previous 6 months
(OR = 6.7, 95% CI = 1.7 to 27, P = .007), anal HPV infection
(OR = 7.5, 95% CI = 4.9 to 11, P<.001), and anal HPV infection
with increasing numbers of HPV types (/><.001 for linear trend)
(Table 2). In unadjusted analyses, the risk of ASILs was also
statistically significantly associated with infection with high-
risk HPV types only (OR = 5.1, 95% CI = 3.1 to 8.4, T^.OOl),
infection with low-risk HPV types only (OR = 9.6, 95% CI = 6.0
to 15, 7><.001), and infection with both high-risk and low-risk
HPV types (OR = 21, 95% CI = 12 to 35, /><.001) compared
with men who were not infected with HPV. However, age, age at
first receptive anal intercourse, and smoking status were not
associated with ASILs (P>. 10).
We constructed a multivariable logistic model to identify fac¬
tors associated with ASILs. Because the number ofmale receptive
anal sex partners in the previous 6 months was highly correlated
with the number of male sex partners in the previous 6 months
fy>.8), only the number of male receptive anal sex partners vari¬
able was used in the final multivariable model. The factors that
showed independent, statistically significant associations with
ASILs were having more than five receptive anal sex partners















Boston Denver New York
Study city
San Francisco
Fig. 2. Prevalence of anal squamous intraepithelial lesions by study city. The total
height of each column represents the prevalence of anal squamous intraepithelial
lesions. HSIL = high-grade squamous intraepithelial lesion; LSIL = low-grade
squamous intraepithelial lesion.
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San Francisco 330 86(26) 1.00
Boston 293 68(23) 0.86
New York 263 56 (21) 0.77
Denver 227 46(20) 0.72
Sexual behavior||
Age at first anal receptive 1.2
intercourse (per 10 y)
No. ofmale sex partners
<2 97 9(9) 1.0
2-5 268 62 (23) 2.1
>5 796 185 (23) 3.1
No. ofmale receptive anal
sex partners
<2 391 52(13) 1.0
2-5 303 59(19) 1.6
>5 546 142 (26) 2.4
Substance use||
Smoker
No 723 159(22) 1.0
Yes 222 53(24) 1.1
Poppers
No 783 140(18) 1.0
Yes 477 116(24) 1.6
Cocaine
No 1040 204 (20) 1.0
Yes 221 52(24) 1.4
Injection drugs
Never 1009 231 (23) 1.0
<2 times/month 75 16(21) 0.9
>2 times/month 9 6(67) 6.7
HPV-related factors
Anal HPV infection#
No 428 29(7) 1.0
Yes 578 203 (35) 7.5
. (0.95 to 1.4)
1.0 (referent)
4.8 (3.3 to 7.1)
8.5 (5.3 to 14)
11 (6.2 to 19)
43 (12 to 157)
1.0 (referent)
9.6 (6.0 to 15)
5.1 (3.1 to 8.4)

















0.92 (0.73 to 1.2)
1.00 (referent)
0.90(0.55 to 1.5)
0.61 (0.37 to 1.03)
0.71 (0.41 to 1.2)
1.32 (1.01 to 1.7)
ND
1.0 (referent)
1.2 (0.7 to 2.0)
1.8(1.1 to 2.8)
1.00 (referent)
1.09 (0.69 to 1.7)
1.0 (referent)
1.4 (0.95 to 2.1)
1.0 (referent)
1.2 (0.73 to 2.0)
1.0 (referent)
1.1 (0.55 to 2.4)
17(1.2 to 223)
1.0 (referent)
2.5 (1.3 to 4.9)
1.0 (referent)
2.7(1.5 to 4.9)
4.2 (2.1 to 8.3)
6.2 (2.8 to 14)















*Totals for n vary because of missing data. OR = odds ratio; CI = confidence interval; HPV = human papillomavirus; ND = not determined.
tEach variable was adjusted for other variables in column.
JTwo-sided P value from simple logistic regression.
§Two-sided P value from multiple logistic regression. Each variable was adjusted for other variables in column.
||During the previous 6 months.
ITest of linear trend across ordered groups specified.
#HPV DNA measured by polymerase chain reaction.
**Low-risk HPV types include types 6, 11,53,54, 55, 66, Pap 155, and Pap 291.
t+High-risk (cancer-associated) HPV types include types 16, 18, 31, 33, 35, 39,45, 51, 52, 56, 58, 59, 68, and 73.
the previous 6 months (OR = 1.8, 95% confidence interval [CI] =
1.1 to 2.8, P = .018), older age at first receptive anal intercourse
(OR = 1.3 per 10-year increase in age, 95% CI = 1.0 to 1.7, P =
.045), injection drug use two or more times per month compared
with no use in the previous 6 months (OR = 17, 95% CI = 1.2 to
223, P =.035), PCR evidence of an anal HPV infection (OR = 2.5,
95% CI = 1.3 to 4.9, P = .008), and anal HPV infection with in¬
creasing numbers ofHPV types (/><.001 for linear trend) (Table 2).
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Geographic location remained unassociated with the risk ofASILs
in the adjusted model. Although neither age nor smoking status
was statistically significantly associated with ASILs in univariate
analyses, both factors were included in the final multivariable
model because results of previous studies (25) had indicated that
they are important risk factors for anal cancer. Neither factor was
statistically significantly associated with the risk ofASILs in the
final multivariable model.
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Risk Factors for LSILs Compared With Risk
Factors for HSILs
Factors that were associated with the risk of LSILs in unad¬
justed analyses were having more than five male receptive anal
sex partners during the previous 6 months compared with hav¬
ing fewer than two receptive anal sex partners (OR = 2.7, 95%
CI = 1.8 to 4.0, P = .001), older age at first receptive anal inter¬
course (OR = 1.3 per 10-year increase in age, 95% CI = 1.02 to
1.5, P = .035), use of poppers during the previous 6 months
compared with no use (OR = 1.9, 95% CI = 1.4 to 2.6, /><.001),
cocaine use during the previous 6 months compared with no use
(OR = 1.3, 95% CI = 1.1 to 2.4, P = .013), use of injection drugs
two or more times per month during the previous 6 months com¬
pared with no use (OR = 7.5, 95% CI = 1.8 to 31, P = .006), anal
HPV infection (OR = 7.6, 95% CI = 4.7 to 12, /><.001), and anal
HPV infection with increasing numbers of HPV types (TKOOl
for linear trend) (Table 3). The risk of LSILs was also associated
with infection with high-risk HPV types only (OR = 4.6, 95%
CI = 2.6 to 8.3, Pc.OOl), with infection with low-risk HPV types
only (OR =11, 95% CI = 6.5 to 18, P<.001), and with infection
with both high-risk and low-risk HPV types (OR = 20, 95%
CI = 11 to 36, /><.001) compared with men who were not in¬
fected with HPV. Factors that showed independent, statistically
significant associations with LSILs in a multivariable model
were having more than five male receptive anal sex partners
during the previous 6 months compared with having fewer than
two receptive anal sex partners (OR = 1.9, 95% CI = 1.1 to 3.2,
P = .028), older age at first receptive anal intercourse (OR = 1.6
per 10-year age increase, 95% CI = 1.2 to 2.1, P = .004), injec¬
tion drug use two or more times per month during the previous
6 months (OR = 19,95% CI =1.3 to 277, P = .03), use ofpoppers
during the previous 6 months (OR = 1.6, 95% CI = 1.1 to 2.5,
P = .03), and anal HPV infection with increasing numbers of
HPV types (/><.001 for linear trend) (Table 3). There was
suggestive evidence that anal HPV infection, as detected by
PCR, may be associated with the risk of LSILs (OR = 2.2, 95%
CI = 0.98 to 5.1, P = .056). There was no statistically significant
association between age or geographic location and the risk of
LSILs in the adjusted model.
Factors that were statistically significantly associated with
the risk of HSILs in unadjusted analyses included residence in
San Francisco compared with residence in Boston (OR = 0.49,
95% CI = 0.25 to 0.96, P = .04) or Denver (OR = 0.46, 95%
CI = 0.22 to 0.98, P = .04), an increasing number of male sex
partners (P = .047 for linear trend); PCR evidence of an anal
HPV infection (OR = 7.0, 95% CI = 3.3 to 15, Pc.OOl), and anal
HPV infection with increasing numbers of HPV types (^<.001
for linear trend). The risk of HSILs was also associated with
infection with high-risk HPV types only (OR = 6.4, 95% CI =
2.7 to 15, P<.001), infection with both high-risk and low-risk
HPV types (OR = 23, 95% CI = 9.6 to 53, /><.001), and infection
with low-risk HPV types only (OR = 5.8, 95% CI = 2.3 to 14,
7)<.001), all compared with no HPV infection. A multivariable
logistic model revealed that residence in New York compared
with residence in San Francisco (OR = 0.41, 95% CI = 0.17 to
0.98, P = .045), PCR evidence of an anal HPV infection (OR =
3.2, 95% CI = 1.1 to 9.4, P = .039), and anal HPV infection
with increasing numbers of HPV types (/><.001 for linear trend)
were independently associated with the risk of HSILs (Table 3).
There was no evidence (i.e., P>.20) for independent associations
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between age or older age at first receptive anal intercourse and
the risk of HSILs. Using a polytomous logistic regression model
to compare risk factors for LSILs with those for HSILs, we
found that older age at first receptive anal intercourse had statis¬
tically significantly different associations with LSILs and HSILs
(P= .012).
Discussion
Here we report the prevalence of ASILs among H1V-
negative MSM, a population that is at an increased risk for the
development of invasive anal cancer compared with the general
population. We found that a high proportion of sexually active
HIV-negative MSM over a wide age range had anal cancer
precursor lesions as determined by anal cytology. Given that a
previous study showed that anal cytology has only 50% sensi¬
tivity for diagnosing HSILs in HIV-negative MSM compared
with the gold standard anal biopsy (26), the true prevalence of
HSILs is likely to be even higher than what we report here. The
substantial prevalence of anal HSILs, in particular, places a
high proportion of MSM at risk for anal cancer. The overall
prevalence of ASILs by cytology was 20% and was similar
across all age groups.
Several studies have demonstrated that, among women, the
prevalence of cervical HPV infection and subsequent CSILs are
strongly associated with age (9,14). Women may acquire HPV
infection at the onset of sexual activity, typically during late
adolescence or during their early 20s. Most of these HPV infec¬
tions are thought to resolve spontaneously. However, a small
proportion ofwomen have a persistent HPV infection that leads
to CSILs, the incidence of which typically peaks 2-3 years after
the initiation of sexual activity and then drops substantially
among older women. An age-related decline in the prevalence of
cervical HPV infection has been observed even among high-risk
populations, such as female sex workers in Spain (27) and
Mexico City (28), as well as among sexually active inner-city
women in New York (29). By contrast, in the cohort of urban
HIV-negative MSM that were recruited for this study, we
previously demonstrated that anal HPV infection was not related
to age, that anal HPV infection was found in 57% of participants,
and that there was no age-related decrease in the prevalence of
anal HPV infection (15). Consistent with this finding is the lack
of any age-related decrease in the prevalence of anal cytologic
abnormalities, in sharp contrast with what has been observed for
CSILs in women.
A number of factors could contribute to differences between
the age associations of epidemiology of CSILs in women and
that of ASILs in MSM. Although the cervix and the anus are
histologically similar, they exist in different hormonal milieus,
and the hormonal milieu of the cervix varies with age and meno¬
pausal status. However, a more likely explanation for the differ¬
ences in age associations between the epidemiology ofCSILs in
women and that ofASILs in MSM is differences in the levels of
sexual activity among women in the previous studies and the
MSM in our study. The MSM in our study reported having a
median of eight male sexual partners during the previous 6
months, a number that remained relatively constant for all age
groups, but is substantially greater than the number of new sex¬
ual partners reported by most women older than 30 years. For
example, behavioral data reported in previous cervical HPV
epidemiologic studies show that sexual activity ranged from
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greater than 50% of subjects having one lifetime sexual partner
in a population-based study of cervical dysplasia in Costa Rica
(9) to means of 2.2 sexual partners during the previous year
among women 30 to 39 years old and 1.4 sexual partners during
the previous year among women older than 40 years in a study
of cervical HPV infection among a group of inner-city women in
New York (29). Studies of cervical HPV in sex workers in
Mexico and Spain reported high numbers of sexual partners
(27,28) but did not report the age-associated prevalence of
cervical cytologic abnormalities and thus cannot be directly
compared with our study.
Most of the men in our study had never been screened for
ASILs before study entry. It was therefore interesting that the
prevalence of LSILs and HSILs did not increase substantially
with age because in the absence of screening and subsequent
treatment of disease, we would expect an increasing proportion
ofmen to developASILs in the older age groups. The fact that we
did not observe a cumulative increase in the proportion of MSM
with anal cytologic changes with increasing age suggests that
many ofthe lesions that develop after HPV infection are transient.
Consistent with this interpretation, we previously reported that
the prevalence of anal HPV infection was consistent across all
age groups (15) and was not cumulative. Our observation that
older age at first receptive anal sex was associated with the risk
of LSILs also suggests that many HPV lesions are transient in
nature. If HPV lesions were transient, men who were younger at
the time of their first sexual experience were probably exposed to
HPV and then developed LSILs that regressed over time. Another,
less likely, explanation for this finding would be a cohort effect:
Older MSM could have been more sexually active and more in¬
tensely exposed to HPV than younger MSM in this prevalence
study. The 20% prevalence of ASILs in the older men could
therefore reflect a true age-related decrease in the prevalence of
ASILs if that particular cohort ofmen had a substantially higher
prevalence ofASILs during their 20s and 30s.
There was no difference in the overall prevalence of ASILs
by geographic location. However, there was some evidence that
location was a risk factor for HSILs, but not for LSILs. San
Francisco had the highest prevalence of HSILs, at 8%, whereas
the other sites each had an HSIL prevalence of approximately
4%. The reasons for this difference in prevalence, if it is a true
difference, are not immediately apparent but may reflect differ¬
ences in behaviors that were not captured by our questionnaire.
This possible regional difference in the prevalence of HSILs
should be explored in future population-based studies.
As has been seen previously (30,31), anal HPV infection and
the number of HPV types were important risk factors for anal
lesions in our study. The strong association between anal HPV
infection and ASILs that we found is consistent with the estab¬
lished role of HPV infection in the development of anal cancer
(4,25). Infection with multiple HPV types may be a marker of
persistent disease and of the progression of LSILs to HSILs (7).
At present, there is little evidence that direct molecular interac¬
tions among different HPV types potentiate disease pathogenesis,
but having multiple HPV types may represent an unmeasured
factor(s) that is important in ASIL pathogenesis, such as attenu¬
ated HPV-specific immunity. Infection with a greater number of
HPV types may also result from having a larger number of sexual
encounters, which could potentially increase exposure to other
unmeasured risk factors associated with anal intercourse, such as
inflammation. Finally, infection with a greater number of HPV
types may also reflect a greater number of lesions, which would
increase the probability that an abnormality would be detected by
anal cytology.
Previous studies have demonstrated that HPV type (i.e., high-
risk versus low-risk) is associated with the type of lesions that
later develop (24,25). Compared with men in whom no HPV
DNA was detected, men infected with low-risk HPV types only
as well as men infected with high-risk HPV types only had an
increased risk of LSILs. Similarly, men who were infected with
low-risk HPV types only or with high-risk HPV types only had
an increased risk of HSILs compared with men with no HPV
infection. Given that earlier studies reported that only high-risk
HPV types are closely linked with the development of invasive
cervical and anal cancers [reviewed in (25)], it is interesting to
note that low-risk HPV types were also associated with the risk
of HSILs in our study population. However, we found that infec¬
tion with both high-risk and low-risk HPV types was more
strongly associated with either LSILs or HSILs than infection
with either high-risk or low-risk HPV types only, consistent with
our observation that an increasing number of HPV types is an
important risk factor for ASILs. Longitudinal studies that examine
the temporal association between type-specific HPV infection
and progression of ASILs are needed to clarify the relationship
between infection with specific HPV types and the risk of
incident and persistent HSILs.
Behavioral determinants that were strongly associated with
the risk ofASILs included the number of male sex partners dur¬
ing the previous 6 months and the number of receptive anal sex
partners during the previous 6 months. These behavioral risk fac¬
tors for ASILs are not surprising, given the strong evidence for
the role of sexual transmission of HPV as a necessary step for
development of anal cancer precursor lesions (4). We also found
evidence for the independent association of injection drug use
and use of poppers with the risk ofASILs. A high prevalence of
ASILs and anal HPV infection was previously reported among
HIV-infected injection drug users who denied having anal inter¬
course (32). The roles of injection drug use and the use of pop¬
pers in the pathogenesis ofASILs is unclear; however, the use of
such substances may be a proxy for partner selection or for risk
behaviors that were not captured in our structured questionnaire.
Strengths of our study include the large number, geographic
diversity, and wide age spectrum of the participants. One limita¬
tion of our study is that study participants of all ages remained
sexually active, with multiple partners. Thus, it is possible that
our results are not generalizable to all HIV-negative MSM. How¬
ever, data collected by the probability-based Urban Men's Health
Study (33) on the sexual behavior ofpredominantly HIV-negative
MSM in four cities (San Francisco, Los Angeles, New York,
and Chicago) suggest that the men in our study are highly repre¬
sentative of urban MSM with respect to age at first anal inter¬
course, any history of anal sex, and history of anal sex during the
previous year. Multiple recent cross-sectional surveys of mostly
HIV-uninfected MSM in San Francisco (34), London (35), and
Amsterdam (36) also report sexual behavior similar to that of the
men in our study. Thus, although participants in our study are
likely to be representative of many urban HIV-negative MSM,
future studies that use probability-based sampling are needed
before these findings can be generalized to all MSM, particularly
to those who have fewer sexual partners than reported by partici¬
pants in this study. Another possible limitation of our study is
the fact that only one pathologist reviewed all of the cytology.
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Moreover, any potential under- or overdiagnosis ofASILs would
probably affect only our prevalence estimates, not the estimates
of associations with potential risk factors. However, the patholo¬
gist who interpreted the slides for this study participated in a
study of interobserver variability in anal cytology, which showed
moderately good interobserver agreement (k = 0.55-0.88) for
anal cytology between experienced pathologists (T. Darragh,
personal communication).
Our data indicate that a high proportion of sexually active HIV-
negative MSM in all age groups have ASILs, including HSILs.
The high prevalence of ASILs may have direct implications for
anal cancer screening. Given the similarities between cervical
cancer and anal cancer and given the success of cervical cancer
screening in reducing mortality, Palefsky et al. (26) have pro¬
posed an anal cytology screening protocol to identify women
and men who may have anal cancer precursor lesions. Results of
cost-effectiveness analyses indicate that a reasonable screening
interval is 2-3 years for HIV-negative MSM (37). It has been
further suggested that patients who have an abnormal anal cytol¬
ogy (i.e.. Pap) test should undergo high-resolution anoscopy,
which uses magnification and characteristic changes in appear¬
ance of diseased tissue after the application of acetic acid to iden¬
tify lesions that should undergo biopsy and staging. Various
treatment options that are based on the grade, size, and location of
these lesions have been described (38). Given that anal cancer oc¬
curs only rarely in HIV-negative men aged younger than 40 years,
one approach would be to initiate screening only among men
older than 40 years. In addition, although the role of anal HPV
testing to identify MSM who are at risk for anal cancer has not
been fully explored, its primary use may rest in its negative pre¬
dictive value.
Our study illustrates that the epidemiology of anal cancer
precursor lesions in sexually active HIV-negative MSM is
different from that of cervical cancer precursor lesions in sexu¬
ally active women. The high prevalence of HPV-related anal
disease at all age groups reflects a population that continues to
have a large number ofnew sexual exposures over many decades
of life. In contrast, the prevalence of HPV-related cervical
disease in women is lower and declines with age. Extrapolations
from the cervical cancer prevention literature to anal cancer
screening cannot be made blindly. Specific knowledge of anal
HPV and ASIL epidemiology is even more relevant today as
advances continue to be made in the therapy ofASILs (39), as
well as in HPV-specific therapeutic (40) and prophylactic (41)
vaccines.
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Human papillomavirus is associated with HIV acquisition: the EXPLORE study.
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Introduction: Human papillomavirus (HPV) is a common sexually transmitted agent
and can cause anal intraepithelial neoplasia (AIN). Abnormal anal cytologic changes
associated with HPV infection include atypical squamous cells (ASC), low-grade
squamous intraepithelial lesions (SIL) and high-grade SIL. We hypothesized that AIN
can enhance susceptibility to HIV infection because of increased microvasculature,
bleeding and recruitment of CD4+ and dendritic cells. We studied the association
between the detection of anal HPV or abnormal anal cytology and HIV acquisition.
Methods: This multisite prospective study recruited 1409 HIV-negative sexually
active men who have sex with men. During each twice-yearly follow-up visit, we
assessed anal HPV infection status by polymerase chain reaction, obtained anal
cytology and behavioral data, and conducted HIV antibody testing.
Results: Of 1409 participants followed for up to 36 months, 51 HIV-seroconverted.
Of the HIV seroconverters, 81% had anal HPV, and 43% had abnormal anal cytology
at the time of HIV seroconversion. The median number of HPV types in HPV-
infected HIV-seroconverters was 2 (IQR. 1-3) at the time of HIV-seroconversion. In
univariate analyses, there was evidence (P<0.05) for an association between anal HPV
infection (HR 2.7, 95% CI 1.0-7.3) and detection of 3 HPV types (HR 3.7, 95% CI
1.4-10.3) in predicting HIV seroconversion, and moderate evidence (P<0.10) for ASC
(HR 2.4, 95% CI 0.9-6.1). After adjustment for sexual activity, substance use and
demographics, there was evidence (P<0.05) for the effect of 3 HPV types isolated
(HR 3.3, 95% CI 1.1-9.9) and ASC (HR 2.8, 95% CI 1.1-7.8).
Conclusions: Anal HPV and ASC on anal cytology are independently associated with
HIV acquisition. Prospective studies that incorporate high-resolution anoscopy for
more sensitive visual and histologic identification of AIN are needed to extend these
cytologic findings. Identification of HPV and HPV-associated lesions may improve
assessment ofHIV transmission risk.
